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Abstract 
Boron Neutron Capture Therapy (BNCT) is a biochemically targeted form of 
binary radiation therapy that has the potential to deliver radiation to cancers with cellular 
dose selectivity. Accurate and efficient treatment planning calculations are essential to 
maximizing the efficacy of BNCT and ensuring patient safety. This thesis investigates 
computational aspects of BNCT treatment planning with the aim of improving both the 
accuracy and efficiency of the planning process as well as developing a better 
understanding of differences in computational dosimetry that exist between the different 
BNCT clinical sites around the world. 
A suite of computational dosimetry reference problems were developed as a basis 
for comprehensively testing, comparing, and analyzing current and future BNCT 
treatment planning systems (TPSs) under conditions relevant to both patient planning and 
planning system calibration. Using these reference problems, four of the TPSs that have 
been used in clinical BNCT (MacNCTPlan, NCTPlan, BNCT_Rtpe, and SERA) were 
compared to reference calculations performed with the well-benchmarked Monte Carlo 
radiation transport code MCNP5. The comparison of multidimensional dose data in the 
form of dose profiles, isodose contours, dose difference distributions and dose-volume 
histograms yielded many clinically significant differences. Additional calculations were 
performed to further investigate and explain significant deviations from the reference 
calculations. 
A combined 81 brain tumor patients have been treated in dose escalation trials of 
Neutron Capture Therapy (NCT) in the USA at Harvard-Massachusetts Institute of 
Technology (MIT) and Brookhaven National Laboratory (BNL). Pooling the clinical data 
from these and other trials will allow the evaluation of the safety and efficacy of NCT 
with more statistical rigor. However, differences in physical and computational dosimetry 
between the institutions that make a direct comparison of the clinical dosimetry difficult 
must first be addressed before clinical data can be compared. This study involves 
normalizing the BNL clinical dosimetry to that of Harvard-MIT for combined NCT dose 
response analysis using analysis of MIT measurements and calculations with the BNL 
treatment planning system (TPS), BNCT_Rtpe, for two different phantoms. The BNL 
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TPS was calibrated to dose measurements made by MIT at the Brookhaven Medical 
Research Reactor (BMRR) in the BNL calibration phantom, a Lucite cube, and then 
validated by MIT dose measurements at the BMRR in an ellipsoidal water phantom. 
Using the newly determined TPS calibration, treatment plans for all BNL patients were 
recomputed, yielding reductions in reported mean brain doses of 10% on average in the 
initial 15 patients treated with the 8 cm collimator and 27% in the latter 38 patients 
treated with a 12 cm collimator. These reductions in reported doses have clinically 
significant implications for those relying on reported BNL doses as a basis for initial dose 
selection in clinical studies and reaffirm the importance of collaborative dosimetric 
comparisons within the NCT community. The dosimetric adjustments allowed the BNL 
clinical data to be legitimately combined with the Harvard-MIT clinical data for a 
combined dose response analysis of the incidence of radiation-induced somnolence 
syndrome. Probit analysis of the composite data set for the incidence of somnolence 
yielded ED50 values of 5.76 Gyw and 14.4 Gyw for mean and maximum brain dose. 
The applicability and optimization of variance reduction techniques for BNCT 
Monte Carlo treatment planning calculations were investigated using MCNP5. The pre-
existing variance reduction scheme in the Monte Carlo model of the fission converter 
beam (FCB) at MIT was optimized, resulting in improved energy-dependent neutron and 
photon weight windows. Using these weight windows, a more precise surface source 
representation of the FCB was produced downstream at the patient position with 
improved statistical properties that increased the mean efficiency of in-phantom dose 
calculations by a factor of 9. The variance reduction techniques available in MCNP were 
also explored as a means of increasing the efficiency of dose calculations in the patient 
model. By disabling implicit neutron capture and using fast neutron source biasing and 
photon production biasing techniques, the mean efficiency of dose calculations was 
improved by a factor of 2.2. 
Constructing an accurate description of a neutron beam is critical to achieving 
accurate calculations of dose in NCT treatment planning. This study compares two 
methods of neutron beam source definition commonly used in BNCT treatment planning 
calculations, the phase space file (MCNP surface source file) and source variable 
probability distributions (MCNP SDef). To facilitate the comparison, a novel software 
tool was developed to analyze MCNP surface source files and construct MCNP SDef 
representations. This tool was applied to the MIT FCB, which has a well-validated Monte 
Carlo model. Each source type (surface source file and SDef) was used to simulate 
transport of the beam through voxel models of the modified Snyder head phantom, where 
doses were calculated. Compared to the surface source file, the initial dose calculations 
with the SDef produced significant errors of ~15%. Using a patched version of MCNP 
that allowed the observed radial dependence of the relative azimuthal angle to be 
modeled in the SDef, errors in all dose components in the head phantom at Dmax were 
reduced to acceptably small levels with none being statistically significant except for the 
induced photon error of 0.5%. Errors in the calculated doses introduced by sampling the 
azimuthal component of particle direction uniformly in the SDef vary spatially, are 
phantom-dependent, and thus cannot be accurately corrected by a simple scaling of 
doses. 
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calculated with the ICRU kerma data as the reference. The INL 
hydrogen kerma data does not include the contribution from the 
recoil deuteron which leads to large differences in the thermal 
neutron energy range. The vertical dashed line represents the 
energy cutoff at 0.5 eV that is used to separate the thermal and 
fast neutron dose components in the reference MCNP5 
calculations. No such energy binning is used in BNCT_Rtpe or 
SERA. 149 
Figure 2.17 Comparison of BNCT_Rtpe and SERA multigroup (94 energy 
groups) nitrogen and hydrogen neutron kerma data to pointwise 
continuous reference total brain neutron kerma data. The percent 
difference between the summed INL nitrogen and hydrogen 
kerma data and the total brain kerma data was calculated with the 
total brain kerma data as the reference. The vertical dashed line 
represents the energy cutoff at 0.5 eV that is used to separate the 
thermal and fast neutron dose components in the reference 
MCNP5 calculations. No such energy binning is used in 
BNCT_Rtpe or SERA. 151 
Figure 2.18 Nitrogen dose rate and percent difference 
(100×[TPS−Ref]/Refmax) as a function of depth along the central 
beam axis in the large rectangular water phantom for each 
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planning system. Multigroup INL nitrogen neutron kerma factors 
were used in MCNP5 calculations of nitrogen dose rates, which 
served as the reference for percent difference calculations. 
Nitrogen dose rates calculated with ICRU 63 nitrogen kerma 
factors are included as a point of comparison. 153 
Figure 2.19 Fast neutron (and hydrogen) dose rate and percent difference 
(100×[TPS−Ref]/Refmax) as a function of depth along the central 
beam axis in the large rectangular water phantom for each 
planning system. MCNP5 served as the reference for percent 
difference calculations. 159 
Figure 2.20 Hydrogen dose rate and percent difference 
(100×[TPS−Ref]/Refmax) as a function of depth along the central 
beam axis in the large rectangular water phantom for each 
planning system. Multigroup INL hydrogen neutron kerma factors 
were used in MCNP5 calculations of hydrogen dose rates, which 
served as the reference for percent difference calculations. The 
fast neutron source biasing run mode was not used for 
BNCT_Rtpe or SERA (i.e., run modes “NGD” were used). 
Hydrogen dose rates calculated with ICRU 63 hydrogen kerma 
factors are included as a point of comparison. 160 
Figure 2.21 Fast neutron flux and percent difference (100×[TPS−Ref]/Refmax) 
as a function of depth along the central beam axis in the large 
rectangular water phantom for different representations of the 
SERA voxel data. The uninterpolated SERA voxel data were read 
and interpolated using MATLAB for comparison to the 
interpolated output of seraPlan to illustrate interpolation errors in 
the line and point edit data. The data produced using 3D cubic 
interpolation served as the reference for percent difference 
calculations since it produced the closest agreement to MCNP5. 161 
Figure 2.22 Total neutron dose rate (thermal+fast and hydrogen+nitrogen) and 
percent difference (100×[TPS−Ref]/Refmax) as a function of depth 
along the central beam axis in the large rectangular water 
phantom for each planning system. MCNP5 served as the 
reference for percent difference calculations. 163 
Figure 2.23 Induced photon dose rate and percent difference 
(100×[TPS−Ref]/Refmax) as a function of depth along the central 
beam axis in the large rectangular water phantom for each 
planning system. MCNP5 served as the reference for percent 
difference calculations. 169 
Figure 2.24 Photon kerma factors used in the reference, BNCT_Rtpe, and 
SERA calculations of induced and incident photon dose and the 
percent difference of the BNCT_Rtpe and SERA kerma data from 
the reference kerma data. The reference data are pointwise 
continuous while the BNCT_Rtpe and SERA kerma data have 70 
and 86 energy groups, respectively. 171 
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Figure 2.25 Induced photon dose rate and percent difference 
(100×[TPS−Ref]/Refmax) as a function of depth along the central 
beam axis in the large rectangular water phantom for each 
planning system. Multigroup photon kerma factors from 
BNCT_Rtpe and SERA were used in MCNP5 calculations of 
induced photon dose rates, which served as the reference for 
BNCT_Rtpe and SERA percent difference calculations, 
respectively. 173 
Figure 2.26 Incident photon dose rate and percent difference 
(100×[TPS−Ref]/Refmax) as a function of depth along the central 
beam axis in the large rectangular water phantom for each 
planning system. MCNP5 served as the reference for percent 
difference calculations. 174 
Figure 2.27 Incident photon dose rate and percent difference 
(100×[TPS−Ref]/Refmax) as a function of depth along the central 
beam axis in the large rectangular water phantom for each 
planning system. Multigroup photon kerma factors from 
BNCT_Rtpe and SERA were used in MCNP5 calculations of 
incident photon dose rates, which served as the reference for 
BNCT_Rtpe and SERA percent difference calculations, 
respectively. The −2% difference reflects a subtle normalization 
error in BNCT_Rtpe and SERA incident photon dose rates. 175 
Figure 2.28 Total biologically weighted brain dose rate and percent difference 
(100×[TPS−Ref]/Refmax) as a function of depth along the central 
beam axis in the large rectangular water phantom for each 
planning system. MCNP5 served as the reference for percent 
difference calculations. 180 
Figure 2.29 Axial sections through the BNCT_Rtpe NURBS model, SERA 
univel model, MacNCTPlan and NCTPlan mixed-material voxel 
models of the ellipsoidal head phantom used to simulate BNCT 
treatment of a brain tumor. 185 
Figure 2.30 Thermal neutron flux and percent difference 
(100×[TPS−Ref]/Refmax) as a function of depth along the central 
beam axis in the ellipsoidal head phantom for each planning 
system. SERA and BNCT_Rtpe data are calculated at (default) 
intervals of 5 mm. MCNP5 served as the reference for percent 
difference calculations. 192 
Figure 2.31 Different NCTPlan voxel models of the head phantom that 
resulted from shifting the phantom image data in 1 mm steps 
along its minor axis (the central axis of the beam). The phantom’s 
biological materials are color coded by density, and white tick 
marks have been added to indicate the front and back edges of the 
un-shifted phantom. 193 
Figure 2.32 Uninterpolated NCTPlan thermal neutron flux voxel data and 
percent difference (100×[TPS−Ref]/Refmax) as a function of depth 
along the central beam axis in the ellipsoidal head phantom for 
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different NCTPlan models of the head phantom that resulted from 
shifting the phantom image data varying distances along the 
central beam axis in relation to the voxel mesh. MCNP5 served as 
the reference for percent difference calculations. 195 
Figure 2.33 Boron dose rate for a 10B concentration of 15 μg/g and percent 
difference (100×[TPS−Ref]/Refmax) as a function of depth along 
the central beam axis in the ellipsoidal head phantom for each 
planning system. MCNP5 served as the reference for percent 
difference calculations. 198 
Figure 2.34 Fast neutron (and hydrogen) dose rate and percent difference 
(100×[TPS−Ref]/Refmax) as a function of depth along the central 
beam axis in the ellipsoidal head phantom for each planning 
system. The fast neutron source biasing run mode was not used 
for BNCT_Rtpe or SERA (i.e., run modes “NGD” were used) 
because doing so results in a significant −47% difference at the 
phantom entrance. MCNP5 served as the reference for percent 
difference calculations. 199 
Figure 2.35 Uninterpolated NCTPlan fast neutron dose rate voxel data and 
percent difference (100×[TPS−Ref]/Refmax) as a function of depth 
along the central beam axis in the ellipsoidal head phantom for 
different NCTPlan models of the head phantom that resulted from 
shifting the phantom image data varying distances along the 
central beam axis in relation to the voxel mesh. MCNP5 served as 
the reference for percent difference calculations. 200 
Figure 2.36 Induced photon dose rate and percent difference 
(100×[TPS−Ref]/Refmax) as a function of depth along the central 
beam axis in the ellipsoidal head phantom for each planning 
system. MCNP5 served as the reference for percent difference 
calculations. 204 
Figure 2.37 Uninterpolated NCTPlan induced photon dose rate voxel data and 
percent difference (100×[TPS−Ref]/Refmax) as a function of depth 
along the central beam axis in the ellipsoidal head phantom for 
different NCTPlan models of the head phantom that resulted from 
shifting the phantom image data varying distances along the 
central beam axis in relation to the voxel mesh. MCNP5 served as 
the reference for percent difference calculations. 205 
Figure 2.38 Total biologically weighted brain dose rate and percent difference 
(100×[TPS−Ref]/Refmax) as a function of depth along the central 
beam axis in the ellipsoidal head phantom for each planning 
system. MCNP5 served as the reference for percent difference 
calculations. 206 
Figure 2.39 Axial sections through the BNCT_Rtpe NURBS model, SERA 
univel model, MacNCTPlan and NCTPlan mixed-material voxel 
models of the leg phantom used to simulate BNCT treatment of 
peripheral melanoma. 209 
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Figure 2.40 Thermal neutron flux and percent difference 
(100×[TPS−Ref]/Refmax) as a function of depth along the central 
beam axis in the leg phantom for each planning system. SERA 
and BNCT_Rtpe data are calculated at (default) intervals of 5 
mm. MCNP5 served as the reference for percent difference 
calculations. 211 
Figure 2.41 Boron dose rate for a 10B concentration of 22.5 μg/g and percent 
difference (100×[TPS−Ref]/Refmax) as a function of depth along 
the central beam axis in the leg phantom for each planning 
system. MCNP5 served as the reference for percent difference 
calculations. 217 
Figure 2.42 Fast neutron (and hydrogen) dose rate and percent difference 
(100×[TPS−Ref]/Refmax) as a function of depth along the central 
beam axis in the leg phantom for each planning system. MCNP5 
served as the reference for percent difference calculations. 218 
Figure 2.43 Induced photon dose rate and percent difference 
(100×[TPS−Ref]/Refmax) as a function of depth along the central 
beam axis in the leg phantom for each planning system. MCNP5 
served as the reference for percent difference calculations. 219 
Figure 2.44 Incident photon dose rate and percent difference 
(100×[TPS−Ref]/Refmax) as a function of depth along the central 
beam axis in the leg phantom for each planning system. MCNP5 
served as the reference for percent difference calculations. 220 
Figure 2.45 Total biologically weighted skin dose rate and percent difference 
(100×[TPS−Ref]/Refmax) as a function of depth along the central 
beam axis in the leg phantom for each planning system. MCNP5 
served as the reference for percent difference calculations. 221 
Figure 2.46 Boron isodose contours for a 10B concentration of 15 μg/g in the 
transverse plane containing the central beam axis for a 1-field 
irradiation of the head phantom. Each planning system’s contours 
(solid) are overlaid with the reference contours (dashed) after the 
treatment time for each planning system from Table 2.3 was used 
to convert the reference dose rates to absolute dose. 227 
Figure 2.47 Difference in boron dose in the transverse plane containing the 
central beam axis expressed as a percentage of the maximum 
reference boron dose for a 1-field irradiation of the head phantom. 229 
Figure 2.48 Incident photon isodose contours in the transverse plane 
containing the central beam axis for a 1-field irradiation of the 
head phantom. Each planning system’s contours (solid) are 
overlaid with the reference contours (dashed) after the treatment 
time for each planning system from Table 2.3 was used to convert 
the reference dose rates to absolute dose. 235 
Figure 2.49 Transverse and coronal views through the ellipsoidal head 
phantom overlaid with the coarse scoring mesh from each TPS to 
illustrate the relative orientation of each mesh with the phantom 
and the beam path (shaded region). The mesh element centers in 
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BNCT_Rtpe and SERA are offset by 5 mm in each dimension 
from the mesh element centers of MacNCTPlan and NCTPlan. 
The beam is aligned with mesh element edges in BNCT_Rtpe and 
SERA whereas it is aligned with mesh element centers in 
MacNCTPlan and NCTPlan. Each tally volume is 1 cm3, and only 
a portion of each mesh is shown. 237 
Figure 2.50 Incident photon dose rate and percent difference 
(100×[TPS−Ref]/Refmax) for each planning system as a function 
of the lateral distance (in the transverse plane) from the central 
beam axis in the ellipsoidal head phantom. MCNP5 served as the 
reference for percent difference calculations. 239 
Figure 2.51 Total biologically weighted brain isodose contours in the coronal 
plane containing the central beam axis for a 1-field irradiation of 
the head phantom. Each planning system’s contours (solid) are 
overlaid with the reference contours (dashed) after the treatment 
time for each planning system from Table 2.3 was used to convert 
the reference dose rates to absolute dose. 243 
Figure 2.52 Difference in total biologically weighted brain dose in the coronal 
plane containing the central beam axis expressed as a percentage 
of the maximum reference total weighted dose for a 1-field 
irradiation of the head phantom. 245 
Figure 2.53 Total biologically weighted brain isodose contours in the 
transverse plane containing the central beam axis for a 3-field 
irradiation of the head phantom. Each planning system’s contours 
(solid) are overlaid with the reference contours (dashed) after the 
treatment time for each planning system from Table 2.3 was used 
to convert the reference dose rates to absolute dose. 247 
Figure 2.54 Total biologically weighted tumor isodose contours in the coronal 
plane containing the central beam axis for a 3-field irradiation of 
the head phantom. Each planning system’s contours (solid) are 
overlaid with the reference contours (dashed) after the treatment 
time for each planning system from Table 2.3 was used to convert 
the reference dose rates to absolute dose. 249 
Figure 2.55 Difference in thermal neutron flux in the transverse plane 
containing the central beam axis expressed as a percentage of the 
maximum reference thermal neutron flux for a 1-field irradiation 
of the leg phantom. 255 
Figure 2.56 Difference in boron dose in the transverse plane containing the 
central beam axis expressed as a percentage of the maximum 
reference boron dose for a 1-field irradiation of the leg phantom. 257 
Figure 2.57 Total biologically weighted tumor isodose contours in the 
transverse plane containing the central beam axis for a 1-field 
irradiation of the leg phantom. Each planning system’s contours 
(solid) are overlaid with the reference contours (dashed) after the 
treatment time for each planning system from Table 2.3 was used 
to convert the reference dose rates to absolute dose. 259 
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Figure 2.58 Total biologically weighted tumor isodose contours in an oblique 
plane containing the central beam axis for a 1-field irradiation of 
the leg phantom. Each planning system’s contours (solid) are 
overlaid with the reference contours (dashed) after the treatment 
time for each planning system from Table 2.3 was used to convert 
the reference dose rates to absolute dose. 261 
Figure 2.59 Total biologically weighted dose-volume histograms for brain for 
a 1-field irradiation of the head phantom. Conventional and 
binned representations of the reference data are included. The 
default output from seraPlot is shown along with a corrected 
interpretation of the SERA dose-volume data (with a −5% shift in 
dose). 270 
Figure 2.60 Total biologically weighted dose-volume histograms for the brain 
tumor for a 1-field irradiation of the head phantom. Conventional 
and binned representations of the reference data are included. A 
corrected interpretation of the SERA dose-volume data (with a 
−5% shift in dose) is shown instead of the default seraPlot output. 271 
Figure 2.61 Total biologically weighted dose-volume histograms for brain for 
a 3-field irradiation of the head phantom. Conventional and 
binned representations of the reference data are included. A 
corrected interpretation of the SERA dose-volume data (with a 
−5% shift in dose) is shown instead of the default seraPlot output. 272 
Figure 2.62 Total biologically weighted dose-volume histograms for the brain 
tumor for a 3-field irradiation of the head phantom. Conventional 
and binned representations of the reference data are included. A 
corrected interpretation of the SERA dose-volume data (with a 
−5% shift in dose) is shown instead of the default seraPlot output. 273 
Figure 2.63 Total biologically weighted dose-volume histograms for skin for a 
1-field irradiation of the leg phantom. Conventional and binned 
representations of the reference data are included. A corrected 
interpretation of the SERA dose-volume data (with a −5% shift in 
dose) is shown instead of the default seraPlot output. 279 
Figure 2.64 Total biologically weighted dose-volume histograms for tumor 1 
(spherical tumor) for a 1-field irradiation of the leg phantom. 
Conventional and binned representations of the reference data are 
included. A corrected interpretation of the SERA dose-volume 
data (with a −5% shift in dose) is shown instead of the default 
seraPlot output. 280 
Figure 2.65 Total biologically weighted dose-volume histograms for tumor 2 
(arc-shaped tumor) for a 1-field irradiation of the leg phantom. 
Conventional and binned representations of the reference data are 
included. A corrected interpretation of the SERA dose-volume 
data (with a −5% shift in dose) is shown instead of the default 
seraPlot output. 281 
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CHAPTER THREE 297 
COMPARISON OF DOSES DELIVERED IN CLINICAL TRIALS OF NEUTRON 
CAPTURE THERAPY IN THE USA 
Figure 3.1 Comparison of (annotated) BNCT_Rtpe raster images of the 12 
cm BMRR collimator used to calibrate the treatment planning 
system and to calculate patient doses for planning. The collimator 
modeled in the TPS calibration (left) using the Lucite cube 
phantom was not as thick and provided less beam collimation and 
thus yielded lower calculated in-phantom doses. The effect of 
calibrating the TPS in this configuration is to overestimate doses 
in the patient (right), where a thicker collimator was used. 304 
Figure 3.2 BNCT_Rtpe calculations scaled to MIT measurements in the 
BNL calibration phantom, a Lucite cube. Dose component scaling 
factors were derived from the least squares fitting of BNCT_Rtpe 
calculations to MIT measurements. The plotted calculation lines 
are the product of the scale factors (shown in the legend) and 
doses calculated by BNCT_Rtpe. 308 
Figure 3.3 Scaled BNCT_Rtpe calculations and MIT dose measurements in 
the MIT ellipsoidal head phantom. Scaling factors are those 
derived from the data of Figure 3.2. The plotted calculation lines 
are the product of the scale factors (shown in the legend) and 
doses calculated by BNCT_Rtpe. 310 
Figure 3.4 Original vs. revised (a) mean and (b) maximum biologically 
weighted brain doses for the BNL patients. The solid line 
represents equality of revised and original dosimetry. 314 
Figure 3.5 Contributions to the adjusted mean and maximum physical brain 
doses (unweighted) for the BNL patients. 315 
Figure 3.6 Original and revised treatment plans for a BNL patient treated 
with 3 fields using the 12 cm collimator after the fuel shuffle. The 
isodose contours are displayed as a percentage of the biologically 
weighted brain dose in the voxel containing the maximum 
thermal neutron flux under the original dosimetry (15.6 Gyw). The 
contours were plotted with the BNL treatment planning system, 
BNCT_Rtpe. 317 
Figure 3.7 Original and revised total biologically weighted dose-volume 
histograms for the brain, tumor, and target volumes of a BNL 
patient treated with 3 fields using the 12 cm collimator after the 
fuel shuffle. 319 
Figure 3.8 Maximum brain dose versus mean brain dose for the combined 
BNL and Harvard-MIT patient data. Filled symbols represent 
patients that developed radiation-induced somnolence syndrome. 
The retreatment of 1 previously treated BNL patient as well as the 
2 Harvard-MIT patients for which somnolence could not be 
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evaluated due to confounding factors were censored from the 
analysis. 320 
Figure 3.9 Dose response curves for radiation-induced somnolence for the 
combined BNL and Harvard-MIT patient data based on the mean 
or maximum weighted brain dose. The 95% confidence intervals 
are indicated by the pairs of dashed lines. 321 
Figure 3.10 Dose response curves for radiation-induced somnolence for the 
revised and original biologically weighted mean brain doses for 
the BNL patients only. The revised BNL doses resulted in an 
ED50 that was 26% lower than for the original dosimetry (6.42 
Gyw vs. 4.75 Gyw). 322 
CHAPTER FOUR 333 
APPLICATION OF VARIANCE REDUCTION IN MONTE CARLO TREATMENT 
PLANNING CALCULATIONS 
Figure 4.1 Neutron current energy spectrum inside the beam aperture (r ≤ 5.9 
cm) of the MIT FCB. The uncertainties have been intentionally 
increased by an order of magnitude to better illustrate the 
effectiveness of the energy-dependent weight windows at 
reducing uncertainties across a broad range of neutron energies. 346 
Figure 4.2 Two dimensional distributions of dose rate, relative error, and 
FOM (Figure-Of-Merit) calculated for the incident photon dose 
component of the MIT FCB in a voxel model of the modified 
Snyder head phantom. Streak artifacts of high in-phantom 
incident photon dose, high uncertainty, and low FOM resulting 
from the “unlucky” rouletting of neutrons and excessive splitting 
of the subsequent induced photons during upstream Monte Carlo 
calculations of the FCB beam line are evident. The color bars are 
log scale. 349 
Figure 4.3 Monte Carlo model of the MITR-II reactor core and FCB beam 
line illustrating the series of MCNP calculations and surface 
source (SS) files used to create a surface source representation of 
the beam downstream at the patient position (beam aperture) for 
use in BNCT treatment planning calculations. 359 
Figure 4.4 Flowchart outlining the systematic approach taken to minimize 
production of problematic high weight tracks and subsequent 
splitting into excessive numbers of duplicate tracks during the 
Monte Carlo simulations of the FCB beam line that resulted from 
neutrons rouletting to high weights and producing photons which 
were split multiple times. The process was repeated until the 
production of high weight tracks, as manifest by excessive 
numbers (> 100) of duplicate tracks recorded on the surface 
source at the patient position, had been sufficiently reduced. 363 
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Figure 4.5 Original (from 2002) and new neutron and photon weight 
windows for those cells along the central axis of the FCB beam 
line. The thin vertical lines that segment the weight windows 
represent the boundaries of different regions of the beam line. 
Neutron and photon weight windows were increased moving 
radially outward from the beam central axis. 368 
Figure 4.6 Histogram of the number of duplicate photon tracks within the 
FCB surface source file at the patient position and the subsequent 
effect they had on in-phantom incident photon dose rates, relative 
errors, and FOM before and after adjustments to upstream weight 
windows. By adjusting the weight windows, the mean number of 
identical photon tracks per independent history was reduced from 
102 to 2.96, and streak-artifacts of high dose and high uncertainty 
were eliminated while the FOM was increased significantly. The 
value plotted at 100 tracks represents the number of unique tracks 
(no duplicates) within the surface source file. The color bars are 
log scale. 369 
Figure 4.7 Boron and fast neutron dose rate, relative error, and FOM 
(Figure-Of-Merit) distributions in the transverse plane of the 
modified Snyder head phantom on the FCB central axis before 
and after adjustments to the weight windows used for transport 
through the beam line. The mean, minimum, and maximum FOM 
values increased for both dose components as a result of the 
adjustments. The color bars are log scale. 371 
Figure 4.8 Induced photon and total weighted brain dose rate, relative error, 
and FOM (Figure-Of-Merit) distributions in the transverse plane 
of the modified Snyder head phantom on the FCB central axis 
before and after adjustments to the weight windows used for 
transport through the beam line. The mean, minimum, and 
maximum FOM values increased for both dose components as a 
result of the adjustments. The color bars are log scale. 373 
Figure 4.9 Detailed description of the series of simulations and surface 
source files used to produce a more accurate surface source 
representation of the FCB at the patient position. In total, 1.07 
CPU years of simulation time and 88 GB of computer storage 
were used. 377 
Figure 4.10 Comparison of calculated and measured1 doses in the MIT 
ellipsoidal head phantom. MCNP calculations with the FCB 
surface source were scaled to match physical dosimetry 
measurements using least squares fitting; dose scale factors for 
each component are listed in the legend. 379 
Figure 4.11 FOM (Figure-Of-Merit) distributions for in-phantom dose tallies 
in the transverse beam line plane which result from employing 
different variance reduction techniques during coupled 
neutron/photon transport simulations of the generic epithermal 
neutron beam in a voxel model of the modified Snyder head 
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phantom. Larger FOM values indicate more efficient dose 
calculations. The color bars are log scale. 383 
Figure 4.12 FOM (Figure-Of-Merit) distributions for in-phantom dose tallies 
in the transverse beam line plane which result from employing 
different variance reduction techniques during coupled 
neutron/photon transport simulations of the generic epithermal 
neutron beam in a voxel model of the modified Snyder head 
phantom. Larger FOM values indicate more efficient dose 
calculations. The color bars are log scale. 385 
Figure 4.13 Percent difference in the mean FOM (Figure-Of-Merit) for in-
phantom dose tallies when compared to simulations using the 
default photon production biasing parameter of −1. As the biasing 
parameter is increased to 0, more induced photons are produced 
with appropriately adjusted (lower) weights so as to maintain a 
fair Monte Carlo game and provide unbiased results. Increasing 
photon production dramatically improves the efficiency of 
calculating the induced photon dose, but this comes with the 
expense of reduced efficiency for other dose components such as 
the boron dose. 389 
Figure 4.14 Cylindrical weight windows mesh superimposed on a 1 cm3 voxel 
model of the modified Snyder head phantom and irradiated with a 
10 cm diameter monodirectional epithermal neutron disc source. 
The neutron and photon weight windows in those regions of the 
mesh labeled with an ‘X’ were intentionally made very large 
(1×1025) to terminate tracking calculations for all particles 
escaping from the phantom. 395 
CHAPTER FIVE 409 
NEUTRON BEAM SOURCE DEFINITION TECHNIQUES FOR NEUTRON 
CAPTURE THERAPY TREATMENT PLANNING 
Figure 5.1 Parameters used to define the particle position and direction 
(indicated by the bold arrow) in the SDef source representations. r 
and φ are sampled to determine position (x,y). The polar angle θ 
and the relative azimuthal angle φ′, defined relative to the track’s 
radial vector, determine particle direction. 416 
Figure 5.2 Track information from the surface source file is scored into an 
array of fine radial, energy, polar angle (θ), and relative azimuthal 
angle (φ') bins such as illustrated here. This finely binned 
information is grouped into coarse regions for the r, E, and θ 
source variables, as indicated by the thick dashed lines. In each 
coarse region (e.g., the shaded region), a unique marginal 
probability distribution is computed for each of the 4 source 
variables. The product of each region’s marginal probability 
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distributions in r, E, θ and φ′ is used to model the joint probability 
distribution Pi,j,k(r, E, θ, φ′) in that region. 418 
Figure 5.3 Comparison of the joint probability distribution of polar angle θ 
and energy (P(θ,E)) with the product of the marginal distributions 
(P(θ)·P(E)) for the radial region corresponding to the beam 
aperture (r ≤ 5.9 cm) of the MIT FCB. Large percent differences 
indicate a high degree of inseparability between the two source 
variables. The alternating shaded/white areas demarcate different 
coarse regions of the r-E-θ phase space. 425 
Figure 5.4 Comparison of the joint probability distribution of radius and 
energy (P(r,E)) with the product of the marginal distributions 
(P(r)·P(E)). The alternating shaded/white areas demarcate 
different coarse regions of the r-E-θ phase space. 427 
Figure 5.5 Comparison of the joint probability distribution of radius and 
polar angle θ (P(r,θ)) with the product of the marginal 
distributions (P(r)·P(θ)) for the thermal, epithermal, and fast 
neutron energy groups. The alternating shaded/white areas 
demarcate different coarse regions of the r-E-θ phase space. 429 
Figure 5.6 Radial distribution of neutron current for different energy and 
angular regions of the phase space at the plane of the beam 
aperture of the MIT FCB. Line thickness encodes the thermal, 
epithermal and fast neutron energy groups while solid and dashed 
lines represent polar angle regions of 0° ≤ θ ≤ 20° and 20° < θ ≤ 
90°, respectively. For the radial region outside the beam 
collimator (r > 11.8 cm, right of the vertical line) where the 
neutron current is orders of magnitude smaller than in the 
aperture, only one θ bin was used to help reduce fluctuations in 
the distribution resulting from few particles. 431 
Figure 5.7 Energy spectrum of the neutron current in different radial and 
angular regions on the beam aperture plane of the MIT FCB.  
Line thickness encodes the different radial regions on each plot 
with the top plot representing 0° ≤ θ ≤ 20° and the bottom 20° < θ 
≤ 90°. In the outermost radial region (11.8 cm < r ≤ 30 cm) θ was 
scored into only one bin (0° ≤ θ ≤ 90°) to reduce statistical 
fluctuations. Energy bins of equal lethargy (10 per decade) were 
used to score the particle weight. 432 
Figure 5.8 Polar angle (θ) probability distributions calculated in each of 4 
radial regions and 3 energy regions. Line thickness encodes the 
thermal, epithermal and fast neutron energy groups. The particle 
weight was scored into 2° bins from 0° to 90°. 433 
Figure 5.9 Radial distribution of incident photon current for different energy 
and angular regions of the phase space at the plane of the beam 
aperture of the MIT FCB. Line thickness encodes the 3 energy 
groups while solid and dashed lines represent polar angle regions 
of 0° ≤ θ ≤ 20° and 20° < θ ≤ 90°, respectively. For the radial 
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region outside the beam collimator (r > 11.8 cm, right of the 
vertical line) where the photon current is orders of magnitude 
smaller than in the aperture, only one θ bin was used to help 
reduce fluctuations in the distribution resulting from few 
particles. 435 
Figure 5.10 Energy spectrum of the incident photon current in different radial 
and angular regions on the beam aperture plane of the MIT FCB. 
Line thickness encodes the different radial regions on each plot 
with the top plot representing 0° ≤ θ ≤ 20° and the bottom 20° < θ 
≤ 90°. In the outermost radial region (11.8 cm < r ≤ 30 cm) θ was 
scored into only one bin (0° ≤ θ ≤ 90°) to reduce statistical 
fluctuations. 100 keV energy bins were used to score the particle 
weight. 436 
Figure 5.11 Polar angle (θ) probability distributions for the incident photons 
calculated in each of 3 radial regions and 3 energy regions. Line 
thickness encodes the energy groups. The particle weight was 
scored into 2° bins from 0° to 90°. 437 
Figure 5.12 Probability distributions of the relative azimuthal angle φ' inside 
the beam aperture of the MIT FCB determined from the surface 
source file and the fitted model. The nonuniform distribution 
shows a preference for outward angles (|φ'| < π/2). r0 is the radius 
of the beam aperture, 5.9 cm, and b is a fitted constant. Radial 
bins range from 0 to 5.9 cm in ~1 cm steps. P(φ') is shown 
averaged over the radial bins and is limited to 0 ≤ φ' ≤ π for this 
comparison. In the modifications to MCNP5, the fitted model is 
symmetric about φ'=0 and is sampled from –π to +π. 439 
Figure 5.13 Comparison of dose rates calculated in the modified Snyder head 
phantom using different beam source models for the MIT FCB 
and a source to surface distance of 3.0 cm. Solid lines represent 
the reference doses calculated with the surface source while 
dashed and dash-dot lines represent data for the SDef models with 
and without φ' dependence, respectively. Isodose labels represent 
a percentage of the maximum dose rate in the phantom computed 
with the surface source for each dose component. Error bars (1 σ) 
in the depth-dose plots are omitted for clarity in cases where they 
are negligibly small. 443 
Figure 5.14 Total biologically weighted brain dose-volume histograms 
produced by simulating the irradiation of the Snyder head 
phantom (SSD=3.0 cm) with the different source representations 
of the MIT FCB. The time required to deliver a maximum brain 
dose of 12.5 Gyw with the surface source model (13.47 minutes) 
was used to convert to units of absolute dose. Dose component 
scaling factors, derived from calculations with the SDef model 
and standard version of MCNP in large rectangular water 
phantom (column 4 of Table 5.1), were applied to the SDef doses 
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in the head phantom to simulate the planning system calibration 
routinely performed at some institutions. The resulting 
disagreement between the uniform φ' SDef and the surface source 
curves (8.7%, 7.3%, and 11.6% in mean, minimum, and 
maximum brain dose, respectively) illustrates that the errors 
introduced during patient planning by sampling φ' uniformly are 
not corrected by calibrating the planning system in a reference 
phantom. 445 
CHAPTER SIX 459 
SUMMARY, CONCLUSIONS AND RECOMMENDATIONS FOR FUTURE WORK 
APPENDIX A 473 
REFERENCE DATA FOR NEUTRON CAPTURE THERAPY TREATMENT 
PLANNING SYSTEMS 
Figure A.1 Thermal neutron flux and percent difference 
(100×[TPS−Ref]/Refmax) as a function of depth along the central 
beam axis in the large rectangular water phantom for each 
planning system. SERA and BNCT_Rtpe data are calculated at 
(default) intervals of 5 mm. MCNP5 served as the reference for 
percent difference calculations. 475 
Figure A.2 Boron dose rate for a 10B concentration of 15 μg/g and percent 
difference (100×[TPS−Ref]/Refmax) as a function of depth along 
the central beam axis in the large rectangular water phantom for 
each planning system. MCNP5 served as the reference for percent 
difference calculations. 476 
Figure A.3 Thermal neutron (and nitrogen) dose rate and percent difference 
(100×[TPS−Ref]/Refmax) as a function of depth along the central 
beam axis in the large rectangular water phantom for each 
planning system. MCNP5 served as the reference for percent 
difference calculations. 477 
Figure A.4 Fast neutron (and hydrogen) dose rate and percent difference 
(100×[TPS−Ref]/Refmax) as a function of depth along the central 
beam axis in the large rectangular water phantom for each 
planning system. MCNP5 served as the reference for percent 
difference calculations. 478 
Figure A.5 Induced photon dose rate and percent difference 
(100×[TPS−Ref]/Refmax) as a function of depth along the central 
beam axis in the large rectangular water phantom for each 
planning system. MCNP5 served as the reference for percent 
difference calculations. 479 
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Figure A.6 Incident photon dose rate and percent difference 
(100×[TPS−Ref]/Refmax) as a function of depth along the central 
beam axis in the large rectangular water phantom for each 
planning system. MCNP5 served as the reference for percent 
difference calculations. 480 
Figure A.7 Total biologically weighted brain dose rate and percent difference 
(100×[TPS−Ref]/Refmax) as a function of depth along the central 
beam axis in the large rectangular water phantom for each 
planning system. MCNP5 served as the reference for percent 
difference calculations. 481 
Figure A.8 Total biologically weighted tumor dose rate and percent 
difference (100×[TPS−Ref]/Refmax) as a function of depth along 
the central beam axis in the large rectangular water phantom for 
each planning system. MCNP5 served as the reference for percent 
difference calculations. 482 
Figure A.9 Thermal neutron flux and percent difference 
(100×[TPS−Ref]/Refmax) as a function of depth along the central 
beam axis in the ellipsoidal head phantom for each planning 
system. SERA and BNCT_Rtpe data are calculated at (default) 
intervals of 5 mm. MCNP5 served as the reference for percent 
difference calculations. 483 
Figure A.10 Boron dose rate for a 10B concentration of 15 μg/g and percent 
difference (100×[TPS−Ref]/Refmax) as a function of depth along 
the central beam axis in the ellipsoidal head phantom for each 
planning system. MCNP5 served as the reference for percent 
difference calculations. 484 
Figure A.11 Thermal neutron (and nitrogen) dose rate and percent difference 
(100×[TPS−Ref]/Refmax) as a function of depth along the central 
beam axis in the ellipsoidal head phantom for each planning 
system. MCNP5 served as the reference for percent difference 
calculations. 485 
Figure A.12 Fast neutron (and hydrogen) dose rate and percent difference 
(100×[TPS−Ref]/Refmax) as a function of depth along the central 
beam axis in the ellipsoidal head phantom for each planning 
system. MCNP5 served as the reference for percent difference 
calculations. 486 
Figure A.13 Induced photon dose rate and percent difference 
(100×[TPS−Ref]/Refmax) as a function of depth along the central 
beam axis in the ellipsoidal head phantom for each planning 
system. MCNP5 served as the reference for percent difference 
calculations. 487 
Figure A.14 Incident photon dose rate and percent difference 
(100×[TPS−Ref]/Refmax) as a function of depth along the central 
beam axis in the ellipsoidal head phantom for each planning 
system. MCNP5 served as the reference for percent difference 
calculations. 488 
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Figure A.15 Total biologically weighted brain dose rate and percent difference 
(100×[TPS−Ref]/Refmax) as a function of depth along the central 
beam axis in the ellipsoidal head phantom for each planning 
system. MCNP5 served as the reference for percent difference 
calculations. 489 
Figure A.16 Total biologically weighted tumor dose rate and percent 
difference (100×[TPS−Ref]/Refmax) as a function of depth along 
the central beam axis in the ellipsoidal head phantom for each 
planning system. MCNP5 served as the reference for percent 
difference calculations. 490 
Figure A.17 Thermal neutron flux and percent difference 
(100×[TPS−Ref]/Refmax) as a function of depth along the central 
beam axis in the leg phantom for each planning system. SERA 
and BNCT_Rtpe data are calculated at (default) intervals of 5 
mm. MCNP5 served as the reference for percent difference 
calculations. 491 
Figure A.18 Boron dose rate for a 10B concentration of 22.5 μg/g and percent 
difference (100×[TPS−Ref]/Refmax) as a function of depth along 
the central beam axis in the leg phantom for each planning 
system. MCNP5 served as the reference for percent difference 
calculations. 492 
Figure A.19 Thermal neutron (and nitrogen) dose rate and percent difference 
(100×[TPS−Ref]/Refmax) as a function of depth along the central 
beam axis in the leg phantom for each planning system. MCNP5 
served as the reference for percent difference calculations. 493 
Figure A.20 Fast neutron (and hydrogen) dose rate and percent difference 
(100×[TPS−Ref]/Refmax) as a function of depth along the central 
beam axis in the leg phantom for each planning system. MCNP5 
served as the reference for percent difference calculations. 494 
Figure A.21 Induced photon dose rate and percent difference 
(100×[TPS−Ref]/Refmax) as a function of depth along the central 
beam axis in the leg phantom for each planning system. MCNP5 
served as the reference for percent difference calculations. 495 
Figure A.22 Incident photon dose rate and percent difference 
(100×[TPS−Ref]/Refmax) as a function of depth along the central 
beam axis in the leg phantom for each planning system. MCNP5 
served as the reference for percent difference calculations. 496 
Figure A.23 Total biologically weighted skin dose rate and percent difference 
(100×[TPS−Ref]/Refmax) as a function of depth along the central 
beam axis in the leg phantom for each planning system. MCNP5 
served as the reference for percent difference calculations. 497 
Figure A.24 Total biologically weighted tumor dose rate and percent 
difference (100×[TPS−Ref]/Refmax) as a function of depth along 
the central beam axis in the leg phantom for each planning 
system. MCNP5 served as the reference for percent difference 
calculations. 498 
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Figure A.25 Boron isodose contours for a 10B concentration of 15 μg/g in the 
transverse plane containing the central beam axis for a 1-field 
irradiation of the head phantom. Each planning system’s contours 
(solid) are overlaid with the reference contours (dashed) after the 
treatment time for each planning system from Table A.1 was used 
to convert the reference dose rates to absolute dose. 499 
Figure A.26 Boron isodose contours for a 10B concentration of 15 μg/g in the 
coronal plane containing the central beam axis for a 1-field 
irradiation of the head phantom. Each planning system’s contours 
(solid) are overlaid with the reference contours (dashed) after the 
treatment time for each planning system from Table A.1 was used 
to convert the reference dose rates to absolute dose. 501 
Figure A.27 Thermal neutron (and nitrogen) isodose contours in the transverse 
plane containing the central beam axis for a 1-field irradiation of 
the head phantom. Each planning system’s contours (solid) are 
overlaid with the reference contours (dashed) after the treatment 
time for each planning system from Table A.1 was used to 
convert the reference dose rates to absolute dose. 503 
Figure A.28 Thermal neutron (and nitrogen) isodose contours in the coronal 
plane containing the central beam axis for a 1-field irradiation of 
the head phantom. Each planning system’s contours (solid) are 
overlaid with the reference contours (dashed) after the treatment 
time for each planning system from Table A.1 was used to 
convert the reference dose rates to absolute dose. 505 
Figure A.29 Fast neutron (and hydrogen) isodose contours in the transverse 
plane containing the central beam axis for a 1-field irradiation of 
the head phantom. Each planning system’s contours (solid) are 
overlaid with the reference contours (dashed) after the treatment 
time for each planning system from Table A.1 was used to 
convert the reference dose rates to absolute dose. 507 
Figure A.30 Fast neutron (and hydrogen) isodose contours in the coronal plane 
containing the central beam axis for a 1-field irradiation of the 
head phantom. Each planning system’s contours (solid) are 
overlaid with the reference contours (dashed) after the treatment 
time for each planning system from Table A.1 was used to 
convert the reference dose rates to absolute dose. 509 
Figure A.31 Induced photon isodose contours in the transverse plane 
containing the central beam axis for a 1-field irradiation of the 
head phantom. Each planning system’s contours (solid) are 
overlaid with the reference contours (dashed) after the treatment 
time for each planning system from Table A.1 was used to 
convert the reference dose rates to absolute dose. 511 
Figure A.32 Induced photon isodose contours in the coronal plane containing 
the central beam axis for a 1-field irradiation of the head 
phantom. Each planning system’s contours (solid) are overlaid 
with the reference contours (dashed) after the treatment time for 
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each planning system from Table A.1 was used to convert the 
reference dose rates to absolute dose. 513 
Figure A.33 Incident photon isodose contours in the transverse plane 
containing the central beam axis for a 1-field irradiation of the 
head phantom. Each planning system’s contours (solid) are 
overlaid with the reference contours (dashed) after the treatment 
time for each planning system from Table A.1 was used to 
convert the reference dose rates to absolute dose. 515 
Figure A.34 Incident photon isodose contours in the coronal plane containing 
the central beam axis for a 1-field irradiation of the head 
phantom. Each planning system’s contours (solid) are overlaid 
with the reference contours (dashed) after the treatment time for 
each planning system from Table A.1 was used to convert the 
reference dose rates to absolute dose. 517 
Figure A.35 Total biologically weighted brain isodose contours in the 
transverse plane containing the central beam axis for a 1-field 
irradiation of the head phantom. Each planning system’s contours 
(solid) are overlaid with the reference contours (dashed) after the 
treatment time for each planning system from Table A.1 was used 
to convert the reference dose rates to absolute dose. 519 
Figure A.36 Total biologically weighted brain isodose contours in the coronal 
plane containing the central beam axis for a 1-field irradiation of 
the head phantom. Each planning system’s contours (solid) are 
overlaid with the reference contours (dashed) after the treatment 
time for each planning system from Table A.1 was used to 
convert the reference dose rates to absolute dose. 521 
Figure A.37 Total biologically weighted tumor isodose contours in the 
transverse plane containing the central beam axis for a 1-field 
irradiation of the head phantom. Each planning system’s contours 
(solid) are overlaid with the reference contours (dashed) after the 
treatment time for each planning system from Table A.1 was used 
to convert the reference dose rates to absolute dose. 523 
Figure A.38 Total biologically weighted tumor isodose contours in the coronal 
plane containing the central beam axis for a 1-field irradiation of 
the head phantom. Each planning system’s contours (solid) are 
overlaid with the reference contours (dashed) after the treatment 
time for each planning system from Table A.1 was used to 
convert the reference dose rates to absolute dose. 525 
Figure A.39 Boron isodose contours for a 10B concentration of 15 μg/g in the 
transverse plane containing the central beam axis for a 3-field 
irradiation of the head phantom. Each planning system’s contours 
(solid) are overlaid with the reference contours (dashed) after the 
treatment time for each planning system from Table A.1 was used 
to convert the reference dose rates to absolute dose. 527 
Figure A.40 Boron isodose contours for a 10B concentration of 15 μg/g in the 
coronal plane containing the central beam axis for a 3-field 
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irradiation of the head phantom. Each planning system’s contours 
(solid) are overlaid with the reference contours (dashed) after the 
treatment time for each planning system from Table A.1 was used 
to convert the reference dose rates to absolute dose. 529 
Figure A.41 Thermal neutron (and nitrogen) isodose contours in the transverse 
plane containing the central beam axis for a 3-field irradiation of 
the head phantom. Each planning system’s contours (solid) are 
overlaid with the reference contours (dashed) after the treatment 
time for each planning system from Table A.1 was used to 
convert the reference dose rates to absolute dose. 531 
Figure A.42 Thermal neutron (and nitrogen) isodose contours in the coronal 
plane containing the central beam axis for a 3-field irradiation of 
the head phantom. Each planning system’s contours (solid) are 
overlaid with the reference contours (dashed) after the treatment 
time for each planning system from Table A.1 was used to 
convert the reference dose rates to absolute dose. 533 
Figure A.43 Fast neutron (and hydrogen) isodose contours in the transverse 
plane containing the central beam axis for a 3-field irradiation of 
the head phantom. Each planning system’s contours (solid) are 
overlaid with the reference contours (dashed) after the treatment 
time for each planning system from Table A.1 was used to 
convert the reference dose rates to absolute dose. 535 
Figure A.44 Fast neutron (and hydrogen) isodose contours in the coronal plane 
containing the central beam axis for a 3-field irradiation of the 
head phantom. Each planning system’s contours (solid) are 
overlaid with the reference contours (dashed) after the treatment 
time for each planning system from Table A.1 was used to 
convert the reference dose rates to absolute dose. 537 
Figure A.45 Induced photon isodose contours in the transverse plane 
containing the central beam axis for a 3-field irradiation of the 
head phantom. Each planning system’s contours (solid) are 
overlaid with the reference contours (dashed) after the treatment 
time for each planning system from Table A.1 was used to 
convert the reference dose rates to absolute dose. 539 
Figure A.46 Induced photon isodose contours in the coronal plane containing 
the central beam axis for a 3-field irradiation of the head 
phantom. Each planning system’s contours (solid) are overlaid 
with the reference contours (dashed) after the treatment time for 
each planning system from Table A.1 was used to convert the 
reference dose rates to absolute dose. 541 
Figure A.47 Incident photon isodose contours in the transverse plane 
containing the central beam axis for a 3-field irradiation of the 
head phantom. Each planning system’s contours (solid) are 
overlaid with the reference contours (dashed) after the treatment 
time for each planning system from Table A.1 was used to 
convert the reference dose rates to absolute dose. 543 
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Figure A.48 Incident photon isodose contours in the coronal plane containing 
the central beam axis for a 3-field irradiation of the head 
phantom. Each planning system’s contours (solid) are overlaid 
with the reference contours (dashed) after the treatment time for 
each planning system from Table A.1 was used to convert the 
reference dose rates to absolute dose. 545 
Figure A.49 Total biologically weighted brain isodose contours in the 
transverse plane containing the central beam axis for a 3-field 
irradiation of the head phantom. Each planning system’s contours 
(solid) are overlaid with the reference contours (dashed) after the 
treatment time for each planning system from Table A.1 was used 
to convert the reference dose rates to absolute dose. 547 
Figure A.50 Total biologically weighted brain isodose contours in the coronal 
plane containing the central beam axis for a 3-field irradiation of 
the head phantom. Each planning system’s contours (solid) are 
overlaid with the reference contours (dashed) after the treatment 
time for each planning system from Table A.1 was used to 
convert the reference dose rates to absolute dose. 549 
Figure A.51 Total biologically weighted tumor isodose contours in the 
transverse plane containing the central beam axis for a 3-field 
irradiation of the head phantom. Each planning system’s contours 
(solid) are overlaid with the reference contours (dashed) after the 
treatment time for each planning system from Table A.1 was used 
to convert the reference dose rates to absolute dose. 551 
Figure A.52 Total biologically weighted tumor isodose contours in the coronal 
plane containing the central beam axis for a 3-field irradiation of 
the head phantom. Each planning system’s contours (solid) are 
overlaid with the reference contours (dashed) after the treatment 
time for each planning system from Table A.1 was used to 
convert the reference dose rates to absolute dose. 553 
Figure A.53 Boron isodose contours for a 10B concentration of 22.5 μg/g in the 
transverse plane containing the central beam axis for a 1-field 
irradiation of the leg phantom. Each planning system’s contours 
(solid) are overlaid with the reference contours (dashed) after the 
treatment time for each planning system from Table A.1 was used 
to convert the reference dose rates to absolute dose. 555 
Figure A.54 Boron isodose contours for a 10B concentration of 22.5 μg/g in the 
oblique plane containing the central beam axis for a 1-field 
irradiation of the leg phantom. Each planning system’s contours 
(solid) are overlaid with the reference contours (dashed) after the 
treatment time for each planning system from Table A.1 was used 
to convert the reference dose rates to absolute dose. 557 
Figure A.55 Thermal neutron (and nitrogen) isodose contours in the transverse 
plane containing the central beam axis for a 1-field irradiation of 
the leg phantom. Each planning system’s contours (solid) are 
overlaid with the reference contours (dashed) after the treatment 
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time for each planning system from Table A.1 was used to 
convert the reference dose rates to absolute dose. 559 
Figure A.56 Thermal neutron isodose contours in the oblique plane containing 
the central beam axis for a 1-field irradiation of the leg phantom. 
Each planning system’s contours (solid) are overlaid with the 
reference contours (dashed) after the treatment time for each 
planning system from Table A.1 was used to convert the 
reference dose rates to absolute dose. 561 
Figure A.57 Fast neutron (and hydrogen) isodose contours in the transverse 
plane containing the central beam axis for a 1-field irradiation of 
the leg phantom. Each planning system’s contours (solid) are 
overlaid with the reference contours (dashed) after the treatment 
time for each planning system from Table A.1 was used to 
convert the reference dose rates to absolute dose. 563 
Figure A.58 Fast neutron isodose contours in the oblique plane containing the 
central beam axis for a 1-field irradiation of the leg phantom. 
Each planning system’s contours (solid) are overlaid with the 
reference contours (dashed) after the treatment time for each 
planning system from Table A.1 was used to convert the 
reference dose rates to absolute dose. 565 
Figure A.59 Induced photon isodose contours in the transverse plane 
containing the central beam axis for a 1-field irradiation of the leg 
phantom. Each planning system’s contours (solid) are overlaid 
with the reference contours (dashed) after the treatment time for 
each planning system from Table A.1 was used to convert the 
reference dose rates to absolute dose. 567 
Figure A.60 Induced photon isodose contours in the oblique plane containing 
the central beam axis for a 1-field irradiation of the leg phantom. 
Each planning system’s contours (solid) are overlaid with the 
reference contours (dashed) after the treatment time for each 
planning system from Table A.1 was used to convert the 
reference dose rates to absolute dose. 569 
Figure A.61 Incident photon isodose contours in the transverse plane 
containing the central beam axis for a 1-field irradiation of the leg 
phantom. Each planning system’s contours (solid) are overlaid 
with the reference contours (dashed) after the treatment time for 
each planning system from Table A.1 was used to convert the 
reference dose rates to absolute dose. 571 
Figure A.62 Incident photon isodose contours in the oblique plane containing 
the central beam axis for a 1-field irradiation of the leg phantom. 
Each planning system’s contours (solid) are overlaid with the 
reference contours (dashed) after the treatment time for each 
planning system from Table A.1 was used to convert the 
reference dose rates to absolute dose. 573 
Figure A.63 Total biologically weighted skin isodose contours in the 
transverse plane containing the central beam axis for a 1-field 
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irradiation of the leg phantom. Each planning system’s contours 
(solid) are overlaid with the reference contours (dashed) after the 
treatment time for each planning system from Table A.1 was used 
to convert the reference dose rates to absolute dose. 575 
Figure A.64 Total biologically weighted skin isodose contours in the oblique 
plane containing the central beam axis for a 1-field irradiation of 
the leg phantom. Each planning system’s contours (solid) are 
overlaid with the reference contours (dashed) after the treatment 
time for each planning system from Table A.1 was used to 
convert the reference dose rates to absolute dose. 577 
Figure A.65 Total biologically weighted tumor isodose contours in the 
transverse plane containing the central beam axis for a 1-field 
irradiation of the leg phantom. Each planning system’s contours 
(solid) are overlaid with the reference contours (dashed) after the 
treatment time for each planning system from Table A.1 was used 
to convert the reference dose rates to absolute dose. 579 
Figure A.66 Total biologically weighted tumor isodose contours in the oblique 
plane containing the central beam axis for a 1-field irradiation of 
the leg phantom. Each planning system’s contours (solid) are 
overlaid with the reference contours (dashed) after the treatment 
time for each planning system from Table A.1 was used to 
convert the reference dose rates to absolute dose. 581 
Figure A.67 Difference in thermal neutron flux in the transverse plane 
containing the central beam axis expressed as a percentage of the 
maximum reference thermal neutron flux for a 1-field irradiation 
of the head phantom. 583 
Figure A.68 Difference in thermal neutron flux in the coronal plane containing 
the central beam axis expressed as a percentage of the maximum 
reference thermal neutron flux for a 1-field irradiation of the head 
phantom. 585 
Figure A.69 Difference in boron dose in the transverse plane containing the 
central beam axis expressed as a percentage of the maximum 
reference boron dose for a 1-field irradiation of the head phantom. 587 
Figure A.70 Difference in boron dose in the coronal plane containing the 
central beam axis expressed as a percentage of the maximum 
reference boron dose for a 1-field irradiation of the head phantom. 589 
Figure A.71 Difference in thermal neutron (and nitrogen) dose in the 
transverse plane containing the central beam axis expressed as a 
percentage of the maximum reference thermal neutron dose for a 
1-field irradiation of the head phantom. 591 
Figure A.72 Difference in thermal neutron (and nitrogen) dose in the coronal 
plane containing the central beam axis expressed as a percentage 
of the maximum reference thermal neutron dose for a 1-field 
irradiation of the head phantom. 593 
Figure A.73 Difference in fast neutron (and hydrogen) dose in the transverse 
plane containing the central beam axis expressed as a percentage 
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of the maximum reference fast neutron dose for a 1-field 
irradiation of the head phantom. 595 
Figure A.74 Difference in fast neutron (and hydrogen) dose in the coronal 
plane containing the central beam axis expressed as a percentage 
of the maximum reference fast neutron dose for a 1-field 
irradiation of the head phantom. 597 
Figure A.75 Difference in induced photon dose in the transverse plane 
containing the central beam axis expressed as a percentage of the 
maximum reference induced photon dose for a 1-field irradiation 
of the head phantom. 599 
Figure A.76 Difference in induced photon dose in the coronal plane containing 
the central beam axis expressed as a percentage of the maximum 
reference induced photon dose for a 1-field irradiation of the head 
phantom. 601 
Figure A.77 Difference in incident photon dose in the transverse plane 
containing the central beam axis expressed as a percentage of the 
maximum reference incident photon dose for a 1-field irradiation 
of the head phantom. 603 
Figure A.78 Difference in incident photon dose in the coronal plane containing 
the central beam axis expressed as a percentage of the maximum 
reference incident photon dose for a 1-field irradiation of the head 
phantom. 605 
Figure A.79 Difference in total biologically weighted brain dose in the 
transverse plane containing the central beam axis expressed as a 
percentage of the maximum reference total weighted dose for a 1-
field irradiation of the head phantom. 607 
Figure A.80 Difference in total biologically weighted brain dose in the coronal 
plane containing the central beam axis expressed as a percentage 
of the maximum reference total weighted dose for a 1-field 
irradiation of the head phantom. 609 
Figure A.81 Difference in total biologically weighted tumor dose in the 
transverse plane containing the central beam axis expressed as a 
percentage of the maximum reference total weighted dose for a 1-
field irradiation of the head phantom. 611 
Figure A.82 Difference in total biologically weighted tumor dose in the 
coronal plane containing the central beam axis expressed as a 
percentage of the maximum reference total weighted dose for a 1-
field irradiation of the head phantom. 613 
Figure A.83 Difference in thermal neutron flux in the transverse plane 
containing the central beam axis expressed as a percentage of the 
maximum reference thermal neutron flux for a 3-field irradiation 
of the head phantom. 615 
Figure A.84 Difference in thermal neutron flux in the coronal plane containing 
the central beam axis expressed as a percentage of the maximum 
reference thermal neutron flux for a 3-field irradiation of the head 
phantom. 617 
 39
Figure A.85 Difference in boron dose in the transverse plane containing the 
central beam axis expressed as a percentage of the maximum 
reference boron dose for a 3-field irradiation of the head phantom. 619 
Figure A.86 Difference in boron dose in the coronal plane containing the 
central beam axis expressed as a percentage of the maximum 
reference boron dose for a 3-field irradiation of the head phantom. 621 
Figure A.87 Difference in thermal neutron (and nitrogen) dose in the 
transverse plane containing the central beam axis expressed as a 
percentage of the maximum reference thermal neutron dose for a 
3-field irradiation of the head phantom. 623 
Figure A.88 Difference in thermal neutron (and nitrogen) dose in the coronal 
plane containing the central beam axis expressed as a percentage 
of the maximum reference thermal neutron dose for a 3-field 
irradiation of the head phantom. 625 
Figure A.89 Difference in fast neutron (and hydrogen) dose in the transverse 
plane containing the central beam axis expressed as a percentage 
of the maximum reference fast neutron dose for a 3-field 
irradiation of the head phantom. 627 
Figure A.90 Difference in fast neutron (and hydrogen) dose in the coronal 
plane containing the central beam axis expressed as a percentage 
of the maximum reference fast neutron dose for a 3-field 
irradiation of the head phantom. 629 
Figure A.91 Difference in induced photon dose in the transverse plane 
containing the central beam axis expressed as a percentage of the 
maximum reference induced photon dose for a 3-field irradiation 
of the head phantom. 631 
Figure A.92 Difference in induced photon dose in the coronal plane containing 
the central beam axis expressed as a percentage of the maximum 
reference induced photon dose for a 3-field irradiation of the head 
phantom. 633 
Figure A.93 Difference in incident photon dose in the transverse plane 
containing the central beam axis expressed as a percentage of the 
maximum reference incident photon dose for a 3-field irradiation 
of the head phantom. 635 
Figure A.94 Difference in incident photon dose in the coronal plane containing 
the central beam axis expressed as a percentage of the maximum 
reference incident photon dose for a 3-field irradiation of the head 
phantom. 637 
Figure A.95 Difference in total biologically weighted brain dose in the 
transverse plane containing the central beam axis expressed as a 
percentage of the maximum reference total weighted dose for a 3-
field irradiation of the head phantom. 639 
Figure A.96 Difference in total biologically weighted brain dose in the coronal 
plane containing the central beam axis expressed as a percentage 
of the maximum reference total weighted dose for a 3-field 
irradiation of the head phantom. 641 
 40
Figure A.97 Difference in total biologically weighted tumor dose in the 
transverse plane containing the central beam axis expressed as a 
percentage of the maximum reference total weighted dose for a 3-
field irradiation of the head phantom. 643 
Figure A.98 Difference in total biologically weighted tumor dose in the 
coronal plane containing the central beam axis expressed as a 
percentage of the maximum reference total weighted dose for a 3-
field irradiation of the head phantom. 645 
Figure A.99 Difference in thermal neutron flux in the transverse plane 
containing the central beam axis expressed as a percentage of the 
maximum reference thermal neutron flux for a 1-field irradiation 
of the leg phantom. 647 
Figure A.100 Difference in thermal neutron flux in the oblique plane containing 
the central beam axis expressed as a percentage of the maximum 
reference thermal neutron flux for a 1-field irradiation of the leg 
phantom. 649 
Figure A.101 Difference in boron dose in the transverse plane containing the 
central beam axis expressed as a percentage of the maximum 
reference boron dose for a 1-field irradiation of the leg phantom. 651 
Figure A.102 Difference in boron dose in the oblique plane containing the 
central beam axis expressed as a percentage of the maximum 
reference boron dose for a 1-field irradiation of the leg phantom. 653 
Figure A.103 Difference in thermal neutron (and nitrogen) dose in the 
transverse plane containing the central beam axis expressed as a 
percentage of the maximum reference thermal neutron dose for a 
1-field irradiation of the leg phantom. 655 
Figure A.104 Difference in thermal neutron dose in the oblique plane 
containing the central beam axis expressed as a percentage of the 
maximum reference thermal neutron dose for a 1-field irradiation 
of the leg phantom. 657 
Figure A.105 Difference in fast neutron (and hydrogen) dose in the transverse 
plane containing the central beam axis expressed as a percentage 
of the maximum reference fast neutron dose for a 1-field 
irradiation of the leg phantom. 659 
Figure A.106 Difference in fast neutron dose in the oblique plane containing the 
central beam axis expressed as a percentage of the maximum 
reference fast neutron dose for a 1-field irradiation of the leg 
phantom. 661 
Figure A.107 Difference in induced photon dose in the transverse plane 
containing the central beam axis expressed as a percentage of the 
maximum reference induced photon dose for a 1-field irradiation 
of the leg phantom. 663 
Figure A.108 Difference in induced photon dose in the oblique plane containing 
the central beam axis expressed as a percentage of the maximum 
reference induced photon dose for a 1-field irradiation of the leg 
phantom. 665 
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Figure A.109 Difference in incident photon dose in the transverse plane 
containing the central beam axis expressed as a percentage of the 
maximum reference incident photon dose for a 1-field irradiation 
of the leg phantom. 667 
Figure A.110 Difference in incident photon dose in the oblique plane containing 
the central beam axis expressed as a percentage of the maximum 
reference incident photon dose for a 1-field irradiation of the leg 
phantom. 669 
Figure A.111 Difference in total biologically weighted skin dose in the 
transverse plane containing the central beam axis expressed as a 
percentage of the maximum reference total weighted dose for a 1-
field irradiation of the leg phantom. 671 
Figure A.112 Difference in total biologically weighted skin dose in the oblique 
plane containing the central beam axis expressed as a percentage 
of the maximum reference total weighted dose for a 1-field 
irradiation of the leg phantom. 673 
Figure A.113 Difference in total biologically weighted tumor dose in the 
transverse plane containing the central beam axis expressed as a 
percentage of the maximum reference total weighted dose for a 1-
field irradiation of the leg phantom. 675 
Figure A.114 Difference in total biologically weighted tumor dose in the 
oblique plane containing the central beam axis expressed as a 
percentage of the maximum reference total weighted dose for a 1-
field irradiation of the leg phantom. 677 
Figure A.115 Boron dose-volume histograms for brain for brain for a 1-field 
irradiation of the head phantom. Conventional and binned 
representations of the reference data are included. The default 
output from seraPlot is shown along with a corrected 
interpretation of the SERA dose-volume data (with a −5% shift in 
dose). 680 
Figure A.116 Thermal neutron (and nitrogen) dose-volume histograms for the 
brain for a 1-field irradiation of the head phantom. Conventional 
and binned representations of the reference data are included. A 
corrected interpretation of the SERA dose-volume data (with a 
−5% shift in dose) is shown instead of the default seraPlot output. 681 
Figure A.117 Fast neutron (and hydrogen) dose-volume histograms for the 
brain for a 1-field irradiation of the head phantom. Conventional 
and binned representations of the reference data are included. A 
corrected interpretation of the SERA dose-volume data (with a 
−5% shift in dose) is shown instead of the default seraPlot output. 682 
Figure A.118 Induced photon dose-volume histograms for the brain for a 1-field 
irradiation of the head phantom. Conventional and binned 
representations of the reference data are included. A corrected 
interpretation of the SERA dose-volume data (with a −5% shift in 
dose) is shown instead of the default seraPlot output. 683 
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Figure A.119 Incident photon dose-volume histograms for the brain for a 1-
field irradiation of the head phantom. Conventional and binned 
representations of the reference data are included. A corrected 
interpretation of the SERA dose-volume data (with a −5% shift in 
dose) is shown instead of the default seraPlot output. 684 
Figure A.120 Total biologically weighted dose-volume histograms for brain for 
a 1-field irradiation of the head phantom. Conventional and 
binned representations of the reference data are included. The 
default output from seraPlot is shown along with a corrected 
interpretation of the SERA dose-volume data (with a −5% shift in 
dose). 685 
Figure A.121 Boron dose-volume histograms for the brain for a 3-field 
irradiation of the head phantom. Conventional and binned 
representations of the reference data are included. A corrected 
interpretation of the SERA dose-volume data (with a −5% shift in 
dose) is shown instead of the default seraPlot output. 686 
Figure A.122 Thermal neutron (and nitrogen) dose-volume histograms for the 
brain for a 3-field irradiation of the head phantom. Conventional 
and binned representations of the reference data are included. A 
corrected interpretation of the SERA dose-volume data (with a 
−5% shift in dose) is shown instead of the default seraPlot output. 687 
Figure A.123 Fast neutron (and hydrogen) dose-volume histograms for the 
brain for a 3-field irradiation of the head phantom. Conventional 
and binned representations of the reference data are included. A 
corrected interpretation of the SERA dose-volume data (with a 
−5% shift in dose) is shown instead of the default seraPlot output. 688 
Figure A.124 Induced photon dose-volume histograms for the brain for a 3-field 
irradiation of the head phantom. Conventional and binned 
representations of the reference data are included. A corrected 
interpretation of the SERA dose-volume data (with a −5% shift in 
dose) is shown instead of the default seraPlot output. 689 
Figure A.125 Incident photon dose-volume histograms for the brain for a 3-
field irradiation of the head phantom. Conventional and binned 
representations of the reference data are included. A corrected 
interpretation of the SERA dose-volume data (with a −5% shift in 
dose) is shown instead of the default seraPlot output. 690 
Figure A.126 Total biologically weighted dose-volume histograms for the brain 
for a 3-field irradiation of the head phantom. Conventional and 
binned representations of the reference data are included. A 
corrected interpretation of the SERA dose-volume data (with a 
−5% shift in dose) is shown instead of the default seraPlot output. 691 
Figure A.127 Boron dose-volume histograms for the brain tumor for a 1-field 
irradiation of the head phantom. Conventional and binned 
representations of the reference data are included. A corrected 
interpretation of the SERA dose-volume data (with a −5% shift in 
dose) is shown instead of the default seraPlot output. 692 
 43
Figure A.128 Thermal neutron (and nitrogen) dose-volume histograms for the 
brain tumor for a 1-field irradiation of the head phantom. 
Conventional and binned representations of the reference data are 
included. A corrected interpretation of the SERA dose-volume 
data (with a −5% shift in dose) is shown instead of the default 
seraPlot output. 693 
Figure A.129 Fast neutron (and hydrogen) dose-volume histograms for the 
brain tumor for a 1-field irradiation of the head phantom. 
Conventional and binned representations of the reference data are 
included. A corrected interpretation of the SERA dose-volume 
data (with a −5% shift in dose) is shown instead of the default 
seraPlot output. 694 
Figure A.130 Induced photon dose-volume histograms for the brain tumor for a 
1-field irradiation of the head phantom. Conventional and binned 
representations of the reference data are included. A corrected 
interpretation of the SERA dose-volume data (with a −5% shift in 
dose) is shown instead of the default seraPlot output. 695 
Figure A.131 Incident photon dose-volume histograms for the brain tumor for a 
1-field irradiation of the head phantom. Conventional and binned 
representations of the reference data are included. A corrected 
interpretation of the SERA dose-volume data (with a −5% shift in 
dose) is shown instead of the default seraPlot output. 696 
Figure A.132 Total biologically weighted dose-volume histograms for the brain 
tumor for a 1-field irradiation of the head phantom. Conventional 
and binned representations of the reference data are included. A 
corrected interpretation of the SERA dose-volume data (with a 
−5% shift in dose) is shown instead of the default seraPlot output. 697 
Figure A.133 Boron dose-volume histograms for the brain tumor for a 3-field 
irradiation of the head phantom. Conventional and binned 
representations of the reference data are included. A corrected 
interpretation of the SERA dose-volume data (with a −5% shift in 
dose) is shown instead of the default seraPlot output. 698 
Figure A.134 Thermal neutron (and nitrogen) dose-volume histograms for the 
brain tumor for a 3-field irradiation of the head phantom. 
Conventional and binned representations of the reference data are 
included. A corrected interpretation of the SERA dose-volume 
data (with a −5% shift in dose) is shown instead of the default 
seraPlot output. 699 
Figure A.135 Fast neutron (and hydrogen) dose-volume histograms for the 
brain tumor for a 3-field irradiation of the head phantom. 
Conventional and binned representations of the reference data are 
included. A corrected interpretation of the SERA dose-volume 
data (with a −5% shift in dose) is shown instead of the default 
seraPlot output. 700 
Figure A.136 Induced photon dose-volume histograms for the brain tumor for a 
3-field irradiation of the head phantom. Conventional and binned 
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representations of the reference data are included. A corrected 
interpretation of the SERA dose-volume data (with a −5% shift in 
dose) is shown instead of the default seraPlot output. 701 
Figure A.137 Incident photon dose-volume histograms for the brain tumor for a 
3-field irradiation of the head phantom. Conventional and binned 
representations of the reference data are included. A corrected 
interpretation of the SERA dose-volume data (with a −5% shift in 
dose) is shown instead of the default seraPlot output. 702 
Figure A.138 Total biologically weighted dose-volume histograms for the brain 
tumor for a 3-field irradiation of the head phantom. Conventional 
and binned representations of the reference data are included. A 
corrected interpretation of the SERA dose-volume data (with a 
−5% shift in dose) is shown instead of the default seraPlot output. 703 
Figure A.139 Boron dose-volume histograms for skin for a 1-field irradiation of 
the leg phantom. Conventional and binned representations of the 
reference data are included. A corrected interpretation of the 
SERA dose-volume data (with a −5% shift in dose) is shown 
instead of the default seraPlot output. 704 
Figure A.140 Thermal neutron (and nitrogen) dose-volume histograms for skin 
for a 1-field irradiation of the leg phantom. Conventional and 
binned representations of the reference data are included. A 
corrected interpretation of the SERA dose-volume data (with a 
−5% shift in dose) is shown instead of the default seraPlot output. 705 
Figure A.141 Fast neutron (and hydrogen) dose-volume histograms for skin for 
a 1-field irradiation of the leg phantom. Conventional and binned 
representations of the reference data are included. A corrected 
interpretation of the SERA dose-volume data (with a −5% shift in 
dose) is shown instead of the default seraPlot output. 706 
Figure A.142 Induced photon dose-volume histograms for skin for a 1-field 
irradiation of the leg phantom. Conventional and binned 
representations of the reference data are included. A corrected 
interpretation of the SERA dose-volume data (with a −5% shift in 
dose) is shown instead of the default seraPlot output. 707 
Figure A.143 Incident photon dose-volume histograms for skin for a 1-field 
irradiation of the leg phantom. Conventional and binned 
representations of the reference data are included. A corrected 
interpretation of the SERA dose-volume data (with a −5% shift in 
dose) is shown instead of the default seraPlot output. 708 
Figure A.144 Total biologically weighted dose-volume histograms for skin for a 
1-field irradiation of the leg phantom. Conventional and binned 
representations of the reference data are included. A corrected 
interpretation of the SERA dose-volume data (with a −5% shift in 
dose) is shown instead of the default seraPlot output. 709 
Figure A.145 Boron dose-volume histograms for tumor 1 (spherical tumor) for 
a 1-field irradiation of the leg phantom. Conventional and binned 
representations of the reference data are included. A corrected 
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interpretation of the SERA dose-volume data (with a −5% shift in 
dose) is shown instead of the default seraPlot output. 710 
Figure A.146 Thermal neutron (and nitrogen) dose-volume histograms for 
tumor 1 (spherical tumor) for a 1-field irradiation of the leg 
phantom. Conventional and binned representations of the 
reference data are included. A corrected interpretation of the 
SERA dose-volume data (with a −5% shift in dose) is shown 
instead of the default seraPlot output. 711 
Figure A.147 Fast neutron (and hydrogen) dose-volume histograms for tumor 1 
(spherical tumor) for a 1-field irradiation of the leg phantom. 
Conventional and binned representations of the reference data are 
included. A corrected interpretation of the SERA dose-volume 
data (with a −5% shift in dose) is shown instead of the default 
seraPlot output. 712 
Figure A.148 Induced photon dose-volume histograms for tumor 1 (spherical 
tumor) for a 1-field irradiation of the leg phantom. Conventional 
and binned representations of the reference data are included. A 
corrected interpretation of the SERA dose-volume data (with a 
−5% shift in dose) is shown instead of the default seraPlot output. 713 
Figure A.149 Incident photon dose-volume histograms for tumor 1 (spherical 
tumor) for a 1-field irradiation of the leg phantom. Conventional 
and binned representations of the reference data are included. A 
corrected interpretation of the SERA dose-volume data (with a 
−5% shift in dose) is shown instead of the default seraPlot output. 714 
Figure A.150 Total biologically weighted dose-volume histograms for tumor 1 
(spherical tumor) for a 1-field irradiation of the leg phantom. 
Conventional and binned representations of the reference data are 
included. A corrected interpretation of the SERA dose-volume 
data (with a −5% shift in dose) is shown instead of the default 
seraPlot output. 715 
Figure A.151 Boron dose-volume histograms for tumor 2 (arc-shaped tumor) 
for a 1-field irradiation of the leg phantom. Conventional and 
binned representations of the reference data are included. A 
corrected interpretation of the SERA dose-volume data (with a 
−5% shift in dose) is shown instead of the default seraPlot output. 716 
Figure A.152 Thermal neutron (and nitrogen) dose-volume histograms for 
tumor 2 (arc-shaped tumor) for a 1-field irradiation of the leg 
phantom. Conventional and binned representations of the 
reference data are included. A corrected interpretation of the 
SERA dose-volume data (with a −5% shift in dose) is shown 
instead of the default seraPlot output. 717 
Figure A.153 Fast neutron (and hydrogen) dose-volume histograms for tumor 2 
(arc-shaped tumor) for a 1-field irradiation of the leg phantom. 
Conventional and binned representations of the reference data are 
included. A corrected interpretation of the SERA dose-volume 
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data (with a −5% shift in dose) is shown instead of the default 
seraPlot output. 718 
Figure A.154 Induced photon dose-volume histograms for tumor 2 (arc-shaped 
tumor) for a 1-field irradiation of the leg phantom. Conventional 
and binned representations of the reference data are included. A 
corrected interpretation of the SERA dose-volume data (with a 
−5% shift in dose) is shown instead of the default seraPlot output. 719 
Figure A.155 Incident photon dose-volume histograms for tumor 2 (arc-shaped 
tumor) for a 1-field irradiation of the leg phantom. Conventional 
and binned representations of the reference data are included. A 
corrected interpretation of the SERA dose-volume data (with a 
−5% shift in dose) is shown instead of the default seraPlot output. 720 
Figure A.156 Total biologically weighted dose-volume histograms for tumor 2 
(arc-shaped tumor) for a 1-field irradiation of the leg phantom. 
Conventional and binned representations of the reference data are 
included. A corrected interpretation of the SERA dose-volume 
data (with a −5% shift in dose) is shown instead of the default 
seraPlot output. 721 
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resulting from a 1-field irradiation with a thermal neutron beam 
for 1.38 minutes. 713 
Table A.37 Incident photon dose statistics for tumor 1 (spherical tumor) 
resulting from a 1-field irradiation with a thermal neutron beam 
for 1.38 minutes. 714 
Table A.38 Total biologically weighted dose statistics for tumor 1 (spherical 
tumor) resulting from a 1-field irradiation with a thermal neutron 
beam for 1.38 minutes. 715 
Table A.39 Boron dose statistics for tumor 2 (arc-shaped tumor) resulting 
from a 1-field irradiation with a thermal neutron beam for 1.38 
minutes. 716 
Table A.40 Thermal neutron (and nitrogen) dose statistics for tumor 2 (arc-
shaped tumor) resulting from a 1-field irradiation with a thermal 
neutron beam for 1.38 minutes. 717 
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Table A.42 Induced photon dose statistics for tumor 2 (arc-shaped tumor) 
resulting from a 1-field irradiation with a thermal neutron beam 
for 1.38 minutes. 719 
Table A.43 Incident photon dose statistics for tumor 2 (arc-shaped tumor) 
resulting from a 1-field irradiation with a thermal neutron beam 
for 1.38 minutes. 720 
Table A.44 Total biologically weighted dose statistics for tumor 2 (arc-
shaped tumor) resulting from a 1-field irradiation with a thermal 
neutron beam for 1.38 minutes. 721 
APPENDIX B 723 
CONSTRUCTION OF A BEOWULF CLUSTER FOR MONTE CARLO 
COMPUTATIONS 
Table B.1 Hardware for the master and 11 slave nodes of the cluster. All 
components were purchased new except the video cards for the 
slave nodes which were purchased used on eBay. The 
components were purchased individually at a total cost of 
10,074.52 and manually assembled over 3.5 months during the 
summer of 2005. 725 
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CHAPTER ONE 
Introduction 
1.1  Introduction to Boron Neutron Capture Therapy 
The ineffectiveness of conventional therapies against certain types of cancer has 
continually led to the search for more effective forms of treatment. However, the primary 
goal of even the experimental forms of cancer therapy remains the ability to deliver 
highly localized damage to cancer cells while sparing the surrounding healthy normal 
tissue. In conventional radiotherapy, this is most often achieved through the geometric 
targeting of the tumor with highly collimated and shaped beams of radiation, but 
selectively targeting cancer at the cellular level remains an elusive goal. If dose targeting 
could be improved, higher doses could be delivered to the tumor cells which could 
potentially lead to better local tumor control, even for those cancers that have proven to 
be radioresistant. An experimental therapy that can provide such selective cellular 
targeting is Boron Neutron Capture Therapy (BNCT).  
1.1.1 Concepts of BNCT 
 
Boron Neutron Capture Therapy is a biochemically targeted form of binary 
radiation therapy that has the potential to treat cancers that have proven to be resistant to 
more conventional therapies due to its selective dose targeting.1,2 In BNCT, dose 
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targeting is achieved by selectively loading the stable isotope 10B into the malignant 
tissue via a tumor-selective boronated pharmaceutical infused directly into the patient’s 
bloodstream. The biochemical selectivity of the boronated compound allows large 
concentrations of 10B to accumulate in the tumor cells relative to normal tissue (3 to 4 
times more),3 essentially differentiating normal and cancer cells. The 10B compound 
alone is (usually) not toxic to cells; actually it is eliminated naturally from the body 
within a reasonable time frame after infusion. However, when the malignant tissue that 
has been preloaded with 10B is irradiated with a collimated beam of low energy neutrons, 
the large (relative to other nuclei present in the tissue) microscopic absorption cross 
section of the 10B nuclei for thermal neutrons results in 10B(n,α)7Li neutron capture 
reactions that produce two densely ionizing particles, 4He and 7Li, that deposit their 
energy along very short tracks (~4 μm for 7Li and ~7 μm for 4He) comparable in length to 
the diameter of most cells. This neutron capture reaction is illustrated in Figure 1.1 and 
forms the basis of the selective targeting in BNCT. The result is that the dose from 10B 
capture reactions is selectively delivered only to those cells where 10B nuclei and thermal 
neutrons are present. While neutrons do interact with the other isotopes present in tissue 
to create a non-specific and unavoidable background dose in BNCT, the preferential 
accumulation of 10B in tumor cells and its large neutron absorption cross section provides 
the dose targeting necessary to ultimately result in a therapeutic gain.  
1.1.2 Dose Components in BNCT 
A complex radiation field is produced in the irradiated volume during BNCT due 
to the presence of 5 different dose components that have different LET (linear energy 
transfer) and different spatial distributions. These 5 dose components include the boron 
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dose produced by the 10B(n,α)7Li reaction, thermal neutron dose mainly from the 
14N(n,p)14C reaction, fast neutron dose mainly from the 1H(n,n′)1H proton recoil reaction, 
induced photon dose from photons created inside the patient mainly via the 1H(n,γ)2H 
reaction, and incident photon dose from those photons that are produced upstream and 
outside of the patient.4 The relevant neutron interactions that occur in tissue during 
BNCT are illustrated in Figure 1.2. 
 
Thermal Neutron
Boron-10
Boron-11 *
α particle
(1.47 MeV)
7 μm 4 μm 
7Li (0.84 MeV)
γ-ray
(0.478 MeV 93%)
+
 
Figure 1.1 The 10B nucleus captures a thermal neutron (σA=3837 b) to produce two 
densely ionizing particles, 4He and 7Li, that deposit their energy along 
very short tracks that are comparable in length to the diameter of most 
cells. This reaction forms the basis of BNCT. (Reprinted from Kiger5). 
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Figure 1.2 Relevant neutron interactions in tissue that are responsible for the majority 
of the patient dose during BNCT. While all contribute to a non-specific 
and unavoidable background dose, the preferential accumulation of 10B in 
tumor cells provides the targeting necessary to achieve therapeutic 
advantage. 
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1.1.2.1 Boron Dose 
The selective cellular dose targeting that forms the basis of BNCT is provided by 
the capture of thermal neutrons (En < 0.5 eV) by 10B nuclei. BNCT takes advantage of the 
high natural probability that a 10B nucleus will capture a thermal neutron that is due to 
the large absorption cross section of 10B which has a 1/v shape (where v is the speed of 
the incident neutron). This 1/v shape is reflected in the boron kerma (kinetic energy 
released per unit mass) shown in Figure 1.3. The 10B absorption cross section for a 0.025 
eV neutron (v=2200 m/s) is 3837 barns while the corresponding cross section for 14N is 
over 3 orders of magnitude less, 1.7 b. Upon capturing a thermal neutron, the 10B 
immediately forms unstable 11B*, which decays within ~10−15 seconds into 4He and 7Li 
nuclei. However, 94% of the 11B* nuclei will initially decay into an unstable excited state 
of 7Li* which releases a 480 keV photon as it deexcites to 7Li. This process is represented 
in an energy level diagram in Figure 1.4. Both of the high LET heavy charged particles 
that result from the capture reaction will deposit their energy along relatively short tracks 
which acts to confine the energy (and dose) to those cells containing the 10B nuclei. 
Conversely, the large mean free path of the 480 keV photon results in energy being 
transported away from the reaction site; therefore, this γ-ray contributes to the non-
specific background dose in BNCT.  
1.1.2.2 Thermal Neutron Dose 
As illustrated in Figure 1.2, thermal neutrons can also be absorbed by the 2.2% of 
normal brain that is 14N to produce a proton and 14C via the 14N(n,p)14C capture reaction, 
releasing 0.626 MeV. This neutron capture reaction is the predominate mechanism by 
which thermal neutrons contribute locally absorbed dose in normal tissue. In Figure 1.3, 
14N kerma contributes 96.3% of the total neutron kerma at thermal neutron energies. 1H 
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nuclei (10.7% of normal brain) can also absorb thermal neutrons to produce high LET 
recoil deuterons and low LET 2.22 MeV photons. While the recoil deuterons are only 
responsible for 2.5% of the total neutron kerma at thermal neutron energies, the induced 
photons, whose dose is separately tracked and accounted for (section 1.1.2.3), contribute 
significantly to the non-specific background dose in BNCT and therefore reduce the 
therapeutic gain. 
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Figure 1.3 Boron and neutron kerma factors4 for ICRU adult brain tissue.6 The boron 
kerma factors reflect the 1/v shape of the 10B neutron absorption cross 
section and are scaled for a 10B concentration of 15 μg/g. The total neutron 
kerma data are the weighted sum of kerma from those isotopes found in 
brain tissue. At thermal neutron energies, the main contribution is from 
nitrogen (via the 14N(n,p)14C reaction) while hydrogen (via the 1H(n,n′)1H 
reaction) is the main contributor at fast neutron energies.   
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Figure 1.4 Energy level diagram representing the deexcitation of 11B* after the 
capture of a thermal neutron to 7Li or to an intermediate excited state 
(7Li*), which releases a 478 keV γ-ray as it deexcites. Although not 
depicted here, an α particle (4He) also results from the deexcitation of 
11B*. 
 
 
1.1.2.3 Photon Dose 
 For computation, the photon dose is often separated into induced and incident 
components. As illustrated in Figure 1.2, induced photons are produced in the patient, 
mainly by the thermal neutron absorption reactions of 1H. Incident photons are produced 
outside of the patient (via neutron interactions in the beam line or from those photons 
originating in the reactor core) and contribute dose in the patient during BNCT. 
However, the relative contribution from the low LET incident photons is usually small 
for well-designed neutron beams. 
1.1.2.4 Fast Neutron Dose 
The external beam of low energy (epithermal) neutrons used to irradiate the 
targeted anatomical region to provide thermal neutrons for capture by 10B is usually 
contaminated with fast neutrons (En > 10 keV). These fast neutrons, unlike the lower 
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energy neutrons, are not initially absorbed on interaction in tissue but rather 
predominantly scatter and thermalize in collisions with 1H to contribute dose mainly via 
the high LET recoil protons that are produced. However, the application of resonance 
scattering materials like Al, F, S, Ar to differentially filter out fast neutrons limits the fast 
neutron contamination of clinical beams to result in a dose component that is usually a 
small percentage of the total. Also, fast neutrons do indeed interact with the other nuclei 
present in tissue in large concentrations (e.g., 12C and 16O), but the dose that results from 
those interactions is a small percentage of the dose contributed by fast neutrons at 
neutron energies below ~1 MeV. At neutron energies above ~1 MeV, the neutron kerma 
contributed by these isotopes increases significantly as shown in Figure 1.3. 
1.1.2.5 Weighted Dose 
Estimating the biological effectiveness of the total dose delivered during BNCT is 
difficult due the complex mixture of high and low LET radiation and the differing 
biological effectiveness of each. Therefore, to account for these differences in radiation 
quality, each dose component is multiplied by a relative biological effectiveness (RBE) 
value that is determined experimentally,7 generally using an animal model, for the 
irradiated tissue and specified relative to low LET photon radiation. Factors relating to 
the biodistribution of the boronated compound used in the therapy are folded into the 
RBE to produce a compound biological effectiveness (CBE) factor for the boron dose 
component that is specific to each boron compound and tissue. The (total) weighted dose 
is the sum of all dose components weighted by the appropriate RBE or CBE and is 
expressed as Gyw (weighted Gray) to indicate that it is a weighted dose. The weighted 
Chapter 1: Introduction  J.R. Albritton 
 
 65
dose is presumed to be approximately equivalent in effect to the same dose of photon 
radiation. 
1.1.3 Physical and Computational Dosimetry of BNCT 
The ability to measure the dose in a clinical beam is an essential aspect of BNCT. 
Usually, this involves performing measurements of the thermal neutron flux, fast neutron 
dose, and photon dose both in-air and in a reference phantom and then using the 
appropriate 10B and 14N kerma factors to convert the measurements of thermal neutron 
flux into boron and thermal neutron dose. At the Massachusetts Institute of Technology 
(MIT), measurements of the 2200 m/s (0.025 eV) thermal neutron flux are made with Au 
foil activation analysis using the cadmium difference method,8 and measurements of fast 
neutron and photon dose rates are performed using the dual ion chamber technique.9,10 
However, the techniques used to make the flux and dose measurements are not 
standardized for NCT11 and therefore the physical dosimetry can vary among clinical 
sites,11,12 which obstructs comparison of clinical data from different sites.  
The measurements of flux and dose in the neutron beam are used to calibrate the 
treatment planning system (TPS) to ensure that the doses calculated during the planning 
process are an accurate representation of those delivered during treatment. The custom 
computer programs used for treatment planning vary among BNCT clinical sites, and that 
is important because significant differences exist between these programs that are 
difficult to quantify. This lack of standardization in NCT computational dosimetry 
presents another obstacle to pooling clinical data. Nevertheless, significant steps have 
been taken by the International Dosimetry Exchange to address both the differences in 
physical12 and computational13 dosimetry. 
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1.1.4 Clinical Trials of BNCT 
Although still an experimental therapy, neutron capture therapy is by no means a 
new concept. It was first suggested by Locher in 1936,14 only 4 years after Chadwick 
discovered the neutron. However, it would not be until the 1950s and 1960s that the very 
first clinical trials of BNCT would be initiated at Brookhaven National Laboratory (BNL) 
and MIT.15-17 The results from these initial clinical trials of BNCT for human brain 
tumors were however discouraging. Retrospective analyses18 of these trials have 
indicated that both failed to sufficiently deliver the two essential components required for 
BNCT; the low energy neutrons beams used did not provide the penetration necessary to 
sufficiently deliver thermal neutrons to the deep malignant tissue and the boron-delivery 
agent was not sufficiently selective for the tumor which resulted in large 10B 
concentrations in the brain and skin. Therefore, the selective cellular dose targeting that 
is essential to BNCT was not achieved, a considerable background dose was delivered to 
the normal tissue, and no noticeable tumor control resulted.  
While these discouraging results led to the closing of the initial BNCT clinical 
trials in the United States in 1961, clinical studies of BNCT using thermal neutron beams 
were resumed in Japan by 1968.19 Basic research in neutron capture therapy continued in 
the United States with the focus on correcting the shortcomings of those initial clinical 
trials. More specifically, this involved the development of higher energy epithermal 
neutron beams with deeper penetration and boron delivery agents with improved 
biological selectivity. These efforts resulted in the design and construction of dedicated 
epithermal (0.5 eV ≤ En ≤ 10 keV) neutron beams20,21 that allowed thermal neutrons to be 
delivered to deep-seated tumors. Also, new boronated pharmaceuticals, such as the amino 
acid derivative p-boronophenylalanine (BPA) and a sulfhydryl borane (BSH),22,23 with 
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much improved biochemical selectivity for the malignancies that are most often the target 
of BNCT were developed. Other technologies important for BNCT were also developed 
like techniques for the macroscopic and microscopic quantification of the boron 
biodistribution (e.g., PGNAA24,25 and HRQAR26,27) along with new techniques for more 
accurate dose measurement and calculation, including three-dimensional treatment 
planning software, that helped maximize the efficacy of the treatment while ensuring the 
safety of the patient. Due to these significant advances, interest in BNCT was renewed, 
which eventually led to clinical trials at various sites in the USA,28-31 Japan,32,33 Europe34-
38 and Argentina39 and extension from primary brain tumors to other diverse sites such as 
subcutaneous melanoma, intracranial melanoma metastacies, head and neck 
malignancies, liver tumors, and other thoracic targets.   
1.1.5 Treatment Planning for BNCT 
As in any form of radiotherapy, accurate treatment planning is essential to BNCT. 
Before a patient is treated with BNCT, detailed treatment planning calculations are 
performed for each patient to customize the therapy to that patient’s anatomy and 
maximize dose to the tumor while respecting dose limits on normal tissues. Evaluating 
dose distributions using isodose contours and dose-volume histograms for different beam 
orientations or different combinations of beams allows development of an optimal 
treatment plan that maximizes dose to the target volume while ensuring that the doses 
that will be delivered during treatment are safe for the patient. An example of the 
different dose data used in BNCT treatment planning are shown in Figure 1.5 and Figure 
1.6, where isodose contours and a dose-volume histogram are shown for a patient treated 
at Harvard-MIT. Calculating the dose delivered during BNCT is complex due to the 
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required radiation transport and the presence of multiple dose components, which depend 
strongly on the tissue composition. Therefore, a treatment planning system for BNCT 
must provide the tools necessary to construct individualized patient models, perform 
particle transport calculations through that model, compute estimates of the various dose 
components, and analyze the dose distribution by calculating isodose contours and dose-
volume histograms for the relevant anatomical structures. A recent review by Kiger and 
Kumada discusses the requirements for BNCT treatment planning in detail.40 
Custom computer programs have been developed that address the computational 
requirements of BNCT treatment planning. Currently, 5 different treatment planning 
systems (TPSs) have been used in the clinical trials of BNCT in the Americas, Europe 
and Asia: BNCT_Rtpe (BNCT Radiation Therapy Planning Environment),41-43 SERA 
(Simulated Environment for Radiotherapy Applications),44,45 MacNCTPlan,46,47 
NCTPlan,48,49 and JCDS (JAERI Computational Dosimetry System).50,51 All of these 
TPSs are similar in that they utilize Monte Carlo algorithms for radiation transport 
exclusively because of their ability to provide a detailed treatment of physics and 
geometry. Nevertheless, despite these similarities and the common goals, significant 
differences exist between these planning systems (e.g., in modeling techniques, kerma 
factors, dose reporting, radiation source definition) that make it difficult to directly 
compare patient doses from different BNCT clinical sites that were calculated with 
different TPSs. As an example of these differences, the techniques employed by the 
planning systems to model the patient anatomy for the particle transport are illustrated in 
Figure 1.7.  
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Figure 1.5 Screen capture of the BNCT treatment planning system, NCTPlan, 
displaying total weighted brain isodose contours (in Gyw) for a patient 
treated at Harvard-MIT.  
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Figure 1.6 Screen capture of the BNCT treatment planning system, NCTPlan, 
displaying the total weighted brain dose-volume histogram for a patient 
treated at Harvard-MIT. 
 
 
 
 
 
 
 
Computational Aspects of Treatment Planning for Neutron Capture Therapy 
 72
 
 
 
 
 
 
 
 
 
 
 
This page has been intentionally left blank. 
 
Chapter 1: Introduction  J.R. Albritton 
 
 73
 
Figure 1.7 2D and 3D representations of the voxel (a,b), univel (c,d), and NURBS 
(e,f) (Non-Uniform Rational B-Splines) modeling techniques employed by 
MacNCTPlan and NCTPlan, SERA, and BNCT_Rtpe, respectively, to 
model the patient anatomy for BNCT treatment planning calculations. 
(Reprinted with permission from Kiger and Kumada40). 
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Although the Monte Carlo method is regarded as the most accurate method for 
radiation transport and dose calculations, the algorithms are not inherently accurate. In 
addition to accurate physics models, cross sections, and geometric models, the accuracy 
of Monte Carlo treatment planning calculations depends on using an accurate 
representation of the radiation source. However, accurately defining the radiation source 
is one of the most difficult aspects of the entire treatment planning process. Two of the 
techniques that exist for defining the radiation source are binary phase space (or MCNP52 
surface source) files and MCNP SDef source probability models. There are advantages 
and disadvantages to each technique. 
Regardless of which technique is used to define the radiation source, it is 
common, especially in reactor-based BNCT, to define the source at a position close to the 
patient (e.g., as close as 1 cm) to allow the computational resources to be focused on dose 
calculations in the patient and not wasted on repeating computationally expensive 
transport computations upstream of the patient. This precalculation is feasible because 
the number of configurations possible with an epithermal neutron beam is very small. 
However, accurately defining the radiation source at a position downstream involves 
performing detailed Monte Carlo (or alternatively discrete-ordinates) calculations of the 
beam line. During these Monte Carlo calculations, the nature of the deep-penetration 
shielding problem often requires that nonanalog Monte Carlo (or variance reduction) 
techniques be employed to ensure that an adequately precise representation of the 
radiation source is produced at the downstream location. 
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1.2 Research Goals and Thesis Organization 
This thesis investigates many of the computational aspects of BNCT treatment 
planning with the aim of improving both the accuracy and efficiency of the planning 
process as well as the understanding of differences in computational dosimetry that exist 
between different clinical sites. Therefore, it begins with an in-depth intercomparison of 
4 of the different TPSs that have been used for treatment planning in BNCT clinical 
trials. Understanding the differences between the planning systems helps to further 
address some of the technical obstacles that prevent patient dose data from different 
clinical sites from being pooled. If differences in physical and computational dosimetry 
are properly addressed, pooling patient dose data from different clinical sites is indeed 
possible as is illustrated in Chapter 3 using patient data from BNL and Harvard-MIT and 
the work of the International Dosimetry Exchange.12,13 
The Monte Carlo variance reduction techniques utilized during the detailed 
calculations of the neutron beam line are essential to ensuring that an accurate 
representation of the source is available in the subsequent treatment planning 
calculations. The techniques available for those calculations are reviewed in Chapter 4 
and are also investigated as a means to increase the computational efficiency of dose 
calculations in the patient. The research described in Chapter 4 is used to produce a more 
precise surface source representation of the MIT Fission Converter Beam (FCB)21,53 with 
improved statistical properties that is used in Chapter 5 to directly compare two of the 
techniques available to model the radiation source for BNCT treatment planning 
calculations. A brief summary of the work presented in this thesis and the conclusions 
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reached in each chapter will be included in Chapter 6 along with recommendations for 
future work. A more detailed introduction to the major thesis chapters follows.  
1.2.1 Intercomparison of Neutron Capture Therapy Treatment Planning Systems 
In Chapter 2, a pre-existing suite of reference computational dosimetry problems4 
is extended from depth-dose profiles in a single phantom to include multiple phantoms (a 
large rectangular water phantom, the modified Snyder head phantom,54 and a cylindrical 
leg phantom derived from CT data from the Visual Human Project55), thermal and 
epithermal neutron beam spectra, and multi-dimensional dose data (isodose contours and 
dose-volume histograms) relevant to BNCT treatment planning. The extended set of 
references problems is then used as the basis for a detailed comparison of the 4 TPSs 
available at Harvard-MIT, BNCT_Rtpe, SERA, MacNCTPlan, and NCTPlan, to 
reference dosimetry calculations performed using the well-benchmarked Monte Carlo 
radiation transport code, MCNP5.52 The complete set of reference data and comparisons 
with data output by each treatment planning system are included in Appendix A. 
1.2.2 Comparison of Doses Delivered in Clinical Trials of Neutron Capture 
Therapy in the USA 
Before patient dose data from different BNCT clinical sites can be pooled 
together for combined dose response analysis, differences in physical and computational 
dosimetry between the clinical sites must first be resolved. Chapter 3 describes the 
normalization of BNL clinical dosimetry to that of Harvard-MIT. Using MIT 
measurements made at BNL11 (as part of the International Dosimetry Exchange12,13) and 
calculations with the BNL treatment planning system (BNCT_Rtpe), a relationship 
between the patient doses reported by BNL and doses measured by MIT in a reference 
phantom is determined. This derived relationship (in the form of dose component scale 
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factors) is then validated using calculations and MIT measurements in a different 
phantom. The BNL patient doses are recomputed using these scale factors, and the 
revised BNL clinical data are pooled with that of Harvard-MIT for a combined dose 
response analysis.  
1.2.3 Application of Variance Reduction in Monte Carlo Treatment Planning 
Calculations for Neutron Capture Therapy 
Chapter 4 investigates the application and optimization of variance reduction in 
the two phases of Monte Carlo treatment planning calculations, radiation transport 
calculations to define the beam source and dose calculations in the patient. First, 
calculations with MCNP are used to investigate and improve the pre-existing variance 
reduction scheme in the Monte Carlo model of the MIT Fission Converter Beam. Using 
an 11 node Beowulf cluster (described in Appendix B), a more precise surface source 
representation of the FCB with improved statistical properties is produced downstream at 
the patient position and validated using physical dosimetry measurements56 in the MIT 
ellipsoidal head phantom. The variance reduction techniques available in MCNP are also 
explored as a means of increasing the computational efficiency of dose calculations in the 
patient. 
1.2.4 Neutron Beam Source Definition Techniques for Neutron Capture Therapy 
Treatment Planning 
Constructing an accurate description of a neutron beam is critical to achieving 
accurate calculations of dose for NCT treatment planning. Chapter 5 uses the more 
precise surface source representation of the FCB created in Chapter 4 to compare two of 
the methods of neutron beam source definition available: MCNP surface source files and 
MCNP SDef source probability distributions. Each source definition type is used to 
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simulate transport of the beam through voxel models of the modified Snyder head 
phantom and a large rectangular water phantom where doses were calculated and 
compared for each source type. The development of a software tool that converts MCNP 
surface source models into MCNP SDefs is described as is the patch of the MCNP5 
source code that allows the neutron and photon source angular distributions to be 
completely specified with an SDef. 
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CHAPTER TWO 
Intercomparison of Neutron 
Capture Therapy Treatment 
Planning Systems 
2.0 Abstract 
Currently, 5 different treatment planning systems (TPSs) are or have been used in 
clinical trials of Neutron Capture Therapy (NCT) at various sites worldwide:  
MacNCTPlan, NCTPlan, BNCT_Rtpe, SERA, and JCDS. This chapter describes work 
performed to comprehensively test and compare 4 of these NCT treatment planning 
systems in order to facilitate the pooling of patient data from the different clinical sites 
for analysis of the combined clinical results as well as to provide an important quality 
assurance tool for existing and future TPSs. Three different phantoms were used to 
evaluate the planning systems under conditions relevant to both patient planning and TPS 
calibration:  the modified Snyder head phantom, a large rectangular water phantom, and a 
human leg phantom simulating a peripheral melanoma treatment. The comparison of dose 
profiles, isodose contours, dose difference distributions and dose-volume histograms to 
reference calculations performed with the well-benchmarked Monte Carlo radiation 
transport code MCNP5 yielded many clinically significant and interesting differences. 
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Each of the planning systems deviated from the reference calculations, with the newer 
systems (i.e., SERA and NCTPlan) most often yielding better agreement than their 
predecessors (i.e., BNCT_Rtpe and MacNCTPlan). Additional calculations were 
performed to further investigate and explain the sources of significant deviations from the 
reference calculations when they were observed in the planning systems. The 
combination of simple phantoms and sources with more complicated and realistic 
planning conditions has produced a well-rounded and useful suite of test problems for 
NCT treatment planning system analysis. Furthermore, such dosimetric comparisons play 
an essential role in helping to overcome obstacles, such as a lack of standardization in 
computational dosimetry, that prevent legitimate comparisons of patient data within the 
global NCT community. 
2.1 Introduction 
 
As in conventional radiotherapy, a detailed treatment plan is required in BNCT to 
ensure both the safety of the patient and to maximize the efficacy of the treatment. 
However, treatment planning for BNCT is more difficult due to the presence of multiple 
dose components as well as the requirement for a detailed physics model to treat this 
scatter-dominated radiation transport problem. Therefore, any treatment planning system 
(TPS) used for BNCT must adequately address these issues as well as provide the dose 
visualization and analysis tools necessary for effective radiotherapy treatment planning. 
Currently, 5 different treatment planning systems have been used in the clinical trials of 
BNCT in the Americas, Europe and Asia: BNCT_Rtpe (BNCT Radiation Therapy 
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Planning Environment),1-3 SERA (Simulated Environment for Radiotherapy 
Applications),4,5 MacNCTPlan,6,7 NCTPlan,8,9 and JCDS (JAERI Computational 
Dosimetry System).10,11  
While all BNCT planning systems depend on Monte Carlo particle transport 
algorithms, each provides a unique planning environment and has been responsible for 
introducing different innovations to the BNCT treatment planning process. However, the 
differences (e.g., in modeling techniques, kerma factors and dose reporting) that make 
each planning system unique also make it difficult to directly compare calculated patient 
doses from different BNCT clinical sites. While differences in physical and 
computational dosimetry have begun to be addressed through the International Dosimetry 
Exchange,12,13 this first order approach to clinical dosimetry normalization would indeed 
benefit from a more detailed comparison of the planning systems under conditions 
relevant to BNCT treatment planning.  
2.1.1 BNCT Treatment Planning Systems 
Each of the treatment planning systems used in BNCT is able to produce a 
treatment plan by providing the tools necessary to construct individualized patient 
models, perform particle transport calculations, and compute estimates of the various 
dose components present during BNCT and analyze the dose distribution. These dose 
components include the boron dose produced by the 10B(n,α)7Li reaction, thermal neutron 
dose mainly from the 14N(n,p)14C reaction, fast neutron dose mainly from the 1H(n,n′)1H 
proton recoil reaction, induced photon dose from photons created inside the phantom 
mainly via the 1H(n,γ)2H reaction, and the incident photon dose from those photons 
which are produced upstream in the beam line, outside the patient.14 In providing the 
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basic functionality required for effective BNCT treatment planning, the planning systems 
provide different techniques for model construction, material (tissue) compositions, 
kerma factors, neutron and photon cross sections, and Monte Carlo based radiation 
transport algorithms. It is significant differences in these essential aspects that make 
comparing calculated patient doses from different clinical sites difficult and that further 
emphasize the need for such a rigorous evaluation of the treatment planning systems. The 
features of each TPS which are relevant to the intercomparison will be discussed below 
and, as such, the following discussion is not meant to be a comprehensive description of 
each TPS. 
2.1.1.1 BNCT_Rtpe 
Developed at Idaho National Laboratory (INL) specifically for BNCT, 
BNCT_Rtpe was first used in 1994 during the BNCT trials at Brookhaven National 
Laboratory (BNL).15 Running on a Hewlett Packard® (HP) Unix workstation, 
BNCT_Rtpe utilizes a special-purpose Monte Carlo transport code, rtt_MC, to perform 
the necessary neutron and photon transport calculations. Before using rtt_MC, the 
patient’s anatomical structures are outlined on each CT or MR image slice by placing a 
set of control points. These user-defined control points are used to construct a 3D 
NURBS (Non-Uniform Rational B-Splines)16 model which defines the geometry for 
Monte Carlo transport calculations. In constructing the model, each user-defined 
anatomical region is assigned a specific user-defined material composition so that the 
appropriate cross section data are used for the transport calculations. The neutron and 
photon sources are defined in BNCT_Rtpe as probability distributions on a planar surface 
among geometric primitives defining those structures external to the patient anatomy 
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such as a collimator and its aperture. Transport calculations are performed during user-
defined run modes with the default being NFGD (Neutron, Fast neutron bias, induced and 
incident Gamma, and dose eDiting modes). During the rtt_MC transport calculations, a 
30×30×30 mesh of 1 cm3 tally volumes is superimposed over the NURBS geometry 
defining the patient for scoring volume-averaged estimates of neutron fluence which are 
integrated against energy-dependent kerma factors to provide estimates of dose in each 1 
cm3 volume of the scoring mesh. The multi-group cross section and kerma data are stored 
in a binary file in a format inherited from the RAFFLE code17 that was developed at INL 
during the 1970’s and 1980’s. 94 energy groups are used to define the neutron cross 
section and kerma data (22 thermal energy groups for 0 ≤ En ≤ 0.414 eV, 40 epithermal 
energy groups for 0.414 eV < En ≤ 9.12 keV, and 32 fast energy groups for 9.12 keV < En 
≤ 16.9 MeV), and 70 groups are used for photon cross section and kerma data. Neutron 
cross section data were derived mainly from the ENDF/B-V nuclear data library,18 but 
neutron cross section data from ENDF/B-IV were used in the thermal neutron energy 
range for select elements (e.g., 10B and 14N). Photon cross section data were derived from 
the DLC-99/HUGO library,19 which is based on ENDF/B-V. The kerma data are read at 
runtime, and the neutron kerma is scaled by the user-defined edit mesh atomic densities 
(in atoms/barn cm and considered constant for the mesh) to provide volume-averaged 
estimates of boron, nitrogen, hydrogen, and photon dose rates for each mesh element. 
The same set of photon kerma factors are used in calculating dose regardless of the 
composition of the anatomical region in which dose is being computed as is done in most 
NCT planning systems. The dose tallies have no energy boundaries, meaning that a 
neutron of any energy can contribute to the neutron dose component tallies. However, in 
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the BNCT_Rtpe fast neutron source biasing mode (i.e., run mode “F”), wherein the fast 
neutron portion of the source spectrum is sampled for better convergence of the hydrogen 
dose rate, only those neutrons above a given energy (the default biasing energy cutoff is 
9.12 keV) contribute to the hydrogen dose rate. A custom 3D cubic interpolation 
subroutine is used to calculate dose or flux at any point within the coarse 30×30×30 tally 
mesh. This interpolated dose and flux information can be displayed as dose vs. depth 
profiles, isodose contours for transverse or coronal planes, and dose-volume histograms 
for any user-defined region of the patient anatomy. In addition to treatment planning for 
the BNL clinical trials, BNCT_Rtpe has been in BNCT clinical trials at Espoo (Finland)20 
and Petten (The Netherlands).21 
2.1.1.2 SERA 
Developed jointly by INL and Montana State University and released in 1998 as a 
successor to BNCT_Rtpe, SERA inherited some source code from BNCT_Rtpe and thus 
shares many of the same features. Therefore, only the differences between BNCT_Rtpe 
and SERA that relevant to this intercomparison will be mentioned here. SERA divides 
the treatment planning process into several logical steps and provides a distinct program 
or module (i.e., seraImage, seraModel, sera3d, seraCalc, seraPlan, seraDose, seraPlot) for 
each step. In SERA, univels (uniform volume elements) replace NURBS as the technique 
for modeling complex patient anatomy and allow faster transport calculations by 
employing integer arithmetic to perform the required ray tracing.22,23 Univels are defined 
as right parallelepipeds with a cross-sectional area equal to that of a pixel and a thickness 
equal to the slice thickness of the CT or MR image. Defining univels in this manner 
preserves the geometric fidelity of the original medical image data while allowing rapid 
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interrogation of the transport geometry. Using graphical interface tools provided by 
seraModel, each pixel on every CT or MR image slice is assigned to a user-defined 
anatomical region (e.g., brain, tumor, bone) by “painting” it a specific color. This user 
input is constructed into a 3D univel model of the patient anatomy that is used by the 
custom transport module, seraMC, to perform the necessary Monte Carlo transport 
calculations. Multiple fields are weighted and combined with seraPlan so that the 
appropriate multi-dimensional dose data can be produced and visualized with seraPlot 
and seraDose. For SERA, boron and photon kerma data as well as photon cross section 
data were updated from BNCT_Rtpe whereas neutron cross section data remained the 
same. However, the cross section library for SERA was expanded to include data for 
other elements (e.g., bismuth, iron, chromium, and molybdenum). A finer energy grid 
was used to represent the updated boron and photon kerma data in SERA resulting in an 
increase in the number of energy groups from 94 to 717 for boron kerma and from 70 to 
86 for photon kerma. Photon cross section data were updated to ENDF/B-VI18 from the 
DLC-99/HUGO library23. SERA has been used for treatment planning for BNCT clinical 
trials at Espoo (Finland),20 Studsvik (Sweden),24 and Kyoto (Japan).25 
2.1.1.3 MacNCTPlan 
MacNCTPlan was developed in the Pascal programming language for the Power 
Macintosh™ platform at Harvard-MIT and imbedded within the public domain image 
processing program NIH Image (developed at the U.S. National Institutes of Health and 
available on the Internet at http://rsb.info.nih.gov/nih-image/). MacNCTPlan thresholds 
the CT image data into primary materials (i.e., air, normal tissue, and bone) with a user-
defined region of interest (ROI) used to delineate tumor. A 21×21×25 mesh of 1 cm3 
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voxels is superimposed over the thresholded image data and MacNCTPlan calculates in 
20% increments the volume fraction of the primary materials and tumor within each 
element of the voxel mesh. Using the calculated volume fractions, the material 
definitions for air, normal tissue, bone, and tumor are mixed accordingly to result in a 
material specification for each voxel. The voxel mesh and the corresponding mixed 
materials are constructed into a lattice model so that a customized version of the Monte 
Carlo transport code MCNP4B,26 modified with the speed tally patch27-30 to decrease 
computation time in specially constructed lattice geometries, can be used to perform the 
necessary transports calculations. Due to its extended development history, MCNP brings 
well-benchmarked and detailed treatments of neutron and photon transport physics as 
well as a broad range of functionality (e.g., in terms of source definition techniques, cross 
section data, variance reduction techniques, and tally specification) to the treatment 
planning process. Along with the neutron or photon source definition, the appropriate 
energy-dependent boron, neutron and photon kerma factors are added to the MCNP input 
deck so that volume-averaged estimates of fluence in each 1 cm3 element of the voxel 
mesh can be converted to estimates of boron, thermal and fast neutron, and photon dose. 
Unlike in BNCT_Rtpe and SERA, a defined neutron energy cutoff of 0.5 eV is used to 
separate the neutron dose into thermal and fast components to facilitate comparison of 
calculated doses with dose measurements. After performing the neutron and photon 
transport calculations with MCNP, the calculation results are loaded into MacNCTPlan 
where the coarse 21×21×25 dose matrix is interpolated to the resolution of the original 
medical image data (i.e., ~ 1 mm). The interpolated data are then visualized in the form 
of dose vs. depth profiles, isodose contours for any arbitrary plane, and dose-volume 
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histograms for each user-defined ROI. MacNCTPlan has been used in the BNCT clinical 
trials at Harvard-MIT (USA)31,32 and Rez (Czech Republic).33 
2.1.1.4 NCTPlan 
NCTPlan was developed in a collaboration between Harvard-MIT and the 
Comisión Nacional de Energía Atómica (CNEA) of Argentina. Despite its many 
similarities to MacNCTPlan, it represents more than a direct port of MacNCTPlan to 
Microsoft Visual BasicTM and the x86 platform. Like MacNCTPlan, NCTPlan constructs 
a mixed-material voxel model from the thresholded CT image data and uses MCNP4B 
with the speed tally patch to perform the neutron and photon transport calculations in the 
lattice model of the patient. Also, like MacNCTPlan, the calculation results are loaded 
into NCTPlan for dose interpolation, analysis and visualization. However, the algorithms 
responsible for voxel model construction, dose interpolation and calculation of dose-
volume histograms were greatly improved in NCTPlan which results in differences 
worthy of further investigation. Clinical trials at Harvard-MIT,31,32 Petten (The 
Netherlands),34 and CNEA (Argentina)35 have used NCTPlan for clinical treatment 
planning.  
2.1.2 Previous Work 
Considerable comparative work between the various treatment planning systems 
has been performed previously. A comparison of voxel-by-voxel dose differences 
between MacNCTPlan and NCTPlan for two randomly selected patients from the 
Harvard-MIT BNCT clinical trials produced agreement within ±4%.36 Another 
comparison of these two planning systems to MCNP reference calculations in the Snyder 
head phantom reported that the improved algorithms in NCTPlan produced more accurate 
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multidimensional dose data than MacNCTPlan.9 Comparing NCTPlan calculations in the 
modified Snyder head phantom with reference calculations14 using monoenergetic, 
monodirectional beams demonstrated generally good agreement except at shallow depths 
where NCTPlan underestimated the dose resulting from the interactions of thermal 
neutrons.8 By simulating a variety of beams and transport geometries (water-filled 
cylinder, water-filled ellipsoid, and a Harvard-MIT patient), a comparative study between 
MacNCTPlan and BNCT_Rtpe found differences in the ellipsoidal phantom as large as 
14.5% in maximum photon doses and 17.5% in maximum fast neutron doses, isodose 
contours in the patient that agreed to within a few millimeters, and dose-volume 
histograms which were similar in shape.37 Comparisons of MacNCTPlan, SERA, and 
MCNP thermal neutron fluence profiles in a rectangular water phantom and an ellipsoidal 
head phantom from various monoenergetic neutron beams produced differences as large 
as 21% for MacNCTPlan and 20% for SERA.38 These differences were attributed to the 
material mixing and voxelization techniques of MacNCTPlan and the inability of the 
multigroup data format of SERA to accurately model resonances in cross section data. 
Similar findings were produced in a separate study that also modeled monoenergetic 
neutron beams with SERA, but better agreement between SERA and MCNP was 
achieved when the energy spectra of the simulated neutron beams spanned at least 1 of 
the 94 neutron energy groups in SERA.39 Previous comparisons of the TPSs have not 
been limited solely to simple phantoms and beams but have included actual BNCT 
clinical beams and patients. A study comparing the dose-volume histograms calculated 
by BNCT_Rtpe and SERA for 10 BNCT patients treated at the Finnish Research Reactor 
(FiR 1) discovered differences as large as ~10%, which were attributed to the more 
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accurate volumetric calculations in SERA.40 A study using the hyperthermal neutron 
beam at the RA-6 reactor in Argentina reported that fast neutron dose rates calculated by 
SERA in both a large rectangular water phantom and a cylindrical water phantom 
underestimated the corresponding physical dosimetry measurements and NCTPlan 
calculations by an average of 22%.41 Similarly, a comparison of SERA and JCDS (using 
a detailed JCDS model with 2×2×2 mm voxels and a 5×5×5 mm scoring mesh) for a 2-
field brain cancer patient resulted in differences of 22% in the maximum fast neutron 
dose rate to brain.42 However, differences in the maximum biologically weighted doses 
for the brain, planning target volume (PTV), and tumor were much smaller at 3%, 3%, 
and 4%, respectively.  
When considered as a whole, the previous work indeed represents a valuable 
resource of intercomparative data, but the rather limited scope of each study (i.e., limited 
in terms of the number of TPS and the type of dose data compared, usually only depth-
dose profiles) combined with the wide variety of different irradiation conditions 
represented makes it difficult to extrapolate the findings of any one particular comparison 
to another. Moreover, the previous studies generally make only limited efforts to 
understand and explain the differences between planning systems. Therefore, preliminary 
work towards standardizing such comparisons of BNCT treatment planning systems was 
done previously through the development of a set of reference dosimetry calculations14 
represented as dose vs. depth profiles in the modified Snyder head phantom, and that 
work serves as the basis for the intercomparison described here.  
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2.1.3 Objectives 
In this chapter, that preliminary work was extended to form a more 
comprehensive set of reference problems which subjects the treatment planning systems 
to a variety of conditions relevant to BNCT treatment planning. The original set of 
reference problems was extended to include both simple and complex phantoms. The 
simulated irradiations of a large rectangular water phantom and the modified Snyder head 
phantom with an epithermal neutron beam as well as the irradiation of a leg phantom 
with a thermal neutron beam allowed the planning systems to be evaluated under 
different geometric conditions that are relevant either to clinical irradiations or 
calibration conditions at some institutions. Using analytical representations of these 3 
phantoms with the well-benchmarked Monte Carlo radiation transport code MCNP543 
and the most up-to-date neutron and photon cross sections, material compositions, and 
kerma factors available, clinically relevant multidimensional dose data in the form of 
dose vs. depth profiles, isodose contours, and dose-volume histograms were calculated 
and compared to the corresponding output from BNCT_Rtpe, SERA, MacNCTPlan, and 
NCTPlan. Using analytical representations of each phantom in the reference calculations 
avoided introducing the geometric approximations that are characteristic of each 
treatment planning system. Extending the reference dose data to include isodose contours 
and dose-volume histograms was also significant since it is those representations of dose 
that are actually used in clinical treatment planning. While the intercomparison includes 
only those treatment planning systems available to the authors at the time the work was 
performed, a primary goal during the development and application of these reference 
dosimetry calculations was to facilitate the inclusion of other BNCT treatment planning 
systems as they become available or are developed in the future.  
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2.2 Methods and Materials 
The reference data consist of MCNP5 calculations of dose and flux at finely 
spaced points in various analytical phantoms which are post-processed with custom 
MATLAB (The MathWorks, Natick, MA) functions in order to produce multi-
dimensional dose and flux data relevant to BNCT treatment planning. This reference data 
are subsequently compared to output from each BNCT treatment planning system to 
produce a comprehensive dosimetric intercomparison. 
2.2.1 Phantoms 
 The criteria for selecting or designing phantoms to include as part of the reference 
calculations were relatively simple. Each of the phantoms had to be simple enough that 
an analytical representation with no geometric approximations could be created but still 
represent irradiation conditions relevant to the BNCT treatment planning calculations. 
The large rectangular water phantom, similar to that used in the International Dosimetry 
Exchange, is a cube 40 cm on a side modeled entirely of light water (H2O). Since both 
the geometry and material are easily modeled by the treatment planning systems, the 
large water phantom provided a good basis with which to begin the intercomparison 
since any potential differences due to modeling technique or material specification are 
avoided. Also, the large water phantom is representative of the phantoms used at some 
BNCT clinical facilities to calibrate their treatment planning systems.  
 To simulate conditions relevant to treatment planning for BNCT of intracranial 
disease, the modified Snyder head phantom was modeled using three ellipsoids to define 
the boundaries of brain, skull, and skin and irradiated with a generic epithermal neutron 
beam.14 To make the phantom more relevant to BNCT of intracranial tumors, a tumor 
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was modeled as a 4 cm diameter sphere (volume of 33.5 cm3), added to the center of the 
brain ellipsoid, and shifted 2 cm along the lateral x-axis to make it tangential to the center 
coordinate of the brain. Sagittal, coronal, and transverse views of the analytical 
representation of the head phantom are shown in Figure 2.1. Each region in the head 
phantom was modeled using the corresponding ICRU 4644 biological material: adult 
whole brain (ρ=1.04 g/cm3), adult whole cranium (ρ=1.61 g/cm3), and adult skin (ρ=1.09 
g/cm3). 10B concentrations of 15, 52.5, and 22.5 μg/g45 were explicitly modeled in brain 
(1.0 × blood [10B]), tumor (3.5 × blood [10B])46 and skin (1.5 × blood [10B]),47 
respectively, to correctly account for neutron flux depression due to the capture of 
thermal neutrons by 10B nuclei. It should be noted that the voxel modeling technique used 
by MacNCTPlan and NCTPlan did not permit the layer of skin to be modeled separately 
due to the limitation of 4 primary materials, so skin was represented as soft tissue (i.e., 
adult whole brain + 15 μg/g 10B) in calculating the mixed materials. With its curved 
surfaces and heterogeneous composition, the head phantom tested the ability of each 
planning system to model the complex anatomical structures and biological materials that 
are required for accurate BNCT treatment planning.  
 Since BNCT has not been limited solely to intracranial tumors,35,48 a leg phantom 
was created to simulate BNCT of peripheral melanoma of the human leg. The dimensions 
of the leg phantom anatomy were derived from CT data from the Visual Human 
Project.49 Cylinders 25 cm in length and 9.75 cm, 9.35 cm, 7.0 cm, 2.25 cm, and 1.15 cm 
in diameter were used to model skin, the connective tissue between the skin and muscle, 
muscle, tibia, and fibula, respectively. Two superficial tumors were also modeled as part 
of the leg phantom: a spherical tumor with a diameter of 1.5 cm and volume of 1.77 cm3 
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and an arc-shaped tumor with a volume of 19.2 cm3. Transverse and oblique slices 
through the leg phantom are shown in Figure 2.2. Each region in the leg phantom was 
modeled with the corresponding ICRU 46 biological material: adult muscle (ρ=1.05 
g/cm3), adult cortical bone (ρ=1.92 g/cm3), adult connective tissue (ρ=1.03 g/cm3), and 
adult skin (ρ=1.09 g/cm3). 10B concentrations of 15, 52.5, 15, and 22.5 μg/g were 
explicitly modeled in muscle (1.0 × blood [10B]), tumor (3.5 × blood [10B]), connective 
tissue (1.0 × blood [10B]), and skin (1.5 × blood [10B]), respectively. The regions of 
connective tissue and skin were both modeled as muscle in MacNCTPlan and NCTPlan 
since their mixed material voxel models were limited to the 4 primary materials of air, 
muscle, bone, and tumor. The greater curvature of the leg phantom surface, the use of a 
thermal neutron beam, and the superficial location of the tumors subjected each planning 
system to irradiation conditions significantly different from the head phantom and large 
rectangular water phantom.  
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Figure 2.1 Sagittal (a), coronal (b), and transverse (c) views through the analytical 
model of the modified Snyder ellipsoidal head phantom used for the 
reference dosimetry calculations. A brain tumor was modeled by a 4 cm 
diameter sphere. The anatomical regions were modeled using ICRU 46 
adult whole brain, adult whole cranium, and adult skin biological 
materials. 
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Figure 2.2 Transverse and oblique views through the analytical model of the leg 
phantom used for the reference dosimetry calculations. The phantom was 
derived from measurements of CT image data of a human leg from the 
Visual Human Project. Two superficial tumors, modeled by a sphere and 
an arc shape, were added to simulate BNCT treatment of peripheral 
melanoma. The different anatomical regions were modeled using ICRU 46 
adult muscle, adult cortical bone, adult connective tissue, and adult skin 
biological materials. 
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2.2.2 Neutron and Photon Sources 
 As for the phantoms, neutron and photons beams that were easy to model in each 
of the treatment planning systems and also relevant to BNCT were selected for the 
reference calculations. The generic epithermal neutron beam from the pre-existing suite 
of reference calculations14 was also used in this work as the neutron source for both the 
large rectangular water phantom and head phantom. The monodirectional 10 cm diameter 
disc source was modeled as 10% thermal neutrons (0.001 eV to 0.5 eV), 89% epithermal 
neutrons (0.5 eV to 10 keV), and 1% fast neutrons (10 keV to 2 MeV). The disc source 
was sampled uniformly in area (i.e., radius sampled from p(r) ~ r) and was normalized to 
a neutron flux of 1×1010 n/cm2s. 
 To simulate treatment planning for BNCT of peripheral melanoma with the leg 
phantom, a monodirectional 10 cm diameter thermal neutron disc source was modeled 
using the energy spectrum of the M11 thermal neutron beam50 at MIT as a basis. For 
MCNP5, a combination of different built-in functions were used to model the source 
probability distributions in the thermal, epithermal and fast regions of the thermal beam’s 
energy spectrum. The Maxwell fission spectrum, with parameters tuned to represent the 
Maxwellian thermal neutron distribution, was employed to model the thermal neutron 
peak below 1 eV. The Power law represented the nearly 1/E distribution in the epithermal 
neutron portion of the spectrum and the Watt fission spectrum modeled the fast neutrons 
above ~100 keV. The Maxwell fission energy spectrum (p(E)=CE1/2exp(−E/a) with 
a=3.25×10−8 MeV), 165 points approximating the Power law (p(E)=c|E|a with 
a=−1.1575) for 0.32 eV ≤ En ≤ 10 MeV, and the Watt fission energy spectrum 
(p(E)=Cexp(−E/a)sinh(bE)1/2 with a=0.988 MeV and b=2.249 MeV−1) were modeled and 
sampled with frequencies of 99.87%, 0.11%, and 0.02%, respectively. In MCNP, the 
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Power law was not available to model energy probability distributions without modifying 
the source code, so a piecewise linear function defined with a fine energy grid was 
instead used to approximate the Power law from 0.32 eV to 10 MeV. For BNCT_Rtpe 
and SERA, the neutron energy spectrum of the thermal beam was modeled using the 
maximum allowed 100 energy bins. For all calculations, the disc source was sampled 
uniformly in area and normalized to a neutron flux of 1×1010 n/cm2s. The generic 
epithermal and thermal neutron beam energy spectra are both shown in Figure 2.3. 
 The same incident photon source was modeled for all 3 phantoms: a 
monoenergetic and monodirectional disc source of 2 MeV photons 10 cm in diameter and 
normalized to a flux of 2×108 γ/cm2s. This normalization was calculated so that the 
maximum incident photon dose rate would be approximately 10% of the maximum 
induced photon dose rate on the central beam axis in the head phantom.  
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Figure 2.3 Energy spectra for the thermal and generic epithermal neutron beams 
simulated as part of the reference dosimetry calculations. The generic 
epithermal neutron beam was taken from the pre-existing suite of 
reference dosimetry calculations14 while the thermal neutron beam was 
modeled after the M11 thermal neutron beam at MIT.50 Both beams were 
normalized to a neutron flux of 1×1010 n/cm2s. 
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2.2.3 Monte Carlo Simulations 
2.2.3.1  Geometric Models 
 An exact analytical model with no geometric approximations of each phantom 
was constructed from geometric primitives using combinatorial geometry in MCNP5 v. 
1.40 and these analytical models were used for the reference dose calculations. 
MATLAB was used to produce the corresponding DICOM format images (with 0.977 
mm/pixel in-plane resolution and 2 mm slice thickness) of each phantom which were 
then processed and imported into each planning system and used to construct a 3D model 
of each phantom native to each TPS (i.e., voxel, NURBS, or univel model) just as if 
planning for an actual patient. It should be noted that the image data for the large water 
phantom was constructed so that the phantom surface was aligned with the voxel mesh of 
MacNCTPlan and NCTPlan to ensure that that no material mixing of water and air 
occurred in any of the voxels at the air-phantom interface. Thus, all voxels in the mesh 
were modeled as either 100% water or 100% air. Also, for MacNCTPlan and NCTPlan, 
additional slabs of water were added around the 21×21×25 cm3 voxel mesh for the large 
rectangular water phantom so that the resulting model was equivalent in size to the 
analytical representation used in the reference calculations (i.e., 40×40×40 cm3). 
2.2.3.2 Cross Sections 
 The most up-to-date cross section data available at the time this work was 
performed were used for the reference calculations. Each treatment planning system used 
its default cross section data. The MCNP5 transport calculations utilized as the reference 
as well as the MCNP4B calculations performed for MacNCTPlan and NCTPlan all used 
neutron and photon cross section data from the MCNP ENDF60 library,51 which were 
derived from the ENDF/B-VI nuclear data library.18 Both BNCT_Rtpe and SERA 
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employed multigroup neutron cross section data (94 energy groups) derived mainly from 
the ENDF/B-V nuclear data library, but cross section data from ENDF/B-IV was used in 
the thermal neutron energy range (i.e., En < 0.414 eV) for some elements (e.g., 10B and 
14N). Thermal neutron cross section data for hydrogen in light water was based on 
experimental work by Nelkin52 and Haywood53 performed in the 1960’s. The neutron 
cross section data modeled by BNCT_Rtpe and SERA for the various materials of the 
three phantoms were compared and found to be identical, but their photon cross section 
data differ. BNCT_Rtpe’s photon cross section data were derived from the DLC-
99/HUGO library,19 which is based on ENDF/B-V, while SERA utilized updated photon 
cross section data from ENDF/B-VI. The S(α,β) thermal neutron scattering treatment for 
hydrogen in light water was utilized for all the Monte Carlo transport calculations. In 
BNCT_Rtpe and SERA, the S(α,β) thermal neutron scattering treatment for CH2 was 
additionally used in modeling the various biological materials.  
2.2.3.3 Kerma Factors and Dose 
 Neutron and photon kerma factors14 for ICRU 46 adult whole brain were used in 
the large rectangular water phantom and head phantom for the reference calculations as 
well as for MacNCTPlan and NCTPlan. For all 3 phantoms, the same 10B kerma factors14 
were used for the reference, MacNCTPlan, and NCTPlan calculations. In BNCT_Rtpe 
and SERA, the edit mesh atomic densities for boron, nitrogen, and hydrogen (in 
atoms/barn cm), which scale the corresponding elemental neutron kerma factors, were 
specified for ICRU 46 adult whole brain. In addition, carbon and oxygen densities were 
input for SERA to include their contributions in the calculation of total dose. In 
calculating photon dose with BNCT_Rtpe and SERA, the same sets of brain photon 
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kerma factors are used regardless of the anatomical region where the photon dose is 
actually being computed. The photon kerma factors are updated in SERA and are 
therefore different from those used by BNCT_Rtpe. Since BNCT_Rtpe and SERA only 
report total photon dose, minor adjustments were made to rtt_MC and seraMC to separate 
the photon dose into induced and incident components. In the irradiation of the leg 
phantom, skin was the dose-limiting tissue, so neutron kerma factors for ICRU 46 adult 
skin were used for reference, MacNCTPlan, and NCTPlan calculations along with photon 
kerma factors for ICRU 4454 adult skeletal muscle, which were calculated from NIST 
data.55 Muscle photon kerma factors differ from skin photon kerma factors by less than 
1% for photon energies above 150 keV and by ~0.4% at 2.2 MeV (i.e., the energy of the 
photon produced by the 1H(n,γ)2H reaction). In the corresponding BNCT_Rtpe and 
SERA simulations with the leg phantom, edit mesh atomic densities corresponding to 
ICRU 46 adult skin were used. In all three phantoms, the energy-dependent kerma factors 
were used to calculate the 5 main dose components present during BNCT. The boron 
dose, thermal and fast neutron dose, induced and incident photon dose were also 
weighted by RBE or CBE factors56 of 1.3, 3.2, 3.2, 1.0, and 1.0, respectively, and 
summed to produce the total biologically weighted brain dose in the head phantom. 
Similarly, RBE factors of 2.5, 3.2, 3.2, 1.0, and 1.0 were used to calculate the total 
biologically weighted skin dose in the leg phantom. The total biologically weighted 
tumor dose was also calculated for the head phantom and leg phantom tumors using the 
same RBE factors as for brain, except for the boron dose, which was scaled by 3.8 
instead of 1.3.  
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2.2.3.4 Field Arrangements 
 Simulated irradiation of the large water phantom utilized a single field 
perpendicular to the phantom surface aligned to the center of the phantom. For the head 
phantom, dose data for single-field and combined 3-field irradiations were calculated. 
The simulated single-field treatment plan used a lateral field (ipsilateral). Contralateral 
and vertex fields were added to produce the 3-field plan. The central axes of the 
ipsilateral and contralateral fields were aligned with the geometric center of the tumor 
while the central axis of the vertex field was aligned with the z-axis which is tangent to 
the tumor. The ipsilateral, contralateral, and vertex fields were fluence-weighted by 
factors of 0.5, 0.25, and 0.25, respectively. For the leg phantom, the disc source was 
rotated 35° from the x-axis for a single lateral anterior oblique field orientation. Figure 
2.4 illustrates the field orientations for the head and leg phantoms.  
2.2.3.5 Dose Data 
 Each treatment planning system was used to produce dose vs. depth profiles along 
the central beam axis (at ~1 mm increments for MacNCTPlan and NCTPlan, at 5 mm 
increments for BNCT_Rtpe and SERA), isodose contours in orthogonal planes on the 
beam central axis, and dose-volume histograms for brain and tumor in the head phantom 
and for skin and both tumors in the leg phantom. Additionally, for a more detailed 
understanding of the agreement between the isodose contours lines, the unmasked, 
interpolated 2D dose data, from which each planning system plots isodose contours, was 
extracted and used to calculate 2D dose difference distributions. To calculate the 
corresponding reference data to which each TPS was compared, MCNP5 mesh tallies of 
various sizes were used in simulations with analytical models of the phantoms. For dose 
vs. depth profiles, a uniform mesh of 1×10×10 mm tally volumes centered on the central 
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beam axis was used. The dose grid for isodose contours was calculated using a 2 mm 
thick tally mesh with 1 mm in-plane resolution. For dose-volume data in the head 
phantom, the brain was enclosed in a mesh of 2×2×2 mm tally volumes while a finer 
mesh of 1×1×1 mm volumes was superimposed over the tumor. For the leg phantom, a 
cylindrical mesh tally was used for both the skin and the arc-shaped tumor (#2) while a 
cartesian mesh of 1×1×1 mm tally volumes was used for the spherical tumor (#1). Figure 
2.5 shows a sample of the mesh tallies used within MCNP to calculate the 
multidimensional reference dose data in the head phantom.  
 The results of the MCNP5 mesh tallies were read into MATLAB and processed to 
produce data that could be directly compared to the output of each treatment planning 
system. Thus, for the sake of this intercomparison, the reference data or calculations refer 
to MCNP5 calculations of dose or particle flux in the analytical phantoms using various 
mesh tallies followed by post-processing with custom MALAB functions. For instance, 
custom MATLAB functions were developed to calculate via numerical integration the 
partial volume fractions for each element of the rectangular or cylindrical scoring mesh 
intersecting the border of a structure, and these partial volumes were used to account for 
partial volume effects when calculating the reference dose-volume histograms. The 
reference isodose contours were directly compared to those plotted separately with 
MCNP5 (using MCPLOT43) to verify the accuracy of the MATLAB post-processing and 
contour plotting functions. To facilitate the direct comparison of isodose contours 
between each TPS and the reference, the contours were plotted for absolute dose rather 
than as a percentage of a reference dose. In order to calculate dose, treatment times for 
each planning system were computed using realistic BNCT dose prescriptions for each 
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phantom: a maximum brain dose of 12.5 Gyw for the head phantom and a minimum 
tumor dose of 24 Gyw for the leg phantom. Similarly, plotting the dose-volume data 
output from each TPS as percent volume vs. percent of the reference dose would have 
made a direct comparison difficult since the reference doses were different for each TPS. 
Therefore, using the treatment times calculated using the reference data, the dose-volume 
data from each TPS and the reference were plotted as percent volume vs. absolute dose. 
 1.5×109 source particles were simulated for each field and phantom during the 
reference MCNP5 coupled neutron/photon (i.e., mode np) and incident photon (i.e., mode 
p) calculations, and each simulation was performed in parallel on an 11 node Beowulf 
cluster. 5×107 source particles were simulated during sequential runs for MacNCTPlan, 
NCTPlan, BNCT_Rtpe, and SERA to sufficiently reduce the uncertainties associated 
with Monte Carlo simulation to insignificant levels. While BNCT_Rtpe and SERA do not 
report uncertainties for tallied quantities, simulating 5×107 particles has been shown to 
produce adequately converged calculations for all dose components.57 The Monte Carlo 
transport module of BNCT_Rtpe, rtt_MC, was ported to x86 Linux so that better 
statistics could be rapidly achieved by running more particle histories with newer 
computer hardware. Source biasing of fast neutrons and photon production biasing was 
used in MCNP5 (for reference calculations) and MCNP4B (for MacNCTPlan and 
NCTPlan calculations) to reduce the variance of the fast neutron and induced photon 
dose component tallies. The lattice speed tally patch30 was utilized for MCNP4B 
transport calculations for the MacNCTPlan and NCTPlan voxel models of all 3 
phantoms. Unless otherwise noted, BNCT_Rtpe and SERA were run in their default 
modes of “NFGD” which includes the default fast neutron source biasing mode.  
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Figure 2.4 Simulated treatment field orientations for the head and leg phantoms. Both 
1- and 3-field irradiations were simulated for the head phantom. The disc 
source for the single field irradiation of the leg phantom was rotated 35° 
from the lateral x axis. 
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Isodose Contours:
Dose-Volume Histograms:
Transverse Coronal Sagittal
Dose vs. Depth Profiles:
 
Figure 2.5 Transverse, coronal, and sagittal views of the various mesh tallies used 
within MCNP5 to produce the reference depth-dose (1×10×10 mm), 
isodose (1×1×2 mm), and dose-volume (2×2×2 mm) data for the 
ellipsoidal head phantom. The mesh used to calculate dose-volume data 
for the brain tumor is not shown but consisted of 1×1×1 mm tally 
volumes. 
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2.3 Results 
 The complete set of reference data (including all dose components) and the 
comparison to corresponding data from each treatment planning system is included in 
Appendix A. Since the complete set includes 156 plots and 44 tables, only a 
representative subset will be presented here for discussion.  
2.3.1 Dose vs. Depth Profiles 
 To facilitate the direct comparison of dose and flux profile data from each 
planning system to that of the reference, differences between each TPS and the reference 
were calculated as a function of depth in the phantoms and plotted as percentages of the 
maximum reference dose or flux (i.e., as 100×[TPS−Ref]/Refmax). Percent differences 
were calculated in this manner to prevent differences in small doses (at depth in the 
phantom) from obscuring the comparison in the more important high dose region. Percent 
difference vs. depth profiles are included directly below the corresponding dose and flux 
profiles for all 3 phantoms.  
2.3.1.1 Large Rectangular Water Phantom 
This section reports the comparison of 1D dose and flux profiles in the large 
rectangular water phantom from each TPS with the reference. 
2.3.1.1.1 Thermal Neutron Flux 
Since in excess of 90% of the total biologically weighted dose in BNCT is 
derived from the interactions of thermal neutrons with boron, nitrogen and hydrogen, 
accurate calculations of the thermal neutron flux are absolutely essential to accurate 
BNCT treatment planning. Therefore, comparisons of thermal neutron flux profiles are an 
appropriate starting point for any intercomparative discussion. Figure 2.6 shows the 
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thermal neutron flux calculated by MCNP5, BNCT_Rtpe, SERA, MacNCTPlan, and 
NCTPlan as well as the percent difference of each TPS from the reference MCNP5 
calculations as a function of depth in the large rectangular water phantom. Each TPS 
deviates from the reference calculations with the largest differences occurring at the 
phantom entrance. The deviations in flux in the rectangular water phantom indicate the 
presence of differences that are independent of both kerma factors and geometric 
modeling technique. For each TPS, the thermal neutron flux data result from 
interpolating the volume-averaged flux from a coarse scoring mesh of 10×10×10 mm 
elements. In each TPS, the geometric center points of these cubic tally volumes 
correspond to ½ integral depths in the rectangular water phantom (e.g., 0.5 cm, 1.5 cm, 
2.5 cm, etc). At these ½ integral depths, MacNCTPlan and NCTPlan produce relatively 
good agreement by underestimating the reference thermal neutron flux by less than 3%, 
which is understandable considering the smaller tally volumes (0.1 cm3 vs. 1 cm3) used in 
the reference calculations. If the reference thermal neutron flux is averaged over an 
equivalent volume (i.e., 10 reference mesh elements) and compared to uninterpolated 
MacNCTPlan and NCTPlan voxel flux data, the differences are not statistically 
significant. It is also worth noting that averaging the reference thermal neutron flux 
profile data over 1 cm3 (i.e., the tally volume utilized by all the TPSs) alone produces a 
1% decrease in the maximum reference thermal neutron flux and a 37% increase in flux 
at the phantom surface. However, the exact effect of volume averaging depends on the 
position on the scoring mesh with respect to the phantom, and that position is different 
for reference, MacNCTPlan/NCTPlan, and BNCT_Rtpe/SERA calculations. 
Nevertheless, the linear interpolation between the voxels is unable to accurately model 
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the curvature of the reference flux profile, especially at the phantom entrance, where 
differences as large as 17% and 13% are observed for MacNCTPlan and NCTPlan, 
respectively. Accordingly, the largest differences for MacNCTPlan and NCTPlan occur 
close to the voxel edges at approximately integral depths in the phantom. On the 
downstream side of the thermal neutron flux peak, at depths greater than ~2.5 cm, the 
curvature of the reference flux profile is relatively low, so the linear interpolation 
performed by MacNCTPlan and NCTPlan produce improved agreement that is within 
~4.5% and ~2% of the reference, respectively. However, the improved agreement at these 
depths uncovers a different “sawtooth” pattern in the percent difference profiles of 
MacNCTPlan and NCTPlan that indicates the presence of subtle interpolation errors in 
both TPSs. Although the pattern for MacNCTPlan is different from that of NCTPlan, 
both are ~1.5% from crest to trough. At the depth corresponding to the reference 
biologically weighted dose maximum (dmax), 1.9 cm, MacNCTPlan and NCTPlan differ 
from the reference thermal neutron flux by 4.2% and 3.8%, respectively. 
In Figure 2.6, BNCT_Rtpe and SERA produce thermal neutron flux profiles very 
similar to each other, as expected, given the similarities in their transport codes and their 
identical neutron cross section data. Both BNCT_Rtpe and SERA overestimate the 
maximum thermal neutron flux at 2.0 cm depth by ~6% and flux along the downstream 
side of the peak from 1% to 5%. The interpolation error observed in both MacNCTPlan 
and NCTPlan in Figure 2.6 motivated calculation of more finely spaced flux data (at 0.1 
mm rather than the 5 mm default intervals) from BNCT_Rtpe and SERA to compare with 
the reference. The resulting finely spaced SERA thermal neutron flux data are shown in 
Figure 2.7 along with the percent difference of that data from the reference MCNP5 
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calculations. The BNCT_Rtpe data are very similar to the SERA data and are omitted for 
clarity. The SERA data exhibits discontinuities in the thermal neutron flux (and percent 
difference) profile at integral depths in the phantom, which correspond to voxel edges. 
For instance, the difference reaches 6.5% at 2.0 mm depth and then suddenly drops to 
3.4% at 2.01 mm depth. This discontinuity in the finely spaced line edit data indicates a 
problem with the SERA (and BNCT_Rtpe) interpolation algorithm. Moreover, when the 
SERA line edit data are compared to the uninterpolated voxel flux data in Figure 2.7, it is 
evident that the (interpolated) line edit data at the voxel centers do not coincide with the 
voxel values. This problem is generally masked by the use of coarser sampling intervals 
(the default is 5 mm) so that the discontinuity is not apparent. If the uninterpolated SERA 
coarse voxel data are read and interpolated using MATLAB’s cubic algorithm 
(BNCT_Rtpe and SERA employ a custom 3D cubic-like interpolation algorithm), the 
discontinuities at the voxel edges are eliminated as expected in Figure 2.7. Similarly, if 
the uninterpolated NCTPlan voxel data are read and linearly interpolated using 
MATLAB (MacNCTPlan and NCTPlan employ a custom 3D linear interpolation), the 
interpolation error in NCTPlan observed in Figure 2.6 and Figure 2.7 is corrected.  
To further investigate the interpolation error in SERA (and BNCT_Rtpe), the 
SERA voxel data was interpolated at 0.1 mm intervals using several different methods in 
MATLAB and compared to uninterpolated voxel data as well as seraPlan line and point 
edits (at positions corresponding to voxel center points). The resulting comparison is 
shown in Figure 2.8 where the percent difference is calculated with respect to 3D cubic 
interpolation since it provides the best agreement with the reference MCNP5 
calculations. The line edit flux data from seraPlan exhibit discontinuities at voxel edges 
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as large as 4%. The magnitude of these jumps depends on the curvature of the voxel data, 
with the largest occurring in regions of high curvature (e.g., the thermal neutron flux 
peak). Moreover, the point edit flux data, which are sampled at the voxel center points 
where the effect of interpolation should be to return the voxel-averaged value, match the 
seraPlan line edit data and exhibit disagreements of up to ~2% with the uninterpolated 
SERA voxel data. While 1D and 3D linear interpolation produce identical flux data, 
neither interpolation method is able to accurately model the curvature of the thermal 
neutron flux peak. Even 1D cubic interpolation results in differences as large as 2.5% in 
regions of high curvature. Nevertheless, when the interpolation error is eliminated by 
using MATLAB to interpolate the coarse voxel data, agreement with the reference 
calculations is improved, as shown in Figure 2.9. Due to the similarities between the 
BNCT_Rtpe and SERA data as well as between the MacNCTPlan and NCTPlan data, 
only data for SERA and NCTPlan are represented in Figure 2.9 for clarity. The 
characteristic patterns of percent difference for NCTPlan are no longer present, resulting 
in ~2% better agreement at a depth of 4.5 cm Also, 3D cubic interpolation of the 
NCTPlan voxel data is better able to model the curvature of the reference flux profile, 
resulting in as much as a 3% improvement in agreement at integral depths over linear 
interpolation. The agreement for SERA at the thermal neutron flux maximum improves 
by ~3% using MATLAB’s 3D cubic interpolation, and discontinuities are eliminated. 
However, even when interpolation errors are corrected in Figure 2.9, SERA (and 
BNCT_Rtpe) still overestimate the reference thermal neutron flux at the peak and along 
the downstream side.  
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Disagreement in flux in the absence of geometric approximations indicates 
differences in transport calculations and therefore warrants closer examination of the 
SERA and MCNP5 neutron cross sections for H2O, shown in Figure 2.10. The MCNP5 
S(α,β) thermal neutron scattering cross sections for hydrogen in light water are defined 
up to higher neutron energies than the corresponding data in SERA, resulting in an 
energy region (0.414 eV ≤ En ≤ 4.46 eV which is highlighted and expanded in Figure 
2.10) where SERA and MCNP5 cross sections differ by up to 15%. Therefore, during 
SERA transport calculations in the large rectangular water phantom, neutrons in this 
energy range (16% of neutrons at the phantom entrance and 9% of neutrons at 2.0 cm 
depth) are subjected to cross sections that are as much as 15% lower than the 
corresponding MCNP5 cross sections, which in SERA (and BNCT_Rtpe) may contribute 
to a higher maximum thermal neutron flux and a more penetrating beam. Conversely, the 
large difference in cross sections at neutron energies below ~1 meV does not 
significantly affect the thermal neutron flux agreement since a very small percentage of 
neutrons are in that very low energy range (0.2% of neutrons at 2.0 cm depth). It should 
also be noted that the comparison of total neutron cross sections in Figure 2.10 is a rather 
simplistic representation of more complex data. Therefore, it is important not to 
oversimplify the explanation of the observed disagreement in thermal neutron flux since 
other factors, like differences in transport physics between rtt_MC, seraMC, and 
MCNP5, are also very likely responsible but difficult to evaluate. 
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Figure 2.6 Thermal neutron flux and percent difference (100×[TPS−Ref]/Refmax) as a 
function of depth along the central beam axis in the large rectangular 
water phantom for each planning system. SERA and BNCT_Rtpe data are 
calculated at (default) intervals of 5 mm. MCNP5 served as the reference 
for percent difference calculations. 
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Figure 2.7 Thermal neutron flux and percent difference (100×[TPS−Ref]/Refmax) as a 
function of depth along the central beam axis in the large rectangular 
water phantom for different representations of the SERA and NCTPlan 
voxel data. The uninterpolated voxel data from SERA and NCTPlan were 
read and interpolated using MATLAB for comparison to the interpolated 
output of each TPS, as well as MCNP5, to illustrate the interpolation 
errors in both TPSs. SERA data (solid line) are evaluated at intervals of 5 
mm. MCNP5 served as the reference for percent difference calculations. 
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Figure 2.8 Thermal neutron flux and percent difference (100×[TPS−Ref]/Refmax) as a 
function of depth along the central beam axis in the large rectangular 
water phantom for different representations of the SERA voxel data. The 
uninterpolated SERA voxel data were read and interpolated using 
MATLAB for comparison to the interpolated output of seraPlan to 
illustrate interpolation errors in the line and point edit data. The data 
produced using 3D cubic interpolation served as the reference for percent 
difference calculations since it produced the closest agreement to the 
reference calculations. 
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Figure 2.9 Thermal neutron flux and percent difference (100×[TPS−Ref]/Refmax) as a 
function of depth along the central beam axis in the large rectangular 
water phantom for MATLAB interpolations of voxel data from each TPS. 
The uninterpolated voxel data from each TPS were read and interpolated 
using MATLAB to illustrate the agreement with MCNP5 when 
interpolation errors are eliminated. MCNP5 served as the reference for 
percent difference calculations. 
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Figure 2.10 Total neutron cross sections for H2O used by MCNP and SERA in 
transport calculations. Cross section data for both include the S(α,β) 
thermal neutron scattering treatment for hydrogen in light water. The 
energy range (0.414 eV ≤ En ≤ 4.46 eV) is highlighted and expanded to 
better illustrate the difference in cross sections. This energy range 
represents ~9% of the neutrons at the thermal neutron flux peak (2.0 cm 
depth) in the large rectangular water phantom. 
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2.3.1.1.2 Boron Dose 
Figure 2.11 shows the comparison of boron dose rate profiles for the 4 TPSs with 
the reference in the large rectangular water phantom for a 10B concentration of 15 μg/g. 
Given the dependence of the boron dose on the thermal neutron flux, it is not surprising 
that the comparison of boron dose rates exhibits many of the same features observed with 
the thermal neutron flux. The −9% to 15% differences for MacNCTPlan and NCTPlan at 
depths less than ~2.5 cm are again due to the inability of linear interpolation to model the 
curvature of the reference dose profile using dose data from a coarse scoring mesh. At 
depths greater than 2.5 cm, interpolation error results in characteristic “sawtooth” 
patterns in the percent difference profiles of MacNCTPlan and NCTPlan, 
underestimating the reference boron dose rates by less than 5% and 2.5%, respectively. 
This agreement is nearly identical to that observed in the comparison of thermal neutron 
flux, which is expected since identical boron kerma factor data are used. However, 
BNCT_Rtpe boron dose rates in Figure 2.11 are ~1.5% larger than the corresponding 
SERA values at most depths despite their nearly identical thermal neutron flux profiles. 
This observation is consistent with the differences in boron kerma data shown in Figure 
2.12. Over the neutron energy range 4 meV ≤ En ≤ 0.25 MeV, the mean differences 
between the multigroup BNCT_Rtpe (94 energy groups) and SERA (717 energy groups) 
boron kerma factors and the pointwise continuous reference boron kerma factors are 
−1.1% and −2.5%, respectively, which explains the ~1.5% difference between the 
BNCT_Rtpe and SERA boron dose rates observed in Figure 2.11. However, the 
disagreement for BNCT_Rtpe and SERA at dmax, 10.5% and 9.1%, respectively, is larger 
than that predicted from the combination of differences in the calculated thermal neutron 
flux, and kerma factors, and the interpolation error. The worse agreement results from 
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both BNCT_Rtpe and SERA improperly scaling the boron, nitrogen, and hydrogen 
neutron kerma factors by the mass density of the edit mesh biological material at runtime. 
This was determined through numerical experiments with the two TPSs and through 
review of their source code. In calculating the edit mesh composition for BNCT_Rtpe 
and SERA, the density of ICRU adult brain (ρ=1.04 g/cm3) is used to convert 1 μg/g 10B, 
2.2% nitrogen, and 10.7% hydrogen into the corresponding atomic densities in 
atoms/barn·cm as required by both TPSs. Since these edit mesh atomic densities are used 
by BNCT_Rtpe and SERA to directly scale the elemental boron, nitrogen, and hydrogen 
kerma data (in units of cGy·barn·g) without any consideration of the edit mesh material 
density* (which should divide energy per unit volume to yield dose), the resulting dose 
rates are improperly multiplied by the density of ICRU adult brain, 1.04 g/cm3. 
Therefore, in addition to the ~3% overestimation of the reference maximum thermal 
neutron flux by BNCT_Rtpe and SERA and the ~3% interpolation error, a 4% error is 
introduced by improperly scaling the boron kerma data, producing maximum boron dose 
rates 9-10% larger than the reference.  
To better illustrate the runtime scaling of INL kerma data, the nitrogen dose rates 
calculated by MCNP5 and SERA in the large rectangular water phantom were divided by 
the corresponding thermal neutron flux to compare the relative scale of the kerma factors 
actually used for dose calculations since the ration of nitrogen dose to thermal neutron 
flux should be relatively constant. An additional SERA simulation was performed in the 
large rectangular water phantom where the density of water was reduced by a factor of 4 
to approximate BNCT dose calculations for human lung, which have been investigated 
                                                 
* This seems to be a result of improperly assuming that the mass density will always be 1.0 g/cm3. 
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using SERA.58 Accordingly, the SERA edit mesh compositions for 10B, nitrogen, and 
hydrogen in that simulation were specified for adult human lung with a density of 0.25 
g/cm3. The resulting ratios of nitrogen dose rate to thermal neutron flux for these three 
simulations are shown in Figure 2.13. When an edit mesh composition for brain is 
specified in SERA, the dose to flux ratio for SERA is larger than the corresponding 
MCNP5 ratio by a factor equal to the mass density of brain in g/cm3, 1.04. Likewise, 
when an edit mesh composition for lung is specified in SERA, the SERA ratio is reduced 
by a factor of 4 confirming that the SERA nitrogen kerma factors had in fact been 
multiplied by the mass density of lung.  
To better understand the influence that different boron kerma factors have on 
calculations of boron dose rates, especially in terms of continuous energy vs. multigroup, 
the multigroup BNCT_Rtpe and SERA boron kerma factors from Figure 2.12 were 
multiplied by 1.04 and used in MCNP5 calculations of boron dose rate profiles in the 
large rectangular water phantom. When the resulting boron dose rate profiles are 
compared to BNCT_Rtpe and SERA as shown in Figure 2.14, the differences (e.g., ~7% 
difference in maximum boron dose rates) are reduced to levels consistent with the 
agreement in thermal neutron flux. If the MCNP5 boron dose rate profiles calculated 
using BNCT_Rtpe and SERA multigroup boron kerma factors are compared to the 
MCNP5 profiles calculated with reference pointwise continuous boron kerma factors, the 
differences that result (3.3% for BNCT_Rtpe kerma data and 1.3% for SERA kerma data 
at 2.0 cm depth) are almost entirely due to differences in magnitude between the boron 
kerma data (−1.1% for BNCT_Rtpe and −2.5% for SERA as shown in Figure 2.12) and 
the 4% error resulting from improperly scaling the INL boron kerma data by mass 
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density. Therefore, when simulating realistic (i.e., polyenergetic) beams with a broad 
neutron spectrum, any differences that are introduced by approximating continuous 
energy kerma data with multigroup kerma data are small compared to these other errors.  
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Figure 2.11 Boron dose rate for a 10B concentration of 15 μg/g and percent difference 
(100×[TPS−Ref]/Refmax) as a function of depth along the central beam 
axis in the large rectangular water phantom for each planning system. 
MCNP5 served as the reference for percent difference calculations. 
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Figure 2.12 Boron neutron kerma factors used in the reference, BNCT_Rtpe, and 
SERA calculations of boron dose and the percent difference of the 
BNCT_Rtpe and SERA kerma data from the reference kerma data. The 
reference data are pointwise continuous while the BNCT_Rtpe and SERA 
kerma data have 94 and 717 energy groups, respectively. 
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Figure 2.13 Ratio of nitrogen dose rate to thermal neutron flux as a function of depth 
in the large rectangular water phantom. For SERA, edit mesh atomic 
densities corresponding to brain (ρ=1.04 g/cm3) and lung (ρ=0.25 g/cm3) 
were specified in two separate simulations. When an edit mesh 
composition of lung was used in SERA, the density of water in the 
phantom was reduced to 0.25 g/cm3 to approximate neutron transport 
through adult human lung. The ratios illustrate that SERA nitrogen 
(hydrogen and boron) kerma factors are scaled at runtime by the mass 
density of the edit mesh material. 
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Figure 2.14 Boron dose rate for a 10B concentration of 15 μg/g and percent difference 
(100×[TPS−Ref]/Refmax) as a function of depth along the central beam 
axis in the large rectangular water phantom for each planning system. 
Multigroup boron neutron kerma factors from BNCT_Rtpe and SERA 
were used in MCNP5 calculations of boron dose rates, which served as the 
reference for BNCT_Rtpe and SERA percent difference calculations, 
respectively. 
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2.3.1.1.3 Thermal Neutron Dose 
The reference MCNP5, MacNCTPlan, and NCTPlan thermal neutron dose rate 
profiles as well as BNCT_Rtpe and SERA nitrogen dose rate profiles in the large 
rectangular water phantom are compared in Figure 2.15. Not surprisingly, MacNCTPlan 
and NCTPlan exhibit similar agreement to that observed in the thermal neutron flux 
comparison in Figure 2.6. Linear interpolation between the elements of the coarse scoring 
mesh, centered at ½ integral depths in the phantom, is unable to accurately model the 
curvature of the reference dose profile which results in significant differences (−9% to 
16%) at shallow depths. When the curvature of the reference profile decreases, agreement 
improves to within 5% for MacNCTPlan and NCTPlan, and characteristic patterns 
produced by interpolation error are observed. Nevertheless, NCTPlan generally produces 
better agreement than MacNCTPlan by 2-3%.  
BNCT_Rtpe and SERA do not calculate the dose from thermal neutrons in the 
same manner as the reference calculations. Whereas the reference calculations, as well as 
MacNCTPlan and NCTPlan, use total brain neutron kerma factors (i.e., weighted sum of 
kerma from 1H, 14N, 12C, 16O, 31P, sulfur, and chlorine) and a definite energy cutoff (En ≤ 
0.5 eV) to define the dose from thermal neutrons, BNCT_Rtpe and SERA use multigroup 
nitrogen kerma factors (represented with 94 energy groups) to calculate the dose from the 
14N(n,p)14C reaction for all neutron energies. In Figure 2.15, BNCT_Rtpe and SERA 
produce nearly identical nitrogen dose rate profiles due to the similarity of their transport 
codes and identical nitrogen kerma factors. BNCT_Rtpe and SERA nitrogen dose rates 
overestimate the reference peak thermal neutron dose rate by ~10%, which is due to 
differences in thermal neutron flux calculations (refer to Figure 2.9), interpolation error 
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(refer to Figure 2.7), and the improper scaling of nitrogen kerma factors by the mass 
density of the edit mesh (refer to Figure 2.13). A comparison of the INL multigroup 
nitrogen kerma factors to nitrogen kerma factors from ICRU Report 6359 indicates an 
average difference of only ~1% as shown in Figure 2.16. When compared to total brain 
neutron kerma factors, as shown in Figure 2.17, the INL nitrogen kerma factors are on 
average 4% lower in the thermal neutron energy range since the total brain neutron kerma 
includes contributions from other elements other than nitrogen. In fact, ~2.5% and ~1% 
of the reference thermal neutron dose rate at 2.0 cm depth is from hydrogen and chlorine, 
respectively. However, the lack of an upper energy boundary to the BNCT_Rtpe and 
SERA nitrogen dose tally allows an epithermal and fast neutron contribution to the 
nitrogen dose (e.g., 2.3% of the nitrogen dose at 2.0 cm depth is from neutrons above 0.5 
eV) that helps compensate for the 4% difference in nitrogen and total brain neutron 
kerma factors. While this epithermal and fast neutron contribution to the nitrogen dose is 
properly accounted for in the thermal and fast neutron dose accounting scheme, it does 
not contribute to the reference thermal neutron dose in Figure 2.15, but it does contribute 
to the nitrogen dose in BNCT_Rtpe and SERA. To further address the significance of 
using different kerma data, the multigroup INL nitrogen kerma factors (which were 
multiplied by 1.04 to simulate BNCT_Rtpe and SERA’s runtime multiplication of kerma 
factors by the mass density of the edit mesh) as well as ICRU nitrogen kerma factors 
from Figure 2.16 were used in MCNP5 to calculate nitrogen dose rates in the large 
rectangular water phantom as shown in Figure 2.18. Using INL nitrogen kerma factors in 
MCNP5 produces a maximum nitrogen dose rate ~6.8% lower than BNCT_Rtpe and 
SERA (which is consistent with the ~3% difference in thermal neutron flux and the ~3% 
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interpolation error) and 4% higher than calculated with ICRU nitrogen kerma factors 
(which is consistent with the runtime multiplication of the INL kerma factors by the mass 
density of the edit mesh).  
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Figure 2.15 Thermal neutron (and nitrogen) dose rate and percent difference 
(100×[TPS−Ref]/Refmax) as a function of depth along the central beam 
axis in the large rectangular water phantom for each planning system. 
MCNP5 served as the reference for percent difference calculations. 
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Figure 2.16 Comparison of BNCT_Rtpe and SERA multigroup (94 energy groups) 
nitrogen and hydrogen neutron kerma data to the corresponding pointwise 
continuous ICRU kerma data. The percent difference between the INL and 
ICRU kerma data was calculated with the ICRU kerma data as the 
reference. The INL hydrogen kerma data does not include the contribution 
from the recoil deuteron which leads to large differences in the thermal 
neutron energy range. The vertical dashed line represents the energy 
cutoff at 0.5 eV that is used to separate the thermal and fast neutron dose 
components in the reference MCNP5 calculations. No such energy 
binning is used in BNCT_Rtpe or SERA. 
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Figure 2.17 Comparison of BNCT_Rtpe and SERA multigroup (94 energy groups) 
nitrogen and hydrogen neutron kerma data to pointwise continuous 
reference total brain neutron kerma data. The percent difference between 
the summed INL nitrogen and hydrogen kerma data and the total brain 
kerma data was calculated with the total brain kerma data as the reference. 
The vertical dashed line represents the energy cutoff at 0.5 eV that is used 
to separate the thermal and fast neutron dose components in the reference 
MCNP5 calculations. No such energy binning is used in BNCT_Rtpe or 
SERA. 
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Figure 2.18 Nitrogen dose rate and percent difference (100×[TPS−Ref]/Refmax) as a 
function of depth along the central beam axis in the large rectangular 
water phantom for each planning system. Multigroup INL nitrogen 
neutron kerma factors were used in MCNP5 calculations of nitrogen dose 
rates, which served as the reference for percent difference calculations. 
Nitrogen dose rates calculated with ICRU 63 nitrogen kerma factors are 
included as a point of comparison. 
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2.3.1.1.4 Fast Neutron Dose 
The reference MCNP5, MacNCTPlan, and NCTPlan fast neutron dose rates as 
well as BNCT_Rtpe and SERA hydrogen dose rates are shown as a function of depth in 
the large rectangular water phantom and compared in Figure 2.19. The nearly −7% 
disagreement for MacNCTPlan and NCTPlan at the surface of the phantom is due to the 
inability of data linearly interpolated from the coarse voxel mesh to model the sudden 
change in the fast neutron dose rate. MacNCTPlan and NCTPlan deviate from the 
reference calculations by less than 3% and 1%, respectively, at ½ integral depths (voxel 
center points). However, at depths in between, characteristic patterns of larger percent 
difference (up to 2.2%) are observed, especially for NCTPlan, and due to error in the 
interpolation algorithms of these TPSs.  
BNCT_Rtpe and SERA do not calculate the dose from fast neutrons in the same 
manner as the reference MCNP5 calculations. BNCT_Rtpe and SERA use multigroup 
hydrogen kerma factors (represented with 94 energy groups) to calculate the dose from 
the 1H(n,n′)1H proton recoil reaction for all neutron energies rather than to tally dose 
from neutrons above 0.5 eV using total brain neutron kerma factors. In Figure 2.19, 
BNCT_Rtpe and SERA hydrogen dose rates underestimate the reference fast neutron 
dose rate by 46% at the phantom entrance. Several factors contribute to this significant 
disagreement. In Figure 2.16, the comparison of INL and ICRU 63 hydrogen kerma 
factors show significant differences at neutron energies below ~50 eV because the INL 
hydrogen kerma factors do not include kerma from the recoil deuteron that results from 
neutron capture by hydrogen [1H(n,γ)2H]. In fact, INL hydrogen kerma factors drop to 0 
at neutron energies below 0.414 eV. A separate MCNP5 simulation with both ICRU and 
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INL hydrogen kerma factors indicated that kerma from the recoil deuteron is responsible 
for 5.4% of the hydrogen dose at a depth of 1.0 cm. Therefore, the underestimation of the 
reference fast neutron dose rates by BNCT_Rtpe and SERA is at least partially due to 
incomplete INL hydrogen kerma factors. Another MCNP5 simulation also showed that 
~13% of the reference fast neutron dose at 1.0 cm depth is from elements other than 
hydrogen (8% from 14N, 4% from 16O, and 1% from chlorine), so the hydrogen dose will 
naturally underestimate the fast neutron dose, especially when the significant thermal 
neutron contribution to the hydrogen dose (via the recoil deuteron) is not included. If 
kerma from the recoil deuteron is included in MCNP5 hydrogen dose calculations (with 
ICRU hydrogen kerma factors), the contribution of thermal neutrons below 0.5 eV to the 
hydrogen dose helps partially compensate for the ~13% of the fast neutron dose that is 
from elements other than hydrogen to result in a hydrogen dose at 1.0 cm depth that 
underestimates the fast neutron dose by only ~5%. Nevertheless, the largest contribution 
to the significant underestimation of the reference fast neutron dose rates in Figure 2.19 
results from an energy cutoff for the BNCT_Rtpe and SERA fast neutron source biasing 
run mode (run mode F) that is set too high. After completing the normal neutron transport 
calculations (run mode N), the hydrogen dose rates are cleared and reset to zero in 
preparation for the biased fast neutron calculations since the codes do not permit 
hydrogen dose data from the two run modes to be combined. When the default biased fast 
neutron run mode is used, neutrons greater than 9.12 keV are sampled from the source 
(with appropriately adjusted weights) and tracked in order to tally hydrogen dose and fast 
neutron flux until their energy falls below 9.12 keV, at which point tracking stops. 
Therefore, only those neutrons with energy greater than 9.12 keV contribute to the 
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BNCT_Rtpe and SERA hydrogen dose rates, but a separate MCNP5 simulation using the 
multigroup INL hydrogen kerma factors indicated that ~33% of the hydrogen dose at 1.0 
cm depth is from neutrons below 9.12 keV. Thus, the default biasing energy cutoff is set 
too high and therefore contributes significantly to the drastic underestimation of 
reference fast neutron dose rates by hydrogen dose rates. If BNCT_Rtpe and SERA 
simulations with the biased fast neutron mode disabled are compared to MCNP5 
calculations using INL multigroup and ICRU 63 pointwise continuous hydrogen kerma 
factors, the agreement improves significantly as shown in Figure 2.20. It is interesting to 
note that in Figure 2.20 the contribution of the recoil deuteron to the ICRU hydrogen 
kerma factors helps to produce higher hydrogen dose rates at depths beyond 6 mm 
despite the INL hydrogen kerma data having been increased by 4% to model the runtime 
scaling by the edit mesh mass density in BNCT_Rtpe and SERA. Also, the presence of 
noticeable statistical fluctuations in the hydrogen dose rate (and percent difference) 
profiles of BNCT_Rtpe and SERA in Figure 2.20 despite having simulated 3.3×108 and 
9.9×107 particles,* respectively, helps illustrate the importance of the biased fast neutron 
run mode. However, the default setting is not appropriate for an epithermal neutron beam 
and results in a significant underestimation of the hydrogen dose rate, so it must be 
adjusted to a value that is appropriate for the neutron source. 
In attempting to compensate for poor convergence of the fast neutron flux and 
“Ultra” dose (typically from carbon and oxygen) in SERA, a subtle error was introduced 
in the interpolation code of seraPlan that affects only interpolated fast neutron flux and 
“Ultra” dose data. To illustrate this error, fast neutron flux data from seraPlan line (at 0.1 
                                                 
* SERA will crash when transitioning from one run mode to another (e.g., N to G) if the number of 
particles simulated exceeds 8 digits or 99,999,999. 
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mm intervals) and point edits are shown in Figure 2.21 and compared to data interpolated 
from the same coarse voxel data using MATLAB. The interpolation error in seraPlan 
results in a stepped fast neutron flux profile that produces differences as large as 15% 
when compared to 3D cubic interpolation from MATLAB; similar results are observed 
for interpolated “Ultra” doses. It is important to understand that this interpolation error is 
different from that shown in Figure 2.7 (which affects all interpolated data in both 
BNCT_Rtpe and SERA) and is only present in interpolated fast neutron flux and “Ultra” 
dose data produced by seraPlan. 
2.3.1.1.5 Total Neutron Dose 
Approximately 98% of the reference total neutron dose (i.e., thermal + fast 
neutron dose) at 2.0 cm depth in the large rectangular water phantom is from neutron 
interactions with nitrogen (77%) and hydrogen (21%), and the rest is mainly from 
interactions with oxygen (0.89%), chlorine (0.84%), and carbon (0.27%). Thus, a 
comparison of the summed nitrogen and hydrogen dose from BNCT_Rtpe and SERA to 
the reference total neutron dose should almost eliminate any disagreement that results 
from differences in dose definitions; one should expect the summed hydrogen and 
nitrogen doses to underestimate the reference total neutron dose by only 2% at 2.0 cm 
depth. The comparison of summed INL nitrogen and hydrogen kerma factors to reference 
total brain neutron kerma factors in Figure 2.17 predicts a larger underestimation since 
the INL hydrogen kerma factors lack the contribution from the recoil deuteron which 
results in an average difference in kerma of −4.3% for 4.1 meV ≤ En ≤ 2 MeV. However, 
the INL nitrogen and hydrogen kerma factors in Figure 2.17 are multiplied at runtime by 
the mass density of the edit mesh material in g/cm3, 1.04. Therefore, if differences in 
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kerma data were the only source of disagreement, the summed nitrogen and hydrogen 
dose from BNCT_Rtpe and SERA would underestimate the reference total neutron dose 
by −0.3%. When other sources of disagreement between BNCT_Rtpe, SERA, and the 
reference are considered, such as differences in thermal neutron flux (~3%) and 
interpolation error (~3%), the predicted percent difference at 2.0 cm depth increases to 
5.7%. This predicted disagreement is actually quite close to the observed disagreement in 
Figure 2.22 where the summed nitrogen and hydrogen dose from BNCT_Rtpe and SERA 
overestimate the reference total neutron dose at 2.0 cm depth by 5.2% and 5.5%, 
respectively. If SERA “Ultra” dose (from carbon and oxygen) is summed with the 
nitrogen and hydrogen dose, the disagreement between SERA and the reference increases 
from 5.5% to 6.5%, which is consistent with the observation that neutron interactions 
with those elements included in the “Ultra” dose are responsible for ~1% of the total 
neutron dose. Thus, although comparing BNCT_Rtpe and SERA nitrogen + hydrogen 
dose to the reference thermal + fast neutron dose avoids differences in dose definition, 
other sources of disagreement persist. Meanwhile, MacNCTPlan and NCTPlan produce 
agreement in total neutron dose rate, −4.3% and −2.9% at 2.0 cm depth, respectively, that 
is simply a combination of the agreement in thermal and fast neutrons dose rate because 
both TPSs defines thermal and fast neutron dose in a manner identical to the reference 
calculations. For instance, the difference for NCTPlan is a combination of the 1.8% 
overestimation of the fast neutron dose rate in Figure 2.19 and the −4.8% 
underestimation of the thermal neutron dose rate in Figure 2.15. 
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Figure 2.19 Fast neutron (and hydrogen) dose rate and percent difference 
(100×[TPS−Ref]/Refmax) as a function of depth along the central beam 
axis in the large rectangular water phantom for each planning system. 
MCNP5 served as the reference for percent difference calculations. 
Computational Aspects of Treatment Planning for Neutron Capture Therapy 
 
 160
−1 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14
0
0.05
0.1
0.15
Hydrogen Dose Rate (Rectangular Water Phantom)
Depth in Rectangular Water Phantom (cm)
D
os
e 
R
at
e 
(G
y/
m
in
)
MCNP5 (INL hydrogen kerma factors)
MCNP5 (ICRU hydrogen kerma factors)
BNCT_Rtpe (no fast neutron src. biasing)
SERA (no fast neutron src. biasing)
−1 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14
−8
−6
−4
−2
0
2
4
Depth in Rectangular Water Phantom (cm)
P
er
ce
nt
 D
iff
er
en
ce
MCNP5 (ICRU hydrogen kerma factors)
BNCT_Rtpe (no fast neutron src. biasing)
SERA (no fast neutron src. biasing)
 
Figure 2.20 Hydrogen dose rate and percent difference (100×[TPS−Ref]/Refmax) as a 
function of depth along the central beam axis in the large rectangular 
water phantom for each planning system. Multigroup INL hydrogen 
neutron kerma factors were used in MCNP5 calculations of hydrogen dose 
rates, which served as the reference for percent difference calculations. 
The fast neutron source biasing run mode was not used for BNCT_Rtpe or 
SERA (i.e., run modes “NGD” were used). Hydrogen dose rates 
calculated with ICRU 63 hydrogen kerma factors are included as a point 
of comparison. 
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Figure 2.21 Fast neutron flux and percent difference (100×[TPS−Ref]/Refmax) as a 
function of depth along the central beam axis in the large rectangular 
water phantom for different representations of the SERA voxel data. The 
uninterpolated SERA voxel data were read and interpolated using 
MATLAB for comparison to the interpolated output of seraPlan to 
illustrate interpolation errors in the line and point edit data. The data 
produced using 3D cubic interpolation served as the reference for percent 
difference calculations since it produced the closest agreement to MCNP5. 
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Figure 2.22 Total neutron dose rate (thermal+fast and hydrogen+nitrogen) and percent 
difference (100×[TPS−Ref]/Refmax) as a function of depth along the 
central beam axis in the large rectangular water phantom for each planning 
system. MCNP5 served as the reference for percent difference 
calculations. 
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2.3.1.1.6 Induced Photon Dose 
Figure 2.23 compares induced photon dose rate profiles from each TPS to the 
reference in the large rectangular water phantom. Since induced photons are produced by 
the interactions of thermal neutrons, it is not surprising that the differences for 
MacNCTPlan and NCTPlan induced photon dose rates are similar to those observed for 
the thermal neutron flux in Figure 2.6. However, the comparison of thermal neutron flux 
produced worse agreement at shallow depths. For instance, at a depth of 8 mm, the 
difference in induced photon dose rate for MacNCTPlan is −2.3% while there is a −6.6% 
difference in thermal neutron flux at the same depth. Similarly, for NCTPlan, the 
difference in induced photon dose rate is −4.1%, and the difference in thermal neutron 
flux at that depth is −9.1%. This improved agreement at shallow depths can be attributed 
to the different shapes and positions of the induced photon dose rate and thermal neutron 
flux peaks. The linear interpolation employed by MacNCTPlan and NCTPlan is better 
able to estimate dose rates along the upstream edge of the induced photon dose rate peak 
since it broader and occurs 4 mm deeper in the phantom than the thermal neutron flux 
peak. On the downstream edge of the peak at depths greater than 2.4 cm, NCTPlan 
produces better agreement than MacNCTPlan by ~2%, and both TPSs exhibit their 
characteristic interpolation error.  
In Figure 2.23, the differences between BNCT_Rtpe and SERA induced photon 
dose rate profiles (e.g., 8% at 2.5 cm depth) are not consistent with the similarities 
expected and largely observed for other dose components with these two TPSs. The 
differences in induced photon dose rates arise from rather significant differences in 
photon kerma factors; comparing BNCT_Rtpe and SERA photon kerma factors with 
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those used in the reference calculations, as shown in Figure 2.24, demonstrates large 
differences that reach a maximum of 136% difference at Eγ=60 keV. BNCT_Rtpe also 
differs from SERA in the number of photon kerma and cross section energy groups (70 
for BNCT_Rtpe vs. 86 for SERA) and in the assignment of a point kerma value of 
9.58×10−12 Gy cm2 to 2.2 MeV photons (from the 1H(n,γ)2H reaction) only which is 4.2% 
larger than the corresponding SERA multigroup kerma and 8.1% larger than the 
reference value calculated from NIST data. However, since a separate MCNP5 
simulation indicated that 97% of the maximum induced photon dose rate is from photons 
above 1 MeV, the differences for BNCT_Rtpe induced photon dose rates (~11% at 2.5 
cm depth) are not as large as might be expected given the differences in photon kerma 
factors shown in Figure 2.24. Therefore, while very significant differences in photon 
kerma are indeed present for BNCT_Rtpe, photons in the energy range where the largest 
differences occur do not significantly contribute to the induced photon dose rate. For 
SERA, better agreement with the reference photon kerma factors (3.7% at 2.2 MeV) 
translates into better agreement in induced photon dose rates (3.6% at 2.5 cm depth). To 
further illustrate that the disagreement in induced photon dose rates is mainly attributable 
to differences in photon kerma factors, BNCT_Rtpe and SERA multigroup photon kerma 
factors were used in MCNP5 simulations to calculate induced photon dose rate profiles in 
the large rectangular water phantom, and the resulting dose data are compared to 
BNCT_Rtpe and SERA in Figure 2.25. When differences in photon kerma are 
eliminated, the agreement of BNCT_Rtpe and SERA with reference MCNP5 calculations 
is within 1.5%. Nevertheless, it is important to point out that BNCT_Rtpe and SERA 
treat induced photons as isotropic volume sources calculated from photon production 
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tallies in each 1 cm3 volume of the tally mesh calculated during the normal neutron run 
mode (run mode N). As a result, the position of induced photons within each tally voxel 
is not preserved as in MCNP5 transport calculations (where neutron-induced photons are 
stored in a bank for later transport), and induced photons will only be sampled in those 
regions of the geometry covered by the 30×30×30 cm3 tally mesh. The limitation of the 
tally mesh size and photon production did not appear to introduce any significant 
differences into the induced photon dose calculations in the large rectangular water 
phantom since the tally mesh sufficiently covered the region of interest along the central 
beam axis. Nevertheless, it is important to be aware of this issue since it may cause 
variable photon production in the collimator in more realistic clinical situations; i.e., 
coverage of the collimator by the tally mesh can affect photon production there. 
2.3.1.1.7 Incident Photon Dose 
Figure 2.26 compares incident photon dose rate profiles from each TPS to the 
reference in the large rectangular water phantom. MacNCTPlan and NCTPlan produce 
excellent agreement to within 1.5% and 1.0% of the reference, respectively. For the 
reference dose profile, the curvature that is characteristic of the other reference dose 
component profiles is not present, so linear interpolation between the coarse voxels is 
better able to model the reference dose rate profile. The voxel doses for MacNCTPlan 
and NCTPlan are not statistically different from the reference incident photon doses, but 
interpolation error causes the interpolated dose data to deviate from the voxel data, 
especially at depth, and produce the observed disagreement. If MATLAB is used to 
linearly interpolate the voxel doses, agreement improves to within 0.4% at all depths. 
BNCT_Rtpe and SERA produce different induced photon dose rates profiles mainly due 
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to the differences in photon kerma data, shown in Figure 2.24. For 2.0 MeV photons, the 
BNCT_Rtpe photon kerma factor is 5% larger than the reference value while the SERA 
photon kerma factor is 1.2% smaller which helps to explain the relative magnitude of 
their dose rate profiles with respect to the reference. If differences due to photon kerma 
factors are removed by using multigroup photon kerma factors from BNCT_Rtpe and 
SERA in MCNP5 calculations of incident photon dose rates in the large rectangular 
water phantom, the percent differences for both TPSs shift to roughly −2% for all depths, 
as shown in Figure 2.27, perhaps indicating the presence of a systematic difference. Upon 
further investigation, a subtle error in the BNCT_Rtpe and SERA photon dose 
calculations was found that resulted in the incident photon dose rates being too low. 
However, the error in the incident photon dose rates can be predicted by 
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totgpratiogam
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orig
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×−+
+=    (2.1) 
where gam_ratio (gamma ratio) is the BNCT_Rtpe or SERA incident photon yield 
(γ/cm2s) divided by the total source particle yield (n+γ/cm2s) and gp_tot (gamma 
production total) is the number of induced photons per source neutron. Both gam_ratio 
and gp_tot are reported in BNCT_Rtpe and SERA output files. Since Eq. 2.1 will always 
evaluate to a value that is greater than 1, the original uncorrected incident photon dose 
rates (Dorig) will always be smaller than the corresponding corrected values (Dcorr). When 
applied to the BNCT_Rtpe and SERA calculations in the large rectangular water 
phantom with the generic epithermal neutron and monoenergetic 2 MeV incident photon 
beams (gam_ratio=0.0196, gp_tot=0.4188), Eq. 2.1 evaluates to 1.019. This indicates that 
the BNCT_Rtpe and SERA incident photon dose rates in Figure 2.26 and Figure 2.27 
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should be scaled up by 1.019 (Dcorr=1.019×Dorig) to correct for the error. This corrective 
scaling compensates for the roughly constant −2% difference in Figure 2.27 to produce 
very good agreement with the incident photon dose rates calculated with MCNP5 using 
BNCT_Rtpe and SERA photon kerma factors. A closer examination revealed that the 
error also affects the induced photon dose as predicted by 
⎟⎟⎠
⎞
⎜⎜⎝
⎛
×−+−= )__(__
_1
2
totgpratiogamtotgpratiogam
ratiogam
D
D
orig
corr    (2.2) 
This equation will always evaluate to less then unity indicating that the original 
uncorrected induced photon dose rates (Dorig) will always be larger than the corrected 
values (Dcorr). However, for the generic epithermal neutron and monoenergetic 2 MeV 
incident photon beams, Eq. 2.2 indicates that Dcorr=0.9991×Dorig, so the error in induced 
photon dose is not actually significant. Although the errors described by Eqs. 2.1 and 2.2 
will affect the total photon dose, they counteract each other to result in a very small net 
difference. For instance, when the incident photon dose is ~10% of the induced photon 
dose, the error in the total photon dose is less than 0.1%, and is therefore neither 
noticeable nor significant. Even if the incident photon yield is increased by a factor of 5 
to produce an incident photon dose that is ~50% of the induced photon dose, the error in 
the total is still only approximately −1.3%. 
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Figure 2.23 Induced photon dose rate and percent difference (100×[TPS−Ref]/Refmax) 
as a function of depth along the central beam axis in the large rectangular 
water phantom for each planning system. MCNP5 served as the reference 
for percent difference calculations. 
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Figure 2.24 Photon kerma factors used in the reference, BNCT_Rtpe, and SERA 
calculations of induced and incident photon dose and the percent 
difference of the BNCT_Rtpe and SERA kerma data from the reference 
kerma data. The reference data are pointwise continuous while the 
BNCT_Rtpe and SERA kerma data have 70 and 86 energy groups, 
respectively. 
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Figure 2.25 Induced photon dose rate and percent difference (100×[TPS−Ref]/Refmax) 
as a function of depth along the central beam axis in the large rectangular 
water phantom for each planning system. Multigroup photon kerma 
factors from BNCT_Rtpe and SERA were used in MCNP5 calculations of 
induced photon dose rates, which served as the reference for BNCT_Rtpe 
and SERA percent difference calculations, respectively. 
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Figure 2.26 Incident photon dose rate and percent difference (100×[TPS−Ref]/Refmax) 
as a function of depth along the central beam axis in the large rectangular 
water phantom for each planning system. MCNP5 served as the reference 
for percent difference calculations. 
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Figure 2.27 Incident photon dose rate and percent difference (100×[TPS−Ref]/Refmax) 
as a function of depth along the central beam axis in the large rectangular 
water phantom for each planning system. Multigroup photon kerma 
factors from BNCT_Rtpe and SERA were used in MCNP5 calculations of 
incident photon dose rates, which served as the reference for BNCT_Rtpe 
and SERA percent difference calculations, respectively. The −2% 
difference reflects a subtle normalization error in BNCT_Rtpe and SERA 
incident photon dose rates. 
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2.3.1.1.8 Total Biologically Weighted Dose 
Total biologically weighted brain dose rate profiles from each TPS are compared 
to the reference in the large rectangular water phantom in Figure 2.28. MacNCTPlan and 
NCTPlan underestimate the reference maximum at 1.8 cm depth by −3.3% and −3.7%, 
respectively, which is mainly due to the inability of the linearly interpolated dose data to 
match the curvature of the reference dose data at the dose peak. Better agreement occurs 
at integral depths in the phantom which correspond to the geometric centers of voxels 
from the coarse scoring mesh, but interpolation error and larger tally volumes produce 
differences even at those depths as large as −1.8%. The largest differences occur at the 
phantom entrance where MacNCTPlan and NCTPlan overestimate the reference by 11% 
and 8%, respectively. BNCT_Rtpe and SERA overestimate the reference maximum 
weighted dose rate by 8.4% and 5.9%, respectively. This disagreement is a rather 
complex combination of disagreement resulting mainly from differences in calculated 
thermal neutron flux, interpolation error, the improper multiplication of the neutron and 
boron kerma factors by the mass density of the edit mesh, and differences in photon 
kerma factors. The better agreement observed for SERA relative to BNCT_Rtpe is 
mainly a result of more accurate photon kerma factors and the resulting better agreement 
in induced photon dose rate, which contributes 23% of the maximum weighted dose rate. 
During an intercomparison such as this, it is important to not only report the 
magnitude of the disagreement but also to understand the causes. Determining the 
source(s) of disagreement observed in the large rectangular water phantom between 
MacNCTPlan/NCTPlan and the reference is relatively simple because differences in 
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kerma factors, cross section data, and Monte Carlo transport calculations∗ are avoided as 
are geometric approximations which limits the possibilities and simplifies the 
explanation. Conversely, several factors contribute to the disagreement between 
BNCT_Rtpe/SERA and the reference calculations, making it more difficult to unfold and 
explain. The disagreement in each dose component is attributable to some combination of 
the following: differences in calculated neutron or photon flux, interpolation error, 
differences in kerma factors, improper runtime multiplication of neutron and boron 
kerma factors by the mass density of the edit mesh material, differences in dose 
definition, a biasing and cutoff energy for the fast neutron source biasing run mode that is 
too high, and the photon normalization error. The contributions of these factors to the 
total disagreement observed for BNCT_Rtpe and SERA in the large rectangular water 
phantom are shown in Table 2.1 and Table 2.2, respectively.  
Some additional explanation is required as to how the different factors were 
assessed. A depth of 2.0 cm was chosen as the evaluation point partially because it is 
approximately the location of the total weighted dose maximum and partially to exclude 
the disagreement at the phantom entrance due to differences in tally volumes between the 
TPSs and the reference (1 cm3 vs. 0.1 cm3). Differences in thermal neutron (defined by 
the INL planning systems as En ≤ 0.414 eV), fast neutron (En > 9.12 eV), induced photon, 
and incident photon flux were calculated by comparing flux data interpolated by 
MATLAB (to eliminate the interpolation error) from coarse BNCT_Rtpe and SERA 
voxel data to corresponding MCNP5 data. To compute photon flux, patched versions of 
both rtt_MC and seraMC with kerma factors set to unity had to be used since neither 
                                                 
∗ Differences between MCNP4B, used with MacNCTPlan and NCTPlan, and MCNP5 v. 1.40 are very 
small. 
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calculates photon flux by default. The interpolation error is not constant for all dose 
components. Instead, it depends upon the gradient of the particular dose component at the 
evaluation point and is therefore larger for peaked profiles (e.g., boron dose) than for 
dose profiles exhibiting little curvature (e.g., incident photon dose). Since the influence 
of different kerma factors depends on the spectrum (and hence depth), the values listed in 
Table 2.1 and Table 2.2 are differences in dose at 2.0 cm depth that result from 
comparing MCNP5 calculations with multigroup INL kerma data to similar calculations 
with reference (boron and photon) or ICRU (hydrogen and nitrogen) pointwise 
continuous kerma data. For instance, the MCNP5 dose rate at 2.0 cm depth from INL 
hydrogen kerma factors was 9.2% smaller than calculated with ICRU hydrogen kerma 
factors, which is mainly because the INL hydrogen kerma factors do not include the 
contribution from the recoil deuteron, so −9.2% is listed as the difference in kerma 
factors for the fast neutron dose component. Kerma scaling refers to the improper 
runtime multiplication of BNCT_Rtpe and SERA boron and neutron kerma data by the 
mass density of the edit mesh material, so using edit mesh densities for ICRU adult brain 
results in a 4% increase in neutron and boron dose rates. To quantify the disagreement 
due solely to differences in dose definitions, MCNP5 calculations of nitrogen and 
hydrogen dose using ICRU nitrogen and hydrogen kerma factors with no energy 
boundaries were compared to MCNP5 calculations of thermal and fast neutron dose with 
total brain neutron kerma factors and an energy boundary at 0.5 eV (distinguishing 
thermal and fast neutron dose). The 4.7% underestimation of the fast neutron dose by the 
hydrogen dose is larger than the 1.3% underestimation of the thermal neutron dose by 
nitrogen dose because nitrogen represents a larger percentage of the thermal neutron dose 
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(96.5%) that hydrogen dose does of the fast neutron dose (87%). MCNP5 was also 
employed to estimate the percentage of the hydrogen dose from neutrons below the 
default energy cutoff (9.12 keV) for the BNCT_Rtpe and SERA fast neutron source 
biasing run mode. The resulting 21.7% indicates that using the default fast neutron source 
biasing run mode is the single largest contributor to the underestimation of the reference 
fast neutron dose rate by BNCT_Rtpe and SERA. The disagreement due to the photon 
normalization error was calculated using Eqs. 2.1 and 2.2 and is specific to the neutron 
and photon source as well as the simulated geometry. The differences predicted by 
combining the independent sources of disagreement (sum of differences) for each dose 
component agree well with the observed values (actual differences), differing by at most 
0.8% for BNCT_Rtpe and 1.5% for SERA. While many of the specific values listed in 
Table 2.1 and Table 2.2 are likely unique to the simulated source and geometry, the more 
general process of identifying the various sources of the observed disagreement should 
apply to any dosimetric intercomparison involving BNCT_Rtpe or SERA. 
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Figure 2.28 Total biologically weighted brain dose rate and percent difference 
(100×[TPS−Ref]/Refmax) as a function of depth along the central beam 
axis in the large rectangular water phantom for each planning system. 
MCNP5 served as the reference for percent difference calculations. 
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Table 2.1 Percent differences between BNCT_Rtpe and reference MCNP5 dose 
rates at 2.0 cm depth along the central beam axis in the large rectangular 
water phantom. The differences for each dose component are resolved into 
contributing components, and the product of these components is shown 
for comparison to the actual differences. BNCT_Rtpe does not calculate 
thermal and fast neutron dose components in the same manner as the 
reference MCNP5 calculations but instead calculates the dose from 
neutron interactions with nitrogen and hydrogen thus leading to 
differences in “Dose Definition”. “Flux” represents differences in thermal 
neutron flux (for boron and thermal neutron dose), fast neutron flux (for 
fast neutron dose), and photon flux (for induced and incident photon 
dose). BNCT_Rtpe overestimates the reference total biologically weighted 
brain and tumor doses by 8.4% and 10.1%, respectively. 
  Dose Components 
Source of Thermal Fast Induced Incident
Disagreement 
Boron 
Neutron Neutron Photon Photon 
Flux 3.2% 3.2% 1.2% 0.6% −0.6% 
Interpolation Error 2.9% 2.9% −1.9% 1.1% −0.1% 
Kerma Factors −0.7% 1.0% −9.2% 9.6% 6.2% 
Kerma Scaling 4.0% 4.0% 4.0% ---- ---- 
Dose Definition ---- −1.3% −4.7% ---- ---- 
Fast Neutron Src. Biasing ---- ---- −21.7% ---- ---- 
Normalization Error ---- ---- ---- ---- −1.9% 
Sum of Differences 9.7% 10.1% −30.0% 11.4% 3.5% 
Actual Differences 10.5% 9.9% −29.3% 11.1% 4.1% 
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Table 2.2 Percent differences between SERA and reference MCNP5 dose rates at 
2.0 cm depth along the central beam axis in the large rectangular water 
phantom. The differences for each dose component are resolved into 
contributing components, and the product of these components is shown 
for comparison to the actual differences. SERA does not calculate thermal 
and fast neutron dose components in the same manner as the reference 
MCNP5 calculations but instead calculates the dose from neutron 
interactions with nitrogen and hydrogen thus leading to differences in 
“Dose Definition”. “Flux” represents differences in thermal neutron flux 
(for boron and thermal neutron dose), fast neutron flux (for fast neutron 
dose), and photon flux (for induced and incident photon dose). SERA 
overestimates the reference total biologically weighted brain and tumor 
doses by 5.9% and 8.5%, respectively. 
  Dose Components 
Source of Thermal Fast Induced Incident
Disagreement 
Boron 
Neutron Neutron Photon Photon 
Flux 3.1% 3.1% 2.0% −0.6% −0.7% 
Interpolation Error 3.0% 3.0% −2.2% 1.3% 0.2% 
Kerma Factors −2.5% 1.0% −9.2% 2.8% −1.1% 
Kerma Scaling 4.0% 4.0% 4.0% ---- ---- 
Dose Definition ---- −1.3% −4.7% ---- ---- 
Fast Neutron Src. Biasing ---- ---- −21.7% ---- ---- 
Normalization Error ---- ---- ---- ---- −1.9% 
Sum of Differences 7.6% 10.0% −29.6% 3.5% −3.4% 
Actual Differences 9.1% 9.7% −29.0% 4.0% −2.9% 
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2.3.1.2 Ellipsoidal Head Phantom 
The features observed during the comparison of depth-dose data in the large 
rectangular water phantom do not arise from approximations in the geometric 
representations of the phantom, so they are present in the comparison in the head 
phantom as well. Therefore, an in-depth discussion of the same features will not be 
repeated. Instead, the main focus in the head phantom is to develop a better 
understanding of how geometric approximations affect the accuracy of dose calculations 
and to compare the multi-dimensional dose data (i.e., isodose contours and dose-volume 
histograms) that is used in clinical treatment planning. The simplest way to identify the 
effect of the geometric approximations introduced by each TPS is to compare agreement 
in the presence of those approximations, as in the head phantom, to agreement in the 
absence of them, as in the large rectangular water phantom. Axial sections through the 
BNCT_Rtpe NURBS model, SERA univel model, and MacNCTPlan/NCTPlan mixed-
material voxel models of the ellipsoidal head phantom are shown in Figure 2.29. Each 
TPS represents the ellipsoidal head phantom in a manner that is clearly distinct from the 
others. Even the mixed-material voxel models produced by MacNCTPlan and NCTPlan 
are different from each other in that different mixed materials are modeled in 192 voxels 
or 5.8% of the total number of non-air voxels. NCTPlan’s improved voxelization 
algorithm result in a more accurate and symmetrical voxel model of the head phantom 
than the asymmetrical model produced by MacNCTPlan.38 
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Figure 2.29 Axial sections through the BNCT_Rtpe NURBS model, SERA univel 
model, MacNCTPlan and NCTPlan mixed-material voxel models of the 
ellipsoidal head phantom used to simulate BNCT treatment of a brain 
tumor. 
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2.3.1.2.1 Thermal Neutron Flux 
Figure 2.30 shows the thermal neutron flux calculated by MCNP5, BNCT_Rtpe, 
SERA, MacNCTPlan, and NCTPlan as well as the difference of each TPS from the 
reference MCNP5 calculations as a function of depth along the central beam axis in the 
ellipsoidal head phantom. The largest differences for MacNCTPlan (25%) and NCTPlan 
(10%) occur at the phantom entrance where data linearly interpolated from the coarse 
scoring mesh are unable to match the sharp increase in the reference thermal neutron flux 
profile. The agreement improves at depths beyond the phantom entrance, but 
MacNCTPlan and NCTPlan still underestimate the maximum reference thermal neutron 
flux (at a depth of 2.1 cm) by −5.1% and −5.4%, respectively. Part of the disagreement at 
all depths in the head phantom is due to interpolation error in both TPSs. If the coarse 
voxel data from MacNCTPlan and NCTPlan are linearly interpolated with MATLAB to 
eliminate interpolation error, agreement improves for both MacNCTPlan (e.g., 10% to 
2%) and NCTPlan (e.g., −2.2% to 0.1%) at 1.0 cm depth. Also, as observed in the large 
rectangular water phantom, averaging over a larger tally volume contributes to the 
underestimation of the maximum reference thermal neutron flux by MacNCTPlan and 
NCTPlan. If the reference thermal neutron flux is averaged over a tally volume 
equivalent to that used by MacNCTPlan and NCTPlan (1 cm3), a 1% decrease in the 
reported maximum reference thermal neutron flux results and the agreement with 
MacNCTPlan and NCTPlan improves slightly. Nevertheless, for both TPSs, the best 
agreement with the reference occurs at depths corresponding to voxel center points. 
However, the differences at those depths are ~2-3 times larger than observed in the 
rectangular water phantom due to the presence of geometric approximations. For 
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instance, on the deep side of the thermal neutron flux peak at a depth of 3.0 cm, 
MacNCTPlan and NCTPlan underestimate the reference thermal neutron flux in the head 
phantom by −8.9% and −6.7%, respectively, whereas in the large rectangular water 
phantom the corresponding percent differences are −4.5% and −2%. 
A specific geometric approximation present in the voxel models of MacNCTPlan 
and NCTPlan is due to the limitation of 4 primary materials. This limitation causes 
MacNCTPlan and NCTPlan to model the head phantom’s skin as brain, which has both a 
lower density (1.09 g/cm3 vs. 1.04 g/cm3) and 10B concentration (22.5 μg/g vs. 15.0 μg/g) 
than skin. A separate simulation with MCNP5 indicated that modeling the skin as brain 
produces a 1.3% increase in the thermal neutron flux at 3 mm depth and a 0.6% increase 
in the maximum thermal neutron flux. Looking along the central beam axis in the head 
phantom provides an example of other geometric approximations introduced in the 
voxelization process which are also partially responsible for the disagreement in Figure 
2.30. The central axis of the beam line intersects the analytical model of the head 
phantom at x=7.25 cm and travels through ~5 mm of skin (ρ=1.09 g/cm3) and ~6 mm of 
bone (ρ=1.61 g/cm3) before entering the brain. However, in the MacNCTPlan and 
NCTPlan voxel models of the head phantom, the beam line enters a mixture of tissue 
(brain) and bone (60% tissue, 40% bone, ρ=1.268 g/cm3) upon crossing the voxel edge at 
x=7.5 cm (0.25 cm earlier) and travels 2 cm through that mixture before entering brain. 
Therefore, in the voxel models, neutrons reaching the phantom surface have already been 
transported though a non-air mixture which increases neutron scattering and 
thermalization beyond that of the analytical model. So, agreement with the analytical 
model will depend to some extent upon the radiological depth of the analytic phantom 
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surface, defined as ρx, where x is the distance neutrons must travel through a non-air 
mixture before reaching the phantom surface and ρ is the density of that mixture. Better 
agreement is expected as the radiological depth of the analytic phantom surface 
approaches zero in the voxel model. If the average radiological depth of the phantom 
surface is calculated in a 6×6 cm2 region about the central beam axis for the 
MacNCTPlan and NCTPlan voxels models of the head phantom, the MacNCTPlan model 
is ~20% larger, which is due to differences in voxelization algorithms between the two 
TPSs9 and is at least partially responsible for the worse agreement between MacNCTPlan 
and the reference calculations. Also, the observed shift in MacNCTPlan’s and NCTPlan’s 
thermal neutron flux peaks (most noticeable on the deep side) is estimated, at a thermal 
neutron flux of 2.0×1010 n/cm2s, to be 5.2 mm and 3.8 mm, respectively, These shifts are 
similar to the corresponding average radiological depths calculated (in a 6×6 cm2 area 
about the central beam axis) for the voxel models of MacNCTPlan (4.5 mm) and 
NCTPlan (3.9 mm).  
To further investigate these observations, different NCTPlan mixed-material 
voxel models of the head phantom were created with NCTPlan by shifting the phantom 
image data in 1 mm steps along its minor axis, which is parallel to the ipsilateral beam 
line. Axial sections through the resulting voxel models are shown in Figure 2.31, and the 
corresponding uninterpolated thermal neutron flux voxel data for a representative subset 
of those models are shown in Figure 2.32 where each is compared to the reference 
calculations. The uninterpolated voxel data are shown to prevent the interpolation error in 
NCTPlan from obscuring the comparison. The voxel model that minimizes the 
radiological depth of the analytic phantom surface (20% smaller than the next closest 
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model) also produces the best agreement with the reference calculations in Figure 2.32 
(e.g., 0.69% at 1.5 cm depth). In other words, shifting the head phantom image data by 8 
mm better aligns the phantom surface with the upstream edges of the first non-air voxels 
encountered by beam neutrons to result in improved agreement with the analytical model. 
The range of agreement displayed in Figure 2.32 illustrates the influence that geometric 
approximations can have on the accuracy of treatment planning calculations and 
therefore underscores the importance of using a model with smaller voxels to help 
minimize that influence. However, assigning the volume-averaged flux or dose to the 
voxel’s center-of-mass rather than to its geometric center for interpolation has been 
proposed as a means to produce better agreement in data interpolated at or near the 
phantom surface.60 The interpolated MacNCTPlan and NCTPlan thermal neutron flux 
data shown in Figure 2.30 suggests that such a change would produce better agreement 
because the linear interpolation between the 1 cm3 tally volumes is unable to match the 
sharp increase in the reference thermal neutron flux at the phantom surface.  
In Figure 2.30, geometric approximations appear to have much less of an adverse 
effect on the agreement between BNCT_Rtpe/SERA and the reference due to the 
modeling techniques those TPSs employ. The agreement at the thermal neutron flux 
maximum in the head phantom is actually 1.5-2 times better than in the large rectangular 
water phantom (3-4% vs. 6%) for both BNCT_Rtpe and SERA, indicating that NURBS 
and univels are as equally capable of modeling the curved surfaces of the head phantom 
as they are the flat surfaces of the large rectangular water phantom. In addition, it is 
possible that the worse agreement in the large rectangular water phantom is due to the 
increased number of interactions (compared to transport calculations in the head 
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phantom) that could magnify the significance of any differences that exist in transport 
physics between rtt_MC, seraMC, and MCNP5. Also, S(α,β) thermal neutron scattering 
data for hydrogen in both light water and polyethylene were defined for each biological 
material (except ICRU cranium where doing so would have meant artificially increasing 
the concentration of hydrogen) in the BNCT_Rtpe and SERA models of the head 
phantom whereas only the S(α,β) treatment for hydrogen in light water was allowed in 
the MCNP5 reference calculations. Further investigation revealed that while using both 
S(α,β) treatments does produce differences in the thermal neutron spectrum when 
compared to using only one, the differences (e.g., 0.5% in the maximum thermal neutron 
flux) are insignificant so long as the free gas treatment is avoided (which supports data 
originally reported by Goorley et al.14). 
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Figure 2.30 Thermal neutron flux and percent difference (100×[TPS−Ref]/Refmax) as a 
function of depth along the central beam axis in the ellipsoidal head 
phantom for each planning system. SERA and BNCT_Rtpe data are 
calculated at (default) intervals of 5 mm. MCNP5 served as the reference 
for percent difference calculations. 
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Figure 2.31 Different NCTPlan voxel models of the head phantom that resulted from 
shifting the phantom image data in 1 mm steps along its minor axis (the 
central axis of the beam). The phantom’s biological materials are color 
coded by density, and white tick marks have been added to indicate the 
front and back edges of the un-shifted phantom. 
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Figure 2.32 Uninterpolated NCTPlan thermal neutron flux voxel data and percent 
difference (100×[TPS−Ref]/Refmax) as a function of depth along the 
central beam axis in the ellipsoidal head phantom for different NCTPlan 
models of the head phantom that resulted from shifting the phantom image 
data varying distances along the central beam axis in relation to the voxel 
mesh. MCNP5 served as the reference for percent difference calculations. 
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2.3.1.2.2 Boron Dose 
 The comparison of boron dose rates in the head phantom is shown in Figure 2.33, 
and the dose rates are scaled for a 10B concentration of 15 μg/g. When compared to the 
agreement in the large rectangular water phantom (Figure 2.11), NCTPlan produces 
better agreement in the head phantom on the shallow side of the peak (−1.0% vs. −7.8% 
at 1.0 cm depth) and worse agreement on the deep side of the peak (−7.2% vs. −2.5% at 
3.0 cm depth) While MacNCTPlan and NCTPlan both underestimate the reference 
maximum boron dose rate by −5.4% (at a depth of 2.2 cm), a more accurate voxel model 
as well as an improved interpolation algorithm helps NCTPlan produce better agreement 
than MacNCTPlan by 4.3% at 1.0 cm depth and by 2.0% at 3.0 cm depth. BNCT_Rtpe 
and SERA produce worse agreement (7.5% at a depth of 2.0 cm) with reference boron 
dose rates than with reference thermal neutron flux due the improper runtime 
multiplication of boron kerma factors by the mass density of ICRU brain, 1.04 g/cm3. 
While geometric approximations do not significantly affect the agreement of either TPS, 
SERA produces 1-2% better agreement than BNCT_Rtpe at deeper depths in the head 
phantom. 
2.3.1.2.3 Fast Neutron Dose 
In Figure 2.34, MacNCTPlan and NCTPlan underestimate the reference fast 
neutron dose rate at the head phantom entrance by 28% and 40%, respectively, which is 
largely due to interpolation error in both TPSs. The agreement at the entrance improves 
significantly, to −7.5%, if MATLAB is used to linearly interpolate the coarse voxel data 
from each TPS. While NCTPlan produces better agreement than MacNCTPlan by 1-5% 
at depths beyond the entrance, agreement with the reference is still 2-3 times worse than 
observed in the rectangular water phantom, in the absence of any geometric 
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approximations. When uninterpolated fast neutron dose rate voxel data from different 
NCTPlan voxel models are compared in Figure 2.35, the significant interpolation error at 
the phantom entrance is removed, indicating better agreement in the NCTPlan 
uninterpolated voxel data than represented by the interpolated profile data in Figure 2.34. 
Also, shifting the phantom by 2 mm produces the worst agreement with the reference 
partially because the resulting voxel model maximizes the radiological depth of the 
analytic phantom surface which contributes to a more significant underestimation of the 
reference fast neutron dose rates (−7.9% at 1.0 cm depth) than observed for any of the 
other models (1-1.5% at 1.0 cm depth).  
Since the default energy cutoff for the fast neutron source biasing run mode of 
BNCT_Rtpe and SERA is inadequate for the generic epithermal neutron beam and results 
in significant underestimations (−46%) of the reference fast neutron dose rates, hydrogen 
dose rates produced with that run mode disabled are shown in Figure 2.34 to allow closer 
examination of the agreement in the absences of such large differences. BNCT_Rtpe and 
SERA underestimate the reference dose rates by 8-10% at the phantom entrance which is 
approximately consistent with the agreement in the large rectangular water phantom and 
the data in Table 2.1 and Table 2.2, which indicate that incomplete INL hydrogen kerma 
factors (i.e., missing kerma from the recoil deuteron) contribute significantly (9.2%) to 
the underestimation of the reference fast neutron dose rates. However, no additional 
significant differences in dose rates are introduced for BNCT_Rtpe or SERA as a result 
of geometric approximations in the head phantom. 
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Figure 2.33 Boron dose rate for a 10B concentration of 15 μg/g and percent difference 
(100×[TPS−Ref]/Refmax) as a function of depth along the central beam 
axis in the ellipsoidal head phantom for each planning system. MCNP5 
served as the reference for percent difference calculations. 
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Figure 2.34 Fast neutron (and hydrogen) dose rate and percent difference 
(100×[TPS−Ref]/Refmax) as a function of depth along the central beam 
axis in the ellipsoidal head phantom for each planning system. The fast 
neutron source biasing run mode was not used for BNCT_Rtpe or SERA 
(i.e., run modes “NGD” were used) because doing so results in a 
significant −47% difference at the phantom entrance. MCNP5 served as 
the reference for percent difference calculations. 
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Figure 2.35 Uninterpolated NCTPlan fast neutron dose rate voxel data and percent 
difference (100×[TPS−Ref]/Refmax) as a function of depth along the 
central beam axis in the ellipsoidal head phantom for different NCTPlan 
models of the head phantom that resulted from shifting the phantom image 
data varying distances along the central beam axis in relation to the voxel 
mesh. MCNP5 served as the reference for percent difference calculations. 
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2.3.1.2.4 Induced Photon Dose 
 The comparison of induced photon dose rates to the reference calculations in the 
head phantom is shown in Figure 2.36. The odd shapes observed in the percent difference 
profiles of MacNCTPlan and NCTPlan at shallow depths up to 1.25 cm are due to 
interpolation error, and these shapes are replaced with much smoother profiles if 
MATLAB is used to perform the 3D linear interpolation. The interpolation error is also 
worse for MacNCTPlan than for NCTPlan, and interpolated doses from MacNCTPlan are 
3-5% different than the MATLAB values which helps give the impression in Figure 2.36 
that doses calculated by MacNCTPlan and NCTPlan are more different from each other 
than they actually are. For instance, at 1 cm depth, the induced photon dose rate 
calculated by MacNCTPlan is 8% larger than the corresponding NCTPlan value. 
However, when the interpolation error in both TPSs is eliminated, the MacNCTPlan dose 
rate is only 2% larger than the NCTPlan value. Nevertheless, both TPSs produce 2-3 
times worse agreement in the head phantom than in the large rectangular water phantom 
(−5.5% vs. −2% at 3.0 cm depth) due to the geometric approximations inherent in 1 cm3 
voxel models. When the head phantom image data are aligned differently with the voxel 
mesh and uninterpolated voxel data are plotted, better agreement in the induced photon 
dose rates are observed at the entrance in Figure 2.37; shifting the phantom image data by 
8 mm results in a 1% difference at the entrance. All of the NCTPlan voxel models shown 
in Figure 2.37 produce agreement at least as good as the interpolated NCTPlan data in 
Figure 2.36.  
 In Figure 2.36, the 9.2% and 3.1% overestimation of the reference maximum 
induced photon dose rate by BNCT_Rtpe and SERA, respectively, is mainly due to those 
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differences in photon kerma factors shown in Figure 2.24 and summarized in Table 2.1 
and Table 2.2. In those tables, differences in photon kerma factors alone are shown to be 
responsible for BNCT_Rtpe and SERA overestimating the reference induced photon dose 
rates by 9.6% and 2.8%, respectively, which is consistent with the disagreement observed 
in Figure 2.36. Also, the agreement between both TPSs and the reference in the head 
phantom is not significantly affected by geometric approximations since both employ 
modeling techniques (i.e., NURBS and univels) that do an adequate job of maintaining 
the geometric fidelity of the phantom. 
2.3.1.2.5 Total Biologically Weighted Dose 
 The total biologically weighted brain depth-dose rate profiles for each TPS and 
the reference are shown in Figure 2.38 along with the corresponding percent differences 
from the reference as a function of depth in the head phantom. At the total weighted dose 
maximum, MacNCTPlan and NCTPlan underestimate the reference value by −5.0% and 
−4.8%, respectively, while BNCT_Rtpe and SERA overestimate the reference value by 
5.0% and 3.5%, respectively. For MacNCTPlan and NCTPlan, the best agreement in total 
biologically weighted brain dose rate occurs at depths corresponding to voxel center 
points. At a depth of 2.3 cm (which corresponds to a voxel center), MacNCTPlan and 
NCTPlan underestimate the reference doses by −5.7% and −4.5%, respectively, where 
the worse agreement for MacNCTPlan is due to a significant interpolation error in that 
TPS. However, in the absence of geometric approximations in the large rectangular water 
phantom, the agreement in total weighted dose at ½ integral depths corresponding to 
voxel center points is better (e.g., −2.9% and −1.9% at a depth of 2.5 cm for 
MacNCTPlan and NCTPlan, respectively). If the head phantom image data are shifted by 
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8 mm to where the phantom surface is better aligned with the upstream edges of the first 
non-air voxels encountered by the source neutrons, the resulting NCTPlan voxel model 
produces improved agreement of −2% at those depths corresponding to voxel center 
points. For BNCT_Rtpe and SERA, the agreement in the head phantom is actually better 
than observed in the large rectangular water phantom by 2-3%, indicating that no 
significant geometric approximations are introduced by modeling the head phantom with 
NURBS or univels. 
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Figure 2.36 Induced photon dose rate and percent difference (100×[TPS−Ref]/Refmax) 
as a function of depth along the central beam axis in the ellipsoidal head 
phantom for each planning system. MCNP5 served as the reference for 
percent difference calculations. 
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Figure 2.37 Uninterpolated NCTPlan induced photon dose rate voxel data and percent 
difference (100×[TPS−Ref]/Refmax) as a function of depth along the 
central beam axis in the ellipsoidal head phantom for different NCTPlan 
models of the head phantom that resulted from shifting the phantom image 
data varying distances along the central beam axis in relation to the voxel 
mesh. MCNP5 served as the reference for percent difference calculations. 
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Figure 2.38 Total biologically weighted brain dose rate and percent difference 
(100×[TPS−Ref]/Refmax) as a function of depth along the central beam 
axis in the ellipsoidal head phantom for each planning system. MCNP5 
served as the reference for percent difference calculations. 
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2.3.1.3 Leg Phantom 
Simulating the treatment of superficial tumors in the leg phantom with a thermal 
neutron beam intentionally shifts the emphasis of comparison closer to the phantom 
surface where the dose from the thermal neutron beam is high and significant 
disagreement is observed in both the large rectangular water phantom and head phantom. 
Axial sections through the BNCT_Rtpe NURBS model, SERA univel model, and 
MacNCTPlan/NCTPlan mixed-material voxel models of the leg phantom are shown in 
Figure 2.39. The mixed-material voxel models produced by MacNCTPlan and NCTPlan 
are different from each other due to the improved voxelization algorithm of NCTPlan. 
While only 1.1% of the non-air voxels are different between the two models, all 
differences occur in voxels at or close to the phantom surface in close proximity to the 
tumors. It is also rather clear in Figure 2.39 that 1 cm3 are too large relative to the 
dimensions of the different regions of the leg phantom and the curvature of the phantom 
surface to accurately model the phantom. 
2.3.1.3.1 Thermal Neutron Flux 
Figure 2.40 shows the thermal neutron flux calculated by MCNP5, BNCT_Rtpe, 
SERA, MacNCTPlan, and NCTPlan as well as the percent difference of each TPS from 
the reference MCNP5 calculations as a function of depth along the central beam axis in 
the leg phantom. Simulating a thermal neutron beam produced a thermal neutron flux 
peak at a depth of 1.5 cm in the leg phantom that was 2.3 cm narrower (evaluated at ¾ 
the maximum flux) and 1.8 cm shallower than observed in the head phantom. 
Interpolating data from a coarse scoring mesh of 1 cm3 tally volumes did not accurately 
model the relatively narrow peak or the very steep dose gradient at the phantom entrance 
which results in BNCT_Rtpe, SERA, MacNCTPlan and NCTPlan underestimating the 
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maximum thermal neutron flux by −10%, −8.9%, −19%, and −15%, respectively. It 
should be noted that the coarseness of the SERA line edit data (calculated at 5 mm 
intervals with seraPlan) masks the actual level of agreement (−8.9%) at the thermal 
neutron flux maximum instead giving the appearance that it is only −5%. Identical 
spacing was requested for BNCT_Rtpe line edit data, but rtt_MC automatically adjusted 
the spacing in order to provide interpolated data at all region boundaries. Given the 
dimensions of the leg phantom, a scoring mesh of 1 cm3 tally volumes does not provide 
the resolution necessary to adequately match the high gradient of the reference thermal 
neutron flux peak. If the reference thermal neutron flux data are averaged over 1 cm3 
(i.e., 10 reference tally volumes), the peak is shifted by 2 mm to a deeper depth, its width 
is increased by 1.0 cm, and the maximum value is decreased by 6.8% as a result of 
volume averaging. On the deep side of the peak at depths beyond ~1.0 cm, where the 
curvature of the reference flux profile is relatively low, the agreement for all TPSs 
improves to within 5% of the reference. In addition to producing the largest 
underestimation of the reference thermal neutron flux maximum, MacNCTPlan is also 
the only TPS that consistently overestimates the reference thermal neutron flux at depths 
greater than ~1.5 cm, and both results are due to inaccuracies in the MacNCTPlan voxel 
model that adversely affect the agreement in the thermal neutron flux. Also, if MATLAB 
is used to interpolate the MacNCTPlan and NCTPlan coarse voxel data, the fluctuations 
observed in Figure 2.40 at depths beyond 1.0 cm are replaced by smoother flux data. 
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Figure 2.39 Axial sections through the BNCT_Rtpe NURBS model, SERA univel 
model, MacNCTPlan and NCTPlan mixed-material voxel models of the 
leg phantom used to simulate BNCT treatment of peripheral melanoma. 
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Figure 2.40 Thermal neutron flux and percent difference (100×[TPS−Ref]/Refmax) as a 
function of depth along the central beam axis in the leg phantom for each 
planning system. SERA and BNCT_Rtpe data are calculated at (default) 
intervals of 5 mm. MCNP5 served as the reference for percent difference 
calculations. 
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2.3.1.3.2 Boron Dose 
When comparing boron dose rates in the leg phantom that have been scaled to a 
10B concentration of 22.5 μg/g (for skin), the agreement shown in Figure 2.41 for 
MacNCTPlan (19% at 4 mm depth) and NCTPlan (15% at 4 mm depth) is nearly 
identical to the agreement observed in thermal neutron flux because the boron dose rates 
were calculated using identical 10B kerma factors and the 1/ν shape of that kerma factor 
emphasizes the thermal portion of the neutron energy spectrum. However, differences in 
10B kerma factors do exist between BNCT_Rtpe, SERA, and the reference, and they 
significantly affect the agreement shown in Figure 2.41. The differences in 10B kerma 
factors are a combination of the average differences shown in Figure 2.12 (−2.5% for 
BNCT_Rtpe and −1.0% for SERA) and those due to the improper runtime scaling of 
BNCT_Rtpe and SERA 10B kerma factors by the mass density of ICRU skin, 1.09 g/cm3. 
Therefore, BNCT_Rtpe and SERA boron dose rates in the leg phantom result in a −4.2% 
and −3.5% underestimation of the maximum reference boron dose rate and a 5.4% and 
3.2% overestimation of the reference on the deep side of the peak at 1 cm depth, 
respectively. 
2.3.1.3.3 Fast Neutron Dose 
Each TPS underestimates the maximum reference fast neutron dose rate in Figure 
2.42; MacNCTPlan and NCTPlan do so by −5.5% while BNCT_Rtpe and SERA 
underestimate it by −3%. MacNCTPlan and NCTPlan also underestimated the maximum 
reference fast neutron dose rate in the head phantom in Figure 2.34, and in Figure 2.35, it 
was shown to be due to the geometric approximations that are characteristic of the 
orientation of the phantom within the voxel mesh. The fluctuations in the MacNCTPlan 
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and NCTPlan fast neutron dose data are produced by the interpolation algorithms within 
each TPS and are eliminated if MATLAB is used to perform the linear interpolation. 
BNCT_Rtpe and SERA underestimate the reference fast neutron dose rates at shallow 
depths by ~3% despite using hydrogen kerma factors that have been improperly 
multiplied by 1.09, the density of ICRU skin in g/cm3. The BNCT_Rtpe and SERA 
hydrogen dose rates do not include contributions from neutrons below 9.12 keV because 
the default fast neutron source biasing run mode was utilized for calculations in the leg 
phantom (refer to section 2.3.1.1.4). A separate MCNP5 calculation of the hydrogen dose 
rate in the leg phantom using ICRU hydrogen kerma factors indicated that 60% of the 
hydrogen dose rate is from interactions of thermal neutrons (via the recoil deuteron) due 
to the nearly 4 orders of magnitude difference between thermal and fast neutron flux. 
Therefore, even if the default fast neutron source biasing run mode were to be disabled, 
allowing all neutron energies to contribute to the hydrogen dose, BNCT_Rtpe and SERA 
would still dramatically underestimate the reference hydrogen dose as a result of their 
incomplete hydrogen kerma factors in the thermal neutron energy region. Thus, 
BNCT_Rtpe and SERA underestimate the maximum reference hydrogen dose rate by 
55%, but the contribution of the hydrogen dose to the total neutron dose is so small (e.g., 
2% of maximum reference total neutron dose) that this large underestimation is not 
significant. However, both codes produce much better agreement with the reference fast 
neutron dose rate because the 0.5 eV energy cutoff employed in the reference 
calculations excludes the contribution from thermal neutrons and the improper runtime 
multiplication of the INL hydrogen kerma factors by 1.09 compensates for the 
contribution of kerma from elements besides hydrogen to the reference fast neutron dose, 
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which is absent in BNCT_Rtpe and SERA. Therefore, the differences observed in Figure 
2.42 between BNCT_Rtpe/SERA hydrogen dose rates and reference fast neutron dose 
rates are largely due to differences in fast neutron flux. 
2.3.1.3.4 Induced Photon Dose 
In Figure 2.43, MacNCTPlan and NCTPlan significantly underestimate the 
maximum reference induced photon dose rate in the leg phantom by −15.5% and 
−12.6%, respectively. Both MacNCTPlan and NCTPlan underestimated the maximum 
thermal neutron flux in Figure 2.40 and that certainly contributed to the underestimation 
of the dose from photons produced by the reactions of thermal neutrons. However, part of 
the significant underestimation of the reference induced photon dose rates is due to the 
limitation of 4 primary materials in the voxel models of MacNCTPlan and NCTPlan. If 
the reference simulation is repeated with the analytical model of the leg phantom changed 
to include only air, bone, normal tissue (muscle) and tumor, the maximum induced 
photon dose rated is decreased by 4%. Also, averaging the reference dose data over 1 cm3 
further reduces the maximum induced photon dose rate by 2%. On the deep side of the 
peak, NCTPlan underestimates the reference induced photon dose rates by 5-10% while 
MacNCTPlan manages to produce better agreement than NCTPlan at deeper depths. 
MacNCTPlan’s overestimation of the thermal neutron flux at those depths results in more 
induced photons, increased induced photon dose rates, and better agreement with the 
reference calculations. 
In Figure 2.43, BNCT_Rtpe overestimates the maximum reference induced 
photon dose rate by 3% while SERA underestimates it by −3.5%. Like MacNCTPlan and 
NCTPlan, both BNCT_Rtpe and SERA significantly underestimate the maximum 
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reference thermal neutron flux in Figure 2.40, but the differences in photon kerma factors 
that are shown in Figure 2.24 help compensate for a lower thermal neutron flux to 
produce the agreement observed. Similarly, on the deep side of the induced photon dose 
rate peak, SERA produces better agreement than BNCT_Rtpe (e.g., −1.4% vs. 5.2% at a 
depth of 2.0 cm) due to SERA’s improved photon kerma factors. It should also be noted 
that discontinuities as large as 5% are observed in the BNCT_Rtpe and SERA flux and 
dose rate data in the leg phantom if finely spaced (i.e., < 1 mm) line edit data are plotted. 
The interpolation error identified in both TPSs (and shown for SERA in Figure 2.7) 
produces these discontinuities at several depths in the phantom.  
2.3.1.3.5 Incident Photon Dose 
 In Figure 2.44, MacNCTPlan and NCTPlan produce agreement within 1% of the 
reference incident photon dose rates in the leg phantom. The fluctuations in the 
MacNCTPlan and NCTPlan incident dose rates, most noticeable in the percent difference 
profiles and larger for MacNCTPlan, are produced by the interpolation algorithms of 
each TPS. BNCT_Rtpe and SERA result in approximately constant 4.3% and −2.8% 
differences, respectively. The observed disagreement for BNCT_Rtpe and SERA is a 
result of differences in photon kerma factors as well as the photon normalization error 
that is defined by Eq. 2.1. For the irradiation of the leg phantom with the thermal neutron 
beam, Eq. 2.1 evaluates to 1.0146 and indicates that the normalization error is 
responsible for BNCT_Rtpe and SERA underestimating the reference incident photon 
dose rates by −1.5%. Table 2.1 and Table 2.2 estimate, albeit for the comparison in the 
large rectangular water phantom, that differences in photon kerma factors alone are 
responsible for BNCT_Rtpe overestimating the reference incident photon dose rates by 
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6.2% and SERA underestimating them by −1.1%. These differences combine with the 
normalization error to produce the disagreement observed in Figure 2.44 for BNCT_Rtpe 
and SERA.  
2.3.1.3.6 Total Biologically Weighted Dose 
The total biologically weighted skin dose rates from each TPS and the reference 
are shown in Figure 2.45 along with the corresponding percent difference of each TPS 
from the reference as a function of depth in the leg phantom. At a depth of 4 mm, 
MacNCTPlan and NCTPlan underestimate the maximum reference total weighted skin 
dose rate by −18% and −14%, respectively, while BNCT_Rtpe and SERA underestimate 
it by −3.5%. In the leg phantom, the BNCT_Rtpe and SERA neutron and boron dose 
rates are improperly scaled up by 1.09 which actually helps compensate for the 
disagreement at shallow depths, where all TPSs significantly underestimate the thermal 
neutron flux and hence the total weighted dose rate, but also contributes to higher dose 
rates on the deep side of the dose peak that overestimate the reference by 3-6%. Due to 
differences in their respective voxel models of the leg phantom, MacNCTPlan and 
NCTPlan result in total weighted skin dose rates that significantly differ from each other 
with MacNCTPlan producing 5-10% lower weighted dose rates than NCTPlan at the 
dose peak and then 5-10% larger values on the backside of the dose peak. Likewise, the 
more accurate NCTPlan voxel model produces 4% better agreement with the maximum 
reference total weighted skin dose than does the MacNCTPlan model.  
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Figure 2.41 Boron dose rate for a 10B concentration of 22.5 μg/g and percent 
difference (100×[TPS−Ref]/Refmax) as a function of depth along the 
central beam axis in the leg phantom for each planning system. MCNP5 
served as the reference for percent difference calculations. 
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Figure 2.42 Fast neutron (and hydrogen) dose rate and percent difference 
(100×[TPS−Ref]/Refmax) as a function of depth along the central beam 
axis in the leg phantom for each planning system. MCNP5 served as the 
reference for percent difference calculations. 
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Figure 2.43 Induced photon dose rate and percent difference (100×[TPS−Ref]/Refmax) 
as a function of depth along the central beam axis in the leg phantom for 
each planning system. MCNP5 served as the reference for percent 
difference calculations. 
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Figure 2.44 Incident photon dose rate and percent difference (100×[TPS−Ref]/Refmax) 
as a function of depth along the central beam axis in the leg phantom for 
each planning system. MCNP5 served as the reference for percent 
difference calculations. 
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Figure 2.45 Total biologically weighted skin dose rate and percent difference 
(100×[TPS−Ref]/Refmax) as a function of depth along the central beam 
axis in the leg phantom for each planning system. MCNP5 served as the 
reference for percent difference calculations. 
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2.3.2 Isodose Contours and Dose Difference Distributions 
To facilitate the direct comparison of 2D dose data from each TPS to the 
reference, screen captures of isodose contours from each TPS were overlaid with 
reference contours after the treatment time (or, equivalently, monitor units) from each 
TPS had been used to convert the dose rate data for both the TPSs and the reference to 
units of absolute dose. The treatment times shown in Table 2.3 for each planning system 
and the reference were calculated based on realistic BNCT dose prescriptions for each 
phantom type:  a maximum brain dose of 12.5 Gyw for the head phantom and a minimum 
tumor dose of 24 Gyw for the leg phantom. For the head phantom, the treatment times are 
all within 5-6% of the reference, but larger disagreement, such as 10% for BNCT_Rtpe 
and 17% for MacNCTPlan, are observed for the leg phantom. It is worth noting that 
limitations in the TPSs often prevented a uniform set of isodose line levels (dose values) 
from being plotted for all the TPSs for a given dose component. However, even in those 
instances, the differences in the plotted contour levels from one TPS to another are small 
and do not in any way affect the comparison between each TPS and the reference 
Table 2.3 Treatment time in minutes required to deliver a maximum brain dose of 
12.5 Gyw for the head phantom or a minimum tumor dose of 24 Gyw for 
the leg phantom. 
 Treatment Time (minutes) 
 Head Phantom  Leg Phantom 
 1 field 3 fields  1 field 
Reference 3.16 5.66  1.38 
BNCT_Rtpe 2.99 5.35  1.25 
SERA 3.04 5.48  1.28 
MacNCTPlan 3.34 6.01  1.18 
NCTPlan 3.33 6.01  1.43 
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contours; the reference contour levels in every plot are matched to those used by the TPS. 
A more detailed analysis of the 2D dose data from each TPS is also included in the form 
of dose difference distributions. Dose differences, defined as TPS – Reference, were 
calculated using the interpolated and unmasked 2D dose matrix from each TPS and 
plotted as percentages of the maximum reference dose for both orthogonal planes 
containing the central beam axis. This finer grained comparison is meant to compliment 
the more conventional but coarser comparison of isodose contours. It is important to note 
that when discussing the agreement observed in 2D dose difference distributions, all 
agreement is specified relative to the reference dose maximum. For example, a 5% 
difference in boron dose for a TPS at a given location indicates that the dose difference 
(TPS – Reference) is 5% of the reference boron dose maximum rather than the reference 
boron dose at that location.  
2.3.2.1 Ellipsoidal Head Phantom  
This section reports the comparison of 2D dose distributions (i.e., isodose 
contours and dose difference distributions) in the head phantom. For all of the dose 
components, refer to sections 8A.3.1 and 9A.4.1 of Appendix A. 
2.3.2.1.1 Boron Dose 
Boron isodose contours from each TPS are shown in Figure 2.46 for a 1-field 
irradiation of the head phantom, and the reference contours have been overlaid as dashed 
lines. BNCT_Rtpe does not allow isodose contours to be color coded, so contour labels 
have been added manually. The comparison of isodose contours demonstrate agreement 
in 2D that is consistent with that observed in the comparison of 1D depth-dose rate 
profiles. In Figure 2.33, BNCT_Rtpe and SERA dose rates along the central beam axis 
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overestimate the maximum reference boron dose rate by ~6%. Likewise, in Figure 2.46, 
both BNCT_Rtpe and SERA overestimate the reference in the high dose region to the 
extent that the highest dose reference contour is not plotted which implies a DTA 
(distance-to-agreement) for contours in that region of at least 4-8 mm. However, the 
agreement for BNCT_Rtpe and SERA improves with depth and lateral distance from the 
central beam axis to result in less than 1 mm of separation for the lower dose contours. In 
Figure 2.33, MacNCTPlan and NCTPlan boron depth-dose rates overestimate the 
reference boron dose rates at shallow depths and subsequently underestimate them at 
depths beyond 0.5-1.5 cm. While the contours for MacNCTPlan and NCTPlan in Figure 
2.46 are too coarse to adequately illustrate the agreement close to the surface, the 
underestimation of the reference boron dose rates by both TPSs is clearly evident and 
results in contours separated by 5-9 mm in the high dose region. While the agreement 
improves for lower dose contours, MacNCTPlan and NCTPlan contours are still shifted 
from the reference by ~4 mm and ~2 mm, respectively. Also, MacNCTPlan’s lowest dose 
contour appears to trace around the edges of voxels from the coarse scoring mesh, 
resulting in a stepped contour that indicates problems in the contouring algorithm of 
MacNCTPlan. 
To illustrate the agreement in between the particular isodose lines shown in 
Figure 2.46, the corresponding boron dose difference distribution for each TPS is shown 
in Figure 2.47 with outlines of the skin, skull, brain, and tumor superimposed in black. 
The largest disagreement for BNCT_Rtpe and SERA occurs at the boron dose maximum 
where larger tally volumes, interpolation error, and improperly scaled boron kerma 
factors combine to overestimate the reference dose by ~6%. Also, the interpolation error 
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in both BNCT_Rtpe and SERA (refer to Figure 2.7) result in two thin vertical, parallel 
strips in the high dose region at approximately x=4.15 cm and x=5.45 cm where the dose 
differences are elevated by ~1% above those on either side. If MATLAB’s cubic 
algorithm is used to interpolate the coarse voxel data from BNCT_Rtpe and SERA, not 
only are those strips eliminated but the dose differences in the high dose regions are 
reduced from 5-6% to 2-3%. For MacNCTPlan and NCTPlan, the 6-7% underestimation 
of the reference dose rates in the high dose region is partially due to interpolation error 
and partially due to the inability of dose data linearly interpolated from the coarse 1 cm3 
scoring mesh to match the curvature of the reference dose data. The very well defined 
“checker board” pattern in the dose difference distributions is actually a 2D 
representation of the “sawtooth” pattern observed when comparing depth-dose profiles in 
Figure 2.33. Interestingly, both MacNCTPlan and NCTPlan produce this characteristic 
pattern. If MATLAB is used to linearly interpolate the coarse voxel data from 
MacNCTPlan and NCTPlan, these checkerboard patterns are eliminated, but the 
agreement does not change significantly for either TPS. It should also be noted that the 
boron dose difference distributions for all TPSs are symmetrical about the central beam 
axis because the phantom itself is symmetrical about the beam axis in the transverse 
plane. 
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Figure 2.46 Boron isodose contours for a 10B concentration of 15 μg/g in the 
transverse plane containing the central beam axis for a 1-field irradiation 
of the head phantom. Each planning system’s contours (solid) are overlaid 
with the reference contours (dashed) after the treatment time for each 
planning system from Table 2.3 was used to convert the reference dose 
rates to absolute dose. 
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Figure 2.47 Difference in boron dose in the transverse plane containing the central 
beam axis expressed as a percentage of the maximum reference boron 
dose for a 1-field irradiation of the head phantom. 
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2.3.2.1.2 Incident Photon Dose 
 Incident photon isodose contours from each TPS are compared to reference 
contours in a transverse plane of the head phantom in Figure 2.48. Due to the 
monodirectionality of the incident photon beam and the relatively low number of 
interactions incident photons experience in the phantom before escape, the dose gradient 
inside the beam is relatively flat, so that even a small difference in incident photon dose 
will translate into a relatively large DTA for contours. BNCT_Rtpe overestimates the 
reference incident photon dose by ~4% due mainly to the differences in photon kerma 
factors shown in Figure 2.24, but that 4% difference results in a separation of ~1.5 cm for 
contours at shallow depths. Similarly, SERA underestimates the reference photon dose by 
~3% due mainly to the incident photon normalization error, but that difference results in 
contours at shallow depths that are shifted by ~1.1 cm from the reference. The reference 
lateral incident photon dose gradient is flat out to the edge of the beam at y=±5 cm where 
the dose decreases by 95% just beyond the edge of the beam. However, BNCT_Rtpe and 
SERA calculate sharp increases in the incident photon dose, as large as 10%, near the 
edge of the beam that subsequently result in isodose contours that extend to deeper 
depths in the phantom within ~1 cm of the lateral beam edges and thus produce ”horns” 
in the isodose contours. These misshapen contours are due to a combination of the 
interpolation algorithms employed by BNCT_Rtpe and SERA and the steep lateral dose 
gradient at the edges of the monodirectional photon beam. Similar shapes are produced 
when MATLAB is used to interpolate the coarse voxel dose data from BNCT_Rtpe and 
SERA with its cubic interpolation algorithm and plot the contours. While these 
differences near the lateral edges of the beam do not produce any significant 
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disagreement in total weighted dose due to the relatively small contribution of the 
incident photon dose, it does emphasize the importance of evaluating the different 
representations and individual components of dose data since differences are not always 
confined to the central beam axis and can potentially be masked by summation.  
 MacNCTPlan and NCTPlan produce very good agreement with the reference 
incident photon isodose contours, especially at shallow depths where the DTA is less 
than 1 mm. However, the agreement gets slightly worse with depth, and the DTA along 
the central beam axis for the lowest dose contour is 6 mm and 3 mm for MacNCTPlan 
and NCTPlan, respectively. Laterally, the contours of MacNCTPlan and NCTPlan do not 
fully extend out to the edges of the beam but instead span to within 5-10 mm of reference 
contours at the phantom surface. To understand this behavior, transverse and coronal 
views through the head phantom are shown in Figure 2.49 with a portion of the coarse 
scoring mesh from each TPS overlaid and with the beam path through each mesh shaded. 
The edges of the beam are aligned with mesh element edges in BNCT_Rtpe and SERA 
whereas they are aligned with mesh elements centers in MacNCTPlan and NCTPlan. 
Therefore, in this case, it happens that BNCT_Rtpe and SERA are better able to model 
the sharp reference dose gradient at the lateral edges of the beam because the beam edges 
align with the edges of the scoring mesh elements. To better illustrate this effect, the 
lateral incident photon dose rate profile from each TPS is shown in Figure 2.50 as a 
function of the distance from the central beam axis. The position of the monodirectional 
photon beam within the coarse scoring mesh and the extremely steep dose gradient 
prevent MacNCTPlan and NCTPlan from accurately estimating the reference incident 
photon dose from 4-6 cm which results in a shallower dose gradient, 35 to −50% 
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differences, and isodose contours that do not fully extend out to the edges of the beam. 
The shifted scoring mesh alone allows BNCT_Rtpe and SERA to better estimate the 
steep reference dose gradient and produce contours that are closer to the reference 
laterally by ~5 mm. The horns in the dose distribution are however visible here near the 
lateral edges of the beam. These observations further emphasize the problems with 
employing such a coarse scoring mesh, especially when steep dose gradients are present; 
although this is an extreme case, alignment of the beam edges with the dose mesh edges 
should not be needed for accurate calculations. 
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Figure 2.48 Incident photon isodose contours in the transverse plane containing the 
central beam axis for a 1-field irradiation of the head phantom. Each 
planning system’s contours (solid) are overlaid with the reference 
contours (dashed) after the treatment time for each planning system from 
Table 2.3 was used to convert the reference dose rates to absolute dose. 
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Figure 2.49 Transverse and coronal views through the ellipsoidal head phantom 
overlaid with the coarse scoring mesh from each TPS to illustrate the 
relative orientation of each mesh with the phantom and the beam path 
(shaded region). The mesh element centers in BNCT_Rtpe and SERA are 
offset by 5 mm in each dimension from the mesh element centers of 
MacNCTPlan and NCTPlan. The beam is aligned with mesh element 
edges in BNCT_Rtpe and SERA whereas it is aligned with mesh element 
centers in MacNCTPlan and NCTPlan. Each tally volume is 1 cm3, and 
only a portion of each mesh is shown. 
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Figure 2.50 Incident photon dose rate and percent difference (100×[TPS−Ref]/Refmax) 
for each planning system as a function of the lateral distance (in the 
transverse plane) from the central beam axis in the ellipsoidal head 
phantom. MCNP5 served as the reference for percent difference 
calculations. 
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2.3.2.1.3 Total Biologically Weighted Dose 
 Figure 2.51 shows the total weighted brain isodose contours for each TPS and the 
reference in the coronal plane containing the central beam axis. BNCT_Rtpe 
underestimates the reference total weighted brain dose in the high dose region by ~5% 
which results in a DTA in that region of at least 7-10 mm. The agreement improves for 
the lower dose contours where the BNCT_Rtpe contours are within 1-2 mm of the 
reference. SERA produces better agreement with the reference contours than 
BNCT_Rtpe due to slight differences in their respective boron kerma factors which, 
when scaled at runtime by the mass density of the edit mesh, places the SERA boron 
kerma factors in better agreement with the reference kerma factors. The largest 
differences occur in the high dose region where SERA overestimates the reference by 
~4% and produces contours 3-5 mm from the reference, but the DTA for the lower dose 
contours is 1 mm or less. MacNCTPlan and NCTPlan produce noticeably worse 
agreement at all depths partially as a result of geometric approximations introduced by 
using a coarse 1 cm3 voxel model. For the 2 highest dose contours, the agreement is also 
not uniform in that both TPSs, especially MacNCTPlan, produce better agreement on the 
shallow side of the contour than on the deep side. Nevertheless, for the highest dose 
contour of 11.9 Gyw, the DTA for MacNCTPlan is 7-9 mm and 6-9 mm for NCTPlan, but 
the agreement improves to result in a DTA of ~4 and ~2.5 mm, respectively, for the 
lower dose contours. Stepped MacNCTPlan contours are also observed indicating the 
presence of problems within the contouring algorithm. 
 The corresponding total biologically weighted brain dose difference distribution 
for each TPS is shown in Figure 2.52 and overlaid with outlines of the skin, skull, brain, 
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and tumor. BNCT_Rtpe and SERA underestimate the reference dose in the skin by 1-4% 
and overestimate the reference dose in the brain by 2-5% and 1-4%, respectively, 
partially because of the difference in tally volumes between the 1×1×2 mm reference 
mesh and the 10×10×10 mm scoring mesh of BNCT_Rtpe and SERA. SERA produces 
slightly better agreement with the reference in the high dose region in the brain because 
the improperly scaled SERA boron kerma factors are closer to the reference by 1-2% 
than the scaled BNCT_Rtpe kerma factors. MacNCTPlan and NCTPlan both 
underestimate the reference maximum total weighted brain dose by ~5% due to 
differences in tally volumes and geometric approximations. 
 Figure 2.53 shows the total biologically weighted brain isodose contours for each 
TPS and the reference that result from a 3-field irradiation of the head phantom. 
BNCT_Rtpe overestimates the reference in the high dose region by ~5% which results in 
a DTA of at least 7-11 mm for the highest dose contour, but the agreement improves to 
~3.5% at deeper depths along the ipsilateral beam axis and to 1-2% laterally. However, 
the parallel opposed beams produce a relatively flat dose gradient on the contralateral 
side of the phantom where there is only a 10% deviation in doses between the depths of 
1.5 and 8 cm. Therefore, the ~3.5% differences in that region actually results in a DTA of 
~1.3 cm for the 6.49 Gyw contour. SERA produces better agreement and overestimates 
the reference doses by ~2% in the high dose region which results in a DTA for the 
highest dose contour of ~3 mm. On the contralateral side of the phantom, the dose 
differences are 1-2% and also result in a DTA of ~3 mm. The agreement is also very 
good laterally with a DTA of less than 1 mm for the lower dose contours. MacNCTPlan 
and NCTPlan both underestimate the reference dose by ~6% in the high dose region 
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which results in a DTA of 5-9 mm and 5-7 mm, respectively. At shallow depths on the 
contralateral side of the phantom, MacNCTPlan produces worse agreement than 
NCTPlan (e.g., −6.4% vs. −2.7% at a depth of 1.5 cm) due to inaccuracies in the 
MacNCTPlan voxel model along the contralateral surface of the phantom like those 
shown in Figure 2.29. For the 3 lowest dose contours, the DTA for both MacNCTPlan 
and NCTPlan is in the 2-4 mm range.  
 Figure 2.54 compares the total biologically weighted tumor isodose contours for 
each TPS and the reference that result from a 3-field irradiation of the head phantom. 
BNCT_Rtpe and SERA overestimate the reference in the high dose region by ~5% and 
~4%, respectively which correspond to a DTA in that region of 5-10 mm. The DTA 
decreases for the lower dose contours, but a noticeable gap of 1.2-2.3 cm is created 
because the ~42 Gyw contours of BNCT_Rtpe and SERA extend further towards the 
contralateral side of the phantom than do the reference contours. However, these large 
gaps represent an overestimation of the reference dose in that region by BNCT_Rtpe and 
SERA of only 5% and 2.5%, respectively. MacNCTPlan and NCTPlan underestimate the 
reference in the high dose region by as much as 10% which results in a DTA of ~1.2 cm 
for the highest dose contour. MacNCTPlan produces similar agreement to NCTPlan on 
the ipsilateral side but worse agreement near the entrance for both the contralateral (e.g., 
2.5× worse at 1.5 cm depth) and vertex (e.g., 1.25× worse at 1.5 cm depth) beams due to 
inaccuracies in the MacNCTPlan voxel model. A large separation is observed in a section 
of the 41.0 Gyw contour where the reference contour extends 2.1 cm and 3.7 cm beyond 
the MacNCTPlan and NCTPlan contours, respectively, towards the contralateral side of 
the phantom. However, these large differences in contours represent a mere 2-4% 
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underestimation of the reference in that region of the phantom where the dose gradient is 
low. 
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Figure 2.51 Total biologically weighted brain isodose contours in the coronal plane 
containing the central beam axis for a 1-field irradiation of the head 
phantom. Each planning system’s contours (solid) are overlaid with the 
reference contours (dashed) after the treatment time for each planning 
system from Table 2.3 was used to convert the reference dose rates to 
absolute dose. 
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Figure 2.52 Difference in total biologically weighted brain dose in the coronal plane 
containing the central beam axis expressed as a percentage of the 
maximum reference total weighted dose for a 1-field irradiation of the 
head phantom. 
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Figure 2.53 Total biologically weighted brain isodose contours in the transverse plane 
containing the central beam axis for a 3-field irradiation of the head 
phantom. Each planning system’s contours (solid) are overlaid with the 
reference contours (dashed) after the treatment time for each planning 
system from Table 2.3 was used to convert the reference dose rates to 
absolute dose. 
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Figure 2.54 Total biologically weighted tumor isodose contours in the coronal plane 
containing the central beam axis for a 3-field irradiation of the head 
phantom. Each planning system’s contours (solid) are overlaid with the 
reference contours (dashed) after the treatment time for each planning 
system from Table 2.3 was used to convert the reference dose rates to 
absolute dose. 
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2.3.2.2 Leg Phantom 
This section reports the comparison of 2D dose and thermal neutron flux 
distributions (i.e., isodose contours and dose or flux difference distributions) in the leg 
phantom. For all of the dose components, refer to sections 9A.3.2 and 1A.4.2 of Appendix 
A. 
2.3.2.2.1 Thermal Neutron Flux 
 Figure 2.55 shows the 2D thermal neutron flux difference distribution for each 
TPS in the traverse plane of the leg phantom on the beam central axis with superimposed 
outlines of skin, tumors, bone and muscle. BNCT_Rtpe and SERA both underestimate 
the reference thermal neutron flux maximum at 4 mm depth in the phantom by 9-10% 
because 1 cm3 tally volumes are too large to accurately represent the narrow thermal 
neutron flux peak. In fact, a region of underestimation ~6.5 cm wide borders the entire 
beam-facing surface of the phantom and encompasses the shallow side of both tumors. 
However, regions where BNCT_Rtpe and SERA overestimate the reference flux by 4-6% 
and 2-4%, respectively, are also observed (e.g., at x=−4.2 cm). If MATLAB is used to 
interpolate (via cubic interpolation) the coarse voxel data from BNCT_Rtpe and SERA, 
the differences in those same regions decrease by 1-2%, thus identifying interpolation 
error as a significant contributor to the disagreement in those regions. Other than in these 
regions, the thermal neutron flux differences in the leg phantom are all within 2% for 
BNCT_Rtpe and SERA. MacNCTPlan and NCTPlan also underestimate the reference 
thermal neutron flux at shallow depths by as much as 19% and 15%, respectively. 
However, on the deep side of the tumors, MacNCTPlan overestimates the reference flux 
by as much as 14% whereas NCTPlan produces agreement in that same region within 
2%. While the underestimation of the reference at shallow depths is due in large part to 
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the coarseness of the scoring mesh and voxel model relative to the dimensions of the leg 
phantom, MacNCTPlan’s significant disagreement at deeper depths are mainly 
attributable to interpolation error and inaccuracies in its voxel model like those shown in 
Figure 2.39. If MATLAB is used to linearly interpolate MacNCTPlan’s coarse voxel 
data, the “checker board” pattern is eliminated and agreement on the deep side of the 
tumors improves by 4-5%. Similarly, two distinct regions of ~4% overestimation are 
present in the flux difference distribution for NCTPlan, but the agreement improves to 
within ~2% at each spot if MATLAB is used to linearly interpolate NCTPlan’s coarse 
voxel data.  
2.3.2.2.2 Boron Dose 
 Figure 2.56 shows the 2D boron dose difference distribution for each TPS in a 
traverse plane of the leg phantom on the beam central axis with superimposed outlines of 
skin, tumors, bone and muscle. The boron dose difference distributions for MacNCTPlan 
and NCTPlan are nearly identical to their respective thermal neutron flux difference 
distributions shown in Figure 2.55 because in the boron kerma factors used are also 
identical. However, that is not the case for BNCT_Rtpe and SERA because their boron 
kerma factors differ, and, more importantly, because they have been improperly scaled at 
runtime by 1.09, the density of ICRU skin in g/cm3. As a result, boron dose differences as 
large as 8-12% are observed on the deep side of the tumors. The scaling also actually 
improves agreement to 5-6% at shallow depths by compensating for BNCT_Rtpe and 
SERA’s underestimation of the reference thermal neutron flux.  
2.3.2.2.3 Total Biologically Weighted Dose 
 Figure 2.57 compares the total biologically weighted tumor isodose contours for 
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each TPS with the reference in the transverse plane of the leg phantom containing the 
central beam axis. Both BNCT_Rtpe and SERA significantly underestimate the reference 
thermal neutron flux in the high dose region as shown in Figure 2.55, but scaling the 
neutron and boron kerma factors up at runtime by the mass density of ICRU skin (1.09) 
actually compensates for the underestimation to produce contours that are 5 mm from the 
reference contour along the beam line and 2-3 mm laterally. However, that scaling also 
results in BNCT_Rtpe and SERA overestimating the reference doses beyond the tumors 
to produce DTA of 2-4 mm for the lower dose contours. MacNCTPlan deviates 
substantially from the reference contour in the high dose region and thus results in a 
contour that is 1/3 the width of the reference contour and shifted by ~1.2 cm laterally. 
These differences are due to interpolation error as well as inaccuracies in the 
MacNCTPlan voxel model. Agreement improves in the lower dose contours where the 
DTA is generally within 5 mm and MacNCTPlan’s contours span the same lateral 
distance as the reference contours. NCTPlan produces better agreement than 
MacNCTPlan in the high dose region as evidenced by its isodose contour being centered 
about the central beam axis and spanning 2/3 the lateral width of the reference contour. 
Agreement improves significantly in the lower dose contours where the DTA are 
generally less than 1 mm which is actually better agreement than observed for the head 
phantom (Figure 2.51). 
 Figure 2.58 compares the total biologically weighted tumor isodose contours of 
MacNCTPlan and NCTPlan with the reference in the oblique plane of the leg phantom 
containing the central beam axis. Since it was not possible to plot contours for this 
oblique plane in BNCT_Rtpe or SERA, they have been omitted from the comparison in 
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this plane.∗ MacNCTPlan produces significant differences in the high dose region where 
its contour does not extend to the same width as the reference either axially or along the 
beam line. On the deep side of the tumor, MacNCTPlan overestimates the reference 
doses by as much as 11% due to interpolation error and inaccuracies in its voxel model 
which results in a DTA as large as 3 mm. Also, the lower dose MacNCTPlan contours 
are stepped and appear to trace along the edges of the 1 cm3 tally volumes rather than 
being smooth like those of NCTPlan. NCTPlan produces better agreement than 
MacNCTPlan like in the transverse plane, but the highest dose NCTPlan contour does not 
span the same axial distance as the reference contour instead extending within ~1.4 cm of 
the reference contour’s superior and inferior edges. However, agreement for the lower 
dose (≤ 16.5 Gyw) contours is excellent with DTA within 1 mm, which is surprising when 
the coarseness of the tally mesh and the voxel model relative to the leg phantom 
dimensions is considered. 
 
 
 
 
 
 
 
                                                 
∗ Isodose contours for the oblique plane were successfully calculated with seraPlan, but seraPlot would not 
display them correctly. 
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Figure 2.55 Difference in thermal neutron flux in the transverse plane containing the 
central beam axis expressed as a percentage of the maximum reference 
thermal neutron flux for a 1-field irradiation of the leg phantom. 
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Figure 2.56 Difference in boron dose in the transverse plane containing the central 
beam axis expressed as a percentage of the maximum reference boron 
dose for a 1-field irradiation of the leg phantom. 
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Figure 2.57 Total biologically weighted tumor isodose contours in the transverse plane 
containing the central beam axis for a 1-field irradiation of the leg 
phantom. Each planning system’s contours (solid) are overlaid with the 
reference contours (dashed) after the treatment time for each planning 
system from Table 2.3 was used to convert the reference dose rates to 
absolute dose. 
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Figure 2.58 Total biologically weighted tumor isodose contours in an oblique plane 
containing the central beam axis for a 1-field irradiation of the leg 
phantom. Each planning system’s contours (solid) are overlaid with the 
reference contours (dashed) after the treatment time for each planning 
system from Table 2.3 was used to convert the reference dose rates to 
absolute dose. 
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2.3.3 Dose-Volume Histograms 
 Each TPS produced a unique reference dose when calculating the treatment plans 
Therefore, the reference treatment times from Table 2.3 were used to convert the dose-
volume data from each TPS into units of absolute dose to allow for a direct comparison 
with the corresponding reference dose-volume data. The volumes calculated by each TPS 
for the various anatomical regions in the head and leg phantoms are shown in Table 2.4 
and the corresponding analytical volumes are included for comparison. Clearly, SERA 
and NCTPlan produce more accurate volume estimates than there respective 
predecessors. For instance, BNCT_Rtpe and MacNCTPlan calculate volumes for brain 
that are 95% and 75% of the analytical volume, respectively, whereas SERA and 
NCTPlan produce volume estimates that are within 0.03% of the analytical volume. 
These more accurate volume estimates are a direct result of the improved accuracy of 
SERA’s univel models over that of BNCT_Rtpe NURBS models and the algorithmic 
improvements in NCTPlan compared to MacNCTPlan. It should be noted, however, that 
Table 2.4 Volumes in cm3 of the various anatomical regions in the head and leg 
phantoms as calculated by each treatment planning system. The analytical 
volumes are also included as a point of comparison. MacNCTPlan and 
NCTPlan skin volumes are not included because neither planning system 
was able to accurately calculate dose-volume data for concave regions like 
skin. 
 Structure Volume (cm3) 
 Head Phantom  Leg Phantom 
 brain tumor  skin tumor 1 tumor 2 
Analytical 1470.27 33.51  84.01 1.77 19.24 
BNCT_Rtpe 1403.52 33.46  98.51 1.56 17.76 
SERA 1469.90 33.65  85.99 1.77 19.93 
MacNCTPlan 1101.41 34.95  ---- 1.63 40.28 
NCTPlan 1470.27 33.42  ---- 1.77 19.93 
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NCTPlan produced a different volume for brain (1403.27 cm3) when calculating the fast 
neutron DVH resulting from a 1-field irradiation of the head phantom. This reproducible 
and erroneous volume calculation was not reproduced for the 3-field irradiation, any 
other regions, or dose components nor was anything similar observed in MacNCTPlan. 
Also, in Table 2.4, there is no MacNCTPlan or NCTPlan entry for leg phantom skin. 
MacNCTPlan and NCTPlan ROI files for skin were successfully created and displayed 
by both TPSs, but their resulting volume estimates were 12× the analytical volume. The 
clearly erroneous DVHs indicated that neither TPS was able to accurately calculate dose-
volume data for regions like skin that have interior holes. In this case, the skin ROI was 
represented by a single concave C-shaped contour with the two ends of the C nearly 
touching.  
When comparing dose-volume data, the level of agreement can be reported as the 
difference in dose for a given volume fraction (the horizontal distance between DVHs) or 
the difference in volume fraction for a given dose (the vertical distance between DVHs). 
The former was utilized for a majority of this analysis. However, since is also common in 
radiotherapy to report the volume fraction of a given anatomical region that received a 
dose greater than some pre-determined value, brain V8 values (i.e., the fraction of brain 
volume that received ≥ 8 Gyw) from each TPS are also reported and compared with the 
reference. To extract such data from the binned BNCT_Rtpe dose-volume histograms, 
the lower left or low dose corner of the each bin for a given DVH was connected, and the 
dose data were linearly interpolated from the resulting curve. 
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2.3.3.1 Ellipsoidal Head Phantom 
Figure 2.59 shows the total biologically weighted dose-volume histograms for 
brain resulting from a 1-field irradiation of the head phantom for 3.16 minutes (i.e., the 
reference treatment time from Table 2.3). Conventional and binned representations of the 
reference data are included to facilitate its comparison to both the binned dose-volume 
data from BNCT_Rtpe and the more conventional integral dose-volume histograms from 
the other TPSs. By default, seraPlan calculates dose-volume data in 10% increments of 
its reference dose, and then seraPlot assigns the corresponding percent volume to the 
center of each dose bin in order to plot a conventional DVH. As shown in Figure 2.59, 
this interpretation of the SERA dose-volume data results in a systematic 5% (i.e., ½ 
default bin width) shift to higher doses and worse agreement with the reference. If the 
same seraPlan dose-volume data are instead re-plotted at the low dose edge of each bin 
rather than at the center, better agreement with the reference DVH is observed in Figure 
2.59. Therefore, only the corrected interpretation of the SERA dose-volume data with a 
−5% shift in dose will be included in subsequent figures, where it will be labeled as such. 
The corresponding mean, minimum, and maximum total weighted brain doses are shown 
in Table 2.5. Data for MacNCTPlan is not listed because the code does not report this 
information. The agreement with the reference in both Figure 2.59 and Table 2.5 is 
consistent with the trends identified when evaluating the other forms of dose data. 
BNCT_Rtpe and SERA generally overestimate the reference whereas MacNCTPlan and 
NCTPlan generally underestimate, and SERA and NCTPlan generally produce better 
agreement than their respective predecessors. In Table 2.5, maximum brain doses for 
BNCT_Rtpe, SERA, and NCTPlan differ from the reference by 5.7%, 4.0%, and −5.3%, 
respectively, which is consistent with the agreement observed in the total weighted dose 
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profiles (refer to Figure 2.38). In Figure 2.59, BNCT_Rtpe, SERA, MacNCTPlan, and 
NCTPlan produce V8 brain volume fractions of 10.0%, 11.1%, 6.0%, and 7.0%, 
respectively. When compared to the reference V8 of 8.6%, BNCT_Rtpe, SERA, 
MacNCTPlan, and NCTPlan result in differences of 16.7%, 29.2%, −29.9%, and −18.2%, 
respectively. When the same SERA dose-volume data are interpreted differently than 
seraPlot and re-plotted correctly, the resulting DVH produces a V8 volume fraction of 
9.3% which overestimates the reference value by only 8.9% and represents much 
improved agreement from the seraPlan interpretation. Both BNCT_Rtpe and 
MacNCTPlan produce improved agreement at higher doses and lower volumes whereas 
SERA and NCTPlan produce relatively consistent agreement across a range of doses. 
SERA produces better agreement than BNCT_Rtpe because of improvements in 
modeling technique (i.e., univels vs. NURBS) that result in a more accurate model of the 
phantom for both transport and DVH calculations. While MacNCTPlan and NCTPlan 
employ the same modeling technique, their DVH algorithms are different. 
MacNCTPlan’s rather simplistic DVH algorithm results in large disagreement whereas 
the clearly significant algorithmic improvements made in NCTPlan are largely 
responsible for the better agreement.  
Figure 2.60 shows the total biologically weighted dose-volume histograms for 
tumor resulting from a 1-field irradiation of the head phantom for 3.16 minutes. The 
corresponding dose statistics are shown in Table 2.5 where BNCT_Rtpe, SERA, and 
NCTPlan minimum tumor doses differ from the reference by 14%, 3.5%, and −6.5%, 
respectively. Overall, the agreement shown in Figure 2.60 is similar to that observed for 
brain. BNCT_Rtpe and SERA on average overestimate the reference dose delivered to a 
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given volume of tumor by ~6.5% and ~4.5%, respectively, while NCTPlan consistently 
underestimates the reference doses by ~4%. At low doses, MacNCTPlan underestimates 
the reference by 10-15%, but the agreement improves significantly to within 2-4% at 
higher doses and small volumes. 
The total biologically weighted dose-volume histograms for brain resulting from a 
3-field irradiation of the head phantom for a total of 5.66 minutes are shown in Figure 
2.61. The corresponding dose statistics are reported in Table 2.6 where maximum brain 
doses for BNCT_Rtpe, SERA, and NCTPlan differ from the reference by 5.8%, 3.2%, 
and −5.9%, respectively. These maximum brain doses indicate agreement similar to that 
observed for the 1-field DVH. The V8 brain volume fractions produced by BNCT_Rtpe, 
SERA, MacNCTPlan and NCTPlan are read from Figure 2.61 to be 21.4%, 17.9%, 
11.0%, and 12.0%, respectively. When compared to the reference value of 15.2%, the 
differences for BNCT_Rtpe, SERA, MacNCTPlan and NCTPlan are calculated to be 
40.5%, 17.6%, −27.6%, and −21.4%, respectively. The agreement for BNCT_Rtpe and 
SERA is significantly worse than observed for the for 1-field irradiation. Closer 
examination of the reference DVH in Figure 2.61 reveals a bend in the reference 
histogram at ~8 Gyw that the coarse BNCT_Rtpe and SERA dose-volume data (the 
default 10% dose bins were used) are not able to accurately match, which results a large 
overestimation of the V8 volume fraction. Otherwise, SERA and NCTPlan again produce 
rather consistent agreement (approximately 2.2% and −5.5%, respectively) in dose in 
Figure 2.61. BNCT_Rtpe overestimates the reference doses at low doses by 10-14%, but 
the agreement improves to ~6.5% at higher doses, which is similar to the behavior 
observed for a 1-field irradiation. At low doses and large volumes, MacNCTPlan 
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significantly underestimates the references doses by more than 25%, but the agreement 
improves significantly, to within 5-8%, at doses above 6 Gyw. While MacNCTPlan is 
observed to underestimate the total weighted reference isodose contours in Figure 2.53, 
the disagreement is significantly less than 25%. Therefore, the large disagreement 
observed in the dose-volume data is an artifact of MacNCTPlan’s simplistic DVH 
algorithm.  
Figure 2.62 shows the total biologically weighted dose-volume histograms for 
tumor resulting from a 3-field irradiation of the head phantom for a total of 5.66 minutes. 
The corresponding dose statistics are listed in Table 2.6 where BNCT_Rtpe, SERA, and 
NCTPlan minimum tumor doses differ from the reference by 11%, 4.4%, and −4.2%, 
respectively. Overall, the agreement observed for each TPS in Figure 2.62 is similar to 
that produced when comparing tumor dose-volume data from a 1-field irradiation. 
BNCT_Rtpe and SERA consistently overestimate the reference doses delivered to a 
given tumor volume fraction by 6.5-7.5% and 3.3-5%, respectively. At low tumor doses, 
MacNCTPlan and NCTPlan underestimate the reference by 6-7.5% and 4.5%, 
respectively, which represents an improvement for MacNCTPlan from the 1-field DVH. 
At higher doses, the agreement for MacNCTPlan improves to within −4% whereas 
NCTPlan’s agreement does not change significantly.  
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Table 2.5 Total biologically weighted dose statistics in Gyw for brain and tumor 
resulting from a single-field irradiation of the head phantom with the 
generic epithermal neutron beam for 3.16 minutes. 
 Dose (Gyw) 
 Brain  Tumor 
 mean minimum maximum  mean minimum maximum
Reference 3.00 0.380 12.50  35.81 17.05 62.37 
BNCT_Rtpe 3.23 0.430 13.21  38.40 19.37 62.29 
SERA 3.08 0.385 13.00  37.41 17.65 64.60 
NCTPlan 2.79 0.355 11.84  33.88 15.94 58.44 
 
 
 
 
Table 2.6 Total biologically weighted dose statistics in Gyw for brain and tumor 
resulting from a 3-field irradiation of the head phantom with the generic 
epithermal neutron beam for 5.66 minutes. 
 Dose (Gyw) 
 Brain  Tumor 
 mean minimum maximum  mean minimum maximum
Reference 5.29 0.87 12.50  41.69 27.22 62.91 
BNCT_Rtpe 5.72 1.01 13.22  44.73 30.24 64.83 
SERA 5.43 0.92 12.90  43.39 28.41 64.61 
NCTPlan 4.94 0.82 11.76  39.65 26.09 59.17 
 
 
 
 
 
 
Computational Aspects of Treatment Planning for Neutron Capture Therapy 
 
 270
0 1 2 3 4 5 6 7 8 9 10 11 12 13
0
10
20
30
40
50
60
70
80
90
100
Total Biologically Weighted Dose (Brain)
Biologically Weighted Dose (Gyw)
V
ol
um
e 
of
 B
ra
in
 (%
)
Reference
Reference (binned)
BNCT_Rtpe
SERA
SERA (corrected)
MacNCTPlan
NCTPlan
 
Figure 2.59 Total biologically weighted dose-volume histograms for brain for a 1-field 
irradiation of the head phantom. Conventional and binned representations 
of the reference data are included. The default output from seraPlot is 
shown along with a corrected interpretation of the SERA dose-volume 
data (with a −5% shift in dose). 
 
 
 
 
 
 
 
Chapter 2: Intercomparison of Neutron Capture Therapy Treatment Planning Systems J.R. Albritton 
 
 271
0 5 10 15 20 25 30 35 40 45 50 55 60 65
0
10
20
30
40
50
60
70
80
90
100
Total Biologically Weighted Dose (Brain Tumor)
Biologically Weighted Dose (Gyw)
V
ol
um
e 
of
 T
um
or
 (%
)
Reference
Reference (binned)
BNCT_Rtpe
SERA (corrected)
MacNCTPlan
NCTPlan
 
Figure 2.60 Total biologically weighted dose-volume histograms for the brain tumor 
for a 1-field irradiation of the head phantom. Conventional and binned 
representations of the reference data are included. A corrected 
interpretation of the SERA dose-volume data (with a −5% shift in dose) is 
shown instead of the default seraPlot output. 
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Figure 2.61 Total biologically weighted dose-volume histograms for brain for a 3-field 
irradiation of the head phantom. Conventional and binned representations 
of the reference data are included. A corrected interpretation of the SERA 
dose-volume data (with a −5% shift in dose) is shown instead of the 
default seraPlot output. 
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Figure 2.62 Total biologically weighted dose-volume histograms for the brain tumor 
for a 3-field irradiation of the head phantom. Conventional and binned 
representations of the reference data are included. A corrected 
interpretation of the SERA dose-volume data (with a −5% shift in dose) is 
shown instead of the default seraPlot output. 
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2.3.3.2 Leg Phantom 
This section reports the comparison of dose-volume data from each TPS with the 
reference for the skin and both tumors in the leg phantom. For all of the dose 
components, refer to section 1A.5.2 of Appendix A. 
2.3.3.2.1 Skin 
The total biologically weighted dose-volume histograms for skin resulting from a 
3-field irradiation of the leg phantom for 1.38 minutes are shown in Figure 2.63. It should 
be noted that the DVHs are only for skin in the treated volume which is bounded axially 
within 6 cm of the beam central axis. Also, MacNCTPlan and NCTPlan are omitted from 
the comparison because neither was able to accurately calculate dose-volume data for 
concave regions like skin. In the Harvard-MIT clinical trials of BNCT for intracranial 
disease using the fission converter beam,32 the biologically weighted dose at 5 mm depth 
along the central beam axis was recorded as the maximum skin dose, so that method was 
repeated for the leg phantom. The MacNCTPlan and NCTPlan total biologically 
weighted dose rates at 5 mm depth were read from Figure 2.45 and multiplied by the 
reference treatment time of 1.38 minutes. The resulting values as well as the other dose 
statistics for skin are shown in Table 2.7 where the BNCT_Rtpe, SERA, MacNCTPlan, 
and NCTPlan maximum skin doses differ from the reference by 5.7%, 6.6%, −5.4%, and 
−10%, respectively. In Figure 2.63, the conventional representation of the reference dose-
volume data is not entirely smooth but rather exhibits some waviness (e.g., at ~12 Gyw) 
because the cylindrical scoring mesh used in the reference calculations did not consist of 
uniform tally volumes. The scoring mesh was intentionally made finer in the high dose 
region to better handle the high dose gradient and coarser in the low dose regions to 
improve dose statistics on the contralateral side of the phantom. Both BNCT_Rtpe and 
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SERA produce significant disagreement at low doses with both underestimating the 
reference by as much as −48% and −18%, respectively, but agreement improves 
significantly to within 10% for doses above 11 Gyw. It is also worth noting that the 
maximum incident photon dose to skin reported by SERA was nearly 7× larger than the 
reference value (0.75 Gy vs. 0.11 Gy; refer to Table A.31) which suggests a potential 
problem with SERA’s custom 3D dose interpolation algorithm and steep dose gradients 
much like that which produced the ”horns” in the incident photon isodose contours in 
Figure 2.48. Nevertheless, while the agreement for skin DVHs is not excellent, it is good 
given that BNCT_Rtpe and SERA use dose interpolated from a mesh of 1 cm3 tally 
volumes to estimate the dose in the 2 mm thick layer of skin. 
2.3.3.2.2 Tumor 1 (spherical tumor) 
Figure 2.64 shows the total biologically weighted dose-volume histograms for 
tumor 1 (i.e., the spherical tumor) resulting from a 1-field irradiation of the leg phantom 
for 1.38 minutes. The corresponding dose statistics are shown in Table 2.7 where 
minimum tumor doses for BNCT_Rtpe, SERA, and NCTPlan differ from the reference 
by 9.9%, 7.9%, and 1.0%, respectively. In Figure 2.64, BNCT_Rtpe overestimates the 
reference DVH doses by as much as 12% at lower doses, but the agreement steadily 
improves to 2.3% at high doses and small volumes. SERA produces slightly better 
agreement by overestimating the reference by 6-10% at smaller doses to actually 
underestimating the reference by 1.5% at the highest doses. These observations are 
consistent with the agreement observed in the 2D boron difference distributions in Figure 
2.56 where both BNCT_Rtpe and SERA underestimate the reference boron in the high 
dose region of the tumor and overestimate the reference doses in the low dose region of 
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the tumor. Since the minimum tumor dose occurs on the deep side of the tumor, 
BNCT_Rtpe and SERA overestimate the reference minimum tumor dose in Table 2.7. 
Similarly, in Figure 2.56, MacNCTPlan underestimates the reference boron dose on the 
shallow or high dose side of the tumor and overestimates the reference dose on the deep 
side or low dose side. Therefore, MacNCTPlan overestimates the reference doses by as 
much as 7% at lower doses and underestimates the reference at the higher doses by as 
much as 9%, which when combined results in a much steeper DVH than the reference. 
NCTPlan does not overestimate the reference on the deep or low dose side of the tumor 
in Figure 2.56, so it produces a very good estimate of the reference minimum tumor dose 
in Table 2.7. However, NCTPlan does underestimate the reference doses on the high dose 
side of the tumor, which produces the disagreement in the dose-volume data, as much as 
−12% in Figure 2.64, observed at high doses.  
2.3.3.2.3 Tumor 2 (arc-shaped tumor) 
The total biologically weighted dose-volume histograms for tumor 2 (i.e., arc-
shaped tumor) resulting from a 1-field irradiation of the leg phantom for 1.38 minutes are 
shown in Figure 2.65. The corresponding dose statistics are reported in Table 2.7 where 
BNCT_Rtpe, SERA, and NCTPlan minimum tumor doses differ from the reference by 
8.0%, 4.5%, and −8.4%, respectively. Due partially to the improper scaling of the boron 
doses, both BNCT_Rtpe and SERA overestimate the references doses on the deep side of 
the tumor in Figure 2.56. Therefore, both BNCT_Rtpe and SERA overestimate the 
minimum reference tumor dose as well as the DVH doses for large volumes by 10-12% 
and 6-8%, respectively. Agreement improves for both TPSs at higher DVH doses and 
smaller tumor volumes to within 2-5%. The agreement is clearly worse for MacNCTPlan 
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and NCTPlan. In Figure 2.56, the arc-shaped tumor is almost completely enclosed within 
a region of significant underestimation where disagreement reaches −25% and −17% for 
MacNCTPlan and NCTPlan, respectively. Therefore, the disagreement in the 
corresponding dose-volume data for that tumor is not particularly surprising. 
MacNCTPlan underestimates the references doses for large tumor volumes in excess of 
40%, but agreement improves at higher doses to within 10-15%. NCTPlan consistently 
underestimates by the reference DVH doses by 10-13%.  
The level of agreement observed for the subcutaneous tumors is significantly 
worse for all TPSs than observed for the brain tumor in Figure 2.59 because the brain 
tumor was positioned deep enough in the head phantom to avoid the region of significant 
disagreement near the phantom surface where, in the thermal neutron beam, the dose 
gradients are even steeper. On the other hand, the superficial location of all of the 
structures of interest in the leg phantom exposed those regions to the significant 
disagreement at shallow depths that resulted from a combination of excessively large 
tally volumes, interpolation error, and geometric approximations (from coarse 
MacNCTPlan and NCTPlan voxel models).  
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Table 2.7 Total biologically weighted dose statistics in Gyw for skin, tumor 1 
(spherical), and tumor 2 (arc-shaped) resulting from a 1-field irradiation of 
the leg phantom with a thermal neutron beam for 1.38 minutes. Maximum 
skin doses for MacNCTPlan and NCTPlan were recorded at a depth of 5 
mm on the central beam axis. 
 Dose (Gyw) 
 mean minimum maximum
 Skin 
Reference 2.88 0.080 13.41 
BNCT_Rtpe 2.46 0.089 14.18 
SERA 2.78 0.078 14.29 
MacNCTPlan ---- ---- 12.69 
NCTPlan ---- ---- 12.07 
 Tumor 1 
Reference 32.80 24.00 40.27 
BNCT_Rtpe 35.09 26.39 40.63 
SERA 34.22 25.89 39.69 
NCTPlan 30.76 24.23 35.59 
 Tumor 2 
Reference 37.44 25.21 42.55 
BNCT_Rtpe 39.39 27.22 44.72 
SERA 38.77 26.34 43.91 
NCTPlan 33.24 23.10 37.86 
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Figure 2.63 Total biologically weighted dose-volume histograms for skin for a 1-field 
irradiation of the leg phantom. Conventional and binned representations of 
the reference data are included. A corrected interpretation of the SERA 
dose-volume data (with a −5% shift in dose) is shown instead of the 
default seraPlot output. 
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Figure 2.64 Total biologically weighted dose-volume histograms for tumor 1 
(spherical tumor) for a 1-field irradiation of the leg phantom. 
Conventional and binned representations of the reference data are 
included. A corrected interpretation of the SERA dose-volume data (with 
a −5% shift in dose) is shown instead of the default seraPlot output. 
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Figure 2.65 Total biologically weighted dose-volume histograms for tumor 2 (arc-
shaped tumor) for a 1-field irradiation of the leg phantom. Conventional 
and binned representations of the reference data are included. A corrected 
interpretation of the SERA dose-volume data (with a −5% shift in dose) is 
shown instead of the default seraPlot output. 
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2.4 Discussion 
This analysis has uncovered a number of differences between planning systems 
and specific issues with individual planning systems, some new and some previously 
reported. Many of the differences are clinically significant and some are quite surprising. 
A number of factors may have contributed to these findings. The TPSs used in BNCT are 
not commercial software packages but are research software with very small user bases 
and are usually developed by small teams of physicists, engineers, and sometimes 
students with very limited budgets. All current BNCT TPSs use Monte Carlo algorithms, 
which are widely regarded as the most accurate method available for dose calculation. 
Monte Carlo dose calculations, however, are not inherently accurate, meaning that the 
particular software implementation must be properly tested to prevent or correct subtle 
problems that frequently arise during the software development process. Statistical error 
in Monte Carlo calculations may have masked some issues; the computational power 
available to rapidly provide results with very low uncertainties in this study has not 
always been available. 
The many deviations from the reference data encountered in this study underscore 
the importance of understanding differences between planning systems before clinical 
dosimetry from different institutions can be legitimately compared. These results also 
emphasize the value and utility of such a reference data set during the TPS development 
process. Many of the issues with the TPSs uncovered in this study could have been easily 
detected and eliminated early in the development process if this suite of test problems 
and reference data had been available. We hope that the availability of the reference data 
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from this suite of test problems will help to improve the accuracy and uniformity of 
BNCT planning systems. 
All of the TPSs produce data deviating from the reference While fully 
understanding the causes behind such deviations is indeed important, the clinical 
significance of the observed differences between the TPSs and the reference calculations 
also needs to be properly addressed. The significance of the differences depends at least 
partially on the measured quantity used to calibrate the planning system because some 
differences will “cancel out” when the TPS is calibrated to measurements while others 
will persist. Since the observed disagreement is actually the sum of differences from 
several different sources, especially for BNCT_Rtpe and SERA, calibrating the planning 
system cannot possibly eliminate them all. For instance, calibrating BNCT_Rtpe or 
SERA to physical dosimetry measurements of thermal neutron flux (as appears to be 
done quite frequently;13,61 refer to Chapter 3) will not correct for the improper 
multiplication of neutron and boron dose rates by the mass density of the edit mesh 
material. Therefore, even if the planning system is tuned to produce good agreement with 
measurements of thermal neutron flux, differences in calculated dose will persist. If, 
however, BNCT_Rtpe and SERA are calibrated to the neutron or boron dose, those 
differences will be eliminated, at least for planning calculations with the same edit mesh 
material density. This observation underscores the importance of calibrating treatment 
planning systems using dose, which is a more clinically relevant quantity, rather than 
relying on thermal neutron flux for calibration. Nevertheless, tuning the planning system 
to the improperly multiplied neutron or boron doses will likewise produce worse 
agreement in thermal neutron flux and the induced photon dose. Some sources of 
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disagreement will persist regardless of how the planning systems are calibrated. 
Differences due to interpolation error or erroneous kerma factors (e.g., BNCT_Rtpe 
photon kerma factors) or geometric approximations cannot be eliminated by tuning the 
planning system because the disagreement they produce is not constant but rather 
dependent on the specific details of the treatment planning calculations. Other sources of 
disagreement, such as that produced by the fast neutron source biasing mode in 
BNCT_Rtpe and SERA or the systematic shift of DVH data by seraPlot, can indeed be 
avoided simply by being aware that they do exist and then taking the steps necessary to 
prevent them. will not correct for the improper multiplication of neutron and boron dose 
rates by the mass density of the edit mesh material. Therefore, even if the planning 
system is tuned to produce good agreement with measurements of thermal neutron flux, 
differences in calculated dose will persist. If, however, BNCT_Rtpe and SERA are 
calibrated to the neutron or boron dose, those differences will be eliminated, at least for 
planning calculations with the same edit mesh material density. This observation 
underscores the importance of calibrating treatment planning systems using dose, which 
is a more clinically relevant quantity, rather than relying on thermal neutron flux for 
calibration. Nevertheless, tuning the planning system to the improperly multiplied 
neutron or boron doses will likewise produce worse agreement in thermal neutron flux 
and the induced photon dose. Some sources of disagreement will persist regardless of 
how the planning systems are calibrated. Differences due to interpolation error or 
erroneous kerma factors (e.g., BNCT_Rtpe photon kerma factors) or geometric 
approximations cannot be eliminated by tuning the planning system because the 
disagreement they produce is not constant but rather dependent on the specific details of 
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the treatment planning calculations. Other sources of disagreement, such as that produced 
by the fast neutron source biasing mode in BNCT_Rtpe and SERA or the systematic shift 
of DVH data by seraPlot, can indeed be avoided simply by being aware that they do exist 
and then taking the steps necessary to prevent them. 
More realistic beams, such the MIT fission converter beam (FCB)62,63, and 
transport geometries, such as the RANDO® anthropomorphic phantom (The Phantom 
Laboratory, Salem, NY), were considered for inclusion in the reference problems but 
were ultimately excluded in favor of more simplistic phantoms and neutron beam spectra. 
Many differences between planning systems and problems with individual planning 
systems were discovered using the simple phantoms and beams in this study. Using more 
realistic phantoms and beams would, in our view, make evaluation and interpretation of 
the results more difficult. Comparisons using more realistic beams and phantoms are 
useful and important, but only after more fundamental evaluations are performed, as in 
this study. One of the conclusions reached in Chapter 5 was that the only way to 
accurately model the complex 5-dimensional probability distribution describing the 
spatial, energy, and angular characteristics of a radiation beam like the FCB was to use a 
patched version of the Monte Carlo transport code or a phase space file. However, neither 
of those methods was feasible for BNCT_Rtpe or SERA, so it would have been nearly 
impossible to accurately model a clinical beam like the FCB in those TPSs. Also, 
comparing calculations to only physical dosimetry measurements severely limits the 
types of dose data that can be compared. So, using a well-benchmarked Monte Carlo 
code like MCNP5 as the reference allowed more flexibility in the types of reference dose 
data that could be calculated and thus enabled a more in-depth and clinically relevant 
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comparison. Other phantoms were considered as was using actual image data of human 
anatomy, but it would have been very difficult to investigate the effects of geometric 
approximations since such anatomy could not be modeled for the reference transport 
calculations without introducing such approximations.  
It was initially intended that electron transport would be included in the reference 
dose calculations, but doing so proved to be difficult. Mesh tallies and the ability to tally 
independently from the transport geometry were absolutely essential to the reference 
calculations, but MCNP5 v. 1.40 unfortunately lacked the ability to tally dose from 
electrons with a mesh tally. Therefore, MCNPX v2.6.a64 was investigated as a possible 
solution as it did include such functionality. However, it was discovered during initial 
simulations that MCNPX mesh tallies produced wrong answers if the boundary of a mesh 
element coincided with that of an internal geometry boundary. Therefore, the only other 
option was to write a custom tally routine for MCNP5, and that is beyond the scope of 
this work.  
During the comparison of multi-dimensional dose data, it was made clear that 1 
cm3 volumes are insufficient for both a scoring mesh and a voxel model. There was 
indeed a time when using a relatively coarse mesh was required because the 
computational resources available could not achieve the desired level of uncertainty in 
smaller tally volumes within a reasonable period of time. However, with the 
computational resources currently available for treatment planning calculations, that 
limitation no longer exists, so smaller tally volumes and a finer voxel model11,65 have 
been and should continue to be implemented to achieve more accurate models of the 
patient anatomy and improved dose calculations.  
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2.5 Conclusions 
The pre-existing suite of reference dosimetry calculations14 has been extended to 
include multiple phantoms, neutron beam spectra, and multi-dimensional dose data 
relevant to BNCT treatment planning. The resulting suite of reference data were used as a 
basis of comparison for four BNCT treatment planning systems: BNCT_Rtpe, SERA, 
MacNCTPlan, and NCTPlan. All 4 planning systems deviated significantly from the 
reference calculations with SERA and NCTPlan generally producing better agreement 
than their respective predecessors, BNCT_Rtpe and MacNCTPlan. Additional effort was 
focused on understanding and explaining the causes of the disagreement observed. Other 
BNCT treatment planning systems could easily be analyzed once they become available. 
This intercomparison of planning systems begins to address the obstacles in 
computational dosimetry that prevent the legitimate pooling of BNCT clinical outcomes 
while also providing a quality assurance tool for existing and future treatment planning 
systems. 
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CHAPTER THREE 
Comparison of Doses Delivered 
in Clinical Trials of Neutron 
Capture Therapy in the USA 
3.0 Abstract 
A combined 81 brain tumor patients have been treated in dose escalation trials of 
Neutron Capture Therapy (NCT) in the USA at Harvard-Massachusetts Institute of 
Technology (MIT) and Brookhaven National Laboratory (BNL). Pooling the clinical 
outcomes from these trials will allow the evaluation of the safety and efficacy of NCT 
with more statistical rigor. However, differences in physical and computational dosimetry 
between the institutions that make a direct comparison of the clinical dosimetry difficult 
must first be addressed before clinical data can be compared. This chapter describes work 
performed to normalize the BNL clinical dosimetry to that of Harvard-MIT for combined 
NCT dose response analysis. This normalization involved analysis of MIT measurements 
and calculations using the BNL treatment planning system (TPS), BNCT_Rtpe, for two 
different phantoms. The BNL TPS was calibrated to dose measurements made by MIT at 
the Brookhaven Medical Research Reactor (BMRR) in the BNL calibration phantom, a 
Lucite cube, and then validated by MIT dose measurements at the BMMR in an 
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ellipsoidal water phantom. Using the newly determined TPS calibration, treatment plans 
for all BNL patients were recomputed, yielding reductions in reported mean brain doses 
of 10% on average in the initial 15 patients treated with the 8 cm collimator and 27% in 
the latter 38 patients treated with a 12 cm collimator. These reductions in reported doses 
have clinically significant implications for those relying on reported BNL doses as a 
basis for initial dose selection in clinical studies and reaffirm the importance of 
collaborative dosimetric comparisons within the NCT community. 
3.1 Introduction 
Given the considerable expense and time required to conduct trials of BNCT 
along with the understanding that the number of patients having been treated with Boron 
Neutron Capture Therapy (BNCT) at the various sites in the Americas, Europe, and Asia 
is steadily growing, it would indeed be advantageous to be able to pool the clinical 
outcomes from different sites together so the safety and efficacy of BNCT could be 
analyzed in much greater detail. However, significant differences in the physical and 
computational dosimetry such as differences in dose measurement techniques, treatment 
planning codes, and methods of dose prescription impede direct comparisons of clinical 
results. Nevertheless, significant steps have been taken to properly address these 
differences in dosimetry,1-3 and these efforts form the foundation for the work described 
in this chapter. 
In order to better understand the differences in dose measurement techniques, 
Massachusetts Institute of Technology (MIT) made measurements of thermal neutron 
flux, fast neutron dose rate, and photon dose rate at the Brookhaven Medical Research 
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Reactor (BMRR) in both the Brookhaven National Laboratory (BNL) and MIT 
calibration phantoms: a 14×14×14 cm Lucite cube and an ellipsoidal head phantom,4,5 
respectively. These MIT measurements in the BNL beam and calibration phantom are 
essential to any retrospective analysis attempting to compare patient doses from the two 
clinical sites. This dosimetric comparison between BNL and MIT was later expanded to 
include clinical sites in Europe as part of the International Dosimetry Exchange.1,2 A 
similar collaboration was necessary to properly analyze differences in computational 
dosimetry. Using the physical dosimetry measurements made by MIT at the different 
clinical sites and treatment plans produced by each group, scale factors were calculated to 
normalize the clinical dosimetry at each site to that of Harvard-MIT.  
Similarly, this chapter describes the normalization of the BNL clinical dosimetry 
to that of Harvard-MIT. Using the MIT measurements made at BNL in the Lucite cube 
calibration phantom as well as the corresponding calculations performed using the BNL 
treatment planning system, dose component scale factors were derived to determine the 
relationship between the patient doses reported by BNL and doses measured by MIT. 
These scale factors were then applied to calculations of dose in the ellipsoidal head 
phantom and compared to MIT measurements in order to confirm that the scale factors 
are valid for phantoms (and patients) other than the BNL cube phantom in which they 
were derived. After using these scale factors to recompute BNL patient doses, the revised 
BNL clinical data were pooled with those of Harvard-MIT for a combined dose response 
analysis.  
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3.1.1 Clinical Trials of BNCT in the USA 
3.1.1.1 Brookhaven National Laboratory 
Between 1994 and 1999, 54 brain tumor patients were treated in dose escalation 
trials at BNL.6-8 During the clinical trials, patients diagnosed with glioblastoma 
multiforme (GBM) were treated in a series of dose escalation protocols via 
boronophenylalanine-fructose (BPA-F) mediated NCT with epithermal neutrons 
delivered at the BMRR in 1 or 2 fractions with between 1 and 3 fields. The BPA-F was 
infused over 2 hours at doses ranging from 250 to 355 mg/kg. Treatment planning at 
BNL was performed using the Monte Carlo-based BNCT_Rtpe (BNCT Radiation 
Therapy Planning Environment)9-11 planning system developed at Idaho National 
Laboratory (INL). For calibration of the treatment planning system, measurements of 
thermal neutron flux via Au foil activation analysis, and photon dose rate with 
thermoluminescent dosimeters (TLDs) were made in the BNL Lucite cube phantom and 
measurements of the fast neutron dose rate via the dual chamber technique were made in-
air.3,12 In addition to calibration measurements, monthly measurements of thermal 
neutron flux and photon dose rate were made in the same cube phantom as part of the 
quality assurance (QA) protocol at BNL. During the clinical trials at BNL, two 
significant changes were made to the epithermal neutron beam at the Brookhaven 
Medical Research Reactor:  the 8 cm collimator was replaced with a 12 cm collimator in 
199612 and the fuel elements were rearranged in 1998 to increase neutron beam intensity. 
The first 15 patients were treated with the 8 cm collimator and the latter 39 were treated 
with the 12 cm collimator: 23 before the fuel shuffle and 16 afterwards. The workstation 
used at BNL for treatment planning as well as records of the BNL QA measurements 
were moved to MIT and used for this analysis. 
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3.1.1.2 Harvard-MIT 
Between 1994 and 2003, 27 patients were treated for intracranial disease in dose 
escalation trials of NCT at Harvard-MIT.13-15 Patients with either GBM or intracranial 
melanoma metastases were treated with BPA-F mediated NCT with the epithermal 
neutrons delivered by either the MIT M67 thermal beam16 or the MIT fission converter 
beam (FCB)17 in 1 or 2 fractions with between 1 and 3 fields. The BPA-F was infused 
over 1-1.5 hours at doses ranging from 250 to 350 mg/kg or 14.0 g/m2.18,19 Planning for 
the Harvard-MIT patients was performed using MacNCTPlan20 and its successor 
NCTPlan4,21 that were developed in-house or in collaboration with the Comisión 
Nacional de Energía Atómica (CNEA) of Argentina, respectively. The planning system 
was calibrated for each beam in an ellipsoidal head phantom22 using measurements of 
thermal neutron flux made with Au foil activation analysis using the cadmium difference 
method23 as well as measurements of fast neutron and photon dose rates made using the 
dual chamber technique.24,25 Planning system calculations for the FCB were also 
validated using measurements on multiple axes in a large rectangular water phantom.26 
For the Harvard-MIT clinical trials, 21 patients were treated with the MIT M67 beam and 
6 with the MIT FCB.  
3.2 Methods and Materials 
3.2.1 Normalization of Clinical Dosimetry 
Normalization of the BNL and Harvard-MIT clinical dosimetry involved the 
determination of dose scale factors to account for the differences in physical and 
computational dosimetry and convert doses reported by BNL to doses reported by MIT. 
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These scale factors were derived through analysis of the MIT measurements made at the 
BMRR3 and comparison with calculations performed by the treatment planning system 
used at BNL, BNCT_Rtpe.  
MIT measurements of the 2200 m/s (0.025 eV) neutron flux in the BNL cube 
phantom and ellipsoidal head phantom were converted to boron and thermal neutron dose 
using the kerma factors27 of 8.67×10−14 Gy cm2 and 1.79×10−13 Gy cm2, respectively. The 
10B kerma factor corresponds to a 10B concentration of 1 μg/g. The thermal neutron 
kerma factor was calculated for ICRU 4628 adult whole brain composition which has a 
density of 1.04 g/cm3 and has a 14N concentration of 2.2% by mass. In addition to these 
measurements of boron and thermal neutron dose, MIT measurements of in-air and in-
phantom photon and fast neutron dose in the cube phantom were used to determine the 
scaling of the fast neutron, incident and induced photon dose components.  
The MIT measurement conditions were modeled in BNCT_Rtpe using BNL’s 
most up-to-date source definition for the BMRR epithermal beam and a NURBS (Non-
Uniform Rational B-Splines) model of the BNL cube phantom. The NURBS modeling 
technique is needed to accurately model the irregular shapes of the human anatomy like 
the skin, skull, tumor, etc. In BNL’s original calibration calculations, the cube phantom 
was modeled in BNCT_Rtpe using simple geometric primitives and combinatorial 
geometry (CG), but a NURBS model of the cube was chosen for this analysis since it is 
the modeling technique used in patient planning. Moreover, when reviewing the original 
BNCT_Rtpe calibration simulations, a subtle geometric error in the modeling of the 
BMRR 12 cm diameter collimator assembly with the CG cube phantom was discovered. 
The full 13.32 cm thickness of the lithiated-polyethylene collimator was truncated at a 
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thickness of 8 cm, with the other 5.32 cm modeled as vacuum. Figure 3.1 illustrates the 
difference between the collimator assembly modeled in the original calibration 
simulations with a CG cube and that used in patient treatment planning with a NURBS 
model of a patient. To determine the effect of this modeling error on the TPS calibration, 
in-phantom doses calculated using the correct model of the NURBS cube were least 
squares fit to doses calculated using the cropped collimator and the CG cube. This error 
was not present in the earlier calibration calculations using the 8 cm diameter collimator 
assembly nor was it present in the patient planning calculations. The atomic densities for 
10B (6.01×10−8 atoms/barn cm or 1 μg/g), hydrogen (6.32×10−2 atoms/barn cm or 10.7% 
by mass) and nitrogen (7.91×10−4 atoms/barn cm or 1.84% by mass) that are used solely 
to scale the elemental kerma factors for dose calculations were the same as used in 
BNL’s patient planning calculations. 50 million neutron and photon histories were 
tracked for the calibration calculations and 10B, thermal and fast neutron, and incident 
and induced photon doses were calculated at depths in the phantom corresponding to the 
MIT measured values. Incident photon and fast neutron doses were also calculated in-air. 
Least squares fitting the resulting BNCT_Rtpe calculations in the cube phantom to the 
MIT measurements produced individual scaling factors for each of the computed dose 
components. These dose component scaling factors were then validated by applying them 
to similar BNCT_Rtpe calculations of dose along the central axis in the MIT calibration 
phantom, the ellipsoidal head phantom (modeled in BNCT_Rtpe using NURBS), and 
comparing the scaled calculations to corresponding MIT measurements made at the 
BMRR. 
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Figure 3.1 Comparison of (annotated) BNCT_Rtpe raster images of the 12 cm 
BMRR collimator used to calibrate the treatment planning system and to 
calculate patient doses for planning. The collimator modeled in the TPS 
calibration (left) using the Lucite cube phantom was not as thick and 
provided less beam collimation and thus yielded lower calculated in-
phantom doses. The effect of calibrating the TPS in this configuration is to 
overestimate doses in the patient (right), where a thicker collimator was 
used. 
 
 
 
Due to changes made at the BMRR during the clinical trials, these dose scale 
factors were not applicable to all of the BNL patients but rather only to those 16 patients 
treated under irradiation conditions similar to when the MIT measurements were made, 
i.e., with the 12 cm collimator after the fuel element shuffle. The effects of the fuel 
element shuffle on patient dose had to be properly assessed as part of the retrospective 
analysis. Since the available BNL measurement data made after the shuffle were limited 
to the monthly QA measurements, averages of the thermal neutron flux and photon dose 
rate from these monthly measurements at two depths (3.5 and 7.0 cm) and 3 axes 
positions (central beam axis and 2 lateral axes) were calculated and least squares fit to 
BNL measurements12 made prior to the fuel element shuffle. The resulting adjustments 
were applied to the neutron and photon dose scaling components to account for changes 
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caused by the fuel shuffle, producing a new set of dose scaling factors for the patients 
treated with the 12 cm diameter collimator and before the fuel rod shuffle in 1998. This 
adjusted set of dose scaling factors was also applied to the 8 cm collimator patients, since 
no changes upstream of the collimator were made. However, before the scale factors 
could be applied to the 8 cm collimator patients, the contribution from the collimator 
modeling error had to be removed since it was not present for those patients.  
3.2.2 Updates to the BNL Treatment Planning System 
The treatment plans for all BNL patients were recomputed with the newly 
determined and validated TPS calibration that provided corrected doses calibrated to 
Harvard-MIT clinical dosimetry. However, adjustments to the BNL patient treatment 
planning data were not limited only to the dose scale factors. The specialized Monte 
Carlo transport module of BNCT_Rtpe, rtt_MC, was ported to run on x86 Linux so that 
better statistics could be rapidly achieved by running more particle histories on newer 
computer hardware. With the capability to run faster, the number of neutron and photon 
histories simulated, originally 0.5 to 1.0 million, was increased to 15 million histories per 
field, significantly reducing the statistical uncertainty of the calculated doses. To avoid 
the repetition of particle histories that could occur if the period of the random number 
generator is exceeded, the random number generator used by rtt_MC29 in the Monte 
Carlo transport calculations, which has a period of ~500 million,30 was replaced with the 
Modified Lagged Fibonacci generator that is part of the Scalable Parallel Random 
Number Generators (SPRNG)31 library v. 2.0 and has a period of ~10394 random numbers. 
The photon kerma factors used by BNCT_Rtpe to calculate photon doses were replaced 
with those updated values used in its successor, SERA (Simulated Environment for 
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Radiotherapy Applications).32 BNCT_Rtpe assigns a point kerma value of 9.58×10−12 Gy 
cm2 to those 2.2 MeV photons resulting from the 1H(n,γ)1H reaction, and this value was 
updated to the corresponding value calculated from NIST data33 of 8.92×10−6 Gy cm2. 
The tissue compositions used in the BNCT_Rtpe NURBS model of each patient were 
updated with a combination of adult whole brain, adult whole cranium, and adult skin 
materials, as defined by ICRU 46 with 10B concentrations in the brain (1.0 × blood [10B]), 
tumor (3.5 × blood [10B]), and skin (1.5 × blood [10B])18,34 explicitly modeled in the 
transport calculations to correctly account for neutron flux depression due to the capture 
of thermal neutrons by 10B nuclei.35,36 Dose-volume histograms for brain, tumor, and 
target were calculated for each patient, and the weighting factors used in the calculation 
of total biologically weighted dose were 3.2 for both fast and thermal neutrons, 1.3 for 
10B, and 1.0 for photons.37 These weighting factors are identical to those used for the 
Harvard-MIT patients with the exception of the photon dose component. For the 21 
patients treated with the MIT M67 beam, a dose rate reduction factor of 0.513 was applied 
to the photon dose component to account for the low dose rate in the M67 beam. The 
most accurate source model of the BMRR epithermal neutron beam was used for all 
patients along with the appropriate model of either the 8 or 12 cm collimator assembly. 
3.2.3 Dose Response Analysis 
Once the dose scale factors were applied to the recomputed BNL patient doses, 
the Harvard-MIT and BNL clinical data were pooled together for a combined dose 
response analysis of radiation-induced somnolence syndrome. Somnolence syndrome is 
characterized by an otherwise unexplained fatigue and drowsiness that develops within a 
few weeks after cranial radiation.38 Somnolence is not a dose-limiting toxicity and is 
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considered to be an acceptable side-effect of radiotherapy. However, somnolence 
precedes more significant and serious neurological changes that occur at higher doses, 
such as brain necrosis, which are desirable to avoid. Although somnolence is not a 
particularly well-defined endpoint, analysis of the somnolence dose response may allow 
important information on the tolerance of normal brain to NCT to be extracted.39 The 
presence or absence of somnolence syndrome for each patient in the combined data set 
was scored (as a binary endpoint), and probit analysis was performed to determine the 
dose that results in somnolence in 50% of the patients (effective dose 50% or ED50). 
3.3 Results 
MIT dose measurements made in the Lucite cube are shown with the scaled 
BNCT_Rtpe calculations (and scale factors) in Figure 3.2, and the scale factors are also 
reported in the top section of Table 3.1 in column 2. The scaled calculations of dose rates 
agree well with measurements and lie within 1 standard deviation of the measured values 
at nearly all measurement points. For the fast neutron dose component, the calculated 
values fall within one standard deviation of the measurements at all depths in the BNL 
cube phantom beyond 1 cm. Due to the large uncertainty (30-100%) associated with the 
in-phantom fast neutron measurements, the fast neutron scaling factor was determined 
from the in-air measurement of fast neutron dose where the measurement error was 
significantly smaller, at 16%. Therefore, the scaled in-air calculation of fast neutron dose 
lies directly beneath the measured value. Similarly, the scaled in-air incident photon 
calculation is beneath the measured value. The scaling factors derived in the cube 
phantom were then applied to BNCT_Rtpe calculations in the ellipsoidal head phantom, 
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and the resulting scaled calculations are compared to MIT measurements in Figure 3.3. 
Agreement between MIT measurements and the scaled BNCT_Rtpe calculations in the 
ellipsoidal head phantom is very good. 
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Figure 3.2 BNCT_Rtpe calculations scaled to MIT measurements in the BNL 
calibration phantom, a Lucite cube. Dose component scaling factors were 
derived from the least squares fitting of BNCT_Rtpe calculations to MIT 
measurements. The plotted calculation lines are the product of the scale 
factors (shown in the legend) and doses calculated by BNCT_Rtpe. 
Chapter 3: Comparison of Doses Delivered in Clinical Trials of NCT in the USA J.R. Albritton  
 309
Table 3.1 Dose component scaling factors used to normalize BNL dosimetry to that 
of Harvard-MIT. The scale factor for each dose component is resolved 
into 3 contributing components which were derived independently from 
the total scale factor. Patients were divided into 3 groups based on the 
changes in beam collimation and rearrangement of the BMRR fuel. A set 
of dose scaling factors was derived for each group. 
Components of scale factor 
Dose 
Component 
Scale 
Factor 
Product of 
Components Measurement 
Techniques 
Collimator 
Error 
Difference between 
BNCT_Rtpe and  
BNL measurements
      
 12 cm collimator after BMRR fuel shuffle (16 patients) 
boron 0.82 0.81 0.93 0.91 0.96 
thermal neutron 1.00 1.00 0.93 0.91 1.18 
fast neutron 0.59 0.59 0.69 0.90 0.94 
incident photon 1.38 1.35 0.85 0.93 1.71 
induced photon 0.70 0.73 0.85 0.91 0.93 
      
 12 cm collimator before BMRR fuel shuffle (23 patients) 
boron 0.78 0.77 0.93 0.91 0.91 
thermal neutron 0.95 0.94 0.93 0.91 1.11 
fast neutron 0.55 0.55 0.69 0.90 0.89 
incident photon 1.34 1.55 0.85 0.93 1.96 
induced photon 0.68 0.69 0.85 0.91 0.89 
      
 8 cm collimator (15 patients) 
boron 0.85 0.83 0.93 --- 0.89 
thermal neutron 1.04 1.02 0.93 --- 1.09 
fast neutron 0.62 0.52 0.69 --- 0.75 
incident photon 1.44 1.37 0.85 --- 1.62 
induced photon 0.74 0.77 0.85 --- 0.90 
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Figure 3.3 Scaled BNCT_Rtpe calculations and MIT dose measurements in the MIT 
ellipsoidal head phantom. Scaling factors are those derived from the data 
of Figure 3.2. The plotted calculation lines are the product of the scale 
factors (shown in the legend) and doses calculated by BNCT_Rtpe. 
 
 
 Without adjustment, these scale factors are only valid for the last 16 patients 
treated at BNL due to changes in beam collimation and the fuel element rearrangement at 
the BMRR during the clinical trials. Thus, to properly address these changes, the BNL 
patients were grouped according to irradiation conditions, and a unique set of dose 
component scaling factors was derived and applied to each group. The effect of the fuel 
element rearrangement in 1998 was found by scaling post-shuffle BNL dose 
measurements to corresponding pre-shuffle measurements via least squares analysis. The 
neutron dose component scale factors (derived from MIT measurements after the shuffle) 
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were scaled by 0.94 while the photon dose scale factors were scaled by 0.97 to account 
for the effects of the shuffle. The resulting set of scale factors are applicable to those 
BNL patients treated with the 12 cm collimator before the fuel shuffle and are shown in 
the middle section of Table 3.1 in column 2. Except for the adjustment due to the 
modeling error of the 12 cm collimator, this set of scale factors should also be applicable 
to the patients treated with the 8 cm collimator since no changes were made in the beam 
line upstream of the collimator, which is modeled in the patient transport calculation as 
illustrated in Figure 3.1. Therefore, to account for the lack of the collimator modeling 
error, the scale factors for the 8 cm collimator patients were derived from the scale 
factors for the 12 cm collimator patients before the fuel shuffle by dividing out the 
contribution of the collimator error (column 5) to the scale factors. The scale factors for 
the 8 cm collimator patients are listed in the bottom section of Table 3.1 in column 2. 
To further analyze the dose scaling factors, calculations independent from those 
used to derive the scale factors were performed to resolve each scale factor into 3 
component parts:  the scaling due to differences in physical dosimetry measurement 
techniques between BNL and MIT, the scaling due to the collimator modeling error, and 
the scaling resulting from differences between BNCT_Rtpe calculations and BNL 
measurements. The scaling due to differences in physical dosimetry was calculated by 
least squares fitting BNL measurements to MIT measurements made in the BNL Lucite 
cube under similar irradiation conditions. This component of the scaling was assumed to 
be constant for all the patients regardless of beam collimation and fuel element 
arrangement. Similarly, the scaling due to the collimator modeling error was assumed to 
be unchanged by the fuel shuffle. For the last component of scaling, BNCT_Rtpe 
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calculations in the BNL cube phantom were least squares fit to the corresponding BNL 
measurements. The 3 resulting components are listed in the last 3 columns of Table 3.1 
under “Components of scale factor” and labeled as “Measurement Techniques”, 
“Collimator Error”, and “Difference between BNCT_Rtpe and BNL measurements”. The 
product of these 3 components is also shown in column 3 of Table 3.1 to provide a point 
of comparison to the independently derived total scale factors shown in column 2. The 
very good agreement between the total scaling and the product of the 3 components is an 
important validation of the dose scale factors.  
The treatment plan for each BNL patient was recomputed, and the appropriate set 
of dose scaling factors from Table 3.1 was applied to normalize the patient doses to 
Harvard-MIT clinical dosimetry. The adjusted mean and maximum brain doses are 
plotted against the original brain doses in Figure 3.4. The mean brain doses of the initial 
15 patients treated with the 8 cm collimator were reduced by 10% while an average 
reduction of 28% was calculated for the 23 patients treated with the 12 cm collimator 
before the fuel shuffle and 25% for the 16 patients treated after the fuel shuffle. 
Corresponding reductions in maximum brain dose of 8%, 26% and 21% were calculated 
for the same groups of patients. Figure 3.5 shows the component doses for the adjusted 
average and maximum brain physical doses.  
Figure 3.6 compares original and adjusted total biologically weighted brain 
isodose contours for an example BNL patient treated with 3 fields using the 12 cm 
diameter collimator after the fuel shuffle. Isodose levels represent a percentage of the 
total biologically weighted brain dose delivered to the point of maximum thermal neutron 
flux using the original BNL dosimetry. The 70% contour from the revised dosimetry is 
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approximately equivalent to the 90% to 95% contours from the original dosimetry which 
is consistent with the average reduction in mean and maximum brain doses of 25% and 
21%, respectively. Figure 3.7 shows original and revised total biologically weighted 
dose-volume histograms for brain, tumor, and target volumes for the same BNL patient. 
The reductions in dose are, as expected, quite large. 
Once properly normalized with the appropriate set of dose scale factors, the BNL 
patient dosimetry was compared to the Harvard-MIT patient dosimetry as is done in 
Figure 3.8, which shows the maximum brain dose vs. the mean brain dose for each 
patient of the combined data set. Filled symbols in Figure 3.8 indicate those patients who 
developed radiation-induced somnolence syndrome. Probit analysis was used to construct 
a dose response curve for the incidence of somnolence syndrome for the combined BNL 
and Harvard-MIT patient data. The resulting probit curves are shown in Figure 3.9 with 
ED50 values of 5.76 Gyw and 14.4 Gyw for mean and maximum brain dose, respectively. 
As Figure 3.9 shows graphically, the corresponding 95% confidence intervals for the 
ED50 values are [5.22 Gyw, 6.56 Gyw] and [12.6 Gyw, 20.3 Gyw]. The dose response 
curves for the original and revised BNL mean brain doses are shown in Figure 3.10. 
Adjusting the BNL dosimetry reduced the ED50 for mean brain dose for the BNL patients 
by 26%, from 6.42 Gyw to 4.75 Gyw. 
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Figure 3.4 Original vs. revised (a) mean and (b) maximum biologically weighted 
brain doses for the BNL patients. The solid line represents equality of 
revised and original dosimetry. 
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Figure 3.5 Contributions to the adjusted mean and maximum physical brain doses 
(unweighted) for the BNL patients. 
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Original Dosimetry Revised Dosimetry
 
Figure 3.6 Original and revised treatment plans for a BNL patient treated with 3 
fields using the 12 cm collimator after the fuel shuffle. The isodose 
contours are displayed as a percentage of the biologically weighted brain 
dose in the voxel containing the maximum thermal neutron flux under the 
original dosimetry (15.6 Gyw). The contours were plotted with the BNL 
treatment planning system, BNCT_Rtpe. 
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Figure 3.7 Original and revised total biologically weighted dose-volume histograms 
for the brain, tumor, and target volumes of a BNL patient treated with 3 
fields using the 12 cm collimator after the fuel shuffle. 
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Figure 3.8 Maximum brain dose versus mean brain dose for the combined BNL and 
Harvard-MIT patient data. Filled symbols represent patients that 
developed radiation-induced somnolence syndrome. The retreatment of 1 
previously treated BNL patient as well as the 2 Harvard-MIT patients for 
which somnolence could not be evaluated due to confounding factors were 
censored from the analysis. 
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Figure 3.9 Dose response curves for radiation-induced somnolence for the combined 
BNL and Harvard-MIT patient data based on the mean or maximum 
weighted brain dose. The 95% confidence intervals are indicated by the 
pairs of dashed lines. 
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Figure 3.10 Dose response curves for radiation-induced somnolence for the revised 
and original biologically weighted mean brain doses for the BNL patients 
only. The revised BNL doses resulted in an ED50 that was 26% lower than 
for the original dosimetry (6.42 Gyw vs. 4.75 Gyw). 
 
 
3.4 Discussion 
The excellent agreement between the adjusted calculations in the ellipsoidal 
phantom and MIT measurements demonstrates that the dose scale factors (derived in the 
cube phantom) are not specific to a particular phantom and validates the application of 
the factors to the BNL patients. The significant deviation of these dose component scale 
factors from unity was determined to be a result of 3 contributors: differences in 
measurement techniques between BNL and MIT, a subtle geometric error in some of 
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BNL’s TPS calibration calculations, and differences between BNCT_Rtpe calculations 
and BNL measurements.  
Differences in physical dosimetry between BNL and MIT, (e.g., BNL’s 
measurement of the group thermal neutron flux vs. MIT’s measurement of the 2200 m/s 
neutron flux, the use of TLDs vs. ionization chambers to measure photon dose) were 
shown to be significant and such differences must be properly addressed when comparing 
dosimetry from different clinical sites. BNL measurements of photon dose yielded values 
larger than corresponding MIT measurements by 15% while differences in fast neutron 
measurements were nearly 30% larger.  
Also contributing to the dose component scaling factors was a geometric error in 
the BNCT_Rtpe model of the 12 cm collimator assembly and the cube phantom used in 
BNL’s original calibration calculations. The thickness the BMRR collimator assembly 
was not modeled correctly, which resulted in less collimation of the neutron beam and 
lower calculated doses in the calibration phantom. Because the beam intensity was 
increased in the TPS to compensate for the lower doses calculated in the phantom and 
because the error present in the calibration simulation was absent in patient calculations, 
the patient doses were overestimated; this factor increases calculated doses by 7-10%. 
Although the convenience of using combinatorial geometry to represent a phantom in 
calibration calculations is tempting, it is important to calibrate the treatment planning 
system under the same computational conditions that are used for patient planning in 
order to avoid such subtle errors. Calculations of the thermal neutron flux using the 
cropped 12 cm collimator assembly and the CG cube phantom produced excellent 
agreement with BNL calculations of thermal flux, as expected since that model was used 
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in calibrating the planning system. However, when BNL measurements of thermal 
neutron flux were converted to dose and compared to BNCT_Rtpe calculations, the 
calculated boron and thermal neutron dose rates were systematically 4% larger than the 
BNL measurements.* This finding, a deviation between calibration to thermal neutron 
flux and calibration to derived dose rates, confirms that it is more appropriate to calibrate 
treatment planning systems using dose, which is a more clinically relevant quantity, 
rather than to rely on thermal neutron flux for calibration.  
The scaling factors for the 10B, thermal neutron, and induced photon dose 
components should be nearly identical since all depend on the thermal neutron flux. 
However, the scale factors in column 2 of Table 3.1 seem to differ. The reason that the 
thermal neutron scale factor is higher than the 10B scale factor is that the thermal neutron 
scale factors account for the difference in thermal neutron kerma factors, which primarily 
is due to the ~20% difference in the 14N concentration used in clinical treatment planning 
between Brooks brain composition (1.84%) used for the original BNL treatment planning 
and ICRU brain composition (2.2%) used for MIT treatment planning. If this difference 
is removed, then the thermal neutron scale factor is reduced to 0.84, which is close to the 
10B scale factor of 0.82. Similarly, the induced photon scale factor was found to be 
different from the 10B scale factor. Differences in photon dose measurement techniques 
(column 4 of Table 3.1) are larger than the corresponding values for the 10B and thermal 
neutron components which results in the total photon scaling being further from unity.  
Previous such analyses of the combined Harvard-MIT and BNL clinical data have 
been reported.39-41 However, these analyses did not fully account for all the differences in 
                                                 
* In Chapter 2, this 4% difference was found to be due to the improper scaling of BNCT_Rtpe neutron and 
boron dose calculations by the mass density of the edit mesh, which was 1.04 g/cm3 for ICRU adult brain. 
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the physical and computational dosimetry between the two sites that are included as part 
of this work. In a previous analysis,41 all of the dose component scaling factors (0.92, 
0.92, 0.73, and 0.74 for boron, thermal neutron, fast neutron, and total photon dose 
scaling, respectively) were significantly closer to unity than those derived in this work. 
The 12 cm collimator modeling error had not been discovered at the time of that analysis, 
so the BNCT_Rtpe simulations that were performed to derive the scaling factors did not 
contain the modeling error.* If the scale factors from that work are multiplied by the 
collimator error (column 5 of Table 3.1), better agreement in the neutron dose scale 
factors is produced. However, the total photon dose scale factors from the two analyses 
will still be different due the different photon kerma factors used in the BNCT_Rtpe 
simulations. Also, in that analysis a single set of scale factors was applied to all patients, 
and the patients’ plans were not recomputed with the updates to the BNCT_Rtpe 
planning system that were an important part of this analysis. Performing the planning 
calculations again on the original BNL workstation for that analysis would have taken 
~280 days whereas porting rtt_MC, the Monte Carlo transport module in BNCT_Rtpe, to 
x86 Linux allowed the planning calculations for all 54 patients to be completed in ~2 
days on an 11 node Beowulf cluster (described in Appendix B). Being able to rapidly 
compute plans with more histories was a significant advantage in that it allowed for 
better statistics and much improved convergence of the Monte Carlo dose calculations. 
The improved dose convergence that directly resulted from simulating 15 to 30 times 
more neutron and photon histories (5×105 or 1×106 vs. 1.5×107) per field than the 
original BNL calculations alone (no other corrections) was significant enough to produce 
                                                 
* To be more precise, the collimator modeling error was inadvertently and unknowingly corrected. 
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biologically weighted reference brain doses as much as 5.1% lower. 
In Figure 3.9, the steeper response curve and the smaller confidence interval for 
the mean dose indicate a stronger correlation between mean brain dose and somnolence 
than for the maximum brain dose. Analyzing the pooled patient data produced confidence 
intervals for the ED50 values for mean and maximum brain dose that were 3.4 and 1.6 
times narrower, respectively, than resulted from analyzing the Harvard-MIT or BNL 
patient data separately, further illustrating the value of patient pooling when attempting 
such statistical analysis in NCT.  
The work described in this chapter defined a quantitative relationship between 
treatment plans calculated for BNL patients and doses measured by MIT and used this 
relationship to make adjustments to clinical doses reported by BNL that are necessary for 
a combined dose response analysis. The BNL patient dosimetry was normalized to the 
Harvard-MIT clinical dosimetry (rather than vice versa) because MIT has made dose 
measurements in 8 of the 11 neutron beams recently used for clinical BNCT with a 
standard dosimetric approach as part of the International Dosimetry Exchange. 
Normalizing the BNL clinical dosimetry to that of Harvard-MIT using the derived 
relationship facilitates the comparison of BNL clinical data not only to Harvard-MIT but 
also to the other clinical sites. The resulting large reductions in reported doses from the 
BNL clinical trials of NCT have clinically significant implications for those in the NCT 
community relying on doses reported by BNL as a basis for initial dose selection in 
clinical studies. These results also demonstrate the validity of the approach to dosimetric 
normalization proposed by the International Dosimetry Exchange26 and the Treatment 
Planning Exchange as well as provide an example of what can be achieved within the 
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framework of such collaborative dosimetric comparisons. These collaborative efforts are 
designed to address differences in physical and computational dosimetry which impede 
the analysis and comparison of NCT clinical data from different sites worldwide and 
provide a dosimetric basis for the collective analysis of clinical data. Furthermore, these 
findings should provide strong motivation for actively participating in such efforts. 
3.5 Conclusions 
A relationship between BNL clinical dosimetry and Harvard-MIT clinical 
dosimetry was determined and validated. This relationship was used to adjust the 
recomputed BNL dosimetry so that it could be legitimately pooled together with 
Harvard-MIT patient data for a dose response analysis for radiation-induced somnolence 
syndrome. The BNL patient doses were significantly lowered due to differences in dose 
measurement techniques between BNL and MIT, a subtle geometric modeling error 
present in BNL’s calibration calculations, and small differences between BNL's 
measurements and calibration calculations. The significantly narrower confidence 
intervals about the resulting ED50 values illustrated the importance of pooling dosimetry 
from different clinical sites as well as participating in those efforts which attempt to 
facilitate the direct comparison of clinical dosimetry.  
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CHAPTER FOUR 
Application of Variance 
Reduction in Monte Carlo 
Treatment Planning Calculations 
4.0 Abstract 
Treatment planning for Neutron Capture Therapy (NCT) most often begins with 
detailed radiation transport calculations of the beam line to produce a radiation source 
definition close to the patient position to avoid repeating the computationally expensive 
calculations of the beam line for each patient. When using Monte Carlo simulations, the 
difficulty associated with this deep-penetration shielding problem often requires that 
nonanalog Monte Carlo algorithms, or variance reduction techniques, be used to ensure 
that enough unique track information reaches the downstream patient position to produce 
a source representation with good accuracy and precision for the subsequent dose 
calculations in the patient. This chapter investigates the applicability and optimization of 
variance reduction for both parts of NCT Monte Carlo treatment planning calculations:  
calculations of the neutron beam line and the subsequent dose calculations in the patient. 
During the first phase of this analysis, MCNP was used to improve the pre-existing 
variance reduction in the Monte Carlo model of the Massachusetts Institute of 
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Technology (MIT) fission converter beam (FCB) resulting in optimized energy 
dependent neutron and photon weight windows. A simulation of the FCB beam line with 
these weight windows using an 11 node Beowulf cluster produced a more precise surface 
source representation of the FCB downstream at the patient position with improved 
statistical properties that directly resulted in a 9× increase in the mean efficiency of in-
phantom dose calculations. The new surface source model of the FCB was also validated 
using physical dosimetry measurements in the MIT ellipsoidal head phantom. During the 
second phase of this analysis, the variance reduction techniques available in MCNP were 
also explored as a means of increasing the computational efficiency of dose calculations 
in the patient using a voxel model of the modified Snyder head phantom and a generic 
epithermal neutron beam. By disabling implicit neutron capture and using fast neutron 
source biasing and photon production biasing techniques, the mean efficiency of the total 
weighted brain dose calculations can be improved by a factor of 2.2. 
4.1 Introduction 
Treatment planning calculations for BNCT are in some ways more complicated 
than those for conventional radiotherapy since a detailed physics model is required to 
properly treat the scatter-dominated radiation transport processes and multiple dose 
components that result. Thus, all current BNCT treatment planning systems use Monte 
Carlo radiation transport algorithms since they are widely considered to be the most 
accurate method of calculation available. However, Monte Carlo simulations are 
computationally intensive, and the precision of the calculated doses depends on the 
number of particle histories simulated. Because dose targeting in NCT is achieved 
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through biochemical selectivity of the neutron capture agent rather than through 
geometric targeting of highly collimated and shaped beams of radiation, epithermal 
neutron beams generally have few degrees of freedom and a very limited number of 
configurations. Beam modifying devices are usually limited to a small number of circular 
collimators or a device that permits insertion of a neutron absorber1 or moderator2 into 
the beam to effect a spectrum shift. The very small number of configurations possible 
with an epithermal neutron beam enables precalculation of radiation sources a short 
distance from the patient, e.g., as close as 1 cm. In contrast, medical linear accelerators, 
with their motorized jaws and multileaf collimators, have an extremely large number of 
possible configurations, effectively preventing precalculation. This approach allows the 
majority of the computational effort in the BNCT treatment planning process to be 
focused on dose calculations in the patient rather than on repeating, for each patient, 
Monte Carlo calculations of the entire fixed beam line which are external to and largely 
independent of the patient geometry and position. Nevertheless, calculations of the beam 
line are obviously an essential part of the treatment planning process since the accuracy 
and precision of dose in the patient are critically dependent on detailed upstream 
calculations.  
Detailed radiation transport computations (using the Monte Carlo or discrete 
ordinates methods) of the neutron beam line are performed to define the radiation source 
at a position close to the patient. In Monte Carlo calculations, exact track characteristics 
such as position, direction, energy, and (statistical) weight of all particle histories 
crossing a plane, which is usually at the beam aperture near the patient position, are 
recorded to a binary phase space file (or “surface source” file in MCNP3 parlance) or are 
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scored to construct a probability distribution for a given source characteristic, similar to 
the result from a discrete ordinates calculation. The binary track information from the 
phase space file can either converted into a set of probability distributions describing the 
beam characteristics4 (as described in Chapter 5) or sampled directly in subsequent 
transport simulations into the patient geometry. In sampling the surface source directly, 
the dose precision in the patient is limited by the amount of unique track information 
sampled; this limitation is referred to as the latent variance5 of the phase space file. While 
the surface source can indeed be sampled multiple times to improve the statistics for 
those dose components that are derived from the thermal neutron flux, the effectiveness 
of oversampling is very limited for fast neutrons and incident photons due to their longer 
mean free paths and comparatively infrequent interactions in the patient. Therefore, 
ensuring that adequate unique track information is recorded to the surface source file 
during upstream calculations of the beam line is essential to achieving acceptably low 
levels of uncertainty for in-patient dose calculations. 
When the phase space file at the beam aperture of the fission converter beam6,7 at 
MIT was calculated, the low natural probability that particles originating in the MITR-II 
reactor core would reach the beam aperture required that nonanalog Monte Carlo 
algorithms be used to ensure that sufficient track information was recorded downstream 
at the beam aperture within a reasonable simulation time using the moderate 
computational resources available. Therefore, mathematical tricks known as variance 
reduction techniques were employed during the Monte Carlo simulations to help 
accomplish that goal and thus reduce the uncertainty or variance for subsequent dose 
calculations in the patient. 
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4.1.1 Variance Reduction Techniques 
An analog Monte Carlo model (which is directly analogous to what naturally 
occurs) is sufficient so long as a significant portion of the naturally sampled particles 
contribute to the estimated quantity. However, in deep-penetration shielding problems, 
this is rarely the case, and as a result unacceptably high natural variance is produced for 
the estimated quantities. So, in those cases, the model is intentionally biased to 
artificially increase the probability that a sampled particle will contribute to a given 
estimated quantity and thus help reduce the uncertainty associated with that quantity. 
While the model will indeed no longer be analogous to the natural transport (i.e., it is 
nonanalog), the estimated quantity itself will be the same as the analog model if the effect 
of biasing is properly accounted for and removed. To accomplish this, each particle track 
is assigned a weight (statistical weight that is unrelated to particle mass) which is updated 
as that track is transported through the simulated geometry and subjected to various 
interactions and variance reduction events. If a given track should contribute to a tally, its 
contribution to the scored quantity will be will be appropriately adjusted using its weight 
to maintain a fair Monte Carlo game and prevent biasing the scored quantity. 
The well-benchmarked Monte Carlo radiation transport code, MCNP,3 provides 
several robust variance reduction techniques that act to reduce the uncertainties inherent 
to Monte Carlo calculations while also ensuring that the estimated quantities are not 
biased as a result of the variance reduction techniques. Most of the techniques involve 
playing Russian Roulette with a particle whereby the weight of a given particle, W0, is 
increased to W1 (where W1 > W0) with probability W0/W1 or set to 0 and terminated (or 
killed) with probability 1 – W0/W1. Thus, on average, particle weight is preserved from 
the corresponding analog Monte Carlo model, but computational time is not wasted 
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tracking particles with low weight. However, effective variance reduction can indeed be 
tricky because it cannot usually be applied universally but rather must be tuned to a 
specific transport problem in order to provide optimal results, which can sometimes be a 
time-consuming trial and error process. To better understand the tuning process, a brief 
introduction to those variance reduction techniques that were explored as part of this 
analysis is included here. Further discussion may be found in the MCNP manual3 or the 
Los Alamos National Laboratory (LANL) report by Booth and Hendricks.8 
4.1.1.1 Implicit Capture 
If a relatively large amount of computational effort has been devoted to 
transporting a particle into a given tally region, it would be highly inefficient if that 
particle were to be absorbed just prior to contributing to the tally. Therefore, implicit 
capture (as opposed to analog capture) is employed to ensure that the particle will always 
survive absorption but with a weight appropriately adjusted to reflect the nonanalog 
event:  W(1−σa/σt) where σa and σt are the microscopic absorption and total cross sections, 
respectively, and W is the incident particle weight. Tracking continues for the particle 
until it escapes the geometry or reaches the weight cutoff. Implicit capture increases the 
probability that a particle will still contribute to the scored quantity but also increases the 
computation time per history. Nevertheless, along with Russian Roulette (via the weight 
cutoff game), implicit capture is the only other variance reduction technique enabled by 
default for neutrons in MCNP.  
4.1.1.2 Geometry Splitting 
It is inefficient to track particles into unimportant parts of the problem geometry 
where the probability of the particle contributing to either the quantity being scored or 
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the surface source being recorded is very low. Therefore, geometry splitting allows 
computational effort to be directed away from such regions of the problem geometry and 
focused on those that have a higher probability of contributing to the tally or surface 
source. To achieve this, the transport geometry is sufficiently segmented into cells, and 
each cell is assigned an importance that is proportional to the estimated contribution that 
the particles in that cell will make to the scored quantity. During the transport 
calculations, if a particle of weight W0 leaves a cell with importance I0 to enter a cell with 
lower importance I1, Russian Roulette is played with the probability of survival being 
I1/I0 and the weight of the surviving particle equal to W0I0/I1. Conversely, if the particle 
enters a cell with higher importance (I1 > I0) and I1/I0 is an integer n, then the particle is 
split upon entering the new cell into n identical particles each with a weight of W0/n. If 
I1/I0 is not an integer value, n is calculated by rounding the ratio down to the nearest 
integer, and then splitting into n+1 particles with I1/I0 − n probability or into n particles 
with 1 − (I1/I0 − n) probability with each particle assigned a new weight of W0I0/I1 
regardless. It is important to note that each particle track resulting from the split will be 
subjected to a different random number sequence in the subsequent tracking calculations 
and will likely experience a different sequence of events. Splitting does not occur in void 
cells since doing so would only result in extra tracking calculations that are not needed 
due to the uninhibited path each particle will travel to the next surface. Overly excessive 
rouletting and/or splitting are generally avoided in order to help prevent both the 
permanent loss of unique track information and the creation of large amounts of duplicate 
track information, which is inefficient.  
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4.1.1.3 Photon Production Biasing 
During coupled neutron/photon transport calculations, photons are created from 
neutron collisions. The weight of the resulting induced photon Wp is calculated as 
Wn(σγ/σT) where Wn is the neutron weight and σγ and σT are the photon production and 
total neutron cross sections, respectively. This photon weight is compared to a threshold 
weight, WiIs/Ii, which is specified as the product of the ratio of the collision cell neutron 
importance to the source cell neutron importance, Is/Ii, and the value of the PWT card in 
MCNP for the given cell, Wi. If Wi < 0, the starting weight of the current neutron history, 
Ws, is folded into the factor to produce a threshold weight of |Wi|WsIs/Ii. When the PWT 
card is not used, Wi is assigned the default value of −1. If the induced photon weight is 
above the threshold, then one or more photons will be banked or saved for subsequent 
tracking calculations each with a weight of Wp/Np where Np is the number of photons 
created as calculated by (WpIi)/(5IsWi). However, if the induced photon weight is below 
the threshold, Russian Roulette is played for the photon with a survival probability of 
WpIi/(WiIs). Therefore, adjusting the threshold weight via the entry on the PWT card in 
MCNP allows the number and weight of neutron-induced photons to be controlled. As 
the threshold is lowered, more neutron-induced photons will be produced, up to a 
maximum of 10 per collision, but with appropriately adjusted weights so as to not bias 
the calculations. A unique random number sequence will be used for each neutron-
induced photon created thereby increasing the probability that one or more will 
contribute to the quantity being scored or the surface source being recorded. If photon 
weight windows are used, the entries on the PWT card are ignored, and Wi is set to the 
minimum photon weight window for the each cell. 
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4.1.1.4 Weight Cutoff 
Once the weight of a particle has dropped to a sufficiently low value, it is 
inefficient to continue tracking the insignificant particle. The weight cutoff helps to 
reduce such inefficiency by rouletting particles when their weight falls below a user-
defined threshold. Since the weight cutoff was originally designed for use with geometry 
splitting, the weight cutoff game depends on the ratio of source cell importance to current 
cell importance, R, as well as two user-defined parameters, WC1 and WC2. Russian 
Roulette is played if the particle’s weight, W0, falls below WC2×R with a probability of 
survival equal to W0/(WC1×R). If the particle survives, it is assigned a weight of WC1×R, 
and the transport continues. If negative values of WC1 or WC2 are specified, then 
|WC1|×Ws and |WC2|×Ws are substituted for WC1 and WC2, respectively, where Ws is the 
minimum weight assigned to a source neutron by MCNP. The default values of WC1 and 
WC2 for neutrons and photons are −0.50 and −0.25, respectively. For coupled 
neutron/photon transport calculations, the photon weight cutoffs are set equal to the 
corresponding neutron values unless explicitly changed by the user using the CUT card. 
4.1.1.5 Weight Windows 
Through the use of particle splitting and Russian Roulette, weight windows help 
focus computational effort on particles that have a higher probability of contributing to 
the scored quantity. To accomplish this, a range of acceptable weights define a “weight 
window” for each cell. If a particle enters the cell or undergoes a collision within the cell, 
the particle’s weight is evaluated to determine whether it falls within, above, or below the 
window so that the appropriate action can be taken. If the weight is within the window, 
then no action is taken for the particle in that cell. If the particle weight is below the 
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window, then the Russian Roulette game is played, and if the particle is not terminated, it 
is assigned a weight that is within the weight window for that cell. When the particle 
weight is above the upper bound of the window, then it is split so that the resulting 
particles all have a weight within the window. For complex transport geometries such as 
the MIT FCB, it is very difficult to manually produce effective neutron and photon 
weight windows. Therefore, MCNP includes the ability to easily generate weight 
windows via the MCNP weight windows generator. The weight windows generator 
calculates the importance of each cell using Eq. 4.19 with the user specifying a tally bin 
for which the weight windows will be optimized. 
cell entering weight total
cell  theenteringprogeny  their and particles
from resulting tally defineduser for  score total
Importance =   (4.1) 
MCNP assigns weight windows that are inversely proportional to the importance 
calculated for a cell. As particles are transported from the source towards a particular 
region of interest, the importance of the cells along its path increases while the weight 
windows for those same cells decrease. By using the weight windows generated in a 
previous run in a subsequent calculation of the weight windows, a more optimal set of 
weight windows can be iteratively calculated. Weight windows can be space-energy or 
space-time dependent, so if using cell-by-cell weight windows it is important to have 
sufficiently segmented the problem geometry to properly model the spatial dependence of 
weight windows. If the weight window is zero for a given cell, then weight windows are 
disabled, and particles in the cell are subjected to the weight cutoff game. Also, the 
relative magnitude of the neutron and photon weight windows in a given cell allow 
control over the number and weight of neutron-induced photons produced in that cell 
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during coupled neutron/photon transport calculations. The value of Wi used to calculate 
the weight threshold for induced photons (section 4.1.1.3) is set to the minimum photon 
weight window for each cell. However, before banking the induced photons, each is 
(appropriately) rouletted if it is below the photon weight window. As with geometry 
splitting, large fluctuations in the weight windows for adjacent cells should be avoided in 
order to prevent significant rouletting and/or splitting of particles. The ratio of weight 
windows between adjacent cells is recommended to be ≤ 4. 
4.1.1.6 Energy Cutoff 
If the energy of a tracked particle falls below a user defined value (neutron default 
is 0.0 MeV, photon default is 100 keV), then the transport calculations for that particle 
are terminated without playing Russian Roulette. Therefore, if the energy cutoff is not 
carefully selected for a given problem, then particles that could potentially contribute to 
one or more tallies could be prematurely terminated resulting in biased or wrong answers. 
However, using an appropriate energy cutoff can increase computational efficiency by 
not wasting computational effort on tracking insignificant histories. 
4.1.1.7 Source Biasing 
It is often advantageous to distort the natural source probability distribution so 
that certain portions of the distribution that would otherwise be sampled infrequently will 
be preferentially sampled in order to help lower the uncertainties for one or more scored 
quantities. For example, in BNCT it is important to minimize the fast neutron 
contamination in the epithermal neutron beam since fast neutrons lead to a non-specific 
background dose that lowers the therapeutic ratio. Therefore, in an analog Monte Carlo 
model of a BNCT neutron beam line, the fast portion of the neutron energy spectrum is 
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sampled relatively infrequently which can lead to large uncertainties when calculating the 
fast neutron dose in the patient. One method of reducing these uncertainties is to sample 
the fast portion of the source neutron energy spectrum more frequently but with a 
reduced particle weight so as to not bias the resulting calculations.  
4.1.2 Original Variance Reduction for the MIT FCB 
In 2002, detailed calculations of the constructed FCB beam line were performed 
in order to produce a surface source representation at the patient position for treatment 
planning calculations for the BNCT clinical trials at Harvard-MIT.10 Past experiences 
using Monte Carlo transport calculations to design the FCB had indicated that neutron 
and photon weight windows would result in the most computationally efficient 
calculations of the beam line.6,11 Therefore, the MCNP weight windows generator was 
used to produce space- and energy-dependent neutron and photon weight windows for 
each cell of the well-segmented FCB model geometry. For neutrons, weight windows 
were generated for 7 energy groups with the following upper energy boundaries: 0.01 eV, 
0.1 eV, 1 eV, 10 keV, 100 keV, 1 MeV, and 20 MeV. Likewise, photon weight windows 
were generated for 2 energy groups with upper energy boundaries of 0.55 MeV and 100 
MeV. Using 7 separate simulations, the neutron weight windows in each of the 7 energy 
groups were optimized using scores from the corresponding energy bin of a neutron 
current12 tally inside the aperture (r ≤ 5.9 cm) at the beam aperture plane. The weight 
windows for the appropriate energy group from these 7 individual simulations were 
manually combined to yield a complete set of energy dependent neutron weight windows. 
Optimizing the neutron weight windows for each energy group independently ensured 
effective variance reduction across a broad range of neutron energies as shown in Figure 
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4.1 where the uncertainties (which have been intentionally increased by an order of 
magnitude to better illustrate the effect) are reasonably uniform at energies outside of the 
epithermal neutron energy range. Photon weight windows were generated during similar 
simulations but were instead optimized for a tally of the A-150 tissue equivalent plastic 
photon dose at the beam aperture plane. Using these neutron and photon weight windows, 
transport calculations of the FCB beam line were performed on a dual 1.7 GHz Intel® 
Xeon™ processor workstation in several steps, beginning with criticality calculations of 
the MITR-II reactor core and ending with the production of a combined neutron and 
photon surface source downstream at the beam aperture plane. In preparation for dose 
calculations in the patient, the neutron and photons tracks were separated so that induced 
and incident photons could be calculated separately. This series of simulations resulted in 
a 337 MB (megabyte) surface source file containing only neutron tracks (3,674,093 
neutron tracks from 59,517 independent histories) and a 351 MB surface source file of 
photons tracks only (3,862,520 photon tracks from 23,891 independent histories). Before 
patient planning commenced, both surface source files were validated using physical 
dosimetry measurements13,14 in the MIT ellipsoidal head phantom15,16 and in a large 
rectangular water phantom.17  
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Figure 4.1 Neutron current energy spectrum inside the beam aperture (r ≤ 5.9 cm) of 
the MIT FCB. The uncertainties have been intentionally increased by an 
order of magnitude to better illustrate the effectiveness of the energy-
dependent weight windows at reducing uncertainties across a broad range 
of neutron energies. 
 
4.1.3 Treatment Planning with the MIT FCB 
After selecting several possible treatment field orientations using NCTPlan,15,18 
the FCB neutron and photon surface source files were each sampled once during separate 
MCNP simulations and tracked into a voxel model of the patient anatomy to calculate the 
dose components present in BNCT. From validation calculations with the FCB neutron 
and photon surface source files, dose component scaling factors were derived by least 
squares fitting calculated doses to physical dosimetry measurements made in-phantom 
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and in-air. The scale factors for the boron, thermal and fast neutron, and induced photon 
dose components were unity while a scale factor of 2.48 was applied to the incident 
photon dose because MCNP is unable to model delayed gammas. These scale factors 
calibrated NCTPlan calculations to physical dose measurements and helped ensure that 
the patient doses calculated during in the treatment planning process were an accurate 
representation of what would be actually delivered during treatment. For the 7 patients 
treated with the FCB, the average CPU times for the coupled neutron/photon (mode np) 
and photon (mode p) treatment planning simulations were 45.9 and 14.2 minutes per 
field, respectively.  
Distinctive streak artifacts of high dose and large uncertainty in the incident 
photon dose distribution would later be identified when examining the 2-dimensional 
dose distributions in the patient; these artifacts were determined to be due to high weight 
or excessive duplicate photon tracks. An example of these streak artifacts is shown in 
Figure 4.2. This problem indicated that the variance reduction used in the upstream 
calculations of the beam line may be suboptimal. The rather large ratio of tracks to 
independent histories, 61.7 for the neutron surface source and 160 for the photon surface 
source, also suggest that there may be too much particle splitting and not enough unique 
track information. The artifacts also make it difficult to accurately calibrate the planning 
system for the incident photon dose component. Despite the dramatic appearance of the 
streak artifacts in Figure 4.2, it is important to understand that the clinical significance of 
these problems is small because the incident photon dose is a small component of the 
total weighted brain dose, contributing 3.4% at Dmax. Also, it is important to recognize 
that the variance reduction scheme that was ultimately responsible for creating the 
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problems was produced by the MCNP weight windows generator and was the best 
variance reduction scheme available at the time and it appeared to perform very well for 
most dose components. 
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Figure 4.2 Two dimensional distributions of dose rate, relative error, and FOM 
(Figure-Of-Merit) calculated for the incident photon dose component of 
the MIT FCB in a voxel model of the modified Snyder head phantom. 
Streak artifacts of high in-phantom incident photon dose, high uncertainty, 
and low FOM resulting from the “unlucky” rouletting of neutrons and 
excessive splitting of the subsequent induced photons during upstream 
Monte Carlo calculations of the FCB beam line are evident. The color bars 
are log scale. 
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4.1.4 Objectives 
With increasingly powerful computational resources routinely available, it is 
understandable to simply employ a brute force approach to Monte Carlo treatment 
planning calculations whereby a sufficiently large number of particles are simulated in 
order to achieve the desired level of dose precision. However, more computationally 
efficient approaches are usually available that would better facilitate the planning process 
and thus help result in a more optimal and accurate treatment plan. Therefore, this 
chapter describes analysis to help reduce the uncertainties that are inherent in Monte 
Carlo treatment planning calculations for BNCT. The analysis was divided into two 
logical phases. In phase I, the original variance reduction of the FCB Monte Carlo model 
was reevaluated and further optimized in an attempt to improve the surface source 
representation of the MIT FCB beam line at the patient position and subsequently 
produce increased dose accuracy and precision in the patient. Having a more accurate 
surface source definition of the MIT FCB would not only benefit future retrospective 
analyses of the FCB patient data but would also facilitate the comparison of the different 
source definitions techniques available for NCT treatment planning (Chapter 5). While 
variance reduction is most often essential, especially in reactor-based BNCT, to the 
Monte Carlo calculations of the beam line, it is not often employed for the subsequent 
dose calculations in the patient. Therefore, in phase II, the focus was shifted to dose 
calculations in the patient where considerable effort was devoted to investigating the 
effectiveness of the various variance reduction techniques at improving the 
computational efficiency. In those calculations, even modest gains in efficiency would be 
advantageous since calculations of patient dose are often repeated several times for 
different beam orientations during the BNCT treatment planning process. 
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4.2 Materials and Methods 
Both phase I and II of this work required the often difficult task of comparing 
different types of variance reduction. So, throughout the course of this analysis, a given 
variance reduction technique was ultimately evaluated based on its ability to reduce the 
uncertainties of in-patient dose calculations. The test case used to evaluate different 
variance reduction schemes in this study was a single-field irradiation of the Snyder head 
phantom.19 NCTPlan was used to create a 1 cm3 voxel model of the modified Snyder 
head phantom, and a 4 cm diameter sphere was added to the phantom to model the 
intracranial disease that is often the target of BNCT. The different regions of the Snyder 
head phantom were modeled using adult whole brain and adult whole cranium, as defined 
by ICRU Report 46.20 A concentration of 15 μg/g of 10B was explicitly modeled in the 
brain and 3.5× that concentration was modeled in the tumor. Neutron, photon, and 10B 
kerma factors21 for ICRU 46 adult whole brain material were used to compute the 5 dose 
components present in BNCT:  the 10B(n,α)7Li reaction, thermal neutron dose mainly 
from the 14N(n,p)14C reaction, fast neutron dose mainly from the 1H(n,n′)1H proton recoil 
reaction, induced photon dose from photons created inside the patient mainly via the 
1H(n,γ)2H reaction, and incident photon dose from those photons which were produced 
upstream and outside of the patient.21 The total biologically weighted brain dose was 
calculated as the sum of the boron, thermal neutron, fast neutron, induced photon and 
incident photon dose components weighted by RBE or CBE factors22 of 1.3, 3.2, 3.2, 1.0, 
and 1.0, respectively.  
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To evaluate the computational efficiency and overall effectiveness of a particular 
variance reduction technique, it is useful to define the Figure-of-Merit (FOM) as 
follows:3 
( )  timeCPUerror relative
1FOM 2 ×≡     (4.2) 
The relative error of a tally is its standard deviation divided by its estimated mean 
and varies inversely with the square root of the number of particle histories simulated. In 
other words, the relative error of a given tally can be reduced by a factor of N by 
simulating N2 times as many particle histories. CPU time is the total time (summed for all 
CPUs for parallel calculations) required to complete the simulation and is directly 
proportional to the number of simulated histories. Given these proportionalities, the FOM 
should roughly be constant and independent of runtime or the number of histories 
simulated. A variance reduction technique with a larger FOM for a given tally is more 
efficient at reducing uncertainties than other techniques with smaller FOM values. To 
facilitate the comparison of the different forms of variance reduction, custom MATLAB 
(The MathWorks, Natick, MA) functions were used to read and graphically display the 2-
dimensional dose, relative error, and FOM distributions for the dose components 
calculated in the 1 cm3 voxels of the head phantom. 
For phase I calculations, the Monte Carlo model of the MIT FCB incorporating 
the 6Li filter assembly1 (with the 6Li filter out) was used with the original energy-
dependent neutron and photon weight windows as a starting point in a search for more 
optimal variance reduction to increase the amount of unique track information reaching 
the beam aperture while also decreasing the excessive numbers of duplicate tracks. Once 
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sufficiently effective variance reduction was obtained, the calculations of the FCB beam 
line were repeated with a significantly increased number of simulated histories to 
produce a new surface source file at the beam aperture plane. Previously reported 
physical dosimetry measurements1 of boron, thermal and fast neutron, and photon dose 
for the FCB along the central axis of the MIT ellipsoidal head phantom were used for 
model validation. The physical dosimetry of the MIT FCB has been described 
elsewhere.17,23 When needed, custom MATLAB functions were employed to read, write, 
and manipulate binary MCNP surface source files. 
In phase II, irradiation of the voxel model of the head phantom with a generic 
epithermal neutron beam21 was simulated using different forms of variance reduction 
available in MCNP (section 4.1.1). The mean efficiency of the in-phantom dose 
calculations resulting from each variance reduction type was compared to a baseline 
MCNP simulation with only the default variance reduction (i.e., implicit capture and 
weight cutoff) enabled to appropriately gauge the effectiveness of that particular 
technique at reducing the variance. For each variance reduction technique, the relevant 
parameters were adjusted in a trial-and-error process to optimize the variance reduction 
for the transport problem without biasing the dose calculations. The monodirectional 10 
cm diameter disc source was modeled as 10% thermal neutrons (1×10−9 eV to 0.5 eV), 
89% epithermal neutrons (0.5 eV to 10 keV), and 1% fast neutrons (10 keV to 2 MeV). 
The disc source was sampled uniformly in area and was normalized to a neutron flux of 
1×1010 n/cm2s. This beam was chosen so that the corresponding MCNP source definition, 
represented as a series of probability distributions, would be an appropriate analogue to 
those actual clinical BNCT beams that are represented in a similar manner. To provide an 
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appropriate incident photon dose component in the calculation of the total weighted dose 
rate, a 2 MeV monoenergetic and monodirectional photon disc source was simulated and 
normalized to 2×108 γ/cm2s. MCNP5 version 1.40 was used to perform all Monte Carlo 
calculations in both phases of the work, and all simulations were performed in parallel on 
a Beowulf cluster (described in Appendix B) composed of 11 nodes with AMD® Athlon 
64™ 3200+ (2.0 GHz) 64 bit processors and 2 GB RAM. 
4.3 Results 
4.3.1 Phase I:  Detailed Calculations of the Neutron Beam Line 
The detailed Monte Carlo calculations of the MIT FCB beam line were divided 
into a series of 3 simulations with each resulting in a surface source file at a different 
location along the beam line. This method of segmenting of the transport geometry 
allowed downstream calculations to be repeated as needed without having to first repeat 
the time-consuming upstream portion of the calculations and does not introduce any 
significant approximations.6,11 A cross-sectional view of the Monte Carlo model of the 
FCB beam line outlining the simulations performed and surface source files written is 
shown in Figure 4.3. In the first simulation, a criticality calculation of the MITR-II 
reactor core was performed and used to produce a fission volume source file in the core, 
and only default variance reduction (no weight windows) was used during the criticality 
calculation. The neutron track information from that fission volume source was sampled 
during the second simulation and transported to the edge of the graphite reflector, 
immediately before the fission converter, where a second surface source file was 
recorded. For the third simulation, the neutron tracks from the surface source file at the 
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edge of the graphite reflector were sampled, transported through the fission converter and 
collimator to the beam aperture plane via coupled neutron/photon calculations, and 
written to a surface source file at the patient position along with photons tracks resulting 
from neutron interactions. It should be noted that photons originating in the core were not 
simulated since they have been shown to represent only a very small fraction of the 
incident photon dose at the beam aperture.11 Since a great majority of the photons that 
contribute to incident photon dose at the patient position originate downstream of the 
fission converter, coupled neutron/photon calculations were used to produce the mixed 
particle surface source representation at the patient position. This single surface source 
file of neutron and photons tracks was split into separate neutron and photon surface 
source files by transporting particles an infinitesimal distance to a new surface where 
new surface source files were written in separate runs.∗ This allows the induced (induced 
in the phantom) and incident (incident on the phantom) photon dose components to be 
calculated separately in subsequent simulations through the patient geometry and for 
those results to be independently scaled for planning system calibration.  
Using the model, simulations, and surface source files depicted in Figure 4.3, 
energy dependent neutron and photon weight windows were calculated for the entire 
FCB beam line from reactor core to patient position using the MCNP weight windows 
generator with the original weight windows serving as initial estimates. Weight windows 
were calculated for the 7 original neutron energy groups (with upper boundaries of 0.01 
eV, 0.1 eV, 1 eV, 10 keV, 100 keV, 1 MeV, and 20 MeV) but only 1 photon energy 
group and were optimized for boron and incident photon dose rate calculations in the 
                                                 
∗ The neutron surface source file was created using the cards “mode n” and “ssw pty n” and the photon 
surface source with “mode p” and “ssw pty p”. 
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spherical tumor of an analytical model of the modified Snyder head phantom simulated at 
the patient position. To better model the energy dependence of the neutron weight 
windows and ensure adequate variance reduction across a range of neutron energies, 7 
simulations were performed (1 simulation for each neutron energy group) in which 
weight windows for each of the seven neutron energy groups were individually optimized 
using the corresponding energy bin of the tumor boron dose tally. The resulting 
optimized weight windows for each neutron energy group were copied from the 
appropriate simulation and manually combined to form a new set of neutron weight 
windows. The entire process was repeated with this new set of weight windows in order 
to further optimize the weight windows. After this second iteration was complete, the 
resulting final set of weight windows was used in calculations of the FCB beam line to 
produce the surface source at the patient position (i.e., “SS 3” in Figure 4.3). It should 
also be noted that the number of particles simulated during computations of weight 
windows was increased by a factor of 36, which was determined so that the storage 
requirements for the 3 surface source files produced would not exceed the limits of the 
hard disk storage available. While significantly increasing the number of particle 
histories used to generate weight windows did not necessarily improve the estimates of 
windows for cells along the central beam axis, those cells that were rarely visited before 
experienced an increase in the number of tracks which improved the estimate of the 
importance function in those regions.  
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Figure 4.3 Monte Carlo model of the MITR-II reactor core and FCB beam line 
illustrating the series of MCNP calculations and surface source (SS) files 
used to create a surface source representation of the beam downstream at 
the patient position (beam aperture) for use in BNCT treatment planning 
calculations. 
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Subsequent in-phantom dose calculations with the newly created surface source 
file exhibited streak artifacts of elevated incident photon dose and uncertainty, as shown 
in Figure 4.2, similar to those produced by the original FCB surface source file created in 
2002. Excessively high weight tracks split into many duplicates were suspected to be 
responsible. To investigate this, custom MATLAB functions were used to read the binary 
track information recorded to SS 3 and calculate the number of identical neutron and 
photon tracks per independent particle history. Excessive numbers of identical neutron 
and photon tracks were identified and determined to be the cause of the observed streak 
artifacts. So, a systematic approach was employed to identify and address the source(s) of 
this duplicate track information, and that process is represented as a flowchart in Figure 
4.4. The first step was to identify those independent particle histories with large numbers 
of duplicate tracks from SS 3. Each of these problematic histories were then read from SS 
2 upstream and written individually to short surface source files along with all their 
associated tracks. The DBCN (debug information) and RAND (random number 
generator) cards were employed in the subsequent MCNP simulations with these short, 
single-history surface source files to exactly reproduce each track’s path from the edge of 
the graphite reflector to the beam aperture and provide detailed information about all 
interactions and variance reduction events along the way. This detailed track information 
revealed that in certain regions of the FCB beam line geometry (off the central beam 
axis) select fission neutrons were being scattered and surviving consecutive 1-for-5 
Russian Roulette events in adjacent cells and being increased in weight by a factor of 5 
each time. In one instance, a neutron survived a series of consecutive Russian Roulette 
events to have its weight increased by nearly 3 orders of magnitude. These high weight 
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neutrons would then produce the maximum of 10 induced photons upon interacting in the 
cadmium layer that lines the upstream edge of the lead photon shield. The resulting 
photons directed downstream towards the beam aperture would then be subjected to 
consecutive 5-for-1 particle splitting events through the lead shield and then multiple 2-
for-1 splitting events in the collimator, all of which helped produce a cascade of identical 
tracks directed towards the beam aperture plane. As these problematic regions were 
identified, the weight windows in these regions were adjusted to reduce the ratio of the 
weight windows in adjacent cells and therefore limit the effect of unlucky variance 
reduction events and excessive particle splitting. This process was repeated until the 
problematic weight windows upstream of the lead shield had been sufficiently corrected. 
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Sample SS 2, transport all particle
histories to patient position using
modified weight windows, and record
SS 3.
Use custom MATLAB functions to 
read and analyze SS 3. Identify those
independent histories with excessive
numbers of duplicate tracks.
For each identified problematic
particle history, read all associated
tracks from the upstream SS 2 and 
write them to a new, short surface
source file using custom MATLAB
functions.
Sample the new, short surface
source file containing the problematic
histories, and debug each track with
the MCNP DBCN card as it is 
transported through the geometry to
identify those regions of the FCB 
beam line geometry where rouletting
to a very high weight or excessive 
splitting occurs.
Manually adjust weight windows in
problematic regions.
Repeat until problematic
high weight tracks have
been eliminated.
 
Figure 4.4 Flowchart outlining the systematic approach taken to minimize production 
of problematic high weight tracks and subsequent splitting into excessive 
numbers of duplicate tracks during the Monte Carlo simulations of the 
FCB beam line that resulted from neutrons rouletting to high weights and 
producing photons which were split multiple times. The process was 
repeated until the production of high weight tracks, as manifest by 
excessive numbers (> 100) of duplicate tracks recorded on the surface 
source at the patient position, had been sufficiently reduced. 
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While that process successfully minimized the production of high weight 
particles, the problem of excessive particle splitting events due to decreasing weight 
windows in the collimator remained. A separate calculation of the beam line indicated 
that 90.7% of the photon track weight reaching the beam aperture was from upstream of 
the beam collimator which meant that decreasing the weight windows through the 
collimator to result in additional particle splitting, as recommended by the MCNP weight 
windows generator, was very likely unnecessary and ultimately counterproductive for 
efficiency. So, the neutron and photon weight windows in the collimator were set to be 
constant in the longitudinal direction for each energy group, using values for the first cell 
after the lead photon shield for cells on the central axis. The original (from 2002) and 
corrected neutron and photon weight windows for those cells along the central axis of the 
beam line are shown in Figure 4.5. Notice that the original weight windows produced by 
the MCNP generator decreased by over 2 orders of magnitude in the collimator. Moving 
radially outward from the beam’s central axis, the new neutron and photon weight 
windows were manually increased to help focus computational effort on transporting 
particles towards the beam aperture. 
Using the corrected neutron and photon weight windows, the calculations of the 
FCB beam line were repeated starting with SS 2 at the edge of the graphite reflector and 
ending with a new surface source at the patient position. Directly as a result of the 
changes in the neutron and photon weight windows, the runtime required to perform the 
transport calculations through the FCB beam line was reduced by a factor of 3.2 and the 
size of the resulting surface source was reduced by a factor of 200, from 34 GB to 170 
MB. The new surface source file contained many fewer duplicate neutron and photon 
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tracks, as illustrated in Figure 4.6, which shows a histogram of the number of duplicate 
photon tracks per history. The mean number of duplicate photon tracks per independent 
history was reduced from 102 to 2.97. Since the problematic high weight particles were 
absent, severe streak artifacts in the subsequent in-phantom incident photon dose rate 
calculations were also resolved. Although the incident photon relative error in Figure 4.6 
is indeed higher (5% vs. 7.5% at incident photon dose maximum) after the adjustments 
due to less track information, limiting the excessive number of identical photon tracks 
and subsequently avoiding the significant wasted computational expense of transporting 
them into the phantom increased the mean efficiency (FOM) of the in-phantom incident 
photon dose calculations by a factor of 185. Similarly, the mean number of duplicate 
neutron tracks per independent history was reduced from 31.0 to 2.37, and select particle 
histories that had in excess of 200,000 identical neutron tracks were eliminated. 
Therefore, the mean efficiency of in-phantom boron and fast neutron dose calculations 
was increased by factors of 5 and 23.8, respectively, as shown in Figure 4.7. The mean 
efficiency of in-phantom induced photon and total weighted brain dose calculations were 
likewise increased by factors if 2.7 and 9.1, respectively, as shown in Figure 4.8. The 
mean, minimum, and maximum FOM values for all in-phantom dose tallies before and 
after the changes to the weight windows are listed in Table 4.1. Small regions of large 
uncertainty and low efficiency (relative to the values in adjacent voxels) in the boron and 
induced photon (and hence total weighted brain) dose were eliminated by adjusting the 
weight windows. It should also be noted that the adjustments to the weight windows 
produced a small but statistically significant 1% decrease in the boron dose in a region on 
the ipsilateral side of the phantom that included the maximum boron dose. However, this 
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difference is small compared to the error in the physical dosimetry measurements used to 
calibrate the planning system and is therefore not clinically significant. 
The adjustments to the neutron and photon weight windows described above 
improved variance reduction and computational efficiency significantly. These 
improvements did not, however, increase the number of unique photon tracks and 
independent histories reaching the beam aperture. To improve this aspect of the 
calculation, other forms of variance reduction were investigated for use in the 
calculations of the FCB beam line. It was thought that developing a scheme whereby 
photon production biasing could be separated and controlled independently from the 
photon population control (splitting and Russian Roulette during transport) would 
produce stronger variance reduction and more unique photons at the beam aperture plane. 
So, the corrected neutron weight windows were still used, but the corrected photon 
weight windows were inverted, appropriately scaled, and input as cell importances to 
guide the resulting biased spatial importance sampling. Similarly, the corrected photon 
weight windows were used to derive cell-by-cell entries for the PWT (photon production 
biasing card) card to control photon production biasing. After expending significant 
effort to find more optimal photon importance functions and photon biasing parameters, 
the mean FOM for in-phantom tallies of boron, fast neutron, and incident photon dose 
rates were still factors of 7.8, 7.7, and 4.8 times lower than the corresponding values 
produced with weight windows. Therefore, it was concluded that the corrected energy-
dependent weight windows were indeed the best available solution for this transport 
problem. 
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Figure 4.5 Original (from 2002) and new neutron and photon weight windows for 
those cells along the central axis of the FCB beam line. The thin vertical 
lines that segment the weight windows represent the boundaries of 
different regions of the beam line. Neutron and photon weight windows 
were increased moving radially outward from the beam central axis. 
Chapter 4: Application of Variance Reduction in Monte Carlo Treatment Planning J.R. Albritton  
 369
 
Figure 4.6 Histogram of the number of duplicate photon tracks within the FCB 
surface source file at the patient position and the subsequent effect they 
had on in-phantom incident photon dose rates, relative errors, and FOM 
before and after adjustments to upstream weight windows. By adjusting 
the weight windows, the mean number of identical photon tracks per 
independent history was reduced from 102 to 2.96, and streak-artifacts of 
high dose and high uncertainty were eliminated while the FOM was 
increased significantly. The value plotted at 100 tracks represents the 
number of unique tracks (no duplicates) within the surface source file. The 
color bars are log scale. 
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Figure 4.7 Boron and fast neutron dose rate, relative error, and FOM (Figure-Of-
Merit) distributions in the transverse plane of the modified Snyder head 
phantom on the FCB central axis before and after adjustments to the 
weight windows used for transport through the beam line. The mean, 
minimum, and maximum FOM values increased for both dose components 
as a result of the adjustments. The color bars are log scale.  
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Figure 4.8 Induced photon and total weighted brain dose rate, relative error, and 
FOM (Figure-Of-Merit) distributions in the transverse plane of the 
modified Snyder head phantom on the FCB central axis before and after 
adjustments to the weight windows used for transport through the beam 
line. The mean, minimum, and maximum FOM values increased for both 
dose components as a result of the adjustments. The color bars are log 
scale. 
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Table 4.1 FOM (Figure-Of-Merit) statistics for dose tallies in the voxel model of the 
modified Snyder head phantom before and after adjustments to the weight 
windows in the Monte Carlo calculations of the FCB beam line. The 
adjustments reduced the number of high weights tracks and excessive 
particle splitting, thereby increasing computational efficiency by limiting 
the duplicate track information recorded to the surface source file used in 
the phantom dose calculations. 
  Before Adjustments  After Adjustments  After/Before Ratio
Dose Component Mean Min. Max. Mean Min. Max.  Mean Min. Max.
Boron 47.4 0.024 190  237 3.5 1118  5.0 147 5.9 
Thermal Neutron 48.0 0.024 190  222 3.5 1082  4.6 146 5.7 
Fast Neutron 1.3 0.003 5.0  30.6 0.56 254  23.8 185 50.6 
Induced Photon 22.3 0.030 79.4  59.5 8.2 213  2.7 274 2.7 
Incident Photon 1.7 0.072 4.6  317 68.9 902  185 956 196 
Total Weighted Brain 30.5 0.041 223  276 14.7 1334  9.1 358 6.0 
 
With confidence that the neutron and photon weight windows were sufficiently 
optimal forms of variance reduction for the FCB beam line calculations, the amount of 
unique neutron and photon track information reaching the patient position was increased 
by brute force. Each neutron track from SS 2 was sampled 50×, at weights appropriately 
reduced to 1/50th their stored values, in a simulation that required in excess of 1 CPU 
year of computer time. Relevant details for the simulations performed and surface source 
files produced for the final calculations of the FCB beam line are shown in Figure 4.9. 
The resulting neutron and photon surfaces sources files at the patient position (i.e., SS 3a 
and SS 3b in Figure 4.3 and Figure 4.9) were used in simulations with the MIT 
ellipsoidal head phantom to produce in-phantom dose rates for comparison to 
corresponding physical dosimetry measurements. Dose component scaling factors were 
derived by least squares fitting calculated doses to measurements. The resulting scaling 
factors for the boron, thermal neutron, fast neutron, and induced photon dose components 
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were determined to be 0.95, which is within 1 σ of previous scale factors.10,15 The 
incident photon dose component scaling factor was determined to be 1.95; this large 
deviation from unity results from the inability of MCNP to model delayed gammas. In 
Figure 4.10, comparison of the scaled calculations with measured dose rates demonstrates 
excellent agreement.  
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Figure 4.9 Detailed description of the series of simulations and surface source files 
used to produce a more accurate surface source representation of the FCB 
at the patient position. In total, 1.07 CPU years of simulation time and 88 
GB of computer storage were used. 
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Figure 4.10 Comparison of calculated and measured1 doses in the MIT ellipsoidal 
head phantom. MCNP calculations with the FCB surface source were 
scaled to match physical dosimetry measurements using least squares 
fitting; dose scale factors for each component are listed in the legend. 
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4.3.2 Phase II:  Dose Calculations in the Patient 
In phase II, the focus of the analysis was shifted from calculations of the beam 
line to dose calculations in a voxel model of the modified Snyder head phantom to 
determine whether any of the variance reduction techniques available in MCNP could 
increase computational efficiency and facilitate the treatment planning process. A simple 
MCNP SDef model of a generic epithermal neutron beam was used instead of the surface 
source model of the FCB since surface source representations usually contain some 
“built-in” variance reduction as a result of the techniques applied in upstream 
calculations. Nevertheless, most of the variance reduction techniques investigated could 
readily be adapted to either form of source definition with little effort. The techniques 
investigated were neutron and photon energy cutoff, neutron and photon weight cutoff, 
fast neutron source biasing, photon production biasing, and neutron and photon weight 
windows. For each of these techniques, a trial and error process was used to tune the 
technique to the given transport problem in order to produce more optimal variance 
reduction. Therefore, the results shown and discussed for each technique are actually the 
culmination of many separate simulations. The different techniques, as well as 
combinations of techniques, were compared based on their ability to increase the FOM 
for in-phantom dose calculations without biasing the calculated dose rates. A coupled 
neutron/photon simulation with each variance reduction technique was compared to a 
corresponding baseline simulation with only the default variance reduction enabled 
(implicit capture and weight cutoff). The resulting 2-dimensional FOM distributions for 
in-phantom boron, fast neutron, induced photon, and total weighted brain dose 
calculations are shown in Figure 4.11 and Figure 4.12 for the baseline simulation (labeled 
implicit capture) and simulations with each variance reduction technique. The 
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corresponding ratios (FOMVR/FOMBase) of mean in-phantom FOM values are listed in 
Table 4.2 for each biasing technique and dose component. In Table 4.2, results are also 
included for both analog and implicit capture when relevant. 
4.3.2.1 Implicit Capture 
With implicit capture enabled for neutrons (as in the baseline simulation), the 
runtime was 30% longer than for analog capture. Therefore, any gains in reducing the 
variance for the in-phantom dose calculations were more than offset by the increased 
computation time per neutron history that is a characteristic disadvantage of implicit 
capture. The mean FOM for the boron and thermal neutron dose components were 
essentially unchanged from the simulation with analog capture, but the corresponding 
mean fast neutron, induced photon and total weighted brain FOM values increased by 
42%, 38%, and 16%, respectively, by disabling implicit capture for neutrons. 
4.3.2.2 Energy Cutoff 
When the neutron energy cutoff was raised to 5×10−4 eV, the maximum boron 
dose was decreased by 2% due to prematurely terminated neutron tracks. Similarly, if the 
photon energy cutoff was increased to 500 keV, the maximum induced photon dose was 
decreased by 2.3%. Therefore, neutron and photon energy cutoffs of 1×10−4 eV and 100 
keV were selected, respectively, to prevent biasing the dose calculations However, such 
relatively small increases in the energy cutoffs (default values are 0.0 eV for neutrons 
and 1 keV for photons) understandably failed to significantly decrease the computation 
time and therefore resulted in no improvement in the efficiency of the dose calculations.  
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Figure 4.11 FOM (Figure-Of-Merit) distributions for in-phantom dose tallies in the 
transverse beam line plane which result from employing different variance 
reduction techniques during coupled neutron/photon transport simulations 
of the generic epithermal neutron beam in a voxel model of the modified 
Snyder head phantom. Larger FOM values indicate more efficient dose 
calculations. The color bars are log scale. 
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Figure 4.12 FOM (Figure-Of-Merit) distributions for in-phantom dose tallies in the 
transverse beam line plane which result from employing different variance 
reduction techniques during coupled neutron/photon transport simulations 
of the generic epithermal neutron beam in a voxel model of the modified 
Snyder head phantom. Larger FOM values indicate more efficient dose 
calculations. The color bars are log scale. 
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Table 4.2 Ratio of the mean in-phantom FOM (Figure-Of-Merit), relative to a 
baseline simulation with the default MCNP variance reduction, implicit 
capture, for dose calculations in the voxel model of the modified Snyder 
head phantom that result from employing different variance reduction 
techniques during coupled neutron/photon simulations with the generic 
epithermal neutron beam. The variance reduction parameters used for each 
technique are the result of a trial and error process performed to tune the 
specific technique to the given transport problem in order to maximize 
effectiveness. Results are included for both analog (A) and implicit (I) 
neutron capture. 
    Ratio of Mean In-Phantom FOM to Baseline 
Variance Neutron  Thermal Fast Induced Total 
Reduction Technique(s) Capture Boron Neutron Neutron Photon Weighted Brain
Implicit Capture (default) I 1.00 1.00 1.00 1.00 1.00 
Analog Capture A 1.01 1.00 1.42 1.38 1.16 
Photon Prod. Biasing A 0.88 0.88 1.24 3.09 1.55 
Photon Prod. Biasing I 0.90 0.90 0.91 2.53 1.44 
Weight Cutoff I 0.95 0.94 1.38 1.33 1.13 
Fast Neutron Src. Biasing A 0.82 0.81 23.0 1.11 1.44 
Fast Neutron Src. Biasing I 0.74 0.74 14.5 0.72 1.18 
Weight Windows Mesh I 0.78 0.78 1.10 2.68 1.42 
Energy Cutoff I 1.00 1.00 1.00 1.00 1.00 
Fast Neutron Src. + Photon 
Production Biasing 
A 0.72 0.71 20.2 2.47 2.21 
Fast Neutron Src. + Photon 
Prod. Biasing + Wgt. Cut 
I 0.75 0.75 14.7 2.03 2.22 
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4.3.2.3 Weight Cutoff 
After performing several simulations with different weight cutoff parameter pairs 
(WC1 and WC2, described in section 4.1.1.4), the parameters were set at −1.5 and −0.75, 
respectively, and resulted in the FOM data listed in Table 4.2 and displayed in Figure 
4.12 for the weight cutoff. The mean efficiency for total weighted brain dose calculations 
was increased by 13% over the baseline simulation, where the default WC1 and WC2 
values of −0.5 and −0.25 were used, due to the significant increase in the efficiency of 
the fast neutron and induced photon dose calculations. Increasing the absolute values of 
the weight cutoff parameters from their default settings helps reduce (via Russian 
Roulette) the number of low weight neutron tracks produced by implicit capture and 
decreases the runtime by 28%. Nevertheless, larger increases (16% for total weighted 
brain dose calculations) in the dose calculation efficiency are observed by simply 
disabling implicit neutron capture.  
4.3.2.4 Photon Production Biasing 
As the photon production biasing parameter (specified via the PWT card) was 
incrementally increased from the default value of −1 to 0 to increase the production of 
induced photons, the mean FOM for the in-phantom induced photon dose calculations 
increased by a factor as large as 5.5, as shown in Figure 4.13. However, that increase in 
FOM comes at the expense of reduced efficiency for other dose components, like the 
boron dose. Therefore, it is important to fully understand how a particular variance 
reduction technique affects the efficiency of all dose calculations. Figure 4.13 also 
indicates that there is no significant benefit, in terms of the efficiency of the total 
weighted brain dose calculations, in increasing the photon production biasing parameter 
above −0.25. So, that value was chosen as the photon production biasing parameter to 
Chapter 4: Application of Variance Reduction in Monte Carlo Treatment Planning J.R. Albritton  
 389
produce the induced photon dose FOM distribution shown in Figure 4.11 where biasing 
photon production more than triples (3.09×) the mean efficiency of induced photon dose 
calculations when used with analog capture. 
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Figure 4.13 Percent difference in the mean FOM (Figure-Of-Merit) for in-phantom 
dose tallies when compared to simulations using the default photon 
production biasing parameter of −1. As the biasing parameter is increased 
to 0, more induced photons are produced with appropriately adjusted 
(lower) weights so as to maintain a fair Monte Carlo game and provide 
unbiased results. Increasing photon production dramatically improves the 
efficiency of calculating the induced photon dose, but this comes with the 
expense of reduced efficiency for other dose components such as the 
boron dose. 
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4.3.2.5 Fast Neutron Source Biasing 
The natural sampling frequency of the generic epithermal neutron beam was 
defined to be 10%, 89%, and 1% for the thermal, epithermal, and fast regions of the 
neutron energy spectrum, respectively. To decrease the uncertainties associated with the 
fast neutron dose rates, the source sampling frequency was biased so that fast neutrons 
would be sampled more frequently but at a decreased weight. Similar to photon 
production biasing, the FOM for the fast neutron dose calculations could be increased 
rather dramatically by significantly biasing the source sampling frequencies. However, 
that increase would come at the expense of decreased efficiency for the other dose 
components. So, a trial-and-error approach was taken to find the fast neutron source 
biasing parameters that provided a sufficient balance. When the thermal, epithermal, and 
fast regions of the source spectrum were sampled with biased frequencies of 1%, 70%, 
and 20% respectively, the fast neutron portion of the energy spectrum was oversampled 
by a factor of 20, and the starting weight of each fast neutron was appropriately 
decreased from the default value of 1 to 0.05 to properly account for the biasing. As a 
result of the biasing alone, the mean FOM for the in-phantom fast neutron dose 
calculations was increased by a factor of 14.5, and the significant increase in efficiency is 
clearly evident in Figure 4.11. However, that increase comes at the expense of decreased 
efficiency of boron, thermal neutron and induced photon dose calculations. Nevertheless, 
the decrease in the efficiency of the other dose calculations is not so dramatic as to 
decrease the efficiency of the total weighted brain dose calculations.  
4.3.2.6 Weight Windows 
Investigation of weight windows for treatment planning calculations was 
motivated by a report that a weight windows variance reduction tool was being 
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developed at the University of Michigan for one of the Idaho National Laboratory 
treatment planning systems.24 The voxel model of the modified Snyder head phantom 
was represented in MCNP as a lattice in order to take advantage of the lattice speed tally 
patch.25,26 Therefore, the most plausible approach to investigating weight windows was to 
use the weight windows mesh since it is independent of the problem geometry and could 
be easily rotated and translated into the desired orientation with the beam during 
treatment planning calculations. Alternatively, if the voxel model were to be constructed 
in the cell model, cell-by-cell importances or weight windows could be specified, but it 
would be much more difficult to adjust the variance reduction as the field orientation is 
changed. Different orientations of the weight windows mesh were calculated, but the 
most efficient calculations with the monodirectional disc source resulted when the edge 
of the cylindrical weight windows mesh was aligned with the front edge of the phantom. 
This increased the efficiency of the transport calculations by preventing those particles 
that scatter out of the phantom from being needlessly split or rouletted since they are no 
longer important to the dose calculation. However, this gain in efficiency was only 
marginal. Each element of the weight windows mesh was 2 cm thick along the beam line 
with a diameter of 10.5 cm just large enough fully enclose the outer boundary of the 
voxel model of the head phantom. An outer layer of mesh elements completely external 
to the phantom were used to terminate tracking calculations for those neutron and 
photons tracks escaping from the phantom. The orientation of the cylindrical weight 
windows mesh with respect to the phantom and the disc source is shown in Figure 4.14.  
The MCNP weight windows generator was used to produce weight windows for 
each element of the mesh for 3 neutron energy groups (with upper boundaries of 0.5 eV, 
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10 keV, 20 MeV) and 1 induced photon energy group. For each neutron and photon 
energy group, 3 separate simulations were performed to produce weight windows 
optimized for the corresponding in-phantom dose tally at 3 different depths (2, 6, and 12 
cm) along the beam line. The resulting 3 sets of weight windows (1 for each depth) were 
examined for each neutron and photon energy group and combined into one set to better 
address the differences in the weight windows for dose calculations at different depths in 
the phantom. The resulting weight windows for each neutron and photon energy group 
were then written into an appropriately formatted wwinp file for use with MCNP.  
For a fixed number of particles, subsequent simulations with these weight 
windows produced runtimes that were over 4× longer than simulations without them. 
Thus, the computational efficiency was actually significantly decreased for all dose 
calculations (e.g., −43% for boron dose calculations) except for a small 5% increase in 
the efficiency of induced photon dose calculations. This decrease in efficiency resulted 
from excessive and unnecessary splitting in the phantom. To eliminate the excessive 
particle splitting occurring in the phantom, the weight windows for all neutron energy 
groups were set to a constant value of unity in all 8 mesh elements. Likewise, a constant 
photon weight window of 0.25 was specified for all 8 mesh elements since the previous 
analysis of photon production biasing had shown that to be a rather optimal value. These 
adjustments to the neutron and photon weight windows decreased the runtime by 80% 
and increased FOM values for all dose component tallies by 2-5× when compared to 
simulations with the steeper weight windows produced by the MCNP generator. These 
constant weight windows failed to produce an increase in efficiency, when compared to 
the baseline simulation, for any of the individual dose component calculations except for 
Chapter 4: Application of Variance Reduction in Monte Carlo Treatment Planning J.R. Albritton  
 393
the induced photon dose where a significant 80% increase was observed. However, that 
increase in efficiency was significant enough to produce a 19% increase in the mean 
efficiency of the total weighted brain dose calculations. To further optimize the variance 
reduction of the weight windows mesh, the appropriate parameter was adjusted so that 
particle weight was evaluated at boundary crossings only (as opposed to the default 
where this is performed at collisions and boundary crossings) to determine if splitting or 
rouletting was required to keep the particle within the boundaries of the weight window. 
This change further increased the mean efficiency of the boron, fast neutron, induced 
photon, and total weighted brain dose calculations by an additional 4%, 3.5%, 3.9% and 
2.7%, respectively. Therefore, these flat weight windows were used to produce the FOM 
distribution shown in Figure 4.12 and the values listed in Table 4.2 for the weight 
windows mesh. Nevertheless, the lack of any spatial variation in the neutron and photon 
weight windows essentially result in variance reduction that could otherwise be achieved 
by combining the weight cutoff game and photon production biasing. Weight windows 
do not provide any additional gain in computational efficiency and are therefore a 
suboptimal variance reduction solution for in-phantom dose calculations. 
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Figure 4.14 Cylindrical weight windows mesh superimposed on a 1 cm3 voxel model 
of the modified Snyder head phantom and irradiated with a 10 cm 
diameter monodirectional epithermal neutron disc source. The neutron and 
photon weight windows in those regions of the mesh labeled with an ‘X’ 
were intentionally made very large (1×1025) to terminate tracking 
calculations for all particles escaping from the phantom. 
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4.3.2.7 Combined Photon Production and Fast Neutron Source Biasing 
The analysis thus far has considered simulations with only a single variance 
reduction technique. However, it is possible to employ more than one variance reduction 
technique in the same simulation. Therefore, different combinations were explored based 
on their observed effectiveness when used individually. Out of the several possible 
combinations investigated, combining fast neutron source biasing and photon production 
biasing produced the largest increases in the mean computational efficiency when all the 
dose component calculations were considered. As shown in Table 4.2, the dramatic 
increase in the efficiency of the fast neutron dose (20.2×) and induced photon dose 
(2.47×) calculations (due in part to disabling implicit neutron capture) overcome the 
comparatively small decrease in the efficiency of the boron and thermal neutron dose 
(0.72×) calculations to result in total weighted brain dose calculations that are 2.2× more 
efficient on average than default MCNP calculations (with neutron implicit capture 
enabled) that are most commonly performed in BNCT treatment planning. As is evident 
in Table 4.2, a similar level of efficiency in the total weighted brain dose calculations can 
be achieved using fast neutron source biasing and photon production biasing with 
implicit capture enabled if the weight cutoff is increased above the default values to limit 
the computational effort devoted to low weight tracks. However, combining implicit 
capture with fast neutron source and photon production biasing results in a rather 
significant decrease in efficiency (compared to the corresponding simulation where it is 
disabled) for the fast neutron and induced photon dose calculations.  
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4.4 Discussion 
Repeating the original radiation transport calculations of the FCB beam line with 
more histories would not correct the issues resulting from the suboptimal weight 
windows produced by the MCNP weight windows generator. The resulting high weight 
tracks produced distinctive regions of large uncertainty in the incident photon dose in the 
patient while the excessive duplicate track information resulted in highly inefficient dose 
calculations and significantly inflated computer storage requirements. Therefore, 
considerable computational effort was spent to identify and correct the cause of these 
problems as well as to investigate the effectiveness of other forms of variance reduction. 
The complexity of the Monte Carlo model of the FCB beam line meant undertaking a 
time consuming trial and error process to evaluate potential variance reduction 
techniques and optimize the effectiveness of the technique determined to be the best 
available (i.e., weight windows). The effectiveness of different forms of variance 
reduction or the differences produced by altering parameters for a given technique were 
all evaluated using relevant in-phantom dose calculations similar to those used in clinical 
BNCT treatment planning. Optimizing weight windows for in-phantom tumor dose tallies 
rather than in-air flux tallies at the beam aperture did not result in many dramatic changes 
in the weight windows plotted in Figure 4.5. The most noticeable change occurred in the 
neutron weight windows for the 0.1 eV to 1 eV energy group where the original weight 
windows (from 2002) are more sloped through the aluminum and lead shield and result in 
a weight window at the collimator entrance that is an order of magnitude lower than the 
corresponding new weight window. However, any differences are relatively small 
compared to those in the collimator that result from manually adjusting the neutron and 
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photon weight windows in that region to a constant value to reduce particle splitting. 
However, the optimal weight windows for the collimator are likely somewhere in 
between the constant values used and the sloped set produced by MCNP. The relatively 
unobstructed path through the collimator along the central beam axis from the lead shield 
to the beam aperture plane suggest that drastically decreasing the weight windows along 
that path to result in particle splitting is not warranted and is counterproductive. 
Conversely, flat weight windows limit the number of unique photon tracks reaching the 
beam aperture plane. Of course, this issue points to the even larger problem of the MCNP 
weight windows generator failing to produce an adequate importance function. The phase 
space was sufficiently subdivided in space and energy, but the weight windows produced 
by MCNP were clearly less than optimal. Adding an angular dependence to the weight 
windows would likely help, but the magnitude of that effect is hard to estimate. 
As a result of the work to optimize the neutron and photon weight windows and 
the computational resources of the Beowulf cluster, the number of independent neutron 
and photon independent particle histories at the beam aperture was increased by factors 
of 352 and 598, respectively. While the increased information is indeed advantageous for 
the precision of all subsequent dose calculations, it is particularly important for the 
calculations of fast neutron and incident photon dose rates in the patient. The 
effectiveness of sampling the surface source file multiple times to increase dose precision 
is more limited for these dose components than the other dose components due to the 
comparatively low number of interactions each experiences in the phantom before 
thermalization or escape. The increase in unique track information in the surface source 
file also allows conversion into an SDef representation using the methods presented in 
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Chapter 5 with greater accuracy and precision. In addition to the significant increase in 
unique track information when compared to the original surface source files from 2002, 
the ratios of the number of tracks to independent histories were decreased from 61.7 and 
160, for the neutron and photon surface source files at the patient position, respectively, 
to 2.0 for both. Therefore, computation time was not spent during the dose calculations in 
the phantom handling duplicate track information which increased in the mean, 
minimum, and maximum FOM for all dose components. For instance, the mean, 
minimum, and maximum FOM values for the total weighted brain dose calculations were 
increased by factors of 9.1, 358, and 6.0, respectively.  
The subsequent validation calculations reaffirmed the earlier findings of good 
agreement with physical dosimetry measurements. All of the calculated dose component 
scale factors, except for the incident photon scale factor, were within 1σ of those used in 
treatment planning for the Harvard-MIT clinical trial of BNCT. The large incident 
photon dose component scale factor was due to the inability of MCNP to properly model 
delayed gammas. Although the incident photon dose is a small contributor to the total 
biologically weighted dose, the 21% decrease in the scale factor underscores the 
importance of devoting computational effort to produce an accurate representation of the 
beam at the patient position. While the exact details of the variance reduction might 
indeed be specific to the FCB beam line, the broader applicability of these findings are in 
the overall process that was used to arrive at those details and the motivation to perform 
such work.  
The work performed on the variance reduction of the FCB beam line provided 
considerable experience in executing MCNP in parallel with surface source files as large 
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as 42 GB. Therefore, a few important observations drawn from that experience will be 
shared. The version of MCNP used for these calculations was compiled with a pre-
release version of a patch from the X-5 Monte Carlo team, which is responsible for 
MCNP development, that allowed the slave processes during parallel simulations to 
access surface source files locally rather than to have 11 complete copies sent over the 
network from the master process at beginning of the simulation. This was essential to the 
completion of this work given the large size of the surface source files involved. 
Consider the parallel simulation executed on 11 nodes that reads the fission volume 
source for transport to the edge of the graphite reflector. The patched MCNP executable 
allowed each of the 11 slave processes to read from the same copy of the fission volume 
source since each slave process had a “local” copy of the file available via an NFS 
mounted directory. If not for this patch, 11 copies of the 33 GB file would have been sent 
to the slave processes over the network only to then be transferred back to the master 
node as each slave process wrote the file to an NFS mounted directory. The startup time 
required to transfer such massive amounts of data over the network, as well as the storage 
requirements (12 copies×33 GB), would have made these simulations impossible with 
our hardware. Since simulations with SS 2 at the edge of the graphite reflector were 
repeated so frequently during the course of this work, a copy of SS 2 was transferred to 
each slave node’s local disk drive so that each slave process would be able to read from 
its own local copy, thus greatly reducing network traffic and the startup times for the 
parallel simulations dependent upon that surface source file. This functionality is now 
included in version 1.50 of MCNP5. There was also a significant variation observed in 
the time required for the slave processes to complete the transport calculations for their 
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assigned portion of tracks from the surface source file. It was not unusual for multiple 
nodes to lie dormant for significant amounts of time (i.e., 30 – 60 minutes) waiting for all 
the nodes to reach the rendezvous point. Since the dormancy seemed (counter intuitively) 
to increase as rendezvous points were made less frequent, shorter rendezvous intervals 
were chosen to prevent nodes from getting out of sync and wasting significant 
computational resources.  
During the 50× sampling of SS2 that required over 1 CPU year to perform, 
unavoidable excessive warning messages regarding track weights starting outside of a 
given weight window were written to the simulation output file until there was no more 
free disk space available, thus causing the simulation to crash. This was a result of the 
error counter, a signed 4-byte integer overflowing from the maximum integer to the 
minimum and causing the error message to be written for every track. Therefore, a 
custom MCNP executable was created with the problematic error message disabled for 
that simulation, and the MCNP development team was notified of the problem. 
Exploring the variance reduction for dose calculations in the head phantom was 
obviously quite different than for the beam line of the FCB. Thus, it is not surprising that 
the variance reduction technique that was found to be the best solution for the beam line 
calculations, energy-dependent weight windows, was found to be suboptimal for the dose 
calculations in the phantom. Despite considerable effort to tune the weight windows 
mesh to produce more efficient dose calculations, the increases in computational 
efficiency were indeed marginal compared to other methods. The relatively small 
transport geometry represented by the voxel model of the phantom did not warrant the 
constant splitting and rouletting that is characteristic of weight windows. Surprisingly, 
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implicit neutron capture, which is enabled by default, proved to be inefficient as well. 
The dimensions of the head phantom or a patient’s anatomy and the distances neutrons 
and photon must be tracked to contribute to a scored quantity are small compared to deep 
penetration problems like the FCB beam line. Therefore, modified sampling methods 
such as fast neutron source biasing and photon production biasing, and perhaps forced 
collisions (for fast neutron and incident photon dose calculations), are more effective 
than population control methods such as weight windows. 
When using the different variance reduction techniques, it was important to 
ensure that the resulting doses were not biased in the process. Increasing the neutron and 
photon energy cutoffs beyond certain energies resulted in the termination of particle 
tracks that would have contributed dose in the phantom, thus resulting in lowered and 
incorrect dose rates. However, most forms of variance reduction employ Russian 
Roulette instead of simply terminating tracks in order to help avoid biasing answers. It is 
also important to understand that an increase in the FOM for a given dose component 
tally usually comes at the expense of another, as Figure 4.13 indicates for the boron and 
induced photon dose rate tallies. Fast neutron source biasing and photon production 
biasing each predictably increased the mean FOM for the fast neutron and induced 
photon dose rate tallies, respectively, but, the effectiveness of a given form of variance 
reduction should be properly investigated for all dose component tallies to ensure that 
other dose calculations are not actually being made more inefficient. Combining fast 
neutron source biasing with photon production biasing resulted in calculations of the total 
weighted brain dose rate that were over twice as efficient as the default MCNP 
calculations (with neutron implicit capture) at reducing the uncertainty. Thus, the same 
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level of precision for the total weighted dose could be achieved in less than half the 
runtime. Although an MCNP SDef representation of an actual clinical neutron beam 
should be substantially more complex than the generic epithermal neutron beam, these 
results indicate that it is indeed possible to achieve more efficient calculations of the total 
weighted dose rate. The need for improvements in computational efficiency will become 
more important as voxel sizes smaller than 1 cm3 become more frequently employed for 
more accurate modeling of the patient anatomy. 
4.5 Conclusions 
Manually optimizing the energy dependent neutron and photon weight windows 
used in the Monte Carlo computations of the FCB beam line help to produce a surface 
source file at the patient position with significantly less duplicate track information 
thereby allowing for increased computationally efficiency while also correcting existing 
problems due to high weight tracks. The more accurate surface source representation was 
successfully validated using physical dosimetry measurements. Also, several variance 
reduction techniques were investigated in an attempt to increase the computational 
efficiency of in-phantom dose calculations for BNCT treatment planning. The different 
variance reduction techniques were each tuned in a trial-and-error process to the transport 
problem and then compared in their effectiveness at reducing the uncertainty associated 
with in-phantom dose calculations while also maintaining sufficient dose accuracy. By 
combining both fast neutron source biasing and photon production biasing and disabling 
implicit neutron capture, the mean computational efficiency of the total weighted brain 
dose calculations was increased by a factor of 2.2. 
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CHAPTER FIVE 
Neutron Beam Source Definition 
Techniques for Neutron Capture 
Therapy Treatment Planning 
5.0 Abstract 
Constructing an accurate description of a neutron beam is critical to achieving 
accurate calculations of dose in neutron capture therapy (NCT) treatment planning. This 
chapter compares two different methods of neutron beam source definition. The first 
method involves performing a detailed simulation of the neutron beam line and recording 
the characteristics of all particle histories to a phase space file referred to as a “surface 
source.” The second method involves representing the beam characteristics as a set of 
probability distributions using the MCNP general source definition card or SDef. To 
facilitate the comparison, a software tool was developed for analyzing surface source 
files and constructing probability distributions to represent the source in treatment 
planning simulations. Simulations in this study were performed using the MCNP Monte 
Carlo radiation transport code with the MIT fission converter beam (FCB), which has a 
well-validated MCNP model, serving as the test neutron beam. Each source type (surface 
source file and SDef) was used to simulate transport of the beam through voxel models of 
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the modified Snyder head phantom and a large rectangular water phantom where doses 
were calculated. When compared to dose calculations with the surface source file, the 
initial calculations with the SDef produced significant errors of 15.2% and 10.7% at Dmax 
in the head phantom and rectangular water phantom, respectively. Using a patched 
version of MCNP that allowed the observed radial dependence of the relative azimuthal 
angle to be modeled in the SDef, errors in all dose components in the head phantom at 
Dmax were reduced to acceptably small levels with none being significant (P ≥ 0.13) 
except for the 0.5% error in the induced photon dose. Similar error reductions were 
obtained for the large water phantom. Errors in the calculated doses introduced by 
sampling the azimuthal component of particle direction uniformly in the SDef vary 
spatially and are phantom-dependent and thus cannot be accurately corrected by a simple 
scaling of doses. 
5.1 Introduction 
Boron Neutron Capture Therapy (BNCT) has been used to treat a variety of 
cancers at various sites worldwide:  in the USA,1-4 in Japan,5,6 in Europe7-11 and in 
Argentina.12 For clinical trials of BNCT, accurate treatment planning calculations are 
required to ensure the safety of the patient and the maximum efficacy of the therapy. 
However, the presence of multiple dose components, some of which depend strongly on 
tissue composition, as well as the scatter-dominated radiation transport require dose 
calculations that are more complicated than those for conventional radiotherapy. Thus, 
BNCT treatment planning systems utilize Monte Carlo simulations exclusively because 
solution of the Boltzmann transport equation is required in this scatter-dominated 
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problem. Due to its ability to provide a detailed treatment of physics and geometry, 
Monte Carlo algorithms are widely held to be the most accurate method of radiation 
transport and dosimetry calculation available. In spite of this ability, Monte Carlo based 
treatment planning is critically dependent on using an accurate model of the radiation 
source for the Monte Carlo radiation transport computations. Failure to use an accurate 
source model adversely affects the accuracy of computations and the resulting treatment 
plan. However, accurately defining the radiation source is one of the most difficult 
aspects of the entire treatment planning process because it requires producing an 
adequately accurate representation of the 5-dimensional probability distribution 
describing the spatial, energy, and angular characteristics of a radiation beam. Several 
methods for defining the radiation source have been used clinically in BNCT treatment 
planning. 
5.1.1 Methods of Source Definition 
 
In Monte Carlo simulations for NCT treatment planning, it is inefficient to 
simulate transport of particles from the reactor core or accelerator target all the way 
through the beam line for each patient. Therefore, other techniques are used that are more 
efficient that define a source term for planning simulations a short distance from the 
patient. Two methods of defining a neutron beam source for NCT treatment planning 
involve the use of binary phase space files (surface sources) or explicitly defining spatial, 
energy and angular probability distributions in the code used for the radiation transport 
calculations. Each of these methods has significant advantages and disadvantages. 
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5.1.1.1 Surface Source Files 
In the first method of source definition, detailed Monte Carlo radiation transport 
computations of the neutron beam line are performed, and the characteristics of all 
particle histories crossing a plane are recorded to a phase space file often referred to as a 
“surface source.” This binary phase space file contains exact track characteristics, such as 
position, direction, energy, and (statistical) weight of all particle histories at a given 
position in the treatment geometry, which is usually at the beam aperture near the patient 
position. The particle tracks from the phase space file are sampled in subsequent 
simulations of particle transport through the patient geometry thus allowing the 
computational resources to be focused on dose calculations in the patient and not wasted 
on repeating expensive transport computations upstream of the patient. The primary 
benefit of using a surface source file is that it introduces no significant approximations 
into the source description, which should lead to improved dose accuracy. The drawbacks 
of this method include the extremely large (GB) size of the unportable binary files, lower 
computational efficiency, increased start-up times for parallel computations, and 
limitations on the number of particles that can be simulated and the dose precision 
achievable, which results from the finite amount of track information recorded in the 
surface source file. This limitation on the dose precision achievable with a surface source 
file is also known as its latent variance.13 
5.1.1.2 Probability Distributions 
Detailed probability distributions describing the spatial, energy and angular 
distribution must be created from previous computations of the neutron beam line. This 
usually involves computing the distributions of particle current14 using a Monte Carlo or 
discrete ordinates transport code, but an auxiliary code may also be used to compute 
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probability distributions from a phase space file. The flexibility and detail allowed in 
defining these probability distributions for the subsequent transport calculations depends 
on the transport code used. In the case of the well-benchmarked code MCNP,15 the 
general source definition card (SDef) is used to define the probability distributions 
usually a few centimeters from the patient on an in-air plane corresponding to the beam 
aperture. Modeling the collimator assembly and other structures upstream of the aperture 
are not necessary for the subsequent dose calculations in the patient since the neutron and 
photon current scattering off the patient and back upstream into the collimator assembly 
and then back into the patient is negligibly small at < 1%. Also, modeling the source in 
this manner does not suffer from any of shortcomings of the surface source files, yet 
regardless of which transport code is used, grouping the track information into discrete 
bins may involve significant approximations and loss of information that reduces the 
accuracy of computed doses. The magnitude of these approximations may be particularly 
sensitive to the binning structure used, especially in those sections of the spectrum where 
the distribution changes rapidly. The fact that the probability distributions for the source 
variables (energy spectrum, spatial distribution, angular distribution) may be inseparable 
is also problematic for this method.  
5.1.2 Objectives 
This chapter compares two different methods of defining a neutron beam source 
for NCT treatment planning calculations, the surface source (phase space file) and SDef 
(probability distributions). A surface source model of a neutron beam is converted into a 
MCNP SDef model using a suite of tools designed and developed specifically for this 
purpose. In-phantom dose data produced by the surface source model are compared to 
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dose data produced by the SDef model to evaluate the accuracy of the doses computed by 
the SDef and hence the magnitude of the approximations introduced by the conversion 
process. If the inherent approximations could be limited to the extent that they produce 
no significant differences in dose when compared to calculations with surface sources, 
then the use of SDefs in NCT treatment planning calculations would indeed be 
advantageous since the shortcomings of using surface sources could be avoided without 
compromising accuracy. The various steps in the conversion process as well as the tools 
developed to perform the conversion will also be discussed. 
5.2 Methods and Materials 
The well-validated Monte Carlo transport code MCNP15 was used for all radiation 
transport calculations. MCNP is also used to perform the transport calculations for NCT 
treatment planning systems such as MacNCTPlan,16 NCTPlan,17 MiMMC,18,19 and 
JCDS.20 
5.2.1 Neutron Beam and Phantoms 
The neutron beam used as a test case in this study is the MIT fission converter 
beam (FCB),21,22 which has been used in clinical trials of BNCT4 and has a Monte Carlo 
model and surface source representation that have been well-validated against physical 
measurements made in both an ellipsoidal head phantom23 and a large rectangular water 
phantom.23,24 In preparation for the work described in this chapter, considerable effort 
was expended to improve the pre-existing variance reduction in the FCB model, resulting 
in energy-dependent neutron and photon weight windows optimized to increase the 
amount of unique track information reaching the beam aperture while also limiting 
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excessive numbers of duplicate tracks. The improvements made to the variance reduction 
of the FCB model, as well as the work used to produce them, are discussed in Chapter 4. 
After producing a new surface source at the FCB beam aperture with a significantly 
increased amount of neutron and photon track information, the FCB model was validated 
again with the new surface source, reaffirming earlier findings of good agreement 
between calculations and in-phantom physical dosimetry measurements. The derived 
dose component scaling factors that are indicative of the agreement of calculations and 
measurements were within 1 standard deviation of unity for all dose components except 
the incident photon dose, which resulted in a scale factor if 1.95 due to the inability of 
MCNP to model delayed gammas. 
5.2.2 Probability Distribution Construction 
The surface source file written at the beam exit of the MIT FCB was converted 
into a set of probability distributions formatted for the MCNP SDef card using a suite of 
custom MATLAB (The MathWorks, Natick, MA) functions. Using MATLAB to 
manipulate and analyze the binary track data rather than relying upon MCNP tallies 
helped to expedite the iterative conversion process greatly. However, an important early 
test of the custom software was to compare its output of binned particle weight directly to 
MCNP tallies to ensure that the binary surface source file was being read and processed 
correctly. Track weight is directly proportional to the probability that a given track will 
occur and is properly adjusted by variance reduction techniques to ensure a fair Monte 
Carlo game and unbiased answers. The neutron and photon track information was read 
directly from the binary surface source file, and track weight was scored into a 4D array 
of radial (r), energy (E), polar angle (θ), and relative azimuthal angle (φ') bins for each 
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particle type, neutron and gamma. As shown in Figure 5.1, the relative azimuthal angle φ' 
is defined for the purposes of this work as the angle between the particle’s radial position 
vector (at an angle φ) and the projection of the particle’s direction onto the source plane. 
The circular symmetry of the FCB collimator and the emerging neutron beam permits 
this compact and convenient representation of the source geometry using polar 
coordinates.  
 
 
X
Z
Y
(x,y)
φ′
θ
r
φ
 
Figure 5.1 Parameters used to define the particle position and direction (indicated by 
the bold arrow) in the SDef source representations. r and φ are sampled to 
determine position (x,y). The polar angle θ and the relative azimuthal 
angle φ′, defined relative to the track’s radial vector, determine particle 
direction. 
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Limiting the loss of information in binning the particle weight meant carefully 
selecting appropriately sized fine bins for each source variable. The scheme for neutrons 
was a mixture of 2, 5 and 10 mm bins for radius, 10 logarithmically spaced bins per 
decade for energy, and 2 degree bins for θ and φ'. Similar binning was used for photons 
except that 100 keV energy bins were used for all energies except below 1 MeV where 
finer bins of 25 keV were needed to more accurately model peaks in the energy 
distribution. To construct the probability distributions needed for the SDef, the r-E-θ 
phase space was broken into several coarse rectangular regions (no segmentation was 
used in the φ' direction). In each coarse region, marginal probability distributions* for 
each source variable (r, E, θ, φ') were computed from the binned track data. Figure 5.2 
illustrates the fine binning of the track information and the coarse rectangular regions of 
the phase space, each of which has a unique marginal probability distribution for each 
source variable. These marginal distributions are sampled in the SDef model and actually 
define the source. The products of these marginal distributions were graphically and 
quantitatively compared to the corresponding joint probability distributions for source 
variable pairs in order to guide selection of the boundaries of the coarse phase space 
regions to minimize the differences between the two and thus produce an accurate 
probability model of the source. This iterative process involved selecting a set of 
boundaries for each source variable to define the coarse phase space, plotting and 
reviewing the agreement between the marginal and joint probability distributions in each 
rectangular region of that phase space, and then adjusting the boundaries as needed to 
                                                 
* For a joint distribution ( )yxf ,  of the random variables X and Y, the marginal distributions of X alone 
and Y alone are given by ( ) ( )∫+∞∞−= dyyxfxg ,  and ( ) ( )∫+∞∞−= dxyxfyh , , respectively. 
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improve agreement. This process was repeated until sufficient agreement was observed 
or until limitations* of MCNP were reached. In order to achieve the required level of 
source dependency with the MCNP SDef, congruent source planes† were used, one for 
each coarse region of the phase space and each with its own marginal probability 
distributions for r, E, θ and φ'. 
 
                                                 
* MCNP allows a maximum of 999 source variable distributions. 
† Degenerate planar surfaces with different MCNP problem numbers but the identical geometric 
parameters. 
r
θ
E
)()()()(),,,( ,,,,,,,,,, φθφθ ′⋅⋅⋅≅′ kjikjikjikjikji PPEPrPErP  
Figure 5.2 Track information from the surface source file is scored into an array of 
fine radial, energy, polar angle (θ), and relative azimuthal angle (φ') bins 
such as illustrated here. This finely binned information is grouped into 
coarse regions for the r, E, and θ source variables, as indicated by the thick 
dashed lines. In each coarse region (e.g., the shaded region), a unique 
marginal probability distribution is computed for each of the 4 source 
variables. The product of each region’s marginal probability distributions 
in r, E, θ and φ′ is used to model the joint probability distribution 
Pi,j,k(r,E,θ,φ′) in that region. 
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5.2.2.1 Direction Sampling in MCNP5 
In the standard method of direction sampling in MCNP, the polar angle θ is first 
sampled from a user-defined distribution in the SDef. Then, the relative azimuthal angle 
φ' is sampled uniformly from –π to +π. However, in this study we determined that for the 
MIT FCB, φ' is not uniformly distributed and thus is not accurately modeled by the 
uniform sampling in MCNP. Instead, values of |φ'| < π/2 are preferred (i.e., particles 
directed radially outward, away from the beam center), and, inside the beam aperture, this 
preference has a radial dependence that increases with distance from the beam center. 
Therefore, MCNP5 v1.40 was modified to allow the radial dependence of φ' to be 
accurately modeled using either a radially dependent offset cosine function or other 
standard user-defined distributions (e.g., a combination of line segments) as needed. The 
accuracy of the model was assessed by plotting the percent difference between the 
modeled and actual φ′ distributions as a function of φ′ for each region of the phase space. 
In the radial region corresponding to the beam aperture, the probability 
distribution of φ′  was modeled by Eq. 5.1, 
)cos(
2
1)(
0
φπφ ′+=′ r
rbP     (5.1) 
where r0 is the radius of the beam aperture, 5.9 cm, and b is a fitted constant which was 
determined via least squares fitting. This function is an empirical fit to the simulated joint 
r-φ′ distribution that was found to match the sampled data well. One of the important 
properties of this probability distribution function is that, at the center of the beam (r=0), 
the φ′ distribution is uniform. From symmetry arguments, one should expect uniformity 
of the φ′ distribution at the center of the beam since there is no preferred direction. Since 
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the integral of Eq. 5.1 is not invertible, the distribution was sampled using the rejection 
method.25 For those radial regions outside of the beam aperture where the particle flux is 
significantly lower and the radial dependence of φ′ is small, the φ′ distribution is not well-
described by the offset cosine function. The radially independent φ′ probability 
distribution in these radial regions was modeled in the source definition by a series of 
line segments determined using least squares fitting. The modified MCNP executable 
was subjected to rigorous testing to ensure the patch worked exactly as intended within 
its limited scope. 
5.2.3 Monte Carlo Computations 
Using the MiMMC (Multi-Modal Monte Carlo) treatment planning system,18 4 
mm mixed-material voxel models of the modified Snyder head phantom26 and the large 
rectangular water phantom were constructed for radiation transport simulation with 
MCNP. The water phantom is a cube 40 cm on a side modeled entirely of light water 
while the Snyder head phantom is modeled using adult whole brain and adult whole 
cranium, as defined by ICRU Report 46.27 These two distinctly different phantoms allow 
the source definition techniques and the dose distributions they produce to be evaluated 
and compared under different geometric conditions, one relevant to clinical irradiations, 
and the other relevant to calibration conditions at some institutions. For consistency with 
both Harvard-MIT patient planning and calibration conditions, a 3 cm air gap was 
modeled between the beam aperture and the head phantom while the large water phantom 
was modeled adjacent to the beam aperture with no air gap. To further investigate the 
agreement of the different source definition techniques as a function of the source to 
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surface distance (SSD), additional simulations in the head and large water phantoms were 
performed with air gaps of 0 and 3 cm, respectively.  
The transport simulations were performed in each phantom using MCNP5 v. 1.40 
with the 3 different source models for the MIT FCB:  a surface source representation and 
SDef models with and without φ′ dependence. Simulations using an SDef with a φ′ 
dependence employed a modified version of MCNP as described above. Two simulations 
per source model were used for dose calculations in each phantom. A coupled 
neutron/photon simulation (via “mode np”) was performed to sample neutrons from the 
source plane and transport them, along with any photons they produce, through the 
phantom while a photon-only simulation (via “mode p”) was performed to sample and 
transport only photons from the source. Neutron, photon, and 10B kerma factors28 for 
ICRU 46 adult whole brain material were used to convert calculations of voxel-averaged 
neutron and photon fluence into the various dose components present in BNCT. The 5 
calculated dose components include the boron dose via the 10B(n,α)7Li reaction, thermal 
neutron dose mainly from the 14N(n,p)14C reaction, fast neutron dose mainly from the 
1H(n,n′)1H proton recoil reaction, induced photon dose from photons created inside the 
phantom mainly via the 1H(n,γ)2H reaction, incident photon dose from those photons that 
were produced upstream and outside of the phantom. The total biologically weighted 
brain dose was calculated as the sum of the boron, thermal neutron, fast neutron, induced 
photon and incident photon dose components weighted by RBE (Relative Biological 
Effectiveness) and CBE (Compound Biological Effectiveness) factors29 of 1.3, 3.2, 3.2, 
1.0, and 1.0, respectively. 
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Doses calculated in the head phantom were compared using isodose contours and 
dose vs. depth profiles along the central beam axis. In the SDef source models, source 
biasing of the fast neutrons was used, and photon production biasing was employed in all 
source models to improve statistics at depth in the phantoms. Although not as flexible or 
transparent as using variance reduction with the SDef, the surface source file has “built-
in” variance reduction as a result of the energy-dependent weight windows used 
throughout the FCB beam model. To improve statistics when using the surface source 
file, which has limited particle information, the surface source file was sampled 15 times. 
Due to scattering in the phantom, sampling each neutron and photon track multiple times 
will result in different particle histories in the phantom and increase the chance that a 
track will be scored in the phantom. This significantly improves statistics for dose 
components that depend on the thermal flux, i.e., the boron, thermal neutron, and induced 
photon dose components. However, the effectiveness of multiple sampling is limited for 
fast neurons and incident photons due to the relatively low number of interactions each 
experiences in the phantom before thermalization or escape. Simulations were performed 
in parallel on a Beowulf cluster (described in Appendix B) of 11 nodes with AMD® 
Athlon 64™ 3200+ (2.0 GHz) 64 bit processors and 2 GB RAM. 
5.3 Results 
For both neutrons and photons, a simple SDef with minimal phase space 
segmentation as well as a more segmented and complex SDef were created using the 
software suite. The simple SDef was created to help clearly illustrate the process while 
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the more complicated SDef was used to obtain a higher level of accuracy for comparisons 
with in-phantom dose calculations using the surface source model of the FCB.  
Using the simple phase space segmentation scheme, Figure 5.3, Figure 5.4, and 
Figure 5.5 show a representative portion of the graphical comparisons used to determine 
the coarse region boundaries of the phase space and evaluate the accuracy of the 
calculated distributions for (θ, E), (r, E), and (r, θ), respectively. Each of these figures 
shows the joint probability distribution(s) for a given source variable pair, the product(s) 
of the marginal distributions and the percent difference between the two. The joint 
distributions were produced by binning the particle weight from the surface source file, 
and the marginal distributions are actually defined in the SDef to model the joint 
distributions. Areas where the differences are very large (e.g., >30%) represent a 
significant degree of coupling between the probability distributions for that pair of source 
variables. The product of the marginal distributions produces adequately good agreement 
(~1% to 5%) with the joint distributions in those regions of the phase space responsible 
for producing a majority of the in-phantom dose, namely the epithermal energy region in 
the beam aperture. Any noticeable features, such as discontinuities or areas of large 
disagreement, in the plots of the marginal and joint distributions were seen as possible 
locations for coarse region boundaries. Once a boundary was assigned, the plots were 
reproduced to assess the change in agreement between the joint distribution and the 
product of the marginal distributions. In Figure 5.3, a noticeable feature is present around 
θ = 20° in the percent difference plot, and assigning a coarse region boundary at θ = 20° 
produced much better agreement between the joint and marginal distributions. In Figure 
5.4, noticeable lines in the percent difference plots are seen at approximately r = 5.9 cm 
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and r = 11.8 cm, so radial region boundaries were set at those particular radii and 
improve agreement. It should be noted that the region boundaries selected are in fact 
connected to the physical geometry of the FCB. For instance, ~20° is the angle between 
the sloped inner wall of the collimator cone and the beam aperture surface while the 
radial region boundaries represent the interfaces of different physical regions. For the 
simple neutron SDef, four concentric radial regions were selected: 0 cm ≤ r ≤ 5.9 cm 
(beam aperture), 5.9 cm < r ≤ 7 cm (aperture/collimator interface to 1 cm inside the 
collimator wall), 7 cm < r ≤ 11.8 cm (the collimator wall), and 11.8 cm < r ≤ 30cm 
(outside the collimator wall). Three energy regions corresponding to thermal (1x10−3 eV 
≤ E ≤ 0.5 eV), epithermal (5 eV < E ≤ 10 keV) and fast (10 keV < E ≤ 20 MeV) neutrons 
were used. For all but the outermost radial region, two θ regions were used (0° ≤ θ ≤ 20°, 
20° < θ ≤ 90°). However, due to the lower number of particle tracks in the outermost 
radial region, θ was not split in that radial region to reduce statistical fluctuations in the 
distribution. The resulting radial distributions of neutron current, neutron current energy 
spectra, and polar angle probability distributions for each region of the phase space are 
shown in Figure 5.6, Figure 5.7, and Figure 5.8, respectively. Inside the beam aperture, 
the neutron current distribution is nearly constant. Therefore, the radial probability 
distribution defined in the SDef for the radial region corresponding to the beam aperture 
increases linearly because the radial distribution of neutron current and the radial 
probability distribution are related by a factor of the radius. 
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Figure 5.3 Comparison of the joint probability distribution of polar angle θ and 
energy (P(θ,E)) with the product of the marginal distributions (P(θ)·P(E)) 
for the radial region corresponding to the beam aperture (r ≤ 5.9 cm) of the 
MIT FCB. Large percent differences indicate a high degree of 
inseparability between the two source variables. The alternating 
shaded/white areas demarcate different coarse regions of the r-E-θ phase 
space. 
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Figure 5.4 Comparison of the joint probability distribution of radius and energy 
(P(r,E)) with the product of the marginal distributions (P(r)·P(E)). The 
alternating shaded/white areas demarcate different coarse regions of the r-
E-θ phase space. 
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Figure 5.5 Comparison of the joint probability distribution of radius and polar angle θ 
(P(r,θ)) with the product of the marginal distributions (P(r)·P(θ)) for the 
thermal, epithermal, and fast neutron energy groups. The alternating 
shaded/white areas demarcate different coarse regions of the r-E-θ phase 
space. 
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Figure 5.6 Radial distribution of neutron current for different energy and angular 
regions of the phase space at the plane of the beam aperture of the MIT 
FCB. Line thickness encodes the thermal, epithermal and fast neutron 
energy groups while solid and dashed lines represent polar angle regions 
of 0° ≤ θ ≤ 20° and 20° < θ ≤ 90°, respectively. For the radial region 
outside the beam collimator (r > 11.8 cm, right of the vertical line) where 
the neutron current is orders of magnitude smaller than in the aperture, 
only one θ bin was used to help reduce fluctuations in the distribution 
resulting from few particles. 
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Figure 5.7 Energy spectrum of the neutron current in different radial and angular 
regions on the beam aperture plane of the MIT FCB.  Line thickness 
encodes the different radial regions on each plot with the top plot 
representing 0° ≤ θ ≤ 20° and the bottom 20° < θ ≤ 90°. In the outermost 
radial region (11.8 cm < r ≤ 30 cm) θ was scored into only one bin (0° ≤ θ 
≤ 90°) to reduce statistical fluctuations. Energy bins of equal lethargy (10 
per decade) were used to score the particle weight. 
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Figure 5.8 Polar angle (θ) probability distributions calculated in each of 4 radial 
regions and 3 energy regions. Line thickness encodes the thermal, 
epithermal and fast neutron energy groups. The particle weight was scored 
into 2° bins from 0° to 90°. 
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In order to produce the more complicated neutron SDef, plots such as those 
shown in Figure 5.3, Figure 5.4, and Figure 5.5 were carefully examined, and the phase 
space was further segmented. Radial boundaries were placed at 4 cm, 5.9 cm, 7.5 cm, 
11.8 cm, 17 cm, 22 cm, and 30 cm, energy boundaries were placed at 0.2 eV, 5 eV, 2 
keV, 50 keV, 1 MeV, and 20 MeV, and θ boundaries were placed at 12°, 18°, 26°, 35°, 
and 60°. It should be noted that increasing the segmentation by adding region boundaries 
has no significant effect on the total simulation time since more than 99.3% of the 
computational effort is spent tracking the particles and not in sampling the SDef. 
However, there is a limit on the amount of segmentation that can be used in constructing 
an SDef since MCNP5 will not allow more than 999 distributions in a SDef. 
For the simple photon SDef model, the radial boundaries were the same as for the 
simple neutron SDef except that the 7 cm boundary was removed resulting in 3 radial 
regions. Three energy regions (0 ≤ E ≤ 600 keV, 600 keV < E ≤ 2 MeV, and 2 MeV < E 
≤ 10 MeV) and two segments in θ ( 0° ≤ θ ≤ 20° and 20° < θ ≤ 90°) were specified. The 
resulting radial distributions of incident photon current, incident photon current energy 
spectra, and polar angle probability distributions for each region of the phase space are 
shown in Figure 5.9, Figure 5.10, and Figure 5.11. To construct the more complicated 
photon SDef, radial boundaries were placed at 2 cm, 4 cm, 5.9 cm, 7 cm, 9 cm, 11.8 cm, 
15 cm, 20 cm, and 30 cm, energy boundaries at 400 keV, 600 keV, 2 MeV, and 10 MeV, 
and θ boundaries at 20°, 26°, 36°, 46°, 56°, and 66°. 
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Figure 5.9 Radial distribution of incident photon current for different energy and 
angular regions of the phase space at the plane of the beam aperture of the 
MIT FCB. Line thickness encodes the 3 energy groups while solid and 
dashed lines represent polar angle regions of 0° ≤ θ ≤ 20° and 20° < θ ≤ 
90°, respectively. For the radial region outside the beam collimator (r > 
11.8 cm, right of the vertical line) where the photon current is orders of 
magnitude smaller than in the aperture, only one θ bin was used to help 
reduce fluctuations in the distribution resulting from few particles. 
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Figure 5.10 Energy spectrum of the incident photon current in different radial and 
angular regions on the beam aperture plane of the MIT FCB. Line 
thickness encodes the different radial regions on each plot with the top 
plot representing 0° ≤ θ ≤ 20° and the bottom 20° < θ ≤ 90°. In the 
outermost radial region (11.8 cm < r ≤ 30 cm) θ was scored into only one 
bin (0° ≤ θ ≤ 90°) to reduce statistical fluctuations. 100 keV energy bins 
were used to score the particle weight. 
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Figure 5.11 Polar angle (θ) probability distributions for the incident photons calculated 
in each of 3 radial regions and 3 energy regions. Line thickness encodes 
the energy groups. The particle weight was scored into 2° bins from 0° to 
90°. 
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Before performing any in-phantom dose calculations with the neutron or photon 
SDef models, the software suite used to create them was verified in a closed loop test. To 
perform the test, the newly created MCNP SDef source model of the MIT FCB was 
sampled in MCNP to write a binary surface source representation of the SDef. The 
software suite was then used to generate a SDef model from this binary surface source for 
the sole purpose of comparison with the original SDef. This testing and the resulting 
excellent agreement between the two SDef models helped to ensure the accuracy of the 
conversion process.  
Figure 5.12 compares the radial dependence of φ' observed in the surface source 
with the fitted model described by Eq. 5.1 for epithermal neutrons in the radial region 
corresponding to the FCB beam aperture for 0° ≤ θ ≤ 90°, demonstrating very good 
agreement. However, as the phase space is segmented in θ, the excellent agreement 
between the fitted model and the sampled φ' distribution deteriorates somewhat. Least 
squares analysis produced b values of 0.043, 0.042, and 0.045 for the thermal, epithermal 
and fast energy regions of the phase space inside the beam aperture for 0° ≤ θ ≤ 20°, 
respectively. For 20° < θ ≤ 90°, the resulting b values were 0.109, 0.077, and 0.092 for 
the same energy regions. Outside the aperture, strong radial dependence of φ' was not 
observed, so other radially independent probability distributions of piecewise linear form 
were used. For photons, the shape of the φ' distribution was more complex than for the 
neutrons. Thus, the φ' distribution in each region of the phase space was analyzed in order 
to determine whether the offset cosine function or other radially independent 
distributions provided the best fit. 
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Figure 5.12 Probability distributions of the relative azimuthal angle φ' inside the beam 
aperture of the MIT FCB determined from the surface source file and the 
fitted model. The nonuniform distribution shows a preference for outward 
angles (| φ'| < π/2). r0 is the radius of the beam aperture, 5.9 cm, and b is a 
fitted constant. Radial bins range from 0 to 5.9 cm in ~1 cm steps. P(φ') is 
shown averaged over the radial bins and is limited to 0 ≤ φ' ≤ π for this 
comparison. In the modifications to MCNP5, the fitted model is 
symmetric about φ'=0 and is sampled from –π to +π. 
 
 
Figure 5.13 compares isodose contours and depth vs. dose profiles along the 
central beam axis for the two complex SDef source models (φ' uniform and nonuniform) 
to reference data computed with the surface source in the head phantom at a source to 
surface distance of 3.0 cm. Table 5.1 summarizes the results for the head phantom and 
the large water phantom, reporting the error in maximum dose rate for the two SDef 
source models as compared to the reference surface source model. Significantly elevated 
dose rates as much as 15.2% higher than the reference surface source results were 
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computed with the SDef model. In the standard version of MCNP, only a uniform φ' 
distribution can be simulated with a SDef source model. Shifts in the isodose contours to 
deeper depths (and higher dose rates) for all dose components are clearly evident with the 
uniform φ' distribution. When the nonuniform φ' distribution was modeled accurately 
using the patched version of MCNP, the agreement between the SDef and the surface 
source improved dramatically, resulting in excellent agreement in the isodose contours. 
However, despite the dramatic improvement in the agreement in the incident photon 
contours between the surface source and the SDef with the nonuniform φ' distribution, 
differences are still evident at deeper depths in the phantom. However, this may be a 
result of noise (latent variance) in the surface source file. Nevertheless, this small 
disagreement (3.0% difference at 4.5 cm) in a dose component which in total represents 
only ~6% of the maximum total biologically weighted dose is acceptable and, given the 
difficulty experienced in modeling the complicated joint probability distributions for the 
incident photon, is not completely unexpected. Also, the data in Table 5.1 show that the 
error produced by not accurately modeling the φ' distribution is dependent upon the 
phantom as well as the distance from the source plane to the surface of the phantom. 
When the observed nonuniform φ' distribution of the FCB was modeled in the neutron 
and photon SDefs, good agreement with the surface source model was achieved 
regardless of the phantom or the distance from its surface to the source plane. However, 
evaluating the agreement in the large water phantom simply by looking in a single voxel 
at Dmax might not be a sufficient means of comparison. Thus, the mean disagreement was 
calculated for those voxels in the large water phantom which received at least 50% of the 
maximum dose for a given dose component. The resulting mean errors were less than 
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0.5% for all dose components except the fast neutrons and incident photons which 
produced mean errors of 3.3 ± 3.7% and 2.7 ± 2.0%, respectively, when compared to the 
surface source model. A similar analysis was also performed in the head phantom for the 
simple and complex neutron and photon SDefs in order to evaluate the effect a more 
complex SDef has on the agreement with the surface source model. The resulting mean 
error values, as well as the error at Dmax for each dose component, are shown in Table 
5.2. As expected, increasing the segmentation of the phase space and hence the 
complexity of the SDef resulted in better agreement with the surface source model. 
However, the improvement for the fast neutrons and incident photons was negligible 
indicating that further improvements in these two components may require another 
approach. Nevertheless, the disagreement between the dosimetry for the surface source 
model and the SDef model with the nonuniform φ' distribution is small compared to the 
uncertainties usually associated with physical dosimetry measurements in NCT.30,31  
To further illustrate the clinical significance of these findings, dose component 
scaling factors, derived from calculations with the uniform φ' SDef model in large 
rectangular water phantom (column 4 of Table 5.1), were applied to the uniform φ' SDef 
doses in the head phantom to simulate the planning system calibration routinely 
performed at some institutions. The total biologically weighted brain dose-volume 
histograms produced by simulating the irradiation of the Snyder head phantom (SSD=3.0 
cm) with the different source representations of the MIT FCB are compared in Figure 
5.14. The time required to deliver a maximum brain dose of 12.5 Gyw with the surface 
source model (13.47 minutes) was used to convert to units of absolute dose to facilitate a 
more direct comparison of the dose-volume data. The resulting disagreement between the 
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scaled SDef and the surface source curves (8.7%, 7.3%, and 11.6% in mean, minimum, 
and maximum total weighted brain dose, respectively) clearly indicates that the errors 
introduced during patient planning by sampling φ' uniformly are not corrected by 
calibrating the planning system in a reference phantom. Meanwhile, the agreement with 
the surface source dose-volume data improves significantly if the nonuniform φ' 
distribution is modeled accurately using the patched version of MCNP (0.5%, 2.4%, 
0.3% in mean, minimum, and maximum total weighted brain dose, respectively). While 
the exact process and/or phantoms used to calibrate the planning system may depend on 
the institution, the approach used here represents a relatively effective analogue of the 
calibration methodology commonly used at various clinical BNCT sites.  
Table 5.3 reports the statistical uncertainty for each dose component at Dmax in the 
ellipsoidal head phantom. The fast neutron and incident photon dose errors from the 
surface source run are the largest at 1.2% and 2.1% respectively, due to the limited 
amount of track information and the limited effect that multiple track sampling has on 
these two dose components. Table 5.4 contains simulation statistics for both the coupled 
neutron/photon and incident photon simulation into the ellipsoidal head phantom using 
the surface source and the SDef. 
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Figure 5.13 Comparison of dose rates calculated in the modified Snyder head phantom 
using different beam source models for the MIT FCB and a source to 
surface distance of 3.0 cm. Solid lines represent the reference doses 
calculated with the surface source while dashed and dash-dot lines 
represent data for the SDef models with and without φ' dependence, 
respectively. Isodose labels represent a percentage of the maximum dose 
rate in the phantom computed with the surface source for each dose 
component. Error bars (1 σ) in the depth-dose plots are omitted for clarity 
in cases where they are negligibly small. 
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Table 5.1  Error in maximum dose rate for SDef source models compared to the 
surface source reference values for the Snyder ellipsoidal head phantom 
and large rectangular water phantom for source to surface distances of 0 
and 3.0 cm. Uncertainties are 1 σ. 
Source to Surface Distance = 0 cm 
  Head Phantom Large Water Phantom 
Dose Component φ' Uniform φ' Nonuniform φ' Uniform φ' Nonuniform 
Boron 7.4 ± 0.2% 0.3 ± 0.2% 3.7 ± 0.2% 0.4 ± 0.2% 
Thermal neutron 7.4 ± 0.2% 0.3 ± 0.2% 3.7 ± 0.2% 0.4 ± 0.2% 
Fast neutron 4.2 ± 1.1% 2.7 ± 1.1% 2.3 ± 1.1% 1.8 ± 1.1% 
Induced photon 8.1 ± 0.2% 0.1 ± 0.2% 2.5 ± 0.1% 0.3 ± 0.1% 
Incident photon 3.0 ± 2.0% 0.3 ± 2.0% 0.0 ± 2.1% −1.0 ± 2.1% 
Total weighted brain 
dose 7.6 ± 0.2% 0.2 ± 0.2% 3.9 ± 0.1% 0.5 ± 0.1% 
 
Source to Surface Distance = 3.0 cm 
  Head Phantom Large Water Phantom 
Dose Component φ' Uniform φ' Nonuniform φ' Uniform φ' Nonuniform 
Boron 14.9 ± 0.2% 0.3 ± 0.2% 10.7 ± 0.2% −0.1 ± 0.2% 
Thermal neutron 14.9 ± 0.2% 0.3 ± 0.2% 10.6 ± 0.2% −0.1 ± 0.2% 
Fast neutron 10.2 ± 1.2% 0.8 ± 1.2% 9.5 ± 1.2% −0.3 ± 1.2% 
Induced photon 13.5 ± 0.2% 0.5 ± 0.2% 7.9 ± 0.1% 0.1 ± 0.1% 
Incident photon 10.0 ± 2.1% −2.8 ± 2.1% 14.7 ± 2.2% 1.2 ± 2.2% 
Total weighted brain 
dose 15.2 ± 0.2% 0.4 ± 0.2% 10.7 ± 0.1% 0.0 ± 0.1% 
 
 
 
Table 5.2  Mean absolute value of dose error for all voxels receiving ≥ 50% of the 
maximum dose and the error in maximum dose rate for the simple and 
complex SDef source models with nonuniform φ' compared to the surface 
source reference values for the Snyder ellipsoidal head phantom and a 
source to surface distances of 3.0 cm. Uncertainties are 1 σ. 
  Simple SDef Complex SDef 
Dose Component Mean Error Error at Dmax Mean Error Error at Dmax 
Boron 1.6 ± 0.4% 2.2 ± 0.2% 0.4 ± 0.3% 0.3 ± 0.2% 
Thermal neutron 1.6 ± 0.4% 2.0 ± 0.2% 0.4 ± 0.3% 0.3 ± 0.2% 
Fast neutron 2.3 ± 1.7% −1.1 ± 1.2% 2.1 ± 1.7% 0.8 ± 1.2% 
Induced photon 1.4 ± 0.3% 2.0 ± 0.2% 0.4 ± 0.2% 0.5 ± 0.2% 
Incident photon 3.2 ± 2.3% 2.2 ± 2.1% 2.9 ± 2.1% −2.8 ± 2.1% 
Total weighted brain 
dose 1.6 ± 0.5% 2.2 ± 0.2% 0.6 ± 0.4% 0.4 ± 0.2% 
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Figure 5.14 Total biologically weighted brain dose-volume histograms produced by 
simulating the irradiation of the Snyder head phantom (SSD=3.0 cm) with 
the different source representations of the MIT FCB. The time required to 
deliver a maximum brain dose of 12.5 Gyw with the surface source model 
(13.47 minutes) was used to convert to units of absolute dose. Dose 
component scaling factors, derived from calculations with the SDef model 
and standard version of MCNP in large rectangular water phantom 
(column 4 of Table 5.1), were applied to the SDef doses in the head 
phantom to simulate the planning system calibration routinely performed 
at some institutions. The resulting disagreement between the uniform φ' 
SDef and the surface source curves (8.7%, 7.3%, and 11.6% in mean, 
minimum, and maximum brain dose, respectively) illustrates that the 
errors introduced during patient planning by sampling φ' uniformly are not 
corrected by calibrating the planning system in a reference phantom. 
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Table 5.3  Statistical uncertainty (1σ) in percent of the maximum dose rates for 
calculations in the head phantom for a source to surface distance of 3.0 
cm. Each neutron and photon track from the surface source was sampled 
15 times to improve in-phantom dose statistics while the SDef data 
corresponds to 400 million neutrons and photons. 
 Statistical Uncertainty at Dmax (%) 
Dose Component Surface Source SDef 
boron 0.12 0.14 
thermal neutron 0.12 0.14 
fast neutron 1.16 0.44 
induced photon 0.10 0.13 
incident photon 2.07 0.25 
total weighted brain dose 0.15 0.09 
 
 
Table 5.4  Simulation statistics for the transport calculations in the ellipsoidal head 
phantom using the surface source and the complex neutron and photon 
SDefs. The np mode represents a coupled neutron/photon simulation while 
mode p simulates only incident photons. The total number of tracks 
sampled for the surface source is the product of the resampling factor and 
the number of distinct tracks in the surface source file, whereas for the 
SDef it is the number of histories from the MCNP input deck. 
   Number of Number of Total Number  CPU 
Source 
Type 
 
Mode 
Independent 
Histories 
Distinct 
Tracks 
of Tracks 
Sampled 
Resampling 
Factor 
Time 
(CPU h) 
np 2.10 x 107 4.29 x 107 6.44 x 108 15 205.2 Surface 
Source p 1.43 x 107 2.86 x 107 4.29 x 108 15 11.4 
np 4.00 x 108 4.00 x 108 4.00 x 108 --- 122.1 SDef p 4.00 x 108 4.00 x 108 4.00 x 108 --- 12.9 
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5.4 Discussion 
The custom suite of MATLAB scripts used in the SDef construction not only 
greatly expedited the iterative conversion process but also facilitated the analysis of the 
SDef at several intermediate steps to help guide the process towards producing optimal 
coarse region boundaries. Our tool produces source definition files for our two treatment 
planning codes, NCTPlan17,23 and MiMMC,18,19 which use MCNP for dose calculations. 
Other NCT treatment planning systems that use MCNP (e.g., JCDS20) could easily use 
this tool to produce source definitions with little or no modification. Producing source 
definition files for other codes, e.g. SERA, would require only minor modifications to our 
software. Since this tool could easily be applied to other neutron beams, it is available on 
request. 
The preference for outwardly directed particle tracks in the actual source 
distribution produces lower dose rates relative to an SDef with a uniform distribution of 
φ' because outwardly directed particles have a greater tendency to miss the phantom and 
not deposit any energy. Modeling the radial dependence of the relative azimuthal angle in 
MCNP produced significantly better agreement between in-phantom dose rates 
calculated using the surface source and SDef, reducing the error in total biologically 
weighted dose from greater than 15% to less than 1%. Using this modification and the 
sophisticated MATLAB tool to analyze the surface source file and construct the SDef, 
the approximations in source modeling were minimized to result in excellent agreement 
with the dose rates in two different phantoms calculated using the surface source file. 
Using versions of MCNP not modified with the patch described here, the SDef 
source model (uniform φ') and surface source models have both been used at Harvard-
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MIT and elsewhere in clinical treatment planning for NCT.32-34 To some extent, the dose 
error resulting from using a uniform φ' distribution with the standard SDef model can be 
accounted for in planning system calibration by dose rate scaling. However, dose rate 
scaling corrects this problem only approximately since the effect of this error is not 
spatially uniform; i.e., with the planning system tuned to give good agreement on the 
central axis, agreement will be poorer laterally. This adjustment is also phantom-
dependent as seen from Table 5.1, indicating that using a set of simple dose-scaling 
factors to correct for the nonuniform φ' distribution is not viable. In Figure 5.14, a 
difference of 11.6% in the maximum total weighted brain dose was observed between the 
SDef (with uniform φ' distribution) and the surface source even though dose component 
scale factors, derived in the large rectangular water phantom, had been applied to the 
SDef doses. Therefore, calibrating the planning system using measurements in a 
reference phantom will not fully correct the error in the subsequent dose calculations in a 
patient. Within this framework, the correct solution is to accurately model the φ' 
distribution using a patched version of MCNP or a surface source file 
The two NCT treatment planning systems developed at Idaho National Lab (INL), 
BNCT_Rtpe (BNCT Radiation Therapy Planning Environment)35 and its successor 
SERA (Simulated Environment for Radiotherapy Applications),36 use special-purpose 
Monte Carlo transport codes that require the neutron and photon sources to be defined as 
probability distributions. For these codes to determine each source particle’s starting 
direction, the polar angle θ is sampled from up to 10 user-defined equiprobable angular 
bins, and then the relative azimuthal angle φ' is sampled uniformly from –π to +π. Thus, 
if the actual φ' distribution is not uniformly distributed as for the MIT FCB, errors for in-
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phantom dose rates similar to those reported in this chapter using the standard unpatched 
version of MCNP might be expected with BNCT_Rtpe and SERA. However, a different 
modeling approach is generally used in these codes that may, at least to some extent, 
avoid the problem observed here with the angular distribution. For example, in the 
clinical trials of BNCT at Brookhaven National Laboratory, the Brookhaven Medical 
Research Reactor (BMRR) was modeled in BNCT_Rtpe in the 15 cm thick beam 
collimator 13.3 cm upstream of the beam aperture and not directly at the beam aperture 
plane as for the MIT FCB.37,38 Requiring BNCT_Rtpe to transport the sampled source 
particles through the collimator for each planning calculation may help to define the 
neutron and photon angular and spatial distribution at the beam exit, thus likely reducing 
errors due to a nonuniform φ' distribution like those observed in the simulations reported 
here. In this chapter we have not studied the question of whether specifying a simple (flat 
radial distribution and uniform φ' distribution) source inside the collimator upstream of 
the exit will provide adequate accuracy for the spatial and angular distributions at the 
beam exit and, more importantly, good dosimetric accuracy in-phantom. Clearly, this is a 
topic that warrants further study. 
The coupled neutron/photon simulation using the surface source took 68% longer 
to run, only to produce larger uncertainties for the fast neutrons and uncertainties of 
comparable magnitude for the other neutron dose components. However, it should be 
noted that the number of histories simulated for each source type was much larger than 
would be needed clinically. Simulating more particle tracks was necessary for this 
analysis to reduce the statistical uncertainty for the fast neutron and incident photon dose 
components. This also made it easier to assess small differences in in-phantom doses 
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between the different source models. Nevertheless, given that the standard deviations 
varies inversely with the square root of the number of sampled tracks, the surface source 
would need to be run factors of 1.2, 7.0, 1.1 and 69 times longer to achieve levels of 
uncertainty in the boron, fast neutron, induced photon and incident photon dose rates, 
respectively, comparable to those in the SDef run. For the boron and induced photon dose 
rates, this could be achieved by further increasing the resampling factor for the surface 
source to beyond 15. However, to further decrease uncertainty in the fast neutron and 
incident photon dose components, the upstream simulation of the neutron beam line 
would need to be run longer to produce more track information in the surface source file, 
which would then lead to issues regarding the size (~400 GB) of the resulting surface 
source file and the length of the simulation needed to produce it (~67 CPU years on our 
cluster).  
As demonstrated here, surface source files and SDefs offer both advantages and 
disadvantages as methods of defining a neutron beam for NCT treatment planning. While 
surface source files introduce no significant approximations into the source definition and 
can potentially provide “built-in” variance reduction for subsequent simulations, 
limitations on dose precision, lower computational efficiency, especially for parallel 
computations, and the large size of the unportable binary files are significant drawbacks. 
While SDefs do not suffer from any of these same disadvantages and also provide greater 
source transparency as well as more flexibility in variance reduction, constructing a SDef 
source model can potentially involve significant approximations that would significantly 
reduce the accuracy of the calculated doses. However, using the tools outlined in this 
chapter, the approximations in the SDef construction process were limited so as to 
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provide excellent agreement with the surface source and thus physical dosimetry 
measurements of the FCB.  
In this chapter, the Monte Carlo model of the FCB epithermal neutron beam, as 
realized through a detailed surface source file, was employed as the reference standard 
for comparison with the SDef models. The accuracy of a computational model depends 
on the physics model as well as the cross sections and the fidelity of the model geometry 
and composition to the real world. The Monte Carlo model of the MIT research reactor 
and FCB is very detailed and has been well-validated with dose measurements in-air and 
in phantoms.23,24,39 Therefore, the FCB surface source model was used as the reference 
because the level of resolution and detail in the neutron spatial, energy, and angular 
probability distributions that can obtained through a Monte Carlo simulation far exceeds 
what is attainable with measurements.40-43 Moreover, it is generally only the marginal 
distribution for a given source variable that is obtained with measurements whereas the 
joint probability distribution is only determined by calculation. Furthermore, these 
findings indicate that a high level of detail regarding the beam’s spectral characteristics is 
required to construct an adequately accurate model of the neutron beam from probability 
distributions and obtain accurate dose calculations throughout the phantom.  
The modification of the MCNP5 source code to enable simulation of angular 
distributions with nonuniform relative azimuthal angles has broader applications than 
those outlined in this work. Essentially, any attempt to model a radiation source with a 
significantly nonuniform relative azimuthal angle distribution will produce errors unless 
that non-uniformity is modeled in the transport calculations. The adjustments to the 
MCNP5 source introduced in here could easily be extended and/or tuned to the needs of a 
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particular transport problem. We expect it may be directly applicable to situations like 
computed tomography (CT) dosimetry and applications with circular collimators (e.g., 
stereotactic radiosurgery or Cyberknife). 
5.5 Conclusions 
A software tool has been developed to convert MCNP surface source models into 
MCNP SDefs. The surface source model of the MIT FCB was successfully converted 
into a MCNP SDef, which produced very good agreement with in-phantom dose rates 
calculated using the well-benchmarked surface source model. However, achieving such 
agreement required modifications to the MCNP source code to allow the nonuniform φ' 
distribution for the FCB to be accurately modeled. Using a surface source file or a 
modified version of MCNP is the only way to accurately model the nonuniform φ' 
distribution since the errors introduced by sampling φ' uniformly are phantom-dependent 
and thus cannot be corrected using a set of dose-scaling factors. The conversion process, 
as well as the software suite used, could be easily employed for other neutron beams. 
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CHAPTER SIX 
Summary, Conclusions and 
Recommendations for Future 
Work 
6.1 Summary and Conclusions 
Accurate and efficient treatment planning calculations are essential to maximizing 
the efficacy of Boron Neutron Capture Therapy (BNCT) and ensuring the safety of the 
patient. Therefore, this thesis has explored many of the computational aspects of BNCT 
treatment planning with the aim of improving both the accuracy and efficiency of the 
planning process. This thesis also sought to develop a better understanding of differences 
in computational dosimetry that exist between BNCT clinical sites to help address the 
obstacles that prevent pooling of clinical data for combined analysis. 
6.1.1 Intercomparison of Neutron Capture Therapy Treatment Planning Systems 
A suite of computational dosimetry reference problems were developed to test, 
compare, and analyze current and future BNCT treatment planning systems under 
conditions relevant to both patient planning and planning system calibration. These 
reference problems were based on an pre-existing set1 of problems which was greatly 
expanded to include multiple phantoms (a large rectangular water phantom, the modified 
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Snyder head phantom,2 and a cylindrical leg phantom), thermal and epithermal neutron 
beam spectra, and the multi-dimensional dose data (isodose contours and dose-volume 
histograms) that are commonly used in treatment planning. While the head and leg 
phantoms are meant to represent the different human anatomy that has been irradiated 
during BNCT, the large rectangular water phantom was included because it is used in 
planning system calibration at some institutions and its simple geometry can be 
represented by all of the planning systems without any geometric approximations. Using 
these newly designed reference problems, 4 of the treatment planning systems (TPSs) 
that have been used clinically (BNCT_Rtpe,3-5 SERA,6,7 MacNCTPlan,8,9 and 
NCTPlan.10,11) were compared to reference dosimetry calculations performed using the 
well-benchmarked Monte Carlo radiation transport code, MCNP5.12 These reference 
calculations made use of analytical representations of the 3 phantoms as well as and the 
most up-to-date neutron and photon cross sections, material compositions, and kerma 
factors available to ensure that the reference data were not adversely influenced by 
geometric approximations or inaccurate transport calculations. The resulting comparison 
of the reference dose data to that directly output by each TPS resulted in many clinically 
significant and interesting differences, and additional effort was focused on 
understanding and explaining the causes of the observed disagreement.  
Each of the planning systems deviated significantly from the reference 
calculations, with SERA and NCTPlan generally producing better agreement than their 
respective predecessors, BNCT_Rtpe and MacNCTPlan. For BNCT_Rtpe and SERA, the 
deviations from the reference calculations observed in the depth-dose profiles were 
resolved into the following factors:  differences in calculated neutron or photon flux 
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(which result from differences in physics models, transport algorithms, and cross section 
data), interpolation errors, differences in kerma factors, the improper runtime 
multiplication of neutron and boron kerma factors by the edit mesh density, differences in 
dose definition, a biasing and cutoff energy for the fast neutron source biasing run mode 
that is too high, and a photon normalization error. Conversely, the observed disagreement 
for MacNCTPlan and NCTPlan was usually easier to resolve into contributing factors 
and was most often attributed to a characteristic interpolation error discovered in both 
TPSs and the geometric approximations associated with relatively large 1 cm3 voxel 
models. During the intercomparison, it became increasingly clear, especially in the leg 
phantom where a thermal neutron beam is used, that the 1 cm3 volumes are insufficient 
for use in either a scoring mesh or a voxel model. Smaller volumes should be used to 
improve dose calculation and geometric modeling accuracy. Furthermore, the differences 
observed between the TPSs are an example of the obstacles that prevent patient data from 
different clinical sites from being combined; doses reported by clinical sites that have 
used different TPSs cannot be legitimately combined until those obstacles are properly 
addressed by developing a better understanding of the magnitudes and causes of the 
differences between the planning systems. This study has done much towards resolving 
these issues. 
6.1.2 Comparison of Doses Delivered in Clinical Trials of Neutron Capture 
Therapy in the USA 
Once differences in physical and computational dosimetry are adequately 
addressed, clinical data from different sites can indeed be pooled together as was 
successfully done for clinical data from BNL (Brookhaven National Laboratory) and 
Harvard-MIT (Massachusetts Institute of Technology). To accomplish that, a relationship 
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between BNL and Harvard-MIT clinical dosimetry was determined and validated using 
MIT physical dosimetry measurements made at BNL in two different phantoms as part of 
the International Dosimetry Exchange.13,14 This relationship was used to recompute the 
BNL patients’ dosimetry, normalizing it to the Harvard-MIT clinical dosimetry. This 
relationship (in the form of dose component scaling factors) was further resolved into 
several contributing factors. Differences in physical dosimetry techniques between BNL 
and Harvard-MIT, the presence of a subtle geometric modeling error in BNL’s 
calibration calculations, and small differences between BNL's measurements and 
calibration calculations combined to lower the reported BNL patient doses significantly. 
The reductions in mean brain doses averaged 10% in the initial 15 patients treated with 
the 8 cm collimator, 28% for the 23 patients treated with the 12 cm collimator before the 
fuel shuffle, and 25% for the final 16 patients treated after the fuel shuffle. This 
adjustment enabled the BNL clinical data to be legitimately pooled together with 
Harvard-MIT patient data for a dose response analysis for radiation-induced somnolence 
syndrome. Probit analysis of the composite data set yielded ED50 values for the incidence 
of somnolence of 5.76 Gyw and 14.4 Gyw for mean and maximum brain dose, 
respectively. As a direct result of the increased sample size of the larger patient pool, the 
confidence intervals of the ED50 values were narrowed significantly. Also, the 
adjustments to the BNL patient doses reduced the ED50 for the mean brain dose of the 
BNL patients alone by 26%. The reductions in the reported doses from the BNL clinical 
trials are clinically significant and have important implications for those within the NCT 
community relying on the BNL clinical data to choose initial doses in clinical trials of 
BNCT. Furthermore, these findings should provide strong motivation for all institutions 
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undertaking human BNCT clinical trials to participate in dosimetric intercomparisons 
like the International Dosimetry Exchange.13,14 
6.1.3 Application of Variance Reduction in Monte Carlo Treatment Planning 
Calculations for Neutron Capture Therapy 
 The energy dependent neutron and photon weight windows used in the detailed 
Monte Carlo computations of the MIT fission converter beam (FCB)15 were optimized to 
produce a surface source file at the patient position with significantly less duplicate track 
information that resulted in a 9-fold increase in the mean computationally efficiency of 
the subsequent in-phantom total weighted dose calculations and a very large, 200-fold 
decrease in the size of the binary file (34 GB vs. 0.17 GB) for the same number of 
starting histories. Problems in the incident photon dose distribution (streak artifacts of 
high dose and large uncertainty) associated with high weight tracks were also corrected. 
The Beowulf cluster (described in Appendix B and constructed to facilitate the work in 
this thesis) was used for simulations with the optimized weight windows to increase the 
unique track information reaching the patient position and result in a more accurate 
surface source representation. The new MCNP surface source representation of the FCB 
was successfully validated using physical dosimetry measurements.16,17  
 Several of the variance reduction techniques available in MCNP were also 
investigated in an attempt to increase the computational efficiency of in-phantom dose 
calculations for BNCT treatment planning using calculations in an NCTPlan voxel model 
of the Snyder head phantom. The efficiency and accuracy of dose calculations in the head 
phantom with different variance reduction techniques were compared to a baseline 
simulation with the default MCNP variance reduction (implicit capture and weight 
cutoff). By combining both fast neutron source biasing and photon production biasing 
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and disabling implicit neutron capture, the mean computational efficiency of the total 
weighted brain dose calculations in the phantom voxel model was increased by a factor 
of 2.2, meaning that by using these techniques the same level of precision for the total 
weighted dose could be achieved in less than half the runtime. 
6.1.4 Neutron Beam Source Definition Techniques for Neutron Capture Therapy 
Treatment Planning 
 Two methods of neutron beam source definition commonly used in BNCT 
treatment planning calculations (MCNP surface source and MCNP SDef) were 
compared. A surface source is a binary file that contains exact track characteristics, such 
as position, direction, energy, and (statistical) weight of all particle histories at a given 
position in the treatment geometry, and the tracks from this file are sampled in 
subsequent simulations of particle transport through the patient geometry. The radiation 
source can also be defined by detailed probability distributions (via the SDef card) that 
describe the spatial, energy and angular characteristics of the beam. These two techniques 
were compared by simulating transport through a 4 mm3 voxel model of the modified 
Snyder head phantom. To facilitate the comparison, a software tool (called ss2sdef) was 
developed to analyze MCNP surface source files and construct MCNP SDef source 
probability models. A novel feature of this software tool is the analysis of the separability 
of different source variable probability distributions. Since it is the marginal distributions 
of the source variables that are sampled to determine source particle characteristics, the 
software tool allows evaluation of how well the product of the marginal probability 
distributions for two source variables (e.g., energy and polar angle) approximate the 
actual joint distribution of the source variables through comparison and error plots. This 
feature, especially the error plots, greatly facilitates selection of boundaries for 
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segmenting the phase space to improve the fidelity of the source representation. This 
software suite was used to analyze the surface source model of the MIT FCB and 
construct a SDef representation. The analysis of the FCB surface source showed that the 
source variables are, to a large degree, inseparable and that a high degree of segmentation 
of the source phase space (e.g., 252 regions) is needed to obtain an accurate 
representation of the source for treatment planning. When compared to dose calculations 
in the head phantom with the surface source file, the SDef produced significant errors 
(e.g., 15.2% at Dmax). Using a patched version of MCNP5 that allowed the observed 
radial dependence of the relative azimuthal angle to be modeled by the SDef, errors in all 
dose components in the head phantom at Dmax were reduced to acceptably small levels 
with none being statistically significant (P ≥ 0.13) except for the 0.5% error in the 
induced photon dose. Therefore, it was concluded that a modified version of MCNP or a 
surface source file is required to accurately model the neutron and photon angular 
distributions since the errors introduced by using a uniform distribution for the relative 
azimuthal angle vary spatially, are phantom-dependent, and thus cannot be corrected 
using a set of dose-scaling factors.  
6.2 Future Work 
The evaluation of the 4 planning systems with the reference data produced results 
that were sometimes alarming. These results provide a compelling argument that 
improved quality assurance is needed for NCT treatment planning systems. The suite of 
test problems developed here could play an important role assessing the other existing 
and future planning systems. A primary goal during the development and application of 
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the suite of reference dosimetry calculations was to facilitate the inclusion of other 
BNCT treatment planning systems as they become available or are developed in the 
future. Other planning systems, such as JCDS,18,19 THORplan,20 and MiMMC,21 could 
easily be included in the intercomparison. Also, now that a basic understanding of how 
the planning systems compare has been developed, the reference problems could be 
extended to include more realistic beams and phantoms based on human image data. 
Also, calculations of dose using electron transport should be included (if a reliable 
computational tool can be found for the coupled neutron-photon-electron dose 
calculations) as part of the reference calculations to properly evaluate the accuracy of 
estimating dose with kerma, especially near the patient surface. 
MIT has made dose measurements in 8 of the 11 neutron beams recently used for 
clinical BNCT with a standard dosimetric approach as part of the International Dosimetry 
Exchange.13,14 This wealth of measurement data provides the basis necessary to address 
differences in physical and computational dosimetry and pool patient data from other 
clinical sites with that from BNL and Harvard-MIT. Analysis of the head phantom 
measurement22 and calculation data for the Treatment Planning Exchange should 
continue. It was analysis of this data for BNL that lead to the detailed dosimetric analysis 
of Chapter 3. 
The variance reduction techniques investigated using the generic epithermal 
neutron beam1 and head phantom should be assessed in a clinical beam, like the surface 
source and SDef representations of the FCB, to ensure that the significant increases in the 
computational efficiency of dose calculations transcend any specific beam or irradiation 
conditions. It should also be possible to partially or fully apply the variance reduction 
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techniques that increased computational efficiency (fast neutron source biasing, photon 
production biasing, disabling implicit capture) to other treatment planning systems, like 
SERA. 
In Chapter 5, two methods of neutron beam source definition were investigated, 
surface source files and SDef probability distributions. As used in NCTPlan, both 
methods locate planar sources in air a short distance from the patient. With the SDef 
representation, a large and rather complicated set of probability distributions is needed to 
accurately model the source. The two INL (Idaho National Laboratory) treatment 
planning systems, BNCT_Rtpe and SERA, take a different approach. In addition to the 
patient, they include part of the collimator in the computational model and sample a 
relatively simple set of source probability distributions inside the collimator to define the 
source. Transporting particles from a source plane through the collimator for each 
planning calculation may help to define the neutron and photon angular and spatial 
distributions at the beam exit and therefore reduce errors due to inaccurately modeling 
the source. The accuracy of this technique should be evaluated, especially for the short 
(e.g., 5 cm) thicknesses of collimator sometimes used in models. The tools developed in 
Chapter 5 would greatly facilitate this analysis and could be easily be adapted, as needed, 
to work with other TPSs.  
Also, further work should be performed to get the patch to MCNP5 that was 
developed to allow the neutron and photon angular distributions to be accurately modeled 
incorporated into standard MCNP. The patch is essential to being able to accurately 
model the FCB with SDef probability distributions, and therefore it is likely to be 
beneficial to other groups within the NCT community. However, it could also be 
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extended to apply to other transport problems, such as computed tomography (CT) 
dosimetry and applications with circular collimators (e.g., stereotactic radiosurgery or 
Cyberknife). 
 This thesis has provided various observations of BNCT treatment planning that 
could be used to improve the MiMMC21 treatment planning system that is currently being 
developed to overcome many of the limitations of NCTPlan. MiMMC provides a unique 
platform to test and incorporate new features into the treatment planning process, and its 
open source licensing also provides a level of transparency that facilitates more rapid 
development and code review than otherwise possible. Given the small group usually 
responsible for the development and testing of BNCT treatment planning systems, 
openness is important as it prevents spending valuable manpower implementing and 
testing features that already exist. Therefore, it is believed that MiMMC may represent a 
positive step forward towards more standardized BNCT computational dosimetry. 
Drawing from the overall experience of this thesis work and extrapolating to the future, it 
is believed that BNCT treatment planning would benefit greatly from some basic level of 
standardization since many of the significant differences that currently exist between the 
planning systems could have been prevented if such standardization had existed during 
their respective development and testing. An appropriate starting point for 
standardization would be acceptance of a common set of kerma factors and dose 
definitions.  
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APPENDIX A 
Reference Data for Neutron 
Capture Therapy Treatment 
Planning Systems 
A.1 Introduction 
The complete set of reference data described in Chapter 2 is included here. For 
the large rectangular water phantom, ellipsoidal head phantom, and leg phantom, relevant 
dose data are displayed from each planning system (BNCT_Rtpe, SERA, MacNCTPlan 
and NCTPlan) and compared to the corresponding reference data (MCNP5 and post-
processing by MATLAB). For the head phantom, both single and multi-field data are 
included. The data are grouped by type: dose vs. depth profiles along the central beam 
axis, isodose contours and dose difference distributions for orthogonal beam planes, and 
dose-volume histograms for the relevant anatomical structures in the phantom. Within 
each type, the data are further organized by dose component: thermal neutron flux, boron 
dose, thermal neutron (and nitrogen) dose, fast neutron (and hydrogen) dose, induced 
photon dose, incident photon dose, and total biologically weighted dose. 
The calculated data in the large water and ellipsoidal head phantoms were 
produced by simulating a monodirectional generic epithermal neutron beam, 10 cm in 
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diameter, normalized to a neutron flux of 1×1010 n/cm2s. For the leg phantom, the 
simulated neutron source was a monodirectional thermal neutron beam 10 cm in diameter 
normalized to a neutron flux of 1×1010 n/cm2s. The simulated photon source for all 3 
phantoms was a 2.0 MeV monoenergetic and monodirectional 10 cm diameter disc 
source normalized to a flux of 2×108 γ/cm2s. 
To facilitate the direct comparison of isodose contours between each treatment 
planning system and the reference, the contours were plotted in units of absolute dose 
rather than as a percentage of a reference dose. In order to calculate dose, treatment times 
for each planning system were calculated based on realistic BNCT dose prescriptions for 
each phantom type: a maximum brain dose of 12.5 Gyw for the head phantom and a 
minimum tumor dose of 24 Gyw for the leg phantom. The resulting treatment times for 
each planning system and the reference are shown in Table A.1. Similarly, plotting the 
dose-volume data from each TPS as percent volume vs. percent of the reference dose 
would have made a direct comparison difficult since the reference doses were different 
for each TPS. So, using the reference treatment times from Table A.1, the dose-volume 
data from each TPS and the reference were plotted as percent volume vs. absolute dose.  
Table A.1 Treatment time in minutes required to deliver a maximum brain dose of 
12.5 Gyw for the head phantom or a minimum tumor dose of 24 Gyw for 
the leg phantom. 
 Head Phantom  Leg Phantom 
 1 field 3 fields  1 field 
Reference 3.16 5.66  1.38 
BNCT_Rtpe 2.99 5.35  1.25 
SERA 3.04 5.48  1.28 
MacNCTPlan 3.34 6.01  1.18 
NCTPlan 3.33 6.01  1.43 
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A.2 Dose vs. Depth Profiles 
A.2.1 Large Rectangular Water Phantom 
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Figure A.1 Thermal neutron flux and percent difference (100×[TPS−Ref]/Refmax) as a 
function of depth along the central beam axis in the large rectangular 
water phantom for each planning system. SERA and BNCT_Rtpe data are 
calculated at (default) intervals of 5 mm. MCNP5 served as the reference 
for percent difference calculations. 
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Figure A.2 Boron dose rate for a 10B concentration of 15 μg/g and percent difference 
(100×[TPS−Ref]/Refmax) as a function of depth along the central beam 
axis in the large rectangular water phantom for each planning system. 
MCNP5 served as the reference for percent difference calculations. 
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Figure A.3 Thermal neutron (and nitrogen) dose rate and percent difference 
(100×[TPS−Ref]/Refmax) as a function of depth along the central beam 
axis in the large rectangular water phantom for each planning system. 
MCNP5 served as the reference for percent difference calculations. 
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Figure A.4 Fast neutron (and hydrogen) dose rate and percent difference 
(100×[TPS−Ref]/Refmax) as a function of depth along the central beam 
axis in the large rectangular water phantom for each planning system. 
MCNP5 served as the reference for percent difference calculations. 
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Figure A.5 Induced photon dose rate and percent difference (100×[TPS−Ref]/Refmax) 
as a function of depth along the central beam axis in the large rectangular 
water phantom for each planning system. MCNP5 served as the reference 
for percent difference calculations. 
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Figure A.6 Incident photon dose rate and percent difference (100×[TPS−Ref]/Refmax) 
as a function of depth along the central beam axis in the large rectangular 
water phantom for each planning system. MCNP5 served as the reference 
for percent difference calculations. 
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Figure A.7 Total biologically weighted brain dose rate and percent difference 
(100×[TPS−Ref]/Refmax) as a function of depth along the central beam 
axis in the large rectangular water phantom for each planning system. 
MCNP5 served as the reference for percent difference calculations. 
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Figure A.8 Total biologically weighted tumor dose rate and percent difference 
(100×[TPS−Ref]/Refmax) as a function of depth along the central beam 
axis in the large rectangular water phantom for each planning system. 
MCNP5 served as the reference for percent difference calculations. 
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A.2.2 Head Phantom 
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Figure A.9 Thermal neutron flux and percent difference (100×[TPS−Ref]/Refmax) as a 
function of depth along the central beam axis in the ellipsoidal head 
phantom for each planning system. SERA and BNCT_Rtpe data are 
calculated at (default) intervals of 5 mm. MCNP5 served as the reference 
for percent difference calculations. 
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Figure A.10 Boron dose rate for a 10B concentration of 15 μg/g and percent difference 
(100×[TPS−Ref]/Refmax) as a function of depth along the central beam 
axis in the ellipsoidal head phantom for each planning system. MCNP5 
served as the reference for percent difference calculations. 
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Figure A.11 Thermal neutron (and nitrogen) dose rate and percent difference 
(100×[TPS−Ref]/Refmax) as a function of depth along the central beam 
axis in the ellipsoidal head phantom for each planning system. MCNP5 
served as the reference for percent difference calculations. 
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Figure A.12 Fast neutron (and hydrogen) dose rate and percent difference 
(100×[TPS−Ref]/Refmax) as a function of depth along the central beam 
axis in the ellipsoidal head phantom for each planning system. MCNP5 
served as the reference for percent difference calculations. 
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Figure A.13 Induced photon dose rate and percent difference (100×[TPS−Ref]/Refmax) 
as a function of depth along the central beam axis in the ellipsoidal head 
phantom for each planning system. MCNP5 served as the reference for 
percent difference calculations. 
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Figure A.14 Incident photon dose rate and percent difference (100×[TPS−Ref]/Refmax) 
as a function of depth along the central beam axis in the ellipsoidal head 
phantom for each planning system. MCNP5 served as the reference for 
percent difference calculations. 
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Figure A.15 Total biologically weighted brain dose rate and percent difference 
(100×[TPS−Ref]/Refmax) as a function of depth along the central beam 
axis in the ellipsoidal head phantom for each planning system. MCNP5 
served as the reference for percent difference calculations. 
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Figure A.16 Total biologically weighted tumor dose rate and percent difference 
(100×[TPS−Ref]/Refmax) as a function of depth along the central beam 
axis in the ellipsoidal head phantom for each planning system. MCNP5 
served as the reference for percent difference calculations. 
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A.2.3 Leg Phantom 
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Figure A.17 Thermal neutron flux and percent difference (100×[TPS−Ref]/Refmax) as a 
function of depth along the central beam axis in the leg phantom for each 
planning system. SERA and BNCT_Rtpe data are calculated at (default) 
intervals of 5 mm. MCNP5 served as the reference for percent difference 
calculations. 
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Figure A.18 Boron dose rate for a 10B concentration of 22.5 μg/g and percent 
difference (100×[TPS−Ref]/Refmax) as a function of depth along the 
central beam axis in the leg phantom for each planning system. MCNP5 
served as the reference for percent difference calculations. 
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Figure A.19 Thermal neutron (and nitrogen) dose rate and percent difference 
(100×[TPS−Ref]/Refmax) as a function of depth along the central beam 
axis in the leg phantom for each planning system. MCNP5 served as the 
reference for percent difference calculations. 
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Figure A.20 Fast neutron (and hydrogen) dose rate and percent difference 
(100×[TPS−Ref]/Refmax) as a function of depth along the central beam 
axis in the leg phantom for each planning system. MCNP5 served as the 
reference for percent difference calculations. 
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Figure A.21 Induced photon dose rate and percent difference (100×[TPS−Ref]/Refmax) 
as a function of depth along the central beam axis in the leg phantom for 
each planning system. MCNP5 served as the reference for percent 
difference calculations. 
 
 
Computational Aspects of Treatment Planning for Neutron Capture Therapy 
 496
−1 0 1 2 3 4 5 6 7 8
0
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
0.09
Incident Photon Dose Rate (Leg Phantom)
Depth in Leg Phantom (cm)
D
os
e 
R
at
e 
(G
y/
m
in
)
MCNP5
BNCT_Rtpe
SERA
MacNCTPlan
NCTPlan
−1 0 1 2 3 4 5 6 7 8
−6
−4
−2
0
2
4
6
Depth in Leg Phantom (cm)
P
er
ce
nt
 D
iff
er
en
ce
BNCT_Rtpe
SERA
MacNCTPlan
NCTPlan
 
Figure A.22 Incident photon dose rate and percent difference (100×[TPS−Ref]/Refmax) 
as a function of depth along the central beam axis in the leg phantom for 
each planning system. MCNP5 served as the reference for percent 
difference calculations. 
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Figure A.23 Total biologically weighted skin dose rate and percent difference 
(100×[TPS−Ref]/Refmax) as a function of depth along the central beam 
axis in the leg phantom for each planning system. MCNP5 served as the 
reference for percent difference calculations. 
 
 
Computational Aspects of Treatment Planning for Neutron Capture Therapy 
 498
−1 0 1 2 3 4 5 6 7 8
0
5
10
15
20
25
30
Total Biologically Weighted Tumor Dose Rate (Leg Phantom)
Depth in Leg Phantom (cm)
D
os
e 
R
at
e 
(G
y w
/m
in
)
MCNP5
BNCT_Rtpe
SERA
MacNCTPlan
NCTPlan
−1 0 1 2 3 4 5 6 7 8
−20
−15
−10
−5
0
5
10
15
Depth in Leg Phantom (cm)
P
er
ce
nt
 D
iff
er
en
ce
BNCT_Rtpe
SERA
MacNCTPlan
NCTPlan
 
Figure A.24 Total biologically weighted tumor dose rate and percent difference 
(100×[TPS−Ref]/Refmax) as a function of depth along the central beam 
axis in the leg phantom for each planning system. MCNP5 served as the 
reference for percent difference calculations. 
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Figure A.25 Boron isodose contours for a 10B concentration of 15 μg/g in the 
transverse plane containing the central beam axis for a 1-field irradiation 
of the head phantom. Each planning system’s contours (solid) are overlaid 
with the reference contours (dashed) after the treatment time for each 
planning system from Table A.1 was used to convert the reference dose 
rates to absolute dose. 
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Figure A.26 Boron isodose contours for a 10B concentration of 15 μg/g in the coronal 
plane containing the central beam axis for a 1-field irradiation of the head 
phantom. Each planning system’s contours (solid) are overlaid with the 
reference contours (dashed) after the treatment time for each planning 
system from Table A.1 was used to convert the reference dose rates to 
absolute dose. 
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Figure A.27 Thermal neutron (and nitrogen) isodose contours in the transverse plane 
containing the central beam axis for a 1-field irradiation of the head 
phantom. Each planning system’s contours (solid) are overlaid with the 
reference contours (dashed) after the treatment time for each planning 
system from Table A.1 was used to convert the reference dose rates to 
absolute dose. 
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Figure A.28 Thermal neutron (and nitrogen) isodose contours in the coronal plane 
containing the central beam axis for a 1-field irradiation of the head 
phantom. Each planning system’s contours (solid) are overlaid with the 
reference contours (dashed) after the treatment time for each planning 
system from Table A.1 was used to convert the reference dose rates to 
absolute dose. 
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Figure A.29 Fast neutron (and hydrogen) isodose contours in the transverse plane 
containing the central beam axis for a 1-field irradiation of the head 
phantom. Each planning system’s contours (solid) are overlaid with the 
reference contours (dashed) after the treatment time for each planning 
system from Table A.1 was used to convert the reference dose rates to 
absolute dose. 
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Figure A.30 Fast neutron (and hydrogen) isodose contours in the coronal plane 
containing the central beam axis for a 1-field irradiation of the head 
phantom. Each planning system’s contours (solid) are overlaid with the 
reference contours (dashed) after the treatment time for each planning 
system from Table A.1 was used to convert the reference dose rates to 
absolute dose. 
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Figure A.31 Induced photon isodose contours in the transverse plane containing the 
central beam axis for a 1-field irradiation of the head phantom. Each 
planning system’s contours (solid) are overlaid with the reference 
contours (dashed) after the treatment time for each planning system from 
Table A.1 was used to convert the reference dose rates to absolute dose. 
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Figure A.32 Induced photon isodose contours in the coronal plane containing the 
central beam axis for a 1-field irradiation of the head phantom. Each 
planning system’s contours (solid) are overlaid with the reference 
contours (dashed) after the treatment time for each planning system from 
Table A.1 was used to convert the reference dose rates to absolute dose. 
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Figure A.33 Incident photon isodose contours in the transverse plane containing the 
central beam axis for a 1-field irradiation of the head phantom. Each 
planning system’s contours (solid) are overlaid with the reference 
contours (dashed) after the treatment time for each planning system from 
Table A.1 was used to convert the reference dose rates to absolute dose. 
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Figure A.34 Incident photon isodose contours in the coronal plane containing the 
central beam axis for a 1-field irradiation of the head phantom. Each 
planning system’s contours (solid) are overlaid with the reference 
contours (dashed) after the treatment time for each planning system from 
Table A.1 was used to convert the reference dose rates to absolute dose. 
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Figure A.35 Total biologically weighted brain isodose contours in the transverse plane 
containing the central beam axis for a 1-field irradiation of the head 
phantom. Each planning system’s contours (solid) are overlaid with the 
reference contours (dashed) after the treatment time for each planning 
system from Table A.1 was used to convert the reference dose rates to 
absolute dose. 
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Figure A.36 Total biologically weighted brain isodose contours in the coronal plane 
containing the central beam axis for a 1-field irradiation of the head 
phantom. Each planning system’s contours (solid) are overlaid with the 
reference contours (dashed) after the treatment time for each planning 
system from Table A.1 was used to convert the reference dose rates to 
absolute dose. 
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Figure A.37 Total biologically weighted tumor isodose contours in the transverse plane 
containing the central beam axis for a 1-field irradiation of the head 
phantom. Each planning system’s contours (solid) are overlaid with the 
reference contours (dashed) after the treatment time for each planning 
system from Table A.1 was used to convert the reference dose rates to 
absolute dose. 
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Figure A.38 Total biologically weighted tumor isodose contours in the coronal plane 
containing the central beam axis for a 1-field irradiation of the head 
phantom. Each planning system’s contours (solid) are overlaid with the 
reference contours (dashed) after the treatment time for each planning 
system from Table A.1 was used to convert the reference dose rates to 
absolute dose. 
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Figure A.39 Boron isodose contours for a 10B concentration of 15 μg/g in the 
transverse plane containing the central beam axis for a 3-field irradiation 
of the head phantom. Each planning system’s contours (solid) are overlaid 
with the reference contours (dashed) after the treatment time for each 
planning system from Table A.1 was used to convert the reference dose 
rates to absolute dose. 
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Figure A.40 Boron isodose contours for a 10B concentration of 15 μg/g in the coronal 
plane containing the central beam axis for a 3-field irradiation of the head 
phantom. Each planning system’s contours (solid) are overlaid with the 
reference contours (dashed) after the treatment time for each planning 
system from Table A.1 was used to convert the reference dose rates to 
absolute dose. 
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Figure A.41 Thermal neutron (and nitrogen) isodose contours in the transverse plane 
containing the central beam axis for a 3-field irradiation of the head 
phantom. Each planning system’s contours (solid) are overlaid with the 
reference contours (dashed) after the treatment time for each planning 
system from Table A.1 was used to convert the reference dose rates to 
absolute dose. 
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Figure A.42 Thermal neutron (and nitrogen) isodose contours in the coronal plane 
containing the central beam axis for a 3-field irradiation of the head 
phantom. Each planning system’s contours (solid) are overlaid with the 
reference contours (dashed) after the treatment time for each planning 
system from Table A.1 was used to convert the reference dose rates to 
absolute dose. 
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Figure A.43 Fast neutron (and hydrogen) isodose contours in the transverse plane 
containing the central beam axis for a 3-field irradiation of the head 
phantom. Each planning system’s contours (solid) are overlaid with the 
reference contours (dashed) after the treatment time for each planning 
system from Table A.1 was used to convert the reference dose rates to 
absolute dose. 
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Figure A.44 Fast neutron (and hydrogen) isodose contours in the coronal plane 
containing the central beam axis for a 3-field irradiation of the head 
phantom. Each planning system’s contours (solid) are overlaid with the 
reference contours (dashed) after the treatment time for each planning 
system from Table A.1 was used to convert the reference dose rates to 
absolute dose. 
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Figure A.45 Induced photon isodose contours in the transverse plane containing the 
central beam axis for a 3-field irradiation of the head phantom. Each 
planning system’s contours (solid) are overlaid with the reference 
contours (dashed) after the treatment time for each planning system from 
Table A.1 was used to convert the reference dose rates to absolute dose. 
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Figure A.46 Induced photon isodose contours in the coronal plane containing the 
central beam axis for a 3-field irradiation of the head phantom. Each 
planning system’s contours (solid) are overlaid with the reference 
contours (dashed) after the treatment time for each planning system from 
Table A.1 was used to convert the reference dose rates to absolute dose. 
 
 
 
 
 
 
 
Computational Aspects of Treatment Planning for Neutron Capture Therapy 
 542
 
 
 
 
 
 
 
 
 
 
 
This page has been intentionally left blank. 
Appendix A: Reference Data for Neutron Capture Therapy Treatment Planning Systems J.R. Albritton 
  543
BNCT_Rtpe
0.24
0.29
0.31
0.38
0.44
0.45
SERA
0.23 Gy
0.28 Gy
0.31 Gy
0.37 Gy
0.43 Gy
0.44 Gy
MacNCTPlan
0.33 Gy
0.34 Gy
0.35 Gy
0.40 Gy
0.47 Gy
0.50 Gy
NCTPlan
0.33 Gy
0.34 Gy
0.35 Gy
0.40 Gy
0.47 Gy
0.50 Gy
Incident Photon Dose
 
Figure A.47 Incident photon isodose contours in the transverse plane containing the 
central beam axis for a 3-field irradiation of the head phantom. Each 
planning system’s contours (solid) are overlaid with the reference 
contours (dashed) after the treatment time for each planning system from 
Table A.1 was used to convert the reference dose rates to absolute dose. 
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Figure A.48 Incident photon isodose contours in the coronal plane containing the 
central beam axis for a 3-field irradiation of the head phantom. Each 
planning system’s contours (solid) are overlaid with the reference 
contours (dashed) after the treatment time for each planning system from 
Table A.1 was used to convert the reference dose rates to absolute dose. 
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BNCT_Rtpe
1.47
2.45
4.29
6.49
9.19
11.9
SERA
1.49 Gyw
2.48 Gyw
4.33 Gyw
6.56 Gyw
9.29 Gyw
11.8 Gyw
MacNCTPlan
1.50 Gyw
2.80 Gyw
5.00 Gyw
7.00 Gyw
9.80 Gyw
12.0 Gyw
NCTPlan
1.50 Gyw
2.80 Gyw
5.00 Gyw
7.00 Gyw
9.80 Gyw
12.0 Gyw
Total Biologically Weighted Brain Dose
6.49
 
Figure A.49 Total biologically weighted brain isodose contours in the transverse plane 
containing the central beam axis for a 3-field irradiation of the head 
phantom. Each planning system’s contours (solid) are overlaid with the 
reference contours (dashed) after the treatment time for each planning 
system from Table A.1 was used to convert the reference dose rates to 
absolute dose. 
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2.70
4.66
6.13
7.96
10.0
12.1
SERA
2.70 Gyw
4.66 Gyw
6.13 Gyw
7.97 Gyw
10.0 Gyw
12.1 Gyw
MacNCTPlan
3.50 Gyw
5.50 Gyw
6.80 Gyw
8.20 Gyw
9.80 Gyw
12.0 Gyw
NCTPlan
3.50 Gyw
5.50 Gyw
6.80 Gyw
8.20 Gyw
9.80 Gyw
12.0 Gyw
Total Biologically Weighted Brain Dose
BNCT_Rtpe
 
Figure A.50 Total biologically weighted brain isodose contours in the coronal plane 
containing the central beam axis for a 3-field irradiation of the head 
phantom. Each planning system’s contours (solid) are overlaid with the 
reference contours (dashed) after the treatment time for each planning 
system from Table A.1 was used to convert the reference dose rates to 
absolute dose. 
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BNCT_Rtpe
7.96
13.9
21.9
49.8
65.0
SERA
8.16 Gyw
14.3 Gyw
22.4 Gyw
33.3 Gyw
51.0 Gyw
65.3 Gyw
MacNCTPlan
8.20 Gyw
14.3 Gyw
22.0 Gyw
32.0 Gyw
49.0 Gyw
62.0 Gyw
NCTPlan
8.20 Gyw
14.3 Gyw
22.0 Gyw
32.0 Gyw
49.0 Gyw
62.0 Gyw
Total Biologically Weighted Tumor Dose
32.5
32.5
 
Figure A.51 Total biologically weighted tumor isodose contours in the transverse plane 
containing the central beam axis for a 3-field irradiation of the head 
phantom. Each planning system’s contours (solid) are overlaid with the 
reference contours (dashed) after the treatment time for each planning 
system from Table A.1 was used to convert the reference dose rates to 
absolute dose. 
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BNCT_Rtpe
12.6
22.6
31.2
41.8
53.1
66.4
SERA
12.8 Gyw
22.9 Gyw
31.6 Gyw
42.3 Gyw
53.8 Gyw
67.2 Gyw
MacNCTPlan
19.0 Gyw
27.5 Gyw
35.0 Gyw
41.0 Gyw
52.0 Gyw
64.0 Gyw
NCTPlan
19.0 Gyw
27.5 Gyw
35.0 Gyw
41.0 Gyw
52.0 Gyw
64.0 Gyw
Total Biologically Weighted Tumor Dose
 
Figure A.52 Total biologically weighted tumor isodose contours in the coronal plane 
containing the central beam axis for a 3-field irradiation of the head 
phantom. Each planning system’s contours (solid) are overlaid with the 
reference contours (dashed) after the treatment time for each planning 
system from Table A.1 was used to convert the reference dose rates to 
absolute dose. 
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A.3.2 Leg Phantom 
 
BNCT_Rtpe
0.320.60
1.16
1.93
2.81
3.70
SERA
0.33 Gy
0.63 Gy
1.21 Gy
2.00 Gy
2.92 Gy
3.84 Gy
MacNCTPlan
0.09 Gy
0.25 Gy
0.56 Gy
1.24 Gy
2.41 Gy
3.08 Gy
NCTPlan
0.11 Gy
0.29 Gy
0.67 Gy
1.51 Gy
2.93 Gy
3.74 Gy
Boron Dose
 
Figure A.53 Boron isodose contours for a 10B concentration of 22.5 μg/g in the 
transverse plane containing the central beam axis for a 1-field irradiation 
of the leg phantom. Each planning system’s contours (solid) are overlaid 
with the reference contours (dashed) after the treatment time for each 
planning system from Table A.1 was used to convert the reference dose 
rates to absolute dose. 
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MacNCTPlan
0.09 Gy
0.25 Gy
0.56 Gy
1.24 Gy
2.41 Gy
3.08 Gy
NCTPlan
0.11 Gy
0.29 Gy
0.67 Gy
1.51 Gy
2.93 Gy
3.74 Gy
Boron Dose
 
Figure A.54 Boron isodose contours for a 10B concentration of 22.5 μg/g in the oblique 
plane containing the central beam axis for a 1-field irradiation of the leg 
phantom. Each planning system’s contours (solid) are overlaid with the 
reference contours (dashed) after the treatment time for each planning 
system from Table A.1 was used to convert the reference dose rates to 
absolute dose. 
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BNCT_Rtpe
0.06
0.10
0.20
0.33
0.48
0.63
SERA
0.06 Gy
0.11 Gy
0.21 Gy
0.35 Gy
0.51 Gy
0.67 Gy
MacNCTPlan
0.02 Gy
0.04 Gy
0.10 Gy
0.21 Gy
0.40 Gy
0.53 Gy
NCTPlan
0.02 Gy
0.06 Gy
0.13 Gy
0.26 Gy
0.49 Gy
0.64 Gy
Thermal Neutron Dose
 
Figure A.55 Thermal neutron (and nitrogen) isodose contours in the transverse plane 
containing the central beam axis for a 1-field irradiation of the leg 
phantom. Each planning system’s contours (solid) are overlaid with the 
reference contours (dashed) after the treatment time for each planning 
system from Table A.1 was used to convert the reference dose rates to 
absolute dose. 
 
 
 
 
 
 
 
 
 
 
Computational Aspects of Treatment Planning for Neutron Capture Therapy 
 560
 
 
 
 
 
 
 
 
 
 
 
This page has been intentionally left blank. 
Appendix A: Reference Data for Neutron Capture Therapy Treatment Planning Systems J.R. Albritton 
  561
MacNCTPlan
0.02 Gy
0.04 Gy
0.10 Gy
0.21 Gy
0.40 Gy
0.53 Gy
NCTPlan
0.02 Gy
0.06 Gy
0.13 Gy
0.26 Gy
0.49 Gy
0.64 Gy
Thermal Neutron Dose
 
Figure A.56 Thermal neutron isodose contours in the oblique plane containing the 
central beam axis for a 1-field irradiation of the leg phantom. Each 
planning system’s contours (solid) are overlaid with the reference 
contours (dashed) after the treatment time for each planning system from 
Table A.1 was used to convert the reference dose rates to absolute dose. 
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BNCT_Rtpe
0.002
0.003
0.004
0.005
0.006
0.007
SERA
0.002 Gy
0.003 Gy
0.004 Gy
0.005 Gy
0.006 Gy
0.007 Gy
MacNCTPlan
0.002 Gy
0.003 Gy
0.004 Gy
0.005 Gy
0.006 Gy
0.007 Gy
NCTPlan
0.002 Gy
0.003 Gy
0.004 Gy
0.005 Gy
0.006 Gy
0.007 Gy
Fast Neutron Dose
 
Figure A.57 Fast neutron (and hydrogen) isodose contours in the transverse plane 
containing the central beam axis for a 1-field irradiation of the leg 
phantom. Each planning system’s contours (solid) are overlaid with the 
reference contours (dashed) after the treatment time for each planning 
system from Table A.1 was used to convert the reference dose rates to 
absolute dose. 
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MacNCTPlan
0.002 Gy
0.003 Gy
0.004 Gy
0.005 Gy
0.006 Gy
0.007 Gy
NCTPlan
0.002 Gy
0.003 Gy
0.004 Gy
0.005 Gy
0.006 Gy
0.007 Gy
Fast Neutron Dose
 
Figure A.58 Fast neutron isodose contours in the oblique plane containing the central 
beam axis for a 1-field irradiation of the leg phantom. Each planning 
system’s contours (solid) are overlaid with the reference contours (dashed) 
after the treatment time for each planning system from Table A.1 was used 
to convert the reference dose rates to absolute dose. 
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BNCT_Rtpe
0.21
0.35
0.53
0.74
0.94
1.12
SERA
0.21 Gy
0.34 Gy
0.52 Gy
0.73 Gy
0.93 Gy
1.07 Gy
MacNCTPlan
0.15 Gy
0.24 Gy
0.38 Gy
0.57 Gy
0.74 Gy
0.88 Gy
NCTPlan
0.18 Gy
0.29 Gy
0.46 Gy
0.69 Gy
0.90 Gy
1.07 Gy
Induced Photon Dose
 
Figure A.59 Induced photon isodose contours in the transverse plane containing the 
central beam axis for a 1-field irradiation of the leg phantom. Each 
planning system’s contours (solid) are overlaid with the reference 
contours (dashed) after the treatment time for each planning system from 
Table A.1 was used to convert the reference dose rates to absolute dose. 
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MacNCTPlan
0.15 Gy
0.24 Gy
0.38 Gy
0.57 Gy
0.74 Gy
0.88 Gy
NCTPlan
0.18 Gy
0.29 Gy
0.46 Gy
0.69 Gy
0.90 Gy
1.07 Gy
Induced Photon Dose
 
Figure A.60 Induced photon isodose contours in the oblique plane containing the 
central beam axis for a 1-field irradiation of the leg phantom. Each 
planning system’s contours (solid) are overlaid with the reference 
contours (dashed) after the treatment time for each planning system from 
Table A.1 was used to convert the reference dose rates to absolute dose. 
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BNCT_Rtpe
0.083
0.088
0.092
0.096
0.100
0.104
SERA
0.078 Gy
0.083 Gy
0.087 Gy
0.091 Gy
0.095 Gy
0.098 Gy
MacNCTPlan
0.075 Gy
0.079 Gy
0.082 Gy
0.086 Gy
0.090 Gy
0.092 Gy
NCTPlan
0.091 Gy
0.096 Gy
0.10 Gy
0.11 Gy
0.11 Gy
0.11 Gy
Incident Photon Dose
 
Figure A.61 Incident photon isodose contours in the transverse plane containing the 
central beam axis for a 1-field irradiation of the leg phantom. Each 
planning system’s contours (solid) are overlaid with the reference 
contours (dashed) after the treatment time for each planning system from 
Table A.1 was used to convert the reference dose rates to absolute dose. 
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MacNCTPlan
0.075 Gy
0.079 Gy
0.082 Gy
0.086 Gy
0.090 Gy
0.092 Gy
NCTPlan
0.091 Gy
0.096 Gy
0.10 Gy
0.11 Gy
0.11 Gy
0.11 Gy
Incident Photon Dose
 
Figure A.62 Incident photon isodose contours in the oblique plane containing the 
central beam axis for a 1-field irradiation of the leg phantom. Each 
planning system’s contours (solid) are overlaid with the reference 
contours (dashed) after the treatment time for each planning system from 
Table A.1 was used to convert the reference dose rates to absolute dose. 
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BNCT_Rtpe
0.81
1.75
3.36
6.18
9.67
12.8
SERA
0.84 Gyw
1.81 Gyw
3.48 Gyw
6.40 Gyw
10.0 Gyw
12.8 Gyw
MacNCTPlan
0.58 Gyw
1.32 Gyw
2.59 Gyw
4.94 Gyw
8.25 Gyw
10.2 Gyw
NCTPlan
0.70 Gyw
1.60 Gyw
3.15 Gyw
6.00 Gyw
10.0 Gyw
12.4 Gyw
Total Biologically Weighted Skin Dose
 
Figure A.63 Total biologically weighted skin isodose contours in the transverse plane 
containing the central beam axis for a 1-field irradiation of the leg 
phantom. Each planning system’s contours (solid) are overlaid with the 
reference contours (dashed) after the treatment time for each planning 
system from Table A.1 was used to convert the reference dose rates to 
absolute dose. 
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2.59 Gyw
4.94 Gyw
8.25 Gyw
10.2 Gyw
NCTPlan
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1.60 Gyw
3.15 Gyw
6.00 Gyw
10.0 Gyw
12.4 Gyw
Total Biologically Weighted Skin Dose
 
Figure A.64 Total biologically weighted skin isodose contours in the oblique plane 
containing the central beam axis for a 1-field irradiation of the leg 
phantom. Each planning system’s contours (solid) are overlaid with the 
reference contours (dashed) after the treatment time for each planning 
system from Table A.1 was used to convert the reference dose rates to 
absolute dose. 
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BNCT_Rtpe
2.34
5.07
9.36
17.5
28.1
37.0
SERA
2.43 Gyw
5.27 Gyw
9.72 Gyw
18.2 Gyw
29.2 Gyw
37.3 Gyw
MacNCTPlan
1.20 Gyw
3.30 Gyw
7.00 Gyw
13.8 Gyw
23.9 Gyw
29.7 Gyw
NCTPlan
1.50 Gyw
4.00 Gyw
8.50 Gyw
16.5 Gyw
29.0 Gyw
36.1 Gyw
Total Biologically Weighted Tumor Dose
 
Figure A.65 Total biologically weighted tumor isodose contours in the transverse plane 
containing the central beam axis for a 1-field irradiation of the leg 
phantom. Each planning system’s contours (solid) are overlaid with the 
reference contours (dashed) after the treatment time for each planning 
system from Table A.1 was used to convert the reference dose rates to 
absolute dose. 
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36.1 Gyw
Total Biologically Weighted Tumor Dose
 
Figure A.66 Total biologically weighted tumor isodose contours in the oblique plane 
containing the central beam axis for a 1-field irradiation of the leg 
phantom. Each planning system’s contours (solid) are overlaid with the 
reference contours (dashed) after the treatment time for each planning 
system from Table A.1 was used to convert the reference dose rates to 
absolute dose. 
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A.4 Dose Difference Distributions 
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Figure A.67 Difference in thermal neutron flux in the transverse plane containing the 
central beam axis expressed as a percentage of the maximum reference 
thermal neutron flux for a 1-field irradiation of the head phantom. 
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Figure A.68 Difference in thermal neutron flux in the coronal plane containing the 
central beam axis expressed as a percentage of the maximum reference 
thermal neutron flux for a 1-field irradiation of the head phantom. 
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Figure A.69 Difference in boron dose in the transverse plane containing the central 
beam axis expressed as a percentage of the maximum reference boron 
dose for a 1-field irradiation of the head phantom. 
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Figure A.70 Difference in boron dose in the coronal plane containing the central beam 
axis expressed as a percentage of the maximum reference boron dose for a 
1-field irradiation of the head phantom. 
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Figure A.71 Difference in thermal neutron (and nitrogen) dose in the transverse plane 
containing the central beam axis expressed as a percentage of the 
maximum reference thermal neutron dose for a 1-field irradiation of the 
head phantom. 
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Figure A.72 Difference in thermal neutron (and nitrogen) dose in the coronal plane 
containing the central beam axis expressed as a percentage of the 
maximum reference thermal neutron dose for a 1-field irradiation of the 
head phantom. 
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Figure A.73 Difference in fast neutron (and hydrogen) dose in the transverse plane 
containing the central beam axis expressed as a percentage of the 
maximum reference fast neutron dose for a 1-field irradiation of the head 
phantom. 
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Figure A.74 Difference in fast neutron (and hydrogen) dose in the coronal plane 
containing the central beam axis expressed as a percentage of the 
maximum reference fast neutron dose for a 1-field irradiation of the head 
phantom. 
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Figure A.75 Difference in induced photon dose in the transverse plane containing the 
central beam axis expressed as a percentage of the maximum reference 
induced photon dose for a 1-field irradiation of the head phantom. 
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Figure A.76 Difference in induced photon dose in the coronal plane containing the 
central beam axis expressed as a percentage of the maximum reference 
induced photon dose for a 1-field irradiation of the head phantom. 
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Figure A.77 Difference in incident photon dose in the transverse plane containing the 
central beam axis expressed as a percentage of the maximum reference 
incident photon dose for a 1-field irradiation of the head phantom. 
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Figure A.78 Difference in incident photon dose in the coronal plane containing the 
central beam axis expressed as a percentage of the maximum reference 
incident photon dose for a 1-field irradiation of the head phantom. 
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Figure A.79 Difference in total biologically weighted brain dose in the transverse plane 
containing the central beam axis expressed as a percentage of the 
maximum reference total weighted dose for a 1-field irradiation of the 
head phantom. 
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Figure A.80 Difference in total biologically weighted brain dose in the coronal plane 
containing the central beam axis expressed as a percentage of the 
maximum reference total weighted dose for a 1-field irradiation of the 
head phantom. 
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Figure A.81 Difference in total biologically weighted tumor dose in the transverse 
plane containing the central beam axis expressed as a percentage of the 
maximum reference total weighted dose for a 1-field irradiation of the 
head phantom. 
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Figure A.82 Difference in total biologically weighted tumor dose in the coronal plane 
containing the central beam axis expressed as a percentage of the 
maximum reference total weighted dose for a 1-field irradiation of the 
head phantom. 
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Figure A.83 Difference in thermal neutron flux in the transverse plane containing the 
central beam axis expressed as a percentage of the maximum reference 
thermal neutron flux for a 3-field irradiation of the head phantom. 
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Figure A.84 Difference in thermal neutron flux in the coronal plane containing the 
central beam axis expressed as a percentage of the maximum reference 
thermal neutron flux for a 3-field irradiation of the head phantom. 
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Figure A.85 Difference in boron dose in the transverse plane containing the central 
beam axis expressed as a percentage of the maximum reference boron 
dose for a 3-field irradiation of the head phantom. 
Computational Aspects of Treatment Planning for Neutron Capture Therapy 
 620
 
 
 
 
 
 
 
 
 
 
 
This page has been intentionally left blank. 
Appendix A: Reference Data for Neutron Capture Therapy Treatment Planning Systems J.R. Albritton 
  621
BNCT_Rtpe
z 
(c
m
)
−8
−6
−4
−2
0
2
4
6
8
SERA
MacNCTPlan
x (cm)
z 
(c
m
)
−6 −4 −2 0 2 4 6
−8
−6
−4
−2
0
2
4
6
8
−15% −10% −5% 0% 5% 10% 15%
NCTPlan
x (cm)
−6 −4 −2 0 2 4 6
Boron Dose Difference (TPS − Reference)
 
Figure A.86 Difference in boron dose in the coronal plane containing the central beam 
axis expressed as a percentage of the maximum reference boron dose for a 
3-field irradiation of the head phantom. 
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Figure A.87 Difference in thermal neutron (and nitrogen) dose in the transverse plane 
containing the central beam axis expressed as a percentage of the 
maximum reference thermal neutron dose for a 3-field irradiation of the 
head phantom. 
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Figure A.88 Difference in thermal neutron (and nitrogen) dose in the coronal plane 
containing the central beam axis expressed as a percentage of the 
maximum reference thermal neutron dose for a 3-field irradiation of the 
head phantom. 
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Figure A.89 Difference in fast neutron (and hydrogen) dose in the transverse plane 
containing the central beam axis expressed as a percentage of the 
maximum reference fast neutron dose for a 3-field irradiation of the head 
phantom. 
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Figure A.90 Difference in fast neutron (and hydrogen) dose in the coronal plane 
containing the central beam axis expressed as a percentage of the 
maximum reference fast neutron dose for a 3-field irradiation of the head 
phantom. 
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Figure A.91 Difference in induced photon dose in the transverse plane containing the 
central beam axis expressed as a percentage of the maximum reference 
induced photon dose for a 3-field irradiation of the head phantom. 
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Figure A.92 Difference in induced photon dose in the coronal plane containing the 
central beam axis expressed as a percentage of the maximum reference 
induced photon dose for a 3-field irradiation of the head phantom. 
 
 
Computational Aspects of Treatment Planning for Neutron Capture Therapy 
 634
 
 
 
 
 
 
 
 
 
 
 
This page has been intentionally left blank. 
Appendix A: Reference Data for Neutron Capture Therapy Treatment Planning Systems J.R. Albritton 
  635
BNCT_Rtpe
y 
(c
m
)
−10
−8
−6
−4
−2
0
2
4
6
8
10
SERA
MacNCTPlan
x (cm)
y 
(c
m
)
−6 −4 −2 0 2 4 6
−10
−8
−6
−4
−2
0
2
4
6
8
10
−15% −10% −5% 0% 5% 10% 15%
NCTPlan
x (cm)
−6 −4 −2 0 2 4 6
Incident Photon Dose Difference (TPS − Reference)
 
Figure A.93 Difference in incident photon dose in the transverse plane containing the 
central beam axis expressed as a percentage of the maximum reference 
incident photon dose for a 3-field irradiation of the head phantom. 
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Figure A.94 Difference in incident photon dose in the coronal plane containing the 
central beam axis expressed as a percentage of the maximum reference 
incident photon dose for a 3-field irradiation of the head phantom. 
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Figure A.95 Difference in total biologically weighted brain dose in the transverse plane 
containing the central beam axis expressed as a percentage of the 
maximum reference total weighted dose for a 3-field irradiation of the 
head phantom. 
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Figure A.96 Difference in total biologically weighted brain dose in the coronal plane 
containing the central beam axis expressed as a percentage of the 
maximum reference total weighted dose for a 3-field irradiation of the 
head phantom. 
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Figure A.97 Difference in total biologically weighted tumor dose in the transverse 
plane containing the central beam axis expressed as a percentage of the 
maximum reference total weighted dose for a 3-field irradiation of the 
head phantom. 
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Figure A.98 Difference in total biologically weighted tumor dose in the coronal plane 
containing the central beam axis expressed as a percentage of the 
maximum reference total weighted dose for a 3-field irradiation of the 
head phantom. 
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Figure A.99 Difference in thermal neutron flux in the transverse plane containing the 
central beam axis expressed as a percentage of the maximum reference 
thermal neutron flux for a 1-field irradiation of the leg phantom. 
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Figure A.100 Difference in thermal neutron flux in the oblique plane containing the 
central beam axis expressed as a percentage of the maximum reference 
thermal neutron flux for a 1-field irradiation of the leg phantom. 
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Figure A.101 Difference in boron dose in the transverse plane containing the central 
beam axis expressed as a percentage of the maximum reference boron 
dose for a 1-field irradiation of the leg phantom. 
 
 
 
 
 
 
Computational Aspects of Treatment Planning for Neutron Capture Therapy 
 652
 
 
 
 
 
 
 
 
 
 
 
This page has been intentionally left blank. 
Appendix A: Reference Data for Neutron Capture Therapy Treatment Planning Systems J.R. Albritton 
  653
MacNCTPlan
z 
(c
m
)
x (cm)
−4 −3 −2 −1 0 1 2 3 4 5
−10
−8
−6
−4
−2
0
2
4
6
8
10
−15% −10% −5% 0% 5% 10% 15%
NCTPlan
x (cm)
−4 −3 −2 −1 0 1 2 3 4 5
Boron Dose Difference (TPS − Reference)
 
Figure A.102 Difference in boron dose in the oblique plane containing the central beam 
axis expressed as a percentage of the maximum reference boron dose for a 
1-field irradiation of the leg phantom. 
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Figure A.103 Difference in thermal neutron (and nitrogen) dose in the transverse plane 
containing the central beam axis expressed as a percentage of the 
maximum reference thermal neutron dose for a 1-field irradiation of the 
leg phantom. 
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Figure A.104 Difference in thermal neutron dose in the oblique plane containing the 
central beam axis expressed as a percentage of the maximum reference 
thermal neutron dose for a 1-field irradiation of the leg phantom. 
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Figure A.105 Difference in fast neutron (and hydrogen) dose in the transverse plane 
containing the central beam axis expressed as a percentage of the 
maximum reference fast neutron dose for a 1-field irradiation of the leg 
phantom. 
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Figure A.106 Difference in fast neutron dose in the oblique plane containing the central 
beam axis expressed as a percentage of the maximum reference fast 
neutron dose for a 1-field irradiation of the leg phantom. 
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Figure A.107 Difference in induced photon dose in the transverse plane containing the 
central beam axis expressed as a percentage of the maximum reference 
induced photon dose for a 1-field irradiation of the leg phantom. 
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Figure A.108 Difference in induced photon dose in the oblique plane containing the 
central beam axis expressed as a percentage of the maximum reference 
induced photon dose for a 1-field irradiation of the leg phantom. 
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Figure A.109 Difference in incident photon dose in the transverse plane containing the 
central beam axis expressed as a percentage of the maximum reference 
incident photon dose for a 1-field irradiation of the leg phantom. 
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Figure A.110 Difference in incident photon dose in the oblique plane containing the 
central beam axis expressed as a percentage of the maximum reference 
incident photon dose for a 1-field irradiation of the leg phantom. 
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Figure A.111 Difference in total biologically weighted skin dose in the transverse plane 
containing the central beam axis expressed as a percentage of the 
maximum reference total weighted dose for a 1-field irradiation of the leg 
phantom. 
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Figure A.112 Difference in total biologically weighted skin dose in the oblique plane 
containing the central beam axis expressed as a percentage of the 
maximum reference total weighted dose for a 1-field irradiation of the leg 
phantom. 
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Figure A.113 Difference in total biologically weighted tumor dose in the transverse 
plane containing the central beam axis expressed as a percentage of the 
maximum reference total weighted dose for a 1-field irradiation of the leg 
phantom. 
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Figure A.114 Difference in total biologically weighted tumor dose in the oblique plane 
containing the central beam axis expressed as a percentage of the 
maximum reference total weighted dose for a 1-field irradiation of the leg 
phantom. 
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A.5 Dose-Volume Histograms 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table A.2 Volumes in cm3 of the various anatomical regions in the head and leg 
phantoms as calculated by each treatment planning system. The analytical 
volumes are also included as a point of comparison. MacNCTPlan and 
NCTPlan skin volumes are not included because neither planning system 
was able to accurately calculate dose-volume data for concave regions like 
skin. 
 Head Phantom  Leg Phantom 
 brain tumor  skin tumor 1 tumor 2 
Analytical 1470.27 33.51  84.01 1.77 19.24 
BNCT_Rtpe 1403.52 33.46  98.51 1.56 17.76 
SERA 1469.90 33.65  85.99 1.77 19.93 
MacNCTPlan 1101.41 34.95  ---- 1.63 40.28 
NCTPlan 1470.27 33.42  ---- 1.77 19.93 
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Figure A.115 Boron dose-volume histograms for brain for brain for a 1-field irradiation 
of the head phantom. Conventional and binned representations of the 
reference data are included. The default output from seraPlot is shown 
along with a corrected interpretation of the SERA dose-volume data (with 
a −5% shift in dose). 
 
 
Table A.3 Boron dose statistics for brain resulting from a 1-field irradiation with the 
generic epithermal neutron beam for 3.16 minutes. 
 Boron Dose (Gy) 
 mean minimum maximum 
Reference 0.95 0.041 4.82 
BNCT_Rtpe 1.02 0.047 5.19 
SERA 0.99 0.047 5.16 
NCTPlan 0.87 0.045 4.55 
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Figure A.116 Thermal neutron (and nitrogen) dose-volume histograms for the brain for 
a 1-field irradiation of the head phantom. Conventional and binned 
representations of the reference data are included. A corrected 
interpretation of the SERA dose-volume data (with a −5% shift in dose) is 
shown instead of the default seraPlot output. 
 
 
 
 
Table A.4 Thermal neutron (and nitrogen) dose statistics for brain resulting from a 1-
field irradiation with the generic epithermal neutron beam for 3.16 
minutes. 
 Thermal Neutron Dose (Gy) 
 mean minimum maximum 
Reference 0.13 0.006 0.65 
BNCT_Rtpe 0.14 0.006 0.70 
SERA 0.14 0.006 0.70 
NCTPlan 0.12 0.006 0.61 
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Figure A.117 Fast neutron (and hydrogen) dose-volume histograms for the brain for a 1-
field irradiation of the head phantom. Conventional and binned 
representations of the reference data are included. A corrected 
interpretation of the SERA dose-volume data (with a −5% shift in dose) is 
shown instead of the default seraPlot output. 
 
 
 
 
Table A.5 Fast neutron (and hydrogen) dose statistics for brain resulting from a 1-
field irradiation with the generic epithermal neutron beam for 3.16 
minutes. 
 Fast Neutron Dose (Gy) 
 mean minimum maximum 
Reference 0.040 0.0011 0.35 
BNCT_Rtpe 0.034 0.0000 0.23 
SERA 0.035 0.0000 0.24 
NCTPlan 0.040 0.0045 0.33 
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Figure A.118 Induced photon dose-volume histograms for the brain for a 1-field 
irradiation of the head phantom. Conventional and binned representations 
of the reference data are included. A corrected interpretation of the SERA 
dose-volume data (with a −5% shift in dose) is shown instead of the 
default seraPlot output. 
 
 
 
 
 
Table A.6 Induced photon dose statistics for brain resulting from a 1-field irradiation 
with the generic epithermal neutron beam for 3.16 minutes. 
 Induced Photon Dose (Gy) 
 mean minimum maximum 
Reference 1.08 0.288 3.21 
BNCT_Rtpe 1.19 0.337 3.49 
SERA 1.09 0.303 3.28 
NCTPlan 1.00 0.273 3.03 
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Figure A.119 Incident photon dose-volume histograms for the brain for a 1-field 
irradiation of the head phantom. Conventional and binned representations 
of the reference data are included. A corrected interpretation of the SERA 
dose-volume data (with a −5% shift in dose) is shown instead of the 
default seraPlot output. 
 
 
 
 
 
Table A.7 Incident photon dose statistics for brain resulting from a 1-field irradiation 
with the generic epithermal neutron beam for 3.16 minutes. 
 Incident Photon Dose (Gy) 
 mean minimum maximum 
Reference 0.15 0.0023 0.31 
BNCT_Rtpe 0.16 0.0000 0.38 
SERA 0.15 0.0000 0.36 
NCTPlan 0.14 0.0032 0.31 
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Figure A.120 Total biologically weighted dose-volume histograms for brain for a 1-field 
irradiation of the head phantom. Conventional and binned representations 
of the reference data are included. The default output from seraPlot is 
shown along with a corrected interpretation of the SERA dose-volume 
data (with a −5% shift in dose). 
 
 
 
Table A.8 Total biologically weighted dose statistics for brain resulting from a 1-
field irradiation with the generic epithermal neutron beam for 3.16 
minutes. 
 Total Biologically Weighted Dose (Gyw) 
 mean minimum maximum 
Reference 3.00 0.380 12.50 
BNCT_Rtpe 3.23 0.430 13.21 
SERA 3.08 0.385 13.00 
NCTPlan 2.79 0.355 11.84 
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Figure A.121 Boron dose-volume histograms for the brain for a 3-field irradiation of the 
head phantom. Conventional and binned representations of the reference 
data are included. A corrected interpretation of the SERA dose-volume 
data (with a −5% shift in dose) is shown instead of the default seraPlot 
output. 
 
 
 
 
 
Table A.9 Boron dose statistics for brain resulting from a 3-field irradiation with the 
generic epithermal neutron beam for 5.66 minutes. 
 Boron Dose (Gy) 
 mean minimum maximum 
Reference 1.68 0.14 4.58 
BNCT_Rtpe 1.82 0.17 4.92 
SERA 1.78 0.17 4.92 
NCTPlan 1.55 0.13 4.32 
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Figure A.122 Thermal neutron (and nitrogen) dose-volume histograms for the brain for 
a 3-field irradiation of the head phantom. Conventional and binned 
representations of the reference data are included. A corrected 
interpretation of the SERA dose-volume data (with a −5% shift in dose) is 
shown instead of the default seraPlot output. 
 
 
 
 
Table A.10 Thermal neutron (and nitrogen) dose statistics for brain resulting from a 3-
field irradiation with the generic epithermal neutron beam for 5.66 
minutes. 
 Thermal Neutron Dose (Gy) 
 mean minimum maximum 
Reference 0.23 0.020 0.62 
BNCT_Rtpe 0.25 0.023 0.66 
SERA 0.24 0.023 0.67 
NCTPlan 0.21 0.018 0.58 
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Figure A.123 Fast neutron (and hydrogen) dose-volume histograms for the brain for a 3-
field irradiation of the head phantom. Conventional and binned 
representations of the reference data are included. A corrected 
interpretation of the SERA dose-volume data (with a −5% shift in dose) is 
shown instead of the default seraPlot output. 
 
 
 
 
Table A.11 Fast neutron (and hydrogen) dose statistics for brain resulting from a 3-
field irradiation with the generic epithermal neutron beam for 5.66 
minutes. 
 Fast Neutron Dose (Gy) 
 mean minimum maximum 
Reference 0.072 0.0022 0.38 
BNCT_Rtpe 0.062 0.0021 0.26 
SERA 0.062 0.0000 0.27 
NCTPlan 0.069 0.0041 0.33 
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Figure A.124 Induced photon dose-volume histograms for the brain for a 3-field 
irradiation of the head phantom. Conventional and binned representations 
of the reference data are included. A corrected interpretation of the SERA 
dose-volume data (with a −5% shift in dose) is shown instead of the 
default seraPlot output. 
 
 
 
 
 
Table A.12 Induced photon dose statistics for brain resulting from a 3-field irradiation 
with the generic epithermal neutron beam for 5.66 minutes. 
 Induced Photon Dose (Gy) 
 mean minimum maximum 
Reference 1.88 0.60 3.56 
BNCT_Rtpe 2.09 0.70 3.89 
SERA 1.91 0.63 3.64 
NCTPlan 1.76 0.57 3.37 
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Figure A.125 Incident photon dose-volume histograms for the brain for a 3-field 
irradiation of the head phantom. Conventional and binned representations 
of the reference data are included. A corrected interpretation of the SERA 
dose-volume data (with a −5% shift in dose) is shown instead of the 
default seraPlot output. 
 
 
 
 
 
Table A.13 Incident photon dose statistics for brain resulting from a 3-field irradiation 
with the generic epithermal neutron beam for 5.66 minutes. 
 Incident Photon Dose (Gy) 
 mean minimum maximum 
Reference 0.27 0.0047 0.51 
BNCT_Rtpe 0.29 0.0000 0.62 
SERA 0.26 0.0000 0.63 
NCTPlan 0.26 0.0051 0.51 
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Figure A.126 Total biologically weighted dose-volume histograms for the brain for a 3-
field irradiation of the head phantom. Conventional and binned 
representations of the reference data are included. A corrected 
interpretation of the SERA dose-volume data (with a −5% shift in dose) is 
shown instead of the default seraPlot output. 
 
 
 
Table A.14 Total biologically weighted dose statistics for brain resulting from a 3-
field irradiation with the generic epithermal neutron beam for 5.66 
minutes. 
 Total Biologically Weighted Dose (Gyw) 
 mean minimum maximum 
Reference 5.29 0.87 12.50 
BNCT_Rtpe 5.72 1.01 13.22 
SERA 5.43 0.92 12.90 
NCTPlan 4.94 0.82 11.76 
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Figure A.127 Boron dose-volume histograms for the brain tumor for a 1-field irradiation 
of the head phantom. Conventional and binned representations of the 
reference data are included. A corrected interpretation of the SERA dose-
volume data (with a −5% shift in dose) is shown instead of the default 
seraPlot output. 
 
 
 
Table A.15 Boron dose statistics for the brain tumor resulting from a 1-field 
irradiation with the generic epithermal neutron beam for 3.16 minutes. 
 Boron Dose (Gy) 
 mean minimum maximum 
Reference 8.40 3.86 14.90 
BNCT_Rtpe 9.00 4.38 14.86 
SERA 8.78 3.98 15.41 
NCTPlan 7.94 3.50 13.85 
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Figure A.128 Thermal neutron (and nitrogen) dose-volume histograms for the brain 
tumor for a 1-field irradiation of the head phantom. Conventional and 
binned representations of the reference data are included. A corrected 
interpretation of the SERA dose-volume data (with a −5% shift in dose) is 
shown instead of the default seraPlot output. 
 
 
 
 
Table A.16 Thermal neutron (and nitrogen) dose statistics for the brain tumor 
resulting from a 1-field irradiation with the generic epithermal neutron 
beam for 3.16 minutes. 
 Thermal Neutron Dose (Gy) 
 mean minimum maximum 
Reference 0.33 0.15 0.58 
BNCT_Rtpe 0.35 0.17 0.57 
SERA 0.34 0.15 0.60 
NCTPlan 0.31 0.14 0.54 
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Figure A.129 Fast neutron (and hydrogen) dose-volume histograms for the brain tumor 
for a 1-field irradiation of the head phantom. Conventional and binned 
representations of the reference data are included. A corrected 
interpretation of the SERA dose-volume data (with a −5% shift in dose) is 
shown instead of the default seraPlot output. 
 
 
 
 
Table A.17 Fast neutron (and hydrogen) dose statistics for the brain tumor resulting 
from a 1-field irradiation with the generic epithermal neutron beam for 
3.16 minutes. 
 Fast Neutron Dose (Gy) 
 mean minimum maximum 
Reference 0.075 0.037 0.14 
BNCT_Rtpe 0.069 0.039 0.11 
SERA 0.066 0.038 0.11 
NCTPlan 0.073 0.036 0.14 
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Figure A.130 Induced photon dose-volume histograms for the brain tumor for a 1-field 
irradiation of the head phantom. Conventional and binned representations 
of the reference data are included. A corrected interpretation of the SERA 
dose-volume data (with a −5% shift in dose) is shown instead of the 
default seraPlot output. 
 
 
 
 
 
Table A.18 Induced photon dose statistics for the brain tumor resulting from a 1-field 
irradiation with the generic epithermal neutron beam for 3.16 minutes. 
 Induced Photon Dose (Gy) 
 mean minimum maximum 
Reference 2.34 1.53 3.19 
BNCT_Rtpe 2.58 1.77 3.38 
SERA 2.39 1.58 3.21 
NCTPlan 2.20 1.43 3.00 
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Figure A.131 Incident photon dose-volume histograms for the brain tumor for a 1-field 
irradiation of the head phantom. Conventional and binned representations 
of the reference data are included. A corrected interpretation of the SERA 
dose-volume data (with a −5% shift in dose) is shown instead of the 
default seraPlot output. 
 
 
 
 
 
Table A.19 Incident photon dose statistics for the brain tumor resulting from a 1-field 
irradiation with the generic epithermal neutron beam for 3.16 minutes. 
 Incident Photon Dose (Gy) 
 mean minimum maximum 
Reference 0.28 0.26 0.30 
BNCT_Rtpe 0.29 0.27 0.31 
SERA 0.27 0.25 0.29 
NCTPlan 0.28 0.26 0.30 
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Figure A.132 Total biologically weighted dose-volume histograms for the brain tumor 
for a 1-field irradiation of the head phantom. Conventional and binned 
representations of the reference data are included. A corrected 
interpretation of the SERA dose-volume data (with a −5% shift in dose) is 
shown instead of the default seraPlot output. 
 
 
 
Table A.20 Total biologically weighted dose statistics for the brain tumor resulting 
from a 1-field irradiation with the generic epithermal neutron beam for 
3.16 minutes. 
 Total Biologically Weighted Dose (Gyw) 
 mean minimum maximum 
Reference 35.81 17.05 62.37 
BNCT_Rtpe 38.40 19.37 62.29 
SERA 37.41 17.65 64.60 
NCTPlan 33.88 15.94 58.44 
Computational Aspects of Treatment Planning for Neutron Capture Therapy 
 698
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
0
10
20
30
40
50
60
70
80
90
100
Boron Dose (Brain Tumor)
Dose (Gy)
V
ol
um
e 
of
 T
um
or
 (%
)
Reference
Reference (binned)
BNCT_Rtpe
SERA (corrected)
MacNCTPlan
NCTPlan
 
Figure A.133 Boron dose-volume histograms for the brain tumor for a 3-field irradiation 
of the head phantom. Conventional and binned representations of the 
reference data are included. A corrected interpretation of the SERA dose-
volume data (with a −5% shift in dose) is shown instead of the default 
seraPlot output. 
 
 
 
 
 
Table A.21 Boron dose statistics for the brain tumor resulting from a 3-field 
irradiation with the generic epithermal neutron beam for 5.66 minutes. 
 Boron Dose (Gy) 
 mean minimum maximum 
Reference 9.65 6.13 14.88 
BNCT_Rtpe 10.34 6.82 15.31 
SERA 10.10 6.53 15.44 
NCTPlan 9.17 5.90 13.92 
Appendix A: Reference Data for Neutron Capture Therapy Treatment Planning Systems J.R. Albritton 
  699
0 0.1 0.2 0.3 0.4 0.5 0.6
0
10
20
30
40
50
60
70
80
90
100
Thermal Neutron Dose (Brain Tumor)
Dose (Gy)
V
ol
um
e 
of
 T
um
or
 (%
)
Reference
Reference (binned)
BNCT_Rtpe
SERA (corrected)
MacNCTPlan
NCTPlan
 
Figure A.134 Thermal neutron (and nitrogen) dose-volume histograms for the brain 
tumor for a 3-field irradiation of the head phantom. Conventional and 
binned representations of the reference data are included. A corrected 
interpretation of the SERA dose-volume data (with a −5% shift in dose) is 
shown instead of the default seraPlot output. 
 
 
 
 
Table A.22 Thermal neutron (and nitrogen) dose statistics for the brain tumor 
resulting from a 3-field irradiation with the generic epithermal neutron 
beam for 5.66 minutes. 
 Thermal Neutron Dose (Gy) 
 mean minimum maximum 
Reference 0.38 0.24 0.58 
BNCT_Rtpe 0.40 0.26 0.59 
SERA 0.39 0.25 0.59 
NCTPlan 0.36 0.23 0.54 
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Figure A.135 Fast neutron (and hydrogen) dose-volume histograms for the brain tumor 
for a 3-field irradiation of the head phantom. Conventional and binned 
representations of the reference data are included. A corrected 
interpretation of the SERA dose-volume data (with a −5% shift in dose) is 
shown instead of the default seraPlot output. 
 
 
 
 
Table A.23 Fast neutron (and hydrogen) dose statistics for the brain tumor resulting 
from a 3-field irradiation with the generic epithermal neutron beam for 
5.66 minutes. 
 Fast Neutron Dose (Gy) 
 mean minimum maximum 
Reference 0.092 0.060 0.15 
BNCT_Rtpe 0.087 0.062 0.12 
SERA 0.085 0.062 0.12 
NCTPlan 0.090 0.061 0.15 
Appendix A: Reference Data for Neutron Capture Therapy Treatment Planning Systems J.R. Albritton 
  701
0 0.5 1 1.5 2 2.5 3 3.5 4
0
10
20
30
40
50
60
70
80
90
100
Induced Photon Dose (Brain Tumor)
Dose (Gy)
V
ol
um
e 
of
 T
um
or
 (%
)
Reference
Reference (binned)
BNCT_Rtpe
SERA (corrected)
MacNCTPlan
NCTPlan
 
Figure A.136 Induced photon dose-volume histograms for the brain tumor for a 3-field 
irradiation of the head phantom. Conventional and binned representations 
of the reference data are included. A corrected interpretation of the SERA 
dose-volume data (with a −5% shift in dose) is shown instead of the 
default seraPlot output. 
 
 
 
 
 
Table A.24 Induced photon dose statistics for the brain tumor resulting from a 3-field 
irradiation with the generic epithermal neutron beam for 5.66 minutes. 
 Induced Photon Dose (Gy) 
 mean minimum maximum 
Reference 3.06 2.48 3.58 
BNCT_Rtpe 3.38 2.82 3.88 
SERA 3.12 2.55 3.61 
NCTPlan 2.89 2.39 3.37 
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Figure A.137 Incident photon dose-volume histograms for the brain tumor for a 3-field 
irradiation of the head phantom. Conventional and binned representations 
of the reference data are included. A corrected interpretation of the SERA 
dose-volume data (with a −5% shift in dose) is shown instead of the 
default seraPlot output. 
 
 
 
 
 
Table A.25 Incident photon dose statistics for the brain tumor resulting from a 3-field 
irradiation with the generic epithermal neutron beam for 5.66 minutes. 
 Incident Photon Dose (Gy) 
 mean minimum maximum 
Reference 0.47 0.45 0.49 
BNCT_Rtpe 0.49 0.47 0.51 
SERA 0.45 0.44 0.48 
NCTPlan 0.47 0.45 0.49 
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Figure A.138 Total biologically weighted dose-volume histograms for the brain tumor 
for a 3-field irradiation of the head phantom. Conventional and binned 
representations of the reference data are included. A corrected 
interpretation of the SERA dose-volume data (with a −5% shift in dose) is 
shown instead of the default seraPlot output. 
 
 
 
 
Table A.26 Total biologically weighted dose statistics for the brain tumor resulting 
from a 3-field irradiation with the generic epithermal neutron beam for 
5.66 minutes. 
 Total Biologically Weighted Dose (Gyw) 
 mean minimum maximum 
Reference 41.69 27.22 62.91 
BNCT_Rtpe 44.73 30.24 64.83 
SERA 43.39 28.41 64.61 
NCTPlan 39.65 26.09 59.17 
Computational Aspects of Treatment Planning for Neutron Capture Therapy 
 704
A.5.2 Leg Phantom 
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Figure A.139 Boron dose-volume histograms for skin for a 1-field irradiation of the leg 
phantom. Conventional and binned representations of the reference data 
are included. A corrected interpretation of the SERA dose-volume data 
(with a −5% shift in dose) is shown instead of the default seraPlot output. 
 
Table A.27 Boron dose statistics for leg phantom skin resulting from a 1-field 
irradiation with a thermal neutron beam for 1.38 minutes. 
 Boron Dose (Gy) 
 mean minimum maximum 
Reference 0.83 0.004 4.03 
BNCT_Rtpe 0.70 0.000 4.30 
SERA 0.80 0.000 4.30 
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Figure A.140 Thermal neutron (and nitrogen) dose-volume histograms for skin for a 1-
field irradiation of the leg phantom. Conventional and binned 
representations of the reference data are included. A corrected 
interpretation of the SERA dose-volume data (with a −5% shift in dose) is 
shown instead of the default seraPlot output. 
 
 
 
 
 
Table A.28 Thermal neutron (and nitrogen) dose statistics for leg phantom skin 
resulting from a 1-field irradiation with a thermal neutron beam for 1.38 
minutes. 
 Thermal Neutron Dose (Gy) 
 mean minimum maximum 
Reference 0.14 0.001 0.70 
BNCT_Rtpe 0.12 0.000 0.74 
SERA 0.14 0.000 0.75 
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Figure A.141 Fast neutron (and hydrogen) dose-volume histograms for skin for a 1-field 
irradiation of the leg phantom. Conventional and binned representations of 
the reference data are included. A corrected interpretation of the SERA 
dose-volume data (with a −5% shift in dose) is shown instead of the 
default seraPlot output. 
 
 
 
 
Table A.29 Fast neutron (and hydrogen) dose statistics for leg phantom skin resulting 
from a 1-field irradiation with a thermal neutron beam for 1.38 minutes. 
 Fast Neutron Dose (Gy) 
 mean minimum maximum 
Reference 0.0025 0.000 0.0074 
BNCT_Rtpe 0.0023 0.000 0.0086 
SERA 0.0028 0.000 0.0110 
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Figure A.142 Induced photon dose-volume histograms for skin for a 1-field irradiation 
of the leg phantom. Conventional and binned representations of the 
reference data are included. A corrected interpretation of the SERA dose-
volume data (with a −5% shift in dose) is shown instead of the default 
seraPlot output. 
 
 
 
Table A.30 Induced photon dose statistics for leg phantom skin resulting from a 1-
field irradiation with a thermal neutron beam for 1.38 minutes. 
 Induced Photon Dose (Gy) 
 mean minimum maximum 
Reference 0.30 0.065 0.98 
BNCT_Rtpe 0.28 0.070 1.06 
SERA 0.28 0.062 1.02 
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Figure A.143 Incident photon dose-volume histograms for skin for a 1-field irradiation 
of the leg phantom. Conventional and binned representations of the 
reference data are included. A corrected interpretation of the SERA dose-
volume data (with a −5% shift in dose) is shown instead of the default 
seraPlot output. 
 
 
 
 
 
Table A.31 Incident photon dose statistics for leg phantom skin resulting from a 1-
field irradiation with a thermal neutron beam for 1.38 minutes. 
 Incident Photon Dose (Gy) 
 mean minimum maximum 
Reference 0.050 0.000 0.11 
BNCT_Rtpe 0.050 0.000 0.17 
SERA 0.048 0.000 0.75 
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Figure A.144 Total biologically weighted dose-volume histograms for skin for a 1-field 
irradiation of the leg phantom. Conventional and binned representations of 
the reference data are included. A corrected interpretation of the SERA 
dose-volume data (with a −5% shift in dose) is shown instead of the 
default seraPlot output. 
 
Table A.32 Total biologically weighted dose statistics for leg phantom skin resulting 
from a 1-field irradiation with a thermal neutron beam for 1.38 minutes. 
The maximum skin dose for MacNCTPlan and NCTPlan was recorded at 
5 mm depth along the central beam axis. 
 Total Biologically Weighted Dose (Gyw) 
 mean minimum maximum 
Reference 2.88 0.080 13.41 
BNCT_Rtpe 2.46 0.089 14.18 
SERA 2.78 0.078 14.29 
MacNCTPlan ---- ---- 12.69 
NCTPlan ---- ---- 12.07 
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A.5.2.2   Leg Phantom Tumor 1 (spherical tumor) 
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Figure A.145 Boron dose-volume histograms for tumor 1 (spherical tumor) for a 1-field 
irradiation of the leg phantom. Conventional and binned representations of 
the reference data are included. A corrected interpretation of the SERA 
dose-volume data (with a −5% shift in dose) is shown instead of the 
default seraPlot output. 
 
 
 
Table A.33 Boron dose statistics for tumor 1 (spherical tumor) resulting from a 1-field 
irradiation with a thermal neutron beam for 1.38 minutes. 
 Boron Dose (Gy) 
 mean minimum maximum 
Reference 7.82 5.66 9.67 
BNCT_Rtpe 8.39 6.25 9.75 
SERA 8.16 6.14 9.53 
NCTPlan 7.36 5.72 8.53 
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Figure A.146 Thermal neutron (and nitrogen) dose-volume histograms for tumor 1 
(spherical tumor) for a 1-field irradiation of the leg phantom. 
Conventional and binned representations of the reference data are 
included. A corrected interpretation of the SERA dose-volume data (with 
a −5% shift in dose) is shown instead of the default seraPlot output. 
 
 
 
 
Table A.34 Thermal neutron (and nitrogen) dose statistics for tumor 1 (spherical 
tumor) resulting from a 1-field irradiation with a thermal neutron beam for 
1.38 minutes. 
 Thermal Neutron Dose (Gy) 
 mean minimum maximum 
Reference 0.58 0.42 0.72 
BNCT_Rtpe 0.62 0.46 0.72 
SERA 0.61 0.46 0.71 
NCTPlan 0.55 0.42 0.63 
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Figure A.147 Fast neutron (and hydrogen) dose-volume histograms for tumor 1 
(spherical tumor) for a 1-field irradiation of the leg phantom. 
Conventional and binned representations of the reference data are 
included. A corrected interpretation of the SERA dose-volume data (with 
a −5% shift in dose) is shown instead of the default seraPlot output. 
 
 
 
 
Table A.35 Fast neutron (and hydrogen) dose statistics for tumor 1 (spherical tumor) 
resulting from a 1-field irradiation with a thermal neutron beam for 1.38 
minutes. 
 Fast Neutron Dose (Gy) 
 mean minimum maximum 
Reference 0.0067 0.0060 0.0072 
BNCT_Rtpe 0.0066 0.0061 0.0069 
SERA 0.0069 0.0055 0.0069 
NCTPlan 0.0069 0.0062 0.0074 
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Figure A.148 Induced photon dose-volume histograms for tumor 1 (spherical tumor) for 
a 1-field irradiation of the leg phantom. Conventional and binned 
representations of the reference data are included. A corrected 
interpretation of the SERA dose-volume data (with a −5% shift in dose) is 
shown instead of the default seraPlot output. 
 
 
 
 
 
Table A.36 Induced photon dose statistics for tumor 1 (spherical tumor) resulting from 
a 1-field irradiation with a thermal neutron beam for 1.38 minutes. 
 Induced Photon Dose (Gy) 
 mean minimum maximum 
Reference 1.08 0.93 1.18 
BNCT_Rtpe 1.09 0.88 1.23 
SERA 1.03 0.83 1.15 
NCTPlan 0.93 0.76 1.02 
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Figure A.149 Incident photon dose-volume histograms for tumor 1 (spherical tumor) for 
a 1-field irradiation of the leg phantom. Conventional and binned 
representations of the reference data are included. A corrected 
interpretation of the SERA dose-volume data (with a −5% shift in dose) is 
shown instead of the default seraPlot output. 
 
 
 
 
 
Table A.37 Incident photon dose statistics for tumor 1 (spherical tumor) resulting 
from a 1-field irradiation with a thermal neutron beam for 1.38 minutes. 
 Incident Photon Dose (Gy) 
 mean minimum maximum 
Reference 0.109 0.106 0.111 
BNCT_Rtpe 0.113 0.112 0.115 
SERA 0.106 0.105 0.109 
NCTPlan 0.108 0.099 0.109 
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Figure A.150 Total biologically weighted dose-volume histograms for tumor 1 
(spherical tumor) for a 1-field irradiation of the leg phantom. 
Conventional and binned representations of the reference data are 
included. A corrected interpretation of the SERA dose-volume data (with 
a −5% shift in dose) is shown instead of the default seraPlot output. 
 
 
 
Table A.38 Total biologically weighted dose statistics for tumor 1 (spherical tumor) 
resulting from a 1-field irradiation with a thermal neutron beam for 1.38 
minutes. 
 Total Biologically Weighted Dose (Gyw) 
 mean minimum maximum 
Reference 32.80 24.00 40.27 
BNCT_Rtpe 35.09 26.39 40.63 
SERA 34.22 25.89 39.69 
NCTPlan 30.76 24.23 35.59 
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A.5.2.3   Leg Phantom Tumor 2 (arc-shaped tumor) 
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Figure A.151 Boron dose-volume histograms for tumor 2 (arc-shaped tumor) for a 1-
field irradiation of the leg phantom. Conventional and binned 
representations of the reference data are included. A corrected 
interpretation of the SERA dose-volume data (with a −5% shift in dose) is 
shown instead of the default seraPlot output. 
 
 
 
Table A.39 Boron dose statistics for tumor 2 (arc-shaped tumor) resulting from a 1-
field irradiation with a thermal neutron beam for 1.38 minutes. 
 Boron Dose (Gy) 
 mean minimum maximum 
Reference 8.97 6.00 10.23 
BNCT_Rtpe 9.45 6.49 10.74 
SERA 9.32 6.28 10.55 
NCTPlan 7.98 5.54 9.08 
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Figure A.152 Thermal neutron (and nitrogen) dose-volume histograms for tumor 2 (arc-
shaped tumor) for a 1-field irradiation of the leg phantom. Conventional 
and binned representations of the reference data are included. A corrected 
interpretation of the SERA dose-volume data (with a −5% shift in dose) is 
shown instead of the default seraPlot output. 
 
 
 
 
Table A.40 Thermal neutron (and nitrogen) dose statistics for tumor 2 (arc-shaped 
tumor) resulting from a 1-field irradiation with a thermal neutron beam for 
1.38 minutes. 
 Thermal Neutron Dose (Gy) 
 mean minimum maximum 
Reference 0.67 0.45 0.76 
BNCT_Rtpe 0.69 0.48 0.79 
SERA 0.69 0.47 0.78 
NCTPlan 0.59 0.41 0.67 
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Figure A.153 Fast neutron (and hydrogen) dose-volume histograms for tumor 2 (arc-
shaped tumor) for a 1-field irradiation of the leg phantom. Conventional 
and binned representations of the reference data are included. A corrected 
interpretation of the SERA dose-volume data (with a −5% shift in dose) is 
shown instead of the default seraPlot output. 
 
 
 
 
Table A.41 Fast neutron (and hydrogen) dose statistics for tumor 2 (arc-shaped tumor) 
resulting from a 1-field irradiation with a thermal neutron beam for 1.38 
minutes. 
 Fast Neutron Dose (Gy) 
 mean minimum maximum 
Reference 0.0069 0.0064 0.0072 
BNCT_Rtpe 0.0068 0.0063 0.0070 
SERA 0.0069 0.0069 0.0083 
NCTPlan 0.0068 0.0061 0.0075 
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Figure A.154 Induced photon dose-volume histograms for tumor 2 (arc-shaped tumor) 
for a 1-field irradiation of the leg phantom. Conventional and binned 
representations of the reference data are included. A corrected 
interpretation of the SERA dose-volume data (with a −5% shift in dose) is 
shown instead of the default seraPlot output. 
 
 
 
 
 
Table A.42 Induced photon dose statistics for tumor 2 (arc-shaped tumor) resulting 
from a 1-field irradiation with a thermal neutron beam for 1.38 minutes. 
 Induced Photon Dose (Gy) 
 mean minimum maximum 
Reference 1.09 0.79 1.24 
BNCT_Rtpe 1.11 0.81 1.31 
SERA 1.04 0.74 1.22 
NCTPlan 0.90 0.60 1.08 
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Figure A.155 Incident photon dose-volume histograms for tumor 2 (arc-shaped tumor) 
for a 1-field irradiation of the leg phantom. Conventional and binned 
representations of the reference data are included. A corrected 
interpretation of the SERA dose-volume data (with a −5% shift in dose) is 
shown instead of the default seraPlot output. 
 
 
 
 
 
Table A.43 Incident photon dose statistics for tumor 2 (arc-shaped tumor) resulting 
from a 1-field irradiation with a thermal neutron beam for 1.38 minutes. 
 Incident Photon Dose (Gy) 
 mean minimum maximum 
Reference 0.109 0.108 0.111 
BNCT_Rtpe 0.114 0.112 0.116 
SERA 0.107 0.105 0.134 
NCTPlan 0.109 0.108 0.110 
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Figure A.156 Total biologically weighted dose-volume histograms for tumor 2 (arc-
shaped tumor) for a 1-field irradiation of the leg phantom. Conventional 
and binned representations of the reference data are included. A corrected 
interpretation of the SERA dose-volume data (with a −5% shift in dose) is 
shown instead of the default seraPlot output. 
 
 
 
 
Table A.44 Total biologically weighted dose statistics for tumor 2 (arc-shaped tumor) 
resulting from a 1-field irradiation with a thermal neutron beam for 1.38 
minutes. 
 Total Biologically Weighted Dose (Gyw) 
 mean minimum maximum 
Reference 37.44 25.21 42.55 
BNCT_Rtpe 39.39 27.22 44.72 
SERA 38.77 26.34 43.91 
NCTPlan 33.24 23.10 37.86 
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APPENDIX B 
Construction of a Beowulf 
Cluster for Monte Carlo 
Computations 
B.1 Introduction 
To facilitate the computationally intensive research described in this thesis, a 
Beowulf cluster was constructed during the summer of 2005. Monte Carlo algorithms are 
very well-known for their parallelizability, so constructing a high-performance 
homogeneous cluster from common personal computer hardware was a relatively 
inexpensive and efficient way to decrease the computation time. Even for large numbers 
of sequential computations such as those performed in Chapter 3, the cluster proved to be 
an invaluable resource that allowed a more thorough investigation than would have 
otherwise been possible within the given time frame. However, the success of a cluster, 
especially one assembled from standard component parts, was certainly not guaranteed, 
so considerable effort was devoted to properly designing, constructing and testing the 
cluster in order to prevent problems that could potentially limit its effectiveness. Since 
the cluster was an essential tool for this thesis work, a brief overview of its hardware, 
software, and performance characteristics will be presented here. 
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B.2 Hardware 
During the initial planning stages, estimates for pre-packaged computing clusters 
were obtained from few different companies, but none were able to provide the desired 
level of customization within the defined price range. Therefore, the decision was made 
to build the cluster from “scratch” using standard off-the-shelf component parts. 
However, before any purchases were made, a variety of research and tests were first 
performed to maximize the computational power to cost ratio (i.e., simulated particle 
histories per minute per dollar). Once an appropriate design was determined, enough 
components were purchased to fully assemble 1 node, and that node was subjected to a 
variety of tests designed to fully stress the system’s hardware. After observing 
satisfactory stability and performance, enough components were ordered to construct 1 
master node and 10 additional slave nodes. The relevant hardware used in the master and 
slave nodes is listed in Table B.1.  
The master or head node consists of dual 250 GB hard drives operating in a 
mirrored RAID (Redundant Array of Independent Disks) array for real time data backup 
to protect against sudden disk failure. In addition, nightly differential backups are 
performed and written to removable DVD media via the dual DVD±RW drives. The 
master node’s video card supplies dual monitor support. The dual integrated gigabit 
network interfaces on the master node allow a connection to both the outside world, so 
that users can gain access remotely, and to each slave node via the gigabit network 
switch. The slave nodes are actually similar to the master node but with a few notable 
differences. Each slave node has 2 GB RAM and an 80 GB hard drive for local storage. 
While each slave node is headless (no monitor), cheap second-hand video cards 
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purchased on eBay were installed so that a monitor could be connected for diagnostic 
purposes in the event that remote login from the master node was not possible. It is also 
worth mentioning that in ~4 years of use the only hardware failures were in motherboard 
and case cooling fans, which were still under warranty at the time and replaced free of 
charge. However, even those hardware failures did not affect the normal operation of the 
cluster as temperatures remained relatively stable until the fans could be replaced. A rear 
view of all 11 fully assembled slave nodes is shown in Figure B.1. 
B.3 Software 
The master and all 11 slave nodes run the 64-bit Debian GNU/Linux operating 
system. It was chosen primarily because it is free, open and has a reputation within the 
Linux community of valuing stability over new cutting-edge features. Also, the robust 
Table B.1 Hardware for the master and 11 slave nodes of the cluster. All components 
were purchased new except the video cards for the slave nodes which 
were purchased used on eBay. The components were purchased 
individually at a total cost of 10,074.52 and manually assembled over 3.5 
months during the summer of 2005. 
Component Master Node  Slave Node (11×) 
CPU single core 2.0 GHz AMD 64-bit Athlon 3200+ 
Motherboard MSI K8N Neo4 Platinum  MSI K8N Neo4-F 
Memory 512MB DDR PC3200 (2×)  1GB DDR PC3200 (2×) 
Hard Disk Seagate 250GB SATA (2×)  Seagate 80GB SATA 
Video Nvidia GeForce 6200 (PCIe)  Matrox Millennium (PCI) 
Network Dual Integrated Gigabit NIC  Integrated Gigabit NIC 
Optical Drive Dual Layer 16× DVD±RW (2×)  none 
Case Antec Plus1000 w/ 480W PS  Antec SLK1650 w/ 350W PS 
Network Switch NETGEAR 24-port 10/100/1000 Mbps 
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software package management system allows easy access to system updates as well as a 
huge repository of over 20,000 software titles. Custom Linux kernels (v. 2.6.18) were 
compiled for the master and slave nodes to better tune the operating system to the 
specific hardware. A 32-bit compatibility layer was also installed so that 32-bit binaries 
could be executed seamlessly. Each user’s home directory on the master node is served to 
all slave nodes via a network file system (NFS) mount, and “passwordless” logins, which 
are essential to parallel simulations, are permitted between the master and slave nodes via 
the Secure Shell (ssh) protocol. Custom shell scripts were developed to perform nightly 
differential backups to DVD as well as monitor the health of the system hardware. The 
Ganglia Monitoring System (http://ganglia.info/) allows certain characteristics of the 
cluster (e.g., CPU load, CPU temperature, network traffic, free disk space) to be 
monitored graphically, even remotely, from a web browser. Robust job scheduling is 
provided by the Sun Grid Engine (http://gridengine.sunsource.net/), and SystemImager 
(http://wiki.systemimager.org/) is used to keep the system software on the 11 slave nodes 
in sync with each other and up-to-date (files and directories related to the operating 
system are not served via NFS but rather are stored locally on each slave node). The 
Cluster Command and Control (C3) tool suite (http://www.csm.ornl.gov/torc/C3/) was 
installed to provide very useful cluster-wide administration and management tools. 
Rather remarkably, the only software that was not free and open source was the Intel® 
Fortran 90 compiler required to compile custom versions of the Monte Carlo transport 
codes, MCNP5 and MCNPX. Planning, assembly, and post-configuration of the cluster 
took 3.5 months total during the summer of 2005.  
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B.4 Performance   
Since completion of the cluster, uptime (i.e., time since last reboot) has 
consistently been measured in months with the current uptime approaching 1 year. 
Planned power outages are the most frequent cause for rebooting the cluster. Over 8,700 
jobs have been submitted to the cluster in ~4 years of use with the research presented in 
Chapter 4 alone requiring over 1000 separate simulations totaling 3.2 CPU years of 
simulation time. Shortly after the cluster was made fully operational, benchmarks were 
performed to test both its efficiency and peak performance. As shown in Figure B.2, the 
simulation speed (i.e., simulated particle histories/minute) increases linearly with the 
number of nodes, and that relationship holds out to 11 nodes. The speedup factor (defined 
relative to the runtime on 1 node) at 11 nodes is actually 10.9, but that still represents 
greater than 99% efficiency. To test the peak performance of the cluster, version 1.0a of 
the High-Performance Linpack Benchmark (http://www.netlib.org/benchmark/hpl/), 
which is the same benchmark used to consistently rank the fastest supercomputer sites in 
the world (http://www.top500.org/), was employed. That benchmark indicated that the 
cluster is capable of performing 33.5 billion floating point operations per second or 33.5 
gigaFLOPS. * 
 
 
 
 
                                                 
* As of 06/2009, a cluster at Los Alamos National Laboratory (LANL), named Roadrunner, is the world’s 
fastest supercomputer and is capable of sustaining more than 1.1 petaFLOPS or 1.1×1015 (1.1 quadrillion) 
floating point operations per second (http://www.top500.org). 
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Figure B.1 All 11 fully assembled and operational slave nodes. Each slave node is 
connected via the gigabit network switch, positioned above the second tier 
of nodes, to the master node (whose dual monitor console is visible in the 
background). The master node also allows remote access. 
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Figure B.2 Simulation speed and speedup factor (defined relative to the runtime on 1 
node) as a function of the number of uniprocessor cluster nodes used in 
the test parallel Monte Carlo simulation with MCNP5 version 1.40. The 
measured efficiency is very close to ideal and is greater than 99% at 11 
nodes. At peak performance, the cluster is capable of performing 33.5 
billion floating point operations per second or 33.5 gigaFLOPS. 
 
